{"dd589b76d5bb55f7536c4e328d529db0973ac4ea": [["IntroductionLiver failure is a common disease with high mortality, and its incidence is increasing with the use of alcohol and the prevalence of obesity and diabetes [1] [2] [3] .", [["IntroductionLiver failure", "DISEASE", 0, 25], ["alcohol", "CHEMICAL", 115, 122], ["obesity", "DISEASE", 145, 152], ["diabetes", "DISEASE", 157, 165], ["alcohol", "CHEMICAL", 115, 122], ["alcohol", "SIMPLE_CHEMICAL", 115, 122], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 166, 177], ["IntroductionLiver failure", "PROBLEM", 0, 25], ["a common disease", "PROBLEM", 29, 45], ["high mortality", "PROBLEM", 51, 65], ["obesity", "PROBLEM", 145, 152], ["diabetes", "PROBLEM", 157, 165], ["obesity", "OBSERVATION", 145, 152]]], ["It has also been reported that the prognosis of acute hepatitis or acute liver injury was affected by the preexistence of chronic liver diseases and cirrhosis [1, 2] , extrahepatic diseases, such as metabolic, malignant, and psychiatric diseases [4] , and host factors, such as older age and obesity [3, 5, 6] , although the etiology of acute insults is one of the most important risk factors for the development of severe liver diseases [1, 7] .IntroductionHepatitis A virus (HAV) infection is still one of the major causes of acute hepatitis worldwide.", [["liver", "ANATOMY", 73, 78], ["liver", "ANATOMY", 130, 135], ["extrahepatic", "ANATOMY", 168, 180], ["liver", "ANATOMY", 423, 428], ["hepatitis", "DISEASE", 54, 63], ["acute liver injury", "DISEASE", 67, 85], ["chronic liver diseases", "DISEASE", 122, 144], ["cirrhosis", "DISEASE", 149, 158], ["extrahepatic diseases", "DISEASE", 168, 189], ["metabolic, malignant, and psychiatric diseases", "DISEASE", 199, 245], ["obesity", "DISEASE", 292, 299], ["acute insults", "DISEASE", 337, 350], ["liver diseases", "DISEASE", 423, 437], ["Hepatitis A virus (HAV) infection", "DISEASE", 458, 491], ["hepatitis", "DISEASE", 534, 543], ["liver", "ORGAN", 73, 78], ["liver", "ORGAN", 130, 135], ["extrahepatic", "ORGAN", 168, 180], ["liver", "ORGAN", 423, 428], ["Hepatitis A virus", "ORGANISM", 458, 475], ["HAV", "ORGANISM", 477, 480], ["Hepatitis A virus", "SPECIES", 458, 475], ["Hepatitis A virus", "SPECIES", 458, 475], ["HAV", "SPECIES", 477, 480], ["acute hepatitis", "PROBLEM", 48, 63], ["acute liver injury", "PROBLEM", 67, 85], ["chronic liver diseases", "PROBLEM", 122, 144], ["cirrhosis", "PROBLEM", 149, 158], ["extrahepatic diseases", "PROBLEM", 168, 189], ["metabolic, malignant, and psychiatric diseases", "PROBLEM", 199, 245], ["obesity", "PROBLEM", 292, 299], ["acute insults", "PROBLEM", 337, 350], ["severe liver diseases", "PROBLEM", 416, 437], ["Hepatitis A virus (HAV) infection", "PROBLEM", 458, 491], ["acute hepatitis worldwide", "PROBLEM", 528, 553], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["hepatitis", "OBSERVATION", 54, 63], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["liver", "ANATOMY", 73, 78], ["injury", "OBSERVATION", 79, 85], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["liver", "ANATOMY", 130, 135], ["diseases", "OBSERVATION", 136, 144], ["cirrhosis", "OBSERVATION", 149, 158], ["extrahepatic", "ANATOMY", 168, 180], ["diseases", "OBSERVATION", 181, 189], ["metabolic", "OBSERVATION_MODIFIER", 199, 208], ["malignant", "OBSERVATION_MODIFIER", 210, 219], ["obesity", "OBSERVATION", 292, 299], ["acute", "OBSERVATION_MODIFIER", 337, 342], ["insults", "OBSERVATION", 343, 350], ["severe", "OBSERVATION_MODIFIER", 416, 422], ["liver", "ANATOMY", 423, 428], ["diseases", "OBSERVATION", 429, 437], ["Hepatitis", "OBSERVATION", 458, 467], ["acute", "OBSERVATION_MODIFIER", 528, 533], ["hepatitis", "OBSERVATION", 534, 543]]], ["HAV infection occasionally causes acute liver failure [4, 8] .", [["liver", "ANATOMY", 40, 45], ["HAV infection", "DISEASE", 0, 13], ["acute liver failure", "DISEASE", 34, 53], ["HAV", "ORGANISM", 0, 3], ["liver", "ORGAN", 40, 45], ["HAV", "SPECIES", 0, 3], ["HAV infection", "PROBLEM", 0, 13], ["acute liver failure", "PROBLEM", 34, 53], ["infection", "OBSERVATION", 4, 13], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["liver", "ANATOMY", 40, 45], ["failure", "OBSERVATION", 46, 53]]], ["It has been reported that a superinfection of HAV in patients with a chronic hepatitis C virus (HCV) infection is associated with fulminant hepatitis [9] , although much research denies this association [5, 10] .", [["HAV", "DISEASE", 46, 49], ["chronic hepatitis C virus (HCV) infection", "DISEASE", 69, 110], ["fulminant hepatitis", "DISEASE", 130, 149], ["HAV", "ORGANISM", 46, 49], ["patients", "ORGANISM", 53, 61], ["chronic hepatitis C virus", "ORGANISM", 69, 94], ["HCV", "ORGANISM", 96, 99], ["patients", "SPECIES", 53, 61], ["hepatitis C virus", "SPECIES", 77, 94], ["HAV", "SPECIES", 46, 49], ["hepatitis C virus", "SPECIES", 77, 94], ["HCV", "SPECIES", 96, 99], ["a superinfection of HAV", "PROBLEM", 26, 49], ["a chronic hepatitis C virus (HCV) infection", "PROBLEM", 67, 110], ["fulminant hepatitis", "PROBLEM", 130, 149], ["superinfection", "OBSERVATION", 28, 42], ["HAV", "OBSERVATION", 46, 49], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["hepatitis", "OBSERVATION", 77, 86], ["associated with", "UNCERTAINTY", 114, 129], ["fulminant", "OBSERVATION_MODIFIER", 130, 139], ["hepatitis", "OBSERVATION", 140, 149]]], ["HAV infection rarely causes acute liver failure in patients without underlying chronic liver diseases [9] .IntroductionThere are excellent, safe, and effective HAV vaccines to prevent HAV infection.", [["liver", "ANATOMY", 34, 39], ["liver", "ANATOMY", 87, 92], ["HAV infection", "DISEASE", 0, 13], ["acute liver failure", "DISEASE", 28, 47], ["chronic liver diseases", "DISEASE", 79, 101], ["HAV infection", "DISEASE", 184, 197], ["HAV", "ORGANISM", 0, 3], ["liver", "ORGAN", 34, 39], ["patients", "ORGANISM", 51, 59], ["liver", "ORGAN", 87, 92], ["HAV", "ORGANISM", 160, 163], ["HAV", "ORGANISM", 184, 187], ["patients", "SPECIES", 51, 59], ["HAV", "SPECIES", 0, 3], ["HAV", "SPECIES", 160, 163], ["HAV", "SPECIES", 184, 187], ["HAV infection", "PROBLEM", 0, 13], ["acute liver failure", "PROBLEM", 28, 47], ["underlying chronic liver diseases", "PROBLEM", 68, 101], ["effective HAV vaccines", "TREATMENT", 150, 172], ["HAV infection", "PROBLEM", 184, 197], ["infection", "OBSERVATION", 4, 13], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["liver", "ANATOMY", 34, 39], ["failure", "OBSERVATION", 40, 47], ["without", "UNCERTAINTY", 60, 67], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["liver", "ANATOMY", 87, 92], ["diseases", "OBSERVATION", 93, 101], ["excellent", "OBSERVATION_MODIFIER", 129, 138], ["infection", "OBSERVATION", 188, 197]]], ["However, HAV vaccination costs a lot.", [["HAV", "ORGANISM", 9, 12], ["HAV", "SPECIES", 9, 12]]], ["As no universal vaccination program against HAV infection exists in certain countries, such as Japan, it may be important to develop potential drugs against HAV infection [11] .", [["HAV infection", "DISEASE", 44, 57], ["HAV infection", "DISEASE", 157, 170], ["HAV", "ORGANISM", 44, 47], ["HAV", "ORGANISM", 157, 160], ["HAV", "SPECIES", 44, 47], ["HAV", "SPECIES", 157, 160], ["universal vaccination program", "TREATMENT", 6, 35], ["HAV infection", "PROBLEM", 44, 57], ["HAV infection", "PROBLEM", 157, 170], ["infection", "OBSERVATION", 48, 57]]], ["Acute-on-chronic liver failure with hepatitis A virus (HAV) infection in patients with nonalcoholic steatohepatitis (NASH) or chronic alcoholic liver diseases (ALD).", [["liver", "ANATOMY", 17, 22], ["liver", "ANATOMY", 144, 149], ["Acute-on-chronic liver failure", "DISEASE", 0, 30], ["hepatitis A virus (HAV) infection", "DISEASE", 36, 69], ["nonalcoholic steatohepatitis", "DISEASE", 87, 115], ["NASH", "DISEASE", 117, 121], ["alcoholic liver diseases", "DISEASE", 134, 158], ["ALD", "DISEASE", 160, 163], ["liver", "ORGAN", 17, 22], ["hepatitis A virus", "ORGANISM", 36, 53], ["HAV", "ORGANISM", 55, 58], ["patients", "ORGANISM", 73, 81], ["liver", "ORGAN", 144, 149], ["hepatitis A virus", "SPECIES", 36, 53], ["patients", "SPECIES", 73, 81], ["hepatitis A virus", "SPECIES", 36, 53], ["HAV", "SPECIES", 55, 58], ["Acute-on-chronic liver failure", "PROBLEM", 0, 30], ["hepatitis A virus (HAV) infection", "PROBLEM", 36, 69], ["nonalcoholic steatohepatitis", "PROBLEM", 87, 115], ["NASH)", "PROBLEM", 117, 122], ["chronic alcoholic liver diseases", "PROBLEM", 126, 158], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["liver", "ANATOMY", 17, 22], ["failure", "OBSERVATION", 23, 30], ["hepatitis", "OBSERVATION", 36, 45], ["virus", "OBSERVATION", 48, 53], ["infection", "OBSERVATION", 60, 69], ["nonalcoholic", "OBSERVATION_MODIFIER", 87, 99], ["steatohepatitis", "OBSERVATION", 100, 115], ["NASH", "OBSERVATION", 117, 121], ["chronic", "OBSERVATION_MODIFIER", 126, 133], ["alcoholic", "OBSERVATION_MODIFIER", 134, 143], ["liver", "ANATOMY", 144, 149], ["diseases", "OBSERVATION", 150, 158]]], ["Fatty liver diseases associated with metabolic dysfunction are common and have a heterogeneous genetic predisposition, metabolic syndrome, and environmental factors [23] .", [["Fatty liver", "ANATOMY", 0, 11], ["Fatty liver diseases", "DISEASE", 0, 20], ["metabolic dysfunction", "DISEASE", 37, 58], ["metabolic syndrome", "DISEASE", 119, 137], ["liver", "ORGAN", 6, 11], ["Fatty liver diseases", "PROBLEM", 0, 20], ["metabolic dysfunction", "PROBLEM", 37, 58], ["a heterogeneous genetic predisposition", "PROBLEM", 79, 117], ["metabolic syndrome", "PROBLEM", 119, 137], ["liver", "ANATOMY", 6, 11], ["metabolic dysfunction", "OBSERVATION", 37, 58], ["heterogeneous", "OBSERVATION_MODIFIER", 81, 94], ["genetic predisposition", "OBSERVATION", 95, 117], ["metabolic syndrome", "OBSERVATION", 119, 137]]], ["Recently, experts suggested \"MAFLD\" should replace NAFLD/NASH [23] .", [["NAFLD", "DISEASE", 51, 56], ["NASH", "DISEASE", 57, 61], ["NASH", "OBSERVATION", 57, 61]]], ["The diagnosis of MAFLD is based on the detection of liver steatosis in the presence of overweight or obesity, diabetes mellitus, and/or clinical evidence of metabolic abnormalities, such as hypertension, dyslipidemia, and hyperglycemia.Authors (Year) [References] N Acute Insults Underlying CLD PrognosisA Japanese nationwide survey of ALF and late-onset hepatic failure (LOHF) caused by HAV infection suggested that diabetic mellitus was more common among deceased patients than among rescued patients (29% vs. 8%; p < 0.05), excluding patients with liver transplantations, and that diabetic mellitus was independently associated with the outcome [24] .", [["liver", "ANATOMY", 52, 57], ["hepatic", "ANATOMY", 355, 362], ["liver", "ANATOMY", 551, 556], ["MAFLD", "DISEASE", 17, 22], ["liver steatosis", "DISEASE", 52, 67], ["overweight", "DISEASE", 87, 97], ["obesity", "DISEASE", 101, 108], ["diabetes mellitus", "DISEASE", 110, 127], ["metabolic abnormalities", "DISEASE", 157, 180], ["hypertension", "DISEASE", 190, 202], ["dyslipidemia", "DISEASE", 204, 216], ["hyperglycemia", "DISEASE", 222, 235], ["ALF", "DISEASE", 336, 339], ["hepatic failure", "DISEASE", 355, 370], ["LOHF", "DISEASE", 372, 376], ["HAV infection", "DISEASE", 388, 401], ["diabetic mellitus", "DISEASE", 417, 434], ["diabetic mellitus", "DISEASE", 584, 601], ["liver", "ORGAN", 52, 57], ["hepatic", "ORGAN", 355, 362], ["HAV", "ORGANISM", 388, 391], ["patients", "ORGANISM", 466, 474], ["patients", "ORGANISM", 494, 502], ["patients", "ORGANISM", 537, 545], ["liver", "ORGAN", 551, 556], ["patients", "SPECIES", 466, 474], ["patients", "SPECIES", 494, 502], ["patients", "SPECIES", 537, 545], ["HAV", "SPECIES", 388, 391], ["MAFLD", "PROBLEM", 17, 22], ["liver steatosis", "PROBLEM", 52, 67], ["overweight or obesity", "PROBLEM", 87, 108], ["diabetes mellitus", "PROBLEM", 110, 127], ["metabolic abnormalities", "PROBLEM", 157, 180], ["hypertension", "PROBLEM", 190, 202], ["dyslipidemia", "PROBLEM", 204, 216], ["hyperglycemia", "PROBLEM", 222, 235], ["Acute Insults", "PROBLEM", 266, 279], ["CLD", "PROBLEM", 291, 294], ["ALF", "PROBLEM", 336, 339], ["hepatic failure", "PROBLEM", 355, 370], ["LOHF)", "PROBLEM", 372, 377], ["HAV infection", "PROBLEM", 388, 401], ["diabetic mellitus", "PROBLEM", 417, 434], ["liver transplantations", "TREATMENT", 551, 573], ["diabetic mellitus", "PROBLEM", 584, 601], ["liver", "ANATOMY", 52, 57], ["steatosis", "OBSERVATION", 58, 67], ["obesity", "OBSERVATION", 101, 108], ["metabolic abnormalities", "OBSERVATION", 157, 180], ["hypertension", "OBSERVATION", 190, 202], ["dyslipidemia", "OBSERVATION", 204, 216], ["hyperglycemia", "OBSERVATION", 222, 235], ["hepatic", "ANATOMY", 355, 362], ["failure", "OBSERVATION", 363, 370], ["infection", "OBSERVATION", 392, 401], ["diabetic", "OBSERVATION_MODIFIER", 417, 425], ["mellitus", "OBSERVATION", 426, 434], ["liver", "ANATOMY", 551, 556], ["transplantations", "OBSERVATION", 557, 573]]], ["Patients with diabetes are at risk of developing severe hepatitis [25] .Authors (Year) [References] N Acute Insults Underlying CLD PrognosisWe observed that HAV HA11-1299 genotype IIIA strain replication is enhanced by the accumulation of lipids or high-concentration glucose in the human hepatoma cell line, Huh7 [26] [27] [28] .", [["hepatoma cell line", "ANATOMY", 289, 307], ["Huh7", "ANATOMY", 309, 313], ["diabetes", "DISEASE", 14, 22], ["hepatitis", "DISEASE", 56, 65], ["CLD", "DISEASE", 127, 130], ["HA11-1299", "CHEMICAL", 161, 170], ["glucose", "CHEMICAL", 268, 275], ["glucose", "CHEMICAL", 268, 275], ["Patients", "ORGANISM", 0, 8], ["HAV HA11-1299", "ORGANISM", 157, 170], ["lipids", "SIMPLE_CHEMICAL", 239, 245], ["glucose", "SIMPLE_CHEMICAL", 268, 275], ["human", "ORGANISM", 283, 288], ["hepatoma cell line", "CELL", 289, 307], ["Huh7", "CELL", 309, 313], ["human hepatoma cell line", "CELL_LINE", 283, 307], ["Patients", "SPECIES", 0, 8], ["human", "SPECIES", 283, 288], ["HAV HA11-1299", "SPECIES", 157, 170], ["human", "SPECIES", 283, 288], ["diabetes", "PROBLEM", 14, 22], ["severe hepatitis", "PROBLEM", 49, 65], ["Acute Insults", "PROBLEM", 102, 115], ["CLD PrognosisWe", "PROBLEM", 127, 142], ["HAV HA11", "TEST", 157, 165], ["genotype IIIA strain replication", "PROBLEM", 171, 203], ["lipids", "TEST", 239, 245], ["concentration glucose", "TEST", 254, 275], ["the human hepatoma cell line", "TREATMENT", 279, 307], ["Huh7", "TEST", 309, 313], ["diabetes", "OBSERVATION", 14, 22], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["hepatitis", "OBSERVATION", 56, 65], ["hepatoma", "ANATOMY", 289, 297], ["cell line", "OBSERVATION", 298, 307]]], ["Hyperglycemia or the accumulation of lipids induces an endoplasmic reticulum (ER) stress response in human hepatocytes.", [["endoplasmic reticulum", "ANATOMY", 55, 76], ["ER", "ANATOMY", 78, 80], ["hepatocytes", "ANATOMY", 107, 118], ["Hyperglycemia", "DISEASE", 0, 13], ["lipids", "SIMPLE_CHEMICAL", 37, 43], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 55, 76], ["ER", "GENE_OR_GENE_PRODUCT", 78, 80], ["human", "ORGANISM", 101, 106], ["hepatocytes", "CELL", 107, 118], ["human hepatocytes", "CELL_TYPE", 101, 118], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["Hyperglycemia", "PROBLEM", 0, 13], ["the accumulation of lipids", "PROBLEM", 17, 43], ["an endoplasmic reticulum", "PROBLEM", 52, 76], ["stress response in human hepatocytes", "PROBLEM", 82, 118], ["endoplasmic reticulum", "OBSERVATION", 55, 76], ["hepatocytes", "ANATOMY", 107, 118]]], ["HAV replicates in the ER of human hepatocytes and induces an ER stress response.", [["ER", "ANATOMY", 22, 24], ["hepatocytes", "ANATOMY", 34, 45], ["ER", "ANATOMY", 61, 63], ["HAV", "ORGANISM", 0, 3], ["ER", "GENE_OR_GENE_PRODUCT", 22, 24], ["human", "ORGANISM", 28, 33], ["hepatocytes", "CELL", 34, 45], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["ER", "PROTEIN", 22, 24], ["human hepatocytes", "CELL_TYPE", 28, 45], ["ER", "PROTEIN", 61, 63], ["human", "SPECIES", 28, 33], ["HAV", "SPECIES", 0, 3], ["human", "SPECIES", 28, 33], ["an ER stress response", "PROBLEM", 58, 79], ["hepatocytes", "ANATOMY", 34, 45], ["stress response", "OBSERVATION", 64, 79]]], ["The ER stress response is mediated by the sensor molecules, inositol-requiring enzyme 1\u03b1 (IRE1\u03b1), PKR-like ER kinase (PERK), and activating transcription factor 6 (ATF6), which are usually associated with molecular chaperone glucose-regulated protein 78 (GRP78) [27] .", [["inositol", "CHEMICAL", 60, 68], ["glucose", "CHEMICAL", 225, 232], ["inositol", "CHEMICAL", 60, 68], ["glucose", "CHEMICAL", 225, 232], ["ER", "GENE_OR_GENE_PRODUCT", 4, 6], ["inositol-requiring enzyme 1\u03b1", "GENE_OR_GENE_PRODUCT", 60, 88], ["IRE1\u03b1", "GENE_OR_GENE_PRODUCT", 90, 95], ["PKR-like ER kinase", "GENE_OR_GENE_PRODUCT", 98, 116], ["PERK", "GENE_OR_GENE_PRODUCT", 118, 122], ["activating transcription factor 6", "GENE_OR_GENE_PRODUCT", 129, 162], ["ATF6", "GENE_OR_GENE_PRODUCT", 164, 168], ["glucose-regulated protein 78", "GENE_OR_GENE_PRODUCT", 225, 253], ["GRP78", "GENE_OR_GENE_PRODUCT", 255, 260], ["ER", "PROTEIN", 4, 6], ["inositol-requiring enzyme 1\u03b1", "PROTEIN", 60, 88], ["IRE1\u03b1", "PROTEIN", 90, 95], ["PKR", "PROTEIN", 98, 101], ["ER kinase", "PROTEIN", 107, 116], ["PERK", "PROTEIN", 118, 122], ["activating transcription factor 6", "PROTEIN", 129, 162], ["ATF6", "PROTEIN", 164, 168], ["molecular chaperone glucose-regulated protein 78", "PROTEIN", 205, 253], ["GRP78", "PROTEIN", 255, 260], ["inositol", "TEST", 60, 68], ["enzyme", "TEST", 79, 85], ["IRE1", "TEST", 90, 94], ["PKR", "TEST", 98, 101], ["activating transcription factor", "TEST", 129, 160], ["molecular chaperone glucose", "TEST", 205, 232], ["protein", "TEST", 243, 250]]], ["GRP78 is a negative regulator of ER stress response.", [["ER", "ANATOMY", 33, 35], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["ER", "GENE_OR_GENE_PRODUCT", 33, 35], ["GRP78", "PROTEIN", 0, 5], ["ER", "PROTEIN", 33, 35]]], ["We also observed that the overexpression of GRP78 could inhibit HAV replication, while the knockdown or knockout of GRP78 enhanced HAV replication [26, 28] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 44, 49], ["HAV", "ORGANISM", 64, 67], ["GRP78", "GENE_OR_GENE_PRODUCT", 116, 121], ["HAV", "ORGANISM", 131, 134], ["GRP78", "PROTEIN", 44, 49], ["GRP78", "PROTEIN", 116, 121], ["HAV", "SPECIES", 64, 67], ["HAV", "SPECIES", 131, 134], ["the overexpression of GRP78", "PROBLEM", 22, 49], ["HAV replication", "TREATMENT", 64, 79], ["GRP78 enhanced HAV replication", "TREATMENT", 116, 146]]], ["In sum, GRP78 is an antiviral protein against HAV replication [28] .HAV Infection and Alcoholic Liver Diseases (ALD)There are several factors affecting the severity of HAV infection and the rates of fulminant hepatic failure [29] .", [["Liver", "ANATOMY", 96, 101], ["hepatic", "ANATOMY", 209, 216], ["HAV Infection", "DISEASE", 68, 81], ["Alcoholic Liver Diseases", "DISEASE", 86, 110], ["ALD", "DISEASE", 112, 115], ["HAV infection", "DISEASE", 168, 181], ["fulminant hepatic failure", "DISEASE", 199, 224], ["GRP78", "GENE_OR_GENE_PRODUCT", 8, 13], ["HAV", "ORGANISM", 46, 49], ["HAV", "ORGANISM", 68, 71], ["Liver", "ORGAN", 96, 101], ["HAV", "ORGANISM", 168, 171], ["hepatic", "ORGAN", 209, 216], ["GRP78", "PROTEIN", 8, 13], ["antiviral protein", "PROTEIN", 20, 37], ["HAV", "SPECIES", 46, 49], ["HAV", "SPECIES", 68, 71], ["HAV", "SPECIES", 168, 171], ["an antiviral protein", "TREATMENT", 17, 37], ["HAV replication", "TREATMENT", 46, 61], ["HAV Infection", "PROBLEM", 68, 81], ["Alcoholic Liver Diseases", "PROBLEM", 86, 110], ["HAV infection", "PROBLEM", 168, 181], ["fulminant hepatic failure", "PROBLEM", 199, 224], ["Infection", "OBSERVATION", 72, 81], ["Alcoholic", "OBSERVATION_MODIFIER", 86, 95], ["Liver", "ANATOMY", 96, 101], ["HAV", "OBSERVATION_MODIFIER", 168, 171], ["infection", "OBSERVATION", 172, 181], ["fulminant", "OBSERVATION_MODIFIER", 199, 208], ["hepatic", "ANATOMY", 209, 216], ["failure", "OBSERVATION", 217, 224]]], ["These important factors include older age, concomitant virus infection, chronic liver disease, sexual orientation, intravenous drug use, and alcohol abuse [6, 29] .", [["liver", "ANATOMY", 80, 85], ["intravenous", "ANATOMY", 115, 126], ["infection", "DISEASE", 61, 70], ["chronic liver disease", "DISEASE", 72, 93], ["alcohol abuse", "DISEASE", 141, 154], ["alcohol", "CHEMICAL", 141, 148], ["liver", "ORGAN", 80, 85], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 115, 126], ["concomitant virus infection", "PROBLEM", 43, 70], ["chronic liver disease", "PROBLEM", 72, 93], ["virus infection", "OBSERVATION", 55, 70], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["liver", "ANATOMY", 80, 85], ["disease", "OBSERVATION", 86, 93]]], ["Feller et al. reported that 12 patients developed hepatic encephalopathy, ascites, or both, among 20 patients with alcoholic cirrhosis and a superimposed episode of acute viral hepatitis [30] .", [["hepatic", "ANATOMY", 50, 57], ["ascites", "ANATOMY", 74, 81], ["hepatic encephalopathy", "DISEASE", 50, 72], ["ascites", "DISEASE", 74, 81], ["alcoholic cirrhosis", "DISEASE", 115, 134], ["acute viral hepatitis", "DISEASE", 165, 186], ["patients", "ORGANISM", 31, 39], ["hepatic", "ORGAN", 50, 57], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 101, 109], ["hepatic encephalopathy", "PROBLEM", 50, 72], ["ascites", "PROBLEM", 74, 81], ["alcoholic cirrhosis", "PROBLEM", 115, 134], ["acute viral hepatitis", "PROBLEM", 165, 186], ["hepatic", "ANATOMY", 50, 57], ["encephalopathy", "OBSERVATION", 58, 72], ["ascites", "OBSERVATION", 74, 81], ["alcoholic cirrhosis", "OBSERVATION", 115, 134], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["viral hepatitis", "OBSERVATION", 171, 186]]], ["HAV infection was excluded in only three of these patients [30] .HAV Infection and Alcoholic Liver Diseases (ALD)Lefilliatre et al. reported that three patients with fulminant hepatitis A had preexisting liver diseases, and one of the three had biopsy-proven alcoholic cirrhosis [21] (Table 1) .", [["Liver", "ANATOMY", 93, 98], ["liver", "ANATOMY", 204, 209], ["HAV infection", "DISEASE", 0, 13], ["HAV Infection", "DISEASE", 65, 78], ["Alcoholic Liver Diseases", "DISEASE", 83, 107], ["ALD", "DISEASE", 109, 112], ["fulminant hepatitis A", "DISEASE", 166, 187], ["liver diseases", "DISEASE", 204, 218], ["alcoholic cirrhosis", "DISEASE", 259, 278], ["HAV", "ORGANISM", 0, 3], ["patients", "ORGANISM", 50, 58], ["HAV", "ORGANISM", 65, 68], ["Liver", "ORGAN", 93, 98], ["patients", "ORGANISM", 152, 160], ["liver", "ORGAN", 204, 209], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 152, 160], ["HAV", "SPECIES", 0, 3], ["HAV", "SPECIES", 65, 68], ["HAV infection", "PROBLEM", 0, 13], ["HAV Infection", "PROBLEM", 65, 78], ["Alcoholic Liver Diseases", "PROBLEM", 83, 107], ["fulminant hepatitis A", "PROBLEM", 166, 187], ["preexisting liver diseases", "PROBLEM", 192, 218], ["biopsy", "TEST", 245, 251], ["alcoholic cirrhosis", "PROBLEM", 259, 278], ["infection", "OBSERVATION", 4, 13], ["Infection", "OBSERVATION", 69, 78], ["Alcoholic", "OBSERVATION_MODIFIER", 83, 92], ["Liver", "ANATOMY", 93, 98], ["fulminant", "OBSERVATION_MODIFIER", 166, 175], ["hepatitis", "OBSERVATION", 176, 185], ["liver", "ANATOMY", 204, 209], ["diseases", "OBSERVATION", 210, 218], ["alcoholic", "OBSERVATION_MODIFIER", 259, 268], ["cirrhosis", "OBSERVATION", 269, 278]]], ["Spada et al. reported that two individuals were HCV-coinfected alcohol abusers, had underlying liver cirrhosis, and died of acute liver failure due to HAV infection [22] (Table 1) .HAV Infection and Alcoholic Liver Diseases (ALD)While the direct effects of alcohol on HAV replication is unknown, excess alcohol intake (binge drinking) could induce hepatic fibrosis.", [["liver", "ANATOMY", 95, 100], ["liver", "ANATOMY", 130, 135], ["Liver", "ANATOMY", 209, 214], ["hepatic", "ANATOMY", 348, 355], ["HCV-coinfected", "DISEASE", 48, 62], ["alcohol", "CHEMICAL", 63, 70], ["liver cirrhosis", "DISEASE", 95, 110], ["acute liver failure", "DISEASE", 124, 143], ["HAV infection", "DISEASE", 151, 164], ["HAV Infection", "DISEASE", 181, 194], ["Alcoholic Liver Diseases", "DISEASE", 199, 223], ["ALD", "DISEASE", 225, 228], ["alcohol", "CHEMICAL", 257, 264], ["HAV", "DISEASE", 268, 271], ["alcohol", "CHEMICAL", 303, 310], ["hepatic fibrosis", "DISEASE", 348, 364], ["alcohol", "CHEMICAL", 63, 70], ["alcohol", "CHEMICAL", 257, 264], ["alcohol", "CHEMICAL", 303, 310], ["HCV", "ORGANISM", 48, 51], ["alcohol", "ORGANISM", 63, 70], ["liver", "ORGAN", 95, 100], ["liver", "ORGAN", 130, 135], ["HAV", "ORGANISM", 151, 154], ["HAV", "ORGANISM", 181, 184], ["Liver", "ORGAN", 209, 214], ["alcohol", "SIMPLE_CHEMICAL", 257, 264], ["HAV", "ORGANISM", 268, 271], ["alcohol", "SIMPLE_CHEMICAL", 303, 310], ["hepatic", "ORGAN", 348, 355], ["HCV", "SPECIES", 48, 51], ["HAV", "SPECIES", 151, 154], ["HAV", "SPECIES", 181, 184], ["HAV", "SPECIES", 268, 271], ["HCV", "PROBLEM", 48, 51], ["underlying liver cirrhosis", "PROBLEM", 84, 110], ["acute liver failure", "PROBLEM", 124, 143], ["HAV infection", "PROBLEM", 151, 164], ["HAV Infection", "PROBLEM", 181, 194], ["Alcoholic Liver Diseases", "PROBLEM", 199, 223], ["HAV replication", "TREATMENT", 268, 283], ["hepatic fibrosis", "PROBLEM", 348, 364], ["liver", "ANATOMY", 95, 100], ["cirrhosis", "OBSERVATION", 101, 110], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["liver", "ANATOMY", 130, 135], ["failure", "OBSERVATION", 136, 143], ["HAV", "OBSERVATION_MODIFIER", 151, 154], ["infection", "OBSERVATION", 155, 164], ["Infection", "OBSERVATION", 185, 194], ["Alcoholic", "OBSERVATION_MODIFIER", 199, 208], ["Liver", "ANATOMY", 209, 214], ["Diseases", "OBSERVATION", 215, 223], ["hepatic", "ANATOMY", 348, 355], ["fibrosis", "OBSERVATION", 356, 364]]], ["As only alcohol intake is responsible for worsening ACLF with alcoholic chronic liver diseases and alcoholic cirrhosis [31] , HAV may have an additive responsibility for worsening ACLF with ALD.Coinfection of HAV with HIVIn Japan, where no universal vaccination programs against HAV infection exist, 10-20% of those with HIV infection tested positive for immunoglobulin G (IgG) anti-hepatitis A (HA) antibodies [32] [33] [34] [35] .", [["liver", "ANATOMY", 80, 85], ["ACLF", "ANATOMY", 180, 184], ["alcohol", "CHEMICAL", 8, 15], ["ACLF", "DISEASE", 52, 56], ["alcoholic chronic liver diseases", "DISEASE", 62, 94], ["alcoholic cirrhosis", "DISEASE", 99, 118], ["HAV", "DISEASE", 126, 129], ["ACLF", "DISEASE", 180, 184], ["ALD", "DISEASE", 190, 193], ["HAV", "DISEASE", 209, 212], ["HAV infection", "DISEASE", 279, 292], ["HIV infection", "DISEASE", 321, 334], ["alcohol", "CHEMICAL", 8, 15], ["alcohol", "SIMPLE_CHEMICAL", 8, 15], ["liver", "ORGAN", 80, 85], ["HAV", "ORGANISM", 126, 129], ["ACLF", "CANCER", 180, 184], ["HAV", "ORGANISM", 209, 212], ["HAV", "ORGANISM", 279, 282], ["HIV", "ORGANISM", 321, 324], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 355, 371], ["IgG) anti-hepatitis A", "SIMPLE_CHEMICAL", 373, 394], ["[32] [33] [34", "SIMPLE_CHEMICAL", 411, 424], ["immunoglobulin G", "PROTEIN", 355, 371], ["IgG", "PROTEIN", 373, 376], ["HIV", "SPECIES", 321, 324], ["HAV", "SPECIES", 126, 129], ["HAV", "SPECIES", 209, 212], ["HAV", "SPECIES", 279, 282], ["HIV", "SPECIES", 321, 324], ["worsening ACLF", "PROBLEM", 42, 56], ["alcoholic chronic liver diseases", "PROBLEM", 62, 94], ["alcoholic cirrhosis", "PROBLEM", 99, 118], ["worsening ACLF", "PROBLEM", 170, 184], ["ALD", "PROBLEM", 190, 193], ["HIVIn Japan", "TREATMENT", 218, 229], ["universal vaccination programs", "TREATMENT", 240, 270], ["HAV infection", "PROBLEM", 279, 292], ["HIV infection", "PROBLEM", 321, 334], ["immunoglobulin G", "TEST", 355, 371], ["IgG", "TEST", 373, 376], ["anti-hepatitis A (HA) antibodies", "TEST", 378, 410], ["responsible for", "UNCERTAINTY", 26, 41], ["worsening", "OBSERVATION_MODIFIER", 42, 51], ["ACLF", "OBSERVATION", 52, 56], ["alcoholic", "OBSERVATION_MODIFIER", 62, 71], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["liver", "ANATOMY", 80, 85], ["diseases", "OBSERVATION", 86, 94], ["alcoholic", "OBSERVATION_MODIFIER", 99, 108], ["cirrhosis", "OBSERVATION", 109, 118], ["worsening", "OBSERVATION_MODIFIER", 170, 179], ["ACLF", "OBSERVATION", 180, 184]]], ["This prevalence is similar to that of IgG anti-HA in those without HIV infection [36, 37] , although a higher prevalence area can also be observed in Japan [38] .", [["HIV infection", "DISEASE", 67, 80], ["IgG anti-HA", "GENE_OR_GENE_PRODUCT", 38, 49], ["IgG anti-HA", "PROTEIN", 38, 49], ["HIV", "SPECIES", 67, 70], ["HIV", "SPECIES", 67, 70], ["IgG anti-HA", "PROBLEM", 38, 49], ["HIV infection", "PROBLEM", 67, 80], ["a higher prevalence area", "PROBLEM", 101, 125]]], ["In general, individuals of high-risk groups, such as healthcare workers, sewage workers, and drug addicts, have~60% of IgG anti-HA worldwide [39, 40] .", [["IgG anti-HA", "GENE_OR_GENE_PRODUCT", 119, 130], ["IgG anti-HA", "PROTEIN", 119, 130]]], ["The seroprevalence of IgG anti-HA is relatively higher in people living with HIV worldwide [41] [42] [43] .Coinfection of HAV with HIVHIV infection has also been reported as a cause of liver damage in patients infected with HIV [40] .", [["liver", "ANATOMY", 185, 190], ["HAV", "DISEASE", 122, 125], ["HIVHIV infection", "DISEASE", 131, 147], ["liver damage", "DISEASE", 185, 197], ["IgG anti-HA", "GENE_OR_GENE_PRODUCT", 22, 33], ["people", "ORGANISM", 58, 64], ["HAV", "ORGANISM", 122, 125], ["liver", "ORGAN", 185, 190], ["patients", "ORGANISM", 201, 209], ["IgG anti-HA", "PROTEIN", 22, 33], ["people", "SPECIES", 58, 64], ["patients", "SPECIES", 201, 209], ["HIV", "SPECIES", 224, 227], ["HIV", "SPECIES", 77, 80], ["HAV", "SPECIES", 122, 125], ["HIVHIV", "SPECIES", 131, 137], ["HIV", "SPECIES", 224, 227], ["The seroprevalence of IgG anti-HA", "TREATMENT", 0, 33], ["Coinfection of HAV", "PROBLEM", 107, 125], ["HIVHIV infection", "PROBLEM", 131, 147], ["liver damage", "PROBLEM", 185, 197], ["HIV", "PROBLEM", 224, 227], ["infection", "OBSERVATION", 138, 147], ["liver", "ANATOMY", 185, 190], ["damage", "OBSERVATION", 191, 197]]], ["Thus, it is as important to consider patients with HIV infection as those with chronic liver disease.", [["liver", "ANATOMY", 87, 92], ["HIV infection", "DISEASE", 51, 64], ["chronic liver disease", "DISEASE", 79, 100], ["patients", "ORGANISM", 37, 45], ["HIV", "ORGANISM", 51, 54], ["liver", "ORGAN", 87, 92], ["patients", "SPECIES", 37, 45], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 51, 54], ["HIV infection", "PROBLEM", 51, 64], ["chronic liver disease", "PROBLEM", 79, 100], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["liver", "ANATOMY", 87, 92], ["disease", "OBSERVATION", 93, 100]]], ["Not only chronic viral hepatitis B or C but also drug-induced liver injury induced by the antiretroviral drugs, NAFLD and ALD, has also been observed in people with HIV [40] .Coinfection of HAV with HIVHAV infection in patients with chronic liver diseases and coinfected with HIV are shown in Table 2 [21, 22, 44, 45] .", [["liver", "ANATOMY", 62, 67], ["liver", "ANATOMY", 241, 246], ["viral hepatitis B", "DISEASE", 17, 34], ["liver injury", "DISEASE", 62, 74], ["NAFLD", "DISEASE", 112, 117], ["ALD", "DISEASE", 122, 125], ["HAV", "DISEASE", 190, 193], ["HIVHAV infection", "DISEASE", 199, 215], ["chronic liver diseases", "DISEASE", 233, 255], ["HIV", "DISEASE", 276, 279], ["liver", "ORGAN", 62, 67], ["people", "ORGANISM", 153, 159], ["HAV", "ORGANISM", 190, 193], ["patients", "ORGANISM", 219, 227], ["liver", "ORGAN", 241, 246], ["people", "SPECIES", 153, 159], ["HIV", "SPECIES", 165, 168], ["patients", "SPECIES", 219, 227], ["HIV", "SPECIES", 276, 279], ["HIV", "SPECIES", 165, 168], ["HAV", "SPECIES", 190, 193], ["HIVHAV", "SPECIES", 199, 205], ["HIV", "SPECIES", 276, 279], ["chronic viral hepatitis B", "PROBLEM", 9, 34], ["liver injury", "PROBLEM", 62, 74], ["the antiretroviral drugs", "TREATMENT", 86, 110], ["NAFLD", "PROBLEM", 112, 117], ["HIV", "PROBLEM", 165, 168], ["HIVHAV infection", "PROBLEM", 199, 215], ["chronic liver diseases", "PROBLEM", 233, 255], ["HIV", "PROBLEM", 276, 279], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["viral", "OBSERVATION_MODIFIER", 17, 22], ["hepatitis", "OBSERVATION", 23, 32], ["liver", "ANATOMY", 62, 67], ["injury", "OBSERVATION", 68, 74], ["infection", "OBSERVATION", 206, 215], ["chronic", "OBSERVATION_MODIFIER", 233, 240], ["liver", "ANATOMY", 241, 246], ["diseases", "OBSERVATION", 247, 255], ["coinfected", "OBSERVATION", 260, 270]]], ["Prolonged HAV infection was also reported in an HIV-seropositive patient [44] .", [["HAV infection", "DISEASE", 10, 23], ["HAV", "ORGANISM", 10, 13], ["patient", "ORGANISM", 65, 72], ["HIV", "SPECIES", 48, 51], ["patient", "SPECIES", 65, 72], ["HAV", "SPECIES", 10, 13], ["HIV", "SPECIES", 48, 51], ["Prolonged HAV infection", "PROBLEM", 0, 23], ["HAV", "OBSERVATION_MODIFIER", 10, 13], ["infection", "OBSERVATION", 14, 23]]], ["It was reported that the recovery of immunity through recently developed anti-HIV therapies may lead to more severe hepatocellular damage in patients with HAV infection [45] .Coinfection of HAV with HIVHAV infects humans through fecal-oral routes, when HAV-contaminated water and food are consumed.", [["hepatocellular", "ANATOMY", 116, 130], ["oral", "ANATOMY", 235, 239], ["hepatocellular damage", "DISEASE", 116, 137], ["HAV infection", "DISEASE", 155, 168], ["HAV", "DISEASE", 190, 193], ["HIVHAV", "CHEMICAL", 199, 205], ["hepatocellular", "CANCER", 116, 130], ["patients", "ORGANISM", 141, 149], ["HAV", "ORGANISM", 155, 158], ["HAV", "ORGANISM", 190, 193], ["humans", "ORGANISM", 214, 220], ["fecal", "ORGANISM_SUBDIVISION", 229, 234], ["oral", "ORGANISM_SUBDIVISION", 235, 239], ["HAV", "ORGANISM", 253, 256], ["patients", "SPECIES", 141, 149], ["humans", "SPECIES", 214, 220], ["HAV", "SPECIES", 155, 158], ["HAV", "SPECIES", 190, 193], ["HIVHAV", "SPECIES", 199, 205], ["humans", "SPECIES", 214, 220], ["HAV", "SPECIES", 253, 256], ["anti-HIV therapies", "TREATMENT", 73, 91], ["more severe hepatocellular damage", "PROBLEM", 104, 137], ["HAV infection", "PROBLEM", 155, 168], ["Coinfection of HAV", "PROBLEM", 175, 193], ["HIVHAV infects humans", "PROBLEM", 199, 220], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["hepatocellular", "OBSERVATION", 116, 130], ["infection", "OBSERVATION", 159, 168], ["fecal", "ANATOMY", 229, 234]]], ["Among men who have sex with men (MSM), HAV is sexually transmitted [46] , and HAV outbreaks have been observed [47] [48] [49] [50] [51] [52] [53] [54] [55] .", [["HAV", "DISEASE", 39, 42], ["HAV outbreaks", "DISEASE", 78, 91], ["[47] [48] [49] [50] [51] [52] [53] [54]", "CHEMICAL", 111, 150], ["men", "ORGANISM", 6, 9], ["men", "ORGANISM", 28, 31], ["HAV", "ORGANISM", 39, 42], ["HAV", "ORGANISM", 78, 81], ["[49] [50] [51] [52] [53] [54", "SIMPLE_CHEMICAL", 121, 149], ["men", "SPECIES", 6, 9], ["men", "SPECIES", 28, 31], ["HAV", "SPECIES", 39, 42], ["HAV", "SPECIES", 78, 81], ["HAV outbreaks", "PROBLEM", 78, 91]]], ["It is noteworthy that acute hepatitis A among MSM is one of the male-dominant diseases, although, in general, no gender difference exists in patients with an HAV infection caused by HAV-contaminated water and food.", [["acute hepatitis A", "DISEASE", 22, 39], ["HAV infection", "DISEASE", 158, 171], ["patients", "ORGANISM", 141, 149], ["HAV", "ORGANISM", 158, 161], ["HAV", "ORGANISM", 182, 185], ["patients", "SPECIES", 141, 149], ["hepatitis A", "SPECIES", 28, 39], ["HAV", "SPECIES", 158, 161], ["HAV", "SPECIES", 182, 185], ["acute hepatitis", "PROBLEM", 22, 37], ["dominant diseases", "PROBLEM", 69, 86], ["an HAV infection", "PROBLEM", 155, 171], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["hepatitis", "OBSERVATION", 28, 37], ["dominant", "OBSERVATION_MODIFIER", 69, 77], ["diseases", "OBSERVATION", 78, 86], ["infection", "OBSERVATION", 162, 171]]], ["While HAV may cause severe hepatitis in people living with HIV, two doses of an HAV vaccine are more effective for them to achieve a sustained HAV seroresponse than a single dose of an HAV vaccine [56] .Coinfection of HAV with HBVSeveral cases of ACLF with HAV as an acute insult and chronic hepatitis or cirrhosis due to HBV, as well as cases with a superinfection of HAV in patients with HBV, have been reported (Table 3 ) [9, 21, [57] [58] [59] [60] [61] [62] .", [["HAV", "DISEASE", 6, 9], ["hepatitis", "DISEASE", 27, 36], ["HIV", "DISEASE", 59, 62], ["HAV", "DISEASE", 218, 221], ["ACLF", "DISEASE", 247, 251], ["HAV", "DISEASE", 257, 260], ["chronic hepatitis", "DISEASE", 284, 301], ["cirrhosis", "DISEASE", 305, 314], ["HAV", "DISEASE", 369, 372], ["HAV", "ORGANISM", 6, 9], ["people", "ORGANISM", 40, 46], ["HAV", "ORGANISM", 80, 83], ["HAV", "ORGANISM", 143, 146], ["HAV", "ORGANISM", 185, 188], ["HAV", "ORGANISM", 218, 221], ["ACLF", "CANCER", 247, 251], ["HAV", "ORGANISM", 257, 260], ["HBV", "ORGANISM", 322, 325], ["HAV", "ORGANISM", 369, 372], ["patients", "ORGANISM", 376, 384], ["HBV", "ORGANISM", 390, 393], ["[57] [58] [59] [60] [61] [62]", "SIMPLE_CHEMICAL", 433, 462], ["people", "SPECIES", 40, 46], ["HIV", "SPECIES", 59, 62], ["patients", "SPECIES", 376, 384], ["HAV", "SPECIES", 6, 9], ["HIV", "SPECIES", 59, 62], ["HAV", "SPECIES", 80, 83], ["HAV", "SPECIES", 143, 146], ["HAV", "SPECIES", 185, 188], ["HAV", "SPECIES", 218, 221], ["HAV", "SPECIES", 257, 260], ["HBV", "SPECIES", 322, 325], ["HAV", "SPECIES", 369, 372], ["HBV", "SPECIES", 390, 393], ["severe hepatitis", "PROBLEM", 20, 36], ["HIV", "PROBLEM", 59, 62], ["an HAV vaccine", "TREATMENT", 77, 91], ["an HAV vaccine", "TREATMENT", 182, 196], ["ACLF", "PROBLEM", 247, 251], ["HAV", "PROBLEM", 257, 260], ["an acute insult", "PROBLEM", 264, 279], ["chronic hepatitis", "PROBLEM", 284, 301], ["cirrhosis", "PROBLEM", 305, 314], ["HBV", "PROBLEM", 322, 325], ["a superinfection of HAV", "PROBLEM", 349, 372], ["HBV", "PROBLEM", 390, 393], ["may cause", "UNCERTAINTY", 10, 19], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["hepatitis", "OBSERVATION", 27, 36], ["ACLF", "OBSERVATION", 247, 251], ["acute", "OBSERVATION_MODIFIER", 267, 272], ["insult", "OBSERVATION", 273, 279], ["chronic", "OBSERVATION_MODIFIER", 284, 291], ["hepatitis", "OBSERVATION", 292, 301], ["cirrhosis", "OBSERVATION", 305, 314], ["HBV", "OBSERVATION", 322, 325], ["superinfection", "OBSERVATION", 351, 365]]], ["A superinfection of HBsAg carriers with HAV seems not to cause more severe conditions [57] .", [["HBsAg", "CHEMICAL", 20, 25], ["HAV", "DISEASE", 40, 43], ["HBsAg", "GENE_OR_GENE_PRODUCT", 20, 25], ["HAV", "ORGANISM", 40, 43], ["HAV", "SPECIES", 40, 43], ["A superinfection of HBsAg carriers", "PROBLEM", 0, 34], ["more severe conditions", "PROBLEM", 63, 85], ["superinfection", "OBSERVATION", 2, 16], ["HBsAg", "OBSERVATION", 20, 25]]], ["Patients with HBV plus HAV infection had a less advanced baseline liver disease and a better prognosis than those with HBV plus hepatitis E virus infection [60] .", [["liver", "ANATOMY", 66, 71], ["HAV infection", "DISEASE", 23, 36], ["liver disease", "DISEASE", 66, 79], ["hepatitis E virus infection", "DISEASE", 128, 155], ["Patients", "ORGANISM", 0, 8], ["HBV", "ORGANISM", 14, 17], ["HAV", "ORGANISM", 23, 26], ["liver", "ORGAN", 66, 71], ["HBV", "ORGANISM", 119, 122], ["hepatitis E virus", "ORGANISM", 128, 145], ["Patients", "SPECIES", 0, 8], ["hepatitis E virus", "SPECIES", 128, 145], ["HBV", "SPECIES", 14, 17], ["HAV", "SPECIES", 23, 26], ["HBV", "SPECIES", 119, 122], ["hepatitis E virus", "SPECIES", 128, 145], ["HBV", "PROBLEM", 14, 17], ["HAV infection", "PROBLEM", 23, 36], ["a less advanced baseline liver disease", "PROBLEM", 41, 79], ["HBV", "PROBLEM", 119, 122], ["hepatitis E virus infection", "PROBLEM", 128, 155], ["HBV", "OBSERVATION", 14, 17], ["infection", "OBSERVATION", 27, 36], ["liver", "ANATOMY", 66, 71], ["disease", "OBSERVATION", 72, 79]]], ["Vento et al. reported that, among 10 patients with an acquired HAV superinfection and chronic HBV infection, one (10%), who had cirrhosis, had marked cholestasis [9] .", [["HAV superinfection", "DISEASE", 63, 81], ["HBV infection", "DISEASE", 94, 107], ["cirrhosis", "DISEASE", 128, 137], ["cholestasis", "DISEASE", 150, 161], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["HBV", "SPECIES", 94, 97], ["an acquired HAV superinfection", "PROBLEM", 51, 81], ["chronic HBV infection", "PROBLEM", 86, 107], ["cirrhosis", "PROBLEM", 128, 137], ["marked cholestasis", "PROBLEM", 143, 161], ["superinfection", "OBSERVATION", 67, 81], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["HBV", "OBSERVATION_MODIFIER", 94, 97], ["infection", "OBSERVATION", 98, 107], ["cirrhosis", "OBSERVATION", 128, 137], ["marked", "OBSERVATION_MODIFIER", 143, 149], ["cholestasis", "OBSERVATION", 150, 161]]], ["Pramoolsinsap et al. evaluated acute superinfection with HAV in 20 HBV asymptomatic carriers and fulminant hepatitis or submassive hepatitis in 11 (55%) of 20 HBsAg carriers [63] .", [["superinfection", "DISEASE", 37, 51], ["HAV", "DISEASE", 57, 60], ["fulminant hepatitis", "DISEASE", 97, 116], ["submassive hepatitis", "DISEASE", 120, 140], ["HBsAg", "CHEMICAL", 159, 164], ["HAV", "ORGANISM", 57, 60], ["HBsAg", "ORGANISM", 159, 164], ["HAV", "SPECIES", 57, 60], ["HBV", "SPECIES", 67, 70], ["acute superinfection", "PROBLEM", 31, 51], ["HAV", "PROBLEM", 57, 60], ["20 HBV asymptomatic carriers", "PROBLEM", 64, 92], ["fulminant hepatitis", "PROBLEM", 97, 116], ["submassive hepatitis", "PROBLEM", 120, 140], ["HBsAg carriers", "TEST", 159, 173], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["superinfection", "OBSERVATION", 37, 51], ["fulminant", "OBSERVATION_MODIFIER", 97, 106], ["hepatitis", "OBSERVATION", 107, 116], ["submassive", "OBSERVATION_MODIFIER", 120, 130], ["hepatitis", "OBSERVATION", 131, 140]]], ["A superinfection of HAV in patients with HBV occasionally leads to critical conditions in HBV carriers with or without cirrhosis, although patients with advanced fibrosis or cirrhosis are more susceptible to severe conditions [9, 21, [57] [58] [59] [60] [61] [62] [63] .Coinfection of HAV with HBVA total of 310,746 cases with acute hepatitis A were observed during the Shanghai hepatitis A epidemic [58] .", [["HAV", "DISEASE", 20, 23], ["cirrhosis", "DISEASE", 119, 128], ["fibrosis", "DISEASE", 162, 170], ["cirrhosis", "DISEASE", 174, 183], ["HAV", "DISEASE", 285, 288], ["acute hepatitis A", "DISEASE", 327, 344], ["hepatitis A", "DISEASE", 379, 390], ["9, 21, [57] [58] [59] [60] [61] [62]", "CHEMICAL", 227, 263], ["HAV", "ORGANISM", 20, 23], ["patients", "ORGANISM", 27, 35], ["HBV", "ORGANISM", 41, 44], ["HBV", "ORGANISM", 90, 93], ["patients", "ORGANISM", 139, 147], ["HAV", "ORGANISM", 285, 288], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 139, 147], ["HAV", "SPECIES", 20, 23], ["HBV", "SPECIES", 41, 44], ["HBV", "SPECIES", 90, 93], ["HAV", "SPECIES", 285, 288], ["Shanghai hepatitis A", "SPECIES", 370, 390], ["A superinfection of HAV", "PROBLEM", 0, 23], ["HBV", "PROBLEM", 41, 44], ["critical conditions", "PROBLEM", 67, 86], ["HBV carriers", "PROBLEM", 90, 102], ["cirrhosis", "PROBLEM", 119, 128], ["advanced fibrosis", "PROBLEM", 153, 170], ["cirrhosis", "PROBLEM", 174, 183], ["severe conditions", "PROBLEM", 208, 225], ["Coinfection of HAV", "PROBLEM", 270, 288], ["acute hepatitis A", "PROBLEM", 327, 344], ["superinfection", "OBSERVATION", 2, 16], ["advanced", "OBSERVATION_MODIFIER", 153, 161], ["fibrosis", "OBSERVATION", 162, 170], ["cirrhosis", "OBSERVATION", 174, 183], ["acute", "OBSERVATION_MODIFIER", 327, 332], ["hepatitis", "OBSERVATION", 333, 342]]], ["A total of 47 fatal cases (0.015%) were reported.", [["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Fatality rates were 0.05% (15/27,346) and 0.009% (25/283,400) in patients with or without HBV infection, respectively.", [["HBV infection", "DISEASE", 90, 103], ["patients", "ORGANISM", 65, 73], ["HBV", "ORGANISM", 90, 93], ["patients", "SPECIES", 65, 73], ["HBV", "SPECIES", 90, 93], ["Fatality rates", "TEST", 0, 14], ["HBV infection", "PROBLEM", 90, 103], ["infection", "OBSERVATION", 94, 103]]], ["It is worth noting that there were 5.6-fold greater fatality rates in patients with HBV infection than in those without [58] .", [["HBV infection", "DISEASE", 84, 97], ["patients", "ORGANISM", 70, 78], ["HBV", "ORGANISM", 84, 87], ["patients", "SPECIES", 70, 78], ["HBV", "SPECIES", 84, 87], ["5.6-fold greater fatality rates", "PROBLEM", 35, 66], ["HBV infection", "PROBLEM", 84, 97], ["infection", "OBSERVATION", 88, 97]]], ["Cooksley et al. reported that patients infected with HBV who have raised ALT levels and high HBV levels have a higher risk of liver failure following HAV superinfection [58] .", [["liver", "ANATOMY", 126, 131], ["liver failure", "DISEASE", 126, 139], ["HAV superinfection", "DISEASE", 150, 168], ["patients", "ORGANISM", 30, 38], ["HBV", "ORGANISM", 53, 56], ["ALT", "GENE_OR_GENE_PRODUCT", 73, 76], ["HBV", "ORGANISM", 93, 96], ["liver", "ORGAN", 126, 131], ["HAV", "ORGANISM", 150, 153], ["ALT", "PROTEIN", 73, 76], ["patients", "SPECIES", 30, 38], ["HBV", "SPECIES", 53, 56], ["HBV", "SPECIES", 93, 96], ["HAV", "SPECIES", 150, 153], ["HBV", "PROBLEM", 53, 56], ["ALT levels", "TEST", 73, 83], ["high HBV levels", "PROBLEM", 88, 103], ["liver failure", "PROBLEM", 126, 139], ["HAV superinfection", "PROBLEM", 150, 168], ["infected", "OBSERVATION", 39, 47], ["liver", "ANATOMY", 126, 131], ["failure", "OBSERVATION", 132, 139], ["superinfection", "OBSERVATION", 154, 168]]], ["HAV vaccination seems to be effective in preventing liver failure associated with HAV in patients with or without HBV infection [64] [65] [66] [67] .", [["liver", "ANATOMY", 52, 57], ["liver failure", "DISEASE", 52, 65], ["HAV", "DISEASE", 82, 85], ["HBV infection", "DISEASE", 114, 127], ["HAV", "ORGANISM", 0, 3], ["liver", "ORGAN", 52, 57], ["HAV", "ORGANISM", 82, 85], ["patients", "ORGANISM", 89, 97], ["HBV", "ORGANISM", 114, 117], ["patients", "SPECIES", 89, 97], ["HAV", "SPECIES", 0, 3], ["HAV", "SPECIES", 82, 85], ["HBV", "SPECIES", 114, 117], ["HAV vaccination", "TREATMENT", 0, 15], ["liver failure", "PROBLEM", 52, 65], ["HAV", "PROBLEM", 82, 85], ["HBV infection", "PROBLEM", 114, 127], ["liver", "ANATOMY", 52, 57], ["failure", "OBSERVATION", 58, 65]]], ["However, HAV vaccination may not be necessary in the case of countries in which HAV is endemic, such as India [68, 69] .Coinfection of HAV with HBVIt has been reported that the transient suppression of HBV replication and the disappearance of HBV DNA with the seroconversion of HBeAg were observed in several cases of double infections with HAV and HBV carries [57] .", [["HAV", "DISEASE", 80, 83], ["HAV", "DISEASE", 135, 138], ["HBeAg", "CHEMICAL", 278, 283], ["infections", "DISEASE", 325, 335], ["HAV", "DISEASE", 341, 344], ["HAV", "ORGANISM", 9, 12], ["HAV", "ORGANISM", 80, 83], ["HAV", "ORGANISM", 135, 138], ["HBV", "ORGANISM", 202, 205], ["HBV", "ORGANISM", 243, 246], ["DNA", "CELLULAR_COMPONENT", 247, 250], ["HBeAg", "GENE_OR_GENE_PRODUCT", 278, 283], ["HAV", "ORGANISM", 341, 344], ["HBV", "ORGANISM", 349, 352], ["HAV", "SPECIES", 9, 12], ["HAV", "SPECIES", 80, 83], ["HAV", "SPECIES", 135, 138], ["HBV", "SPECIES", 202, 205], ["HBV", "SPECIES", 243, 246], ["HAV", "SPECIES", 341, 344], ["HBV", "SPECIES", 349, 352], ["HAV vaccination", "TREATMENT", 9, 24], ["Coinfection of HAV", "PROBLEM", 120, 138], ["HBV replication", "TREATMENT", 202, 217], ["HBV DNA", "PROBLEM", 243, 250], ["HBeAg", "PROBLEM", 278, 283], ["double infections", "PROBLEM", 318, 335], ["endemic", "OBSERVATION_MODIFIER", 87, 94], ["HBV", "OBSERVATION", 202, 205], ["infections", "OBSERVATION", 325, 335]]], ["Beisel et al. also reported that an HBsAg carrier case with HAV superinfection presented the seroconversion of HBsAg, suggesting that unspecific immunological responses to HAV could lead to a functional cure of HBV [62] .", [["HBsAg", "CHEMICAL", 36, 41], ["HAV superinfection", "DISEASE", 60, 78], ["HBsAg", "CHEMICAL", 111, 116], ["HAV", "DISEASE", 172, 175], ["HBsAg", "GENE_OR_GENE_PRODUCT", 36, 41], ["HAV", "ORGANISM", 60, 63], ["HBsAg", "GENE_OR_GENE_PRODUCT", 111, 116], ["HAV", "ORGANISM", 172, 175], ["HBV", "ORGANISM", 211, 214], ["HBsAg", "PROTEIN", 111, 116], ["HAV", "SPECIES", 60, 63], ["HAV", "SPECIES", 172, 175], ["HBV", "SPECIES", 211, 214], ["an HBsAg carrier case", "PROBLEM", 33, 54], ["HAV superinfection", "PROBLEM", 60, 78], ["HBsAg", "PROBLEM", 111, 116], ["unspecific immunological responses to HAV", "PROBLEM", 134, 175], ["HBV", "PROBLEM", 211, 214], ["superinfection", "OBSERVATION", 64, 78]]], ["It was reported that the sharp peak in interferon-gamma production induced by a superinfection of HAV may lead to the suppression of HBV replication in patients with chronic hepatitis B [70] .", [["HAV", "DISEASE", 98, 101], ["chronic hepatitis B", "DISEASE", 166, 185], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 39, 55], ["HAV", "ORGANISM", 98, 101], ["HBV", "ORGANISM", 133, 136], ["patients", "ORGANISM", 152, 160], ["interferon", "PROTEIN", 39, 49], ["patients", "SPECIES", 152, 160], ["HAV", "SPECIES", 98, 101], ["HBV", "SPECIES", 133, 136], ["the sharp peak in interferon", "PROBLEM", 21, 49], ["a superinfection of HAV", "PROBLEM", 78, 101], ["HBV replication", "TREATMENT", 133, 148], ["chronic hepatitis B", "PROBLEM", 166, 185], ["sharp", "OBSERVATION_MODIFIER", 25, 30], ["peak", "OBSERVATION_MODIFIER", 31, 35], ["superinfection", "OBSERVATION", 80, 94], ["HBV", "OBSERVATION", 133, 136], ["chronic", "OBSERVATION_MODIFIER", 166, 173], ["hepatitis", "OBSERVATION", 174, 183]]], ["This peak in interferon-gamma production occurred just before the rise in serum transaminase activity, resulting in a decrease in HBV DNA and HBeAg.Coinfection of HAV with HBVBerthillon et al. infected the human hepatoma cell line, PLC/PRF/5 [71] , which integrates HBV DNA and produces HBsAg, with the HAV CF53 strain [72] .", [["serum", "ANATOMY", 74, 79], ["hepatoma cell line", "ANATOMY", 212, 230], ["HBeAg", "CHEMICAL", 142, 147], ["HAV", "DISEASE", 163, 166], ["HBsAg", "CHEMICAL", 287, 292], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 13, 29], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["transaminase", "SIMPLE_CHEMICAL", 80, 92], ["HBV", "ORGANISM", 130, 133], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["HBeAg", "GENE_OR_GENE_PRODUCT", 142, 147], ["HAV", "ORGANISM", 163, 166], ["human", "ORGANISM", 206, 211], ["hepatoma cell line", "CELL", 212, 230], ["PLC", "CELL", 232, 235], ["5", "GENE_OR_GENE_PRODUCT", 240, 241], ["HBV", "ORGANISM", 266, 269], ["DNA", "CELLULAR_COMPONENT", 270, 273], ["HBsAg", "GENE_OR_GENE_PRODUCT", 287, 292], ["HAV CF53", "ORGANISM", 303, 311], ["interferon", "PROTEIN", 13, 23], ["human hepatoma cell line", "CELL_LINE", 206, 230], ["PLC", "PROTEIN", 232, 235], ["PRF", "PROTEIN", 236, 239], ["HBV DNA", "DNA", 266, 273], ["HBsAg", "PROTEIN", 287, 292], ["human", "SPECIES", 206, 211], ["HBV", "SPECIES", 130, 133], ["HAV", "SPECIES", 163, 166], ["human", "SPECIES", 206, 211], ["HBV", "SPECIES", 266, 269], ["HAV CF53 strain", "SPECIES", 303, 318], ["interferon", "TREATMENT", 13, 23], ["serum transaminase activity", "TEST", 74, 101], ["a decrease in HBV DNA", "PROBLEM", 116, 137], ["HBeAg", "PROBLEM", 142, 147], ["HBVBerthillon et al", "TREATMENT", 172, 191], ["infected the human hepatoma cell line", "PROBLEM", 193, 230], ["PLC/PRF", "TREATMENT", 232, 239], ["HBV DNA", "PROBLEM", 266, 273], ["HBsAg", "TEST", 287, 292], ["the HAV CF53 strain", "PROBLEM", 299, 318], ["gamma production", "OBSERVATION", 24, 40], ["decrease", "OBSERVATION_MODIFIER", 118, 126], ["HBV DNA", "OBSERVATION", 130, 137], ["HBeAg", "OBSERVATION", 142, 147], ["human", "ANATOMY", 206, 211], ["hepatoma cell line", "OBSERVATION", 212, 230], ["HBsAg", "OBSERVATION", 287, 292]]], ["The inhibition of HBsAg production in PLC/PRF/5 cells infected with HAV was observed, compared with those without HAV infection, demonstrating that HAV interferes with the expression of HBsAg from hepatocytes harboring integrated HBV DNA sequences [71] .", [["PLC/PRF/5 cells", "ANATOMY", 38, 53], ["hepatocytes", "ANATOMY", 197, 208], ["HBsAg", "CHEMICAL", 18, 23], ["HAV infection", "DISEASE", 114, 127], ["HBsAg", "CHEMICAL", 186, 191], ["HBsAg", "GENE_OR_GENE_PRODUCT", 18, 23], ["PLC/PRF/5 cells", "CELL", 38, 53], ["HAV", "ORGANISM", 68, 71], ["HAV", "ORGANISM", 114, 117], ["HAV", "ORGANISM", 148, 151], ["HBsAg", "GENE_OR_GENE_PRODUCT", 186, 191], ["hepatocytes", "CELL", 197, 208], ["HBV", "ORGANISM", 230, 233], ["DNA", "CELLULAR_COMPONENT", 234, 237], ["HBsAg", "PROTEIN", 18, 23], ["PLC/PRF/5 cells", "CELL_LINE", 38, 53], ["HBsAg", "PROTEIN", 186, 191], ["hepatocytes", "CELL_TYPE", 197, 208], ["HBV DNA sequences", "DNA", 230, 247], ["HAV", "SPECIES", 68, 71], ["HAV", "SPECIES", 114, 117], ["HAV", "SPECIES", 148, 151], ["HBV", "SPECIES", 230, 233], ["HBsAg production", "PROBLEM", 18, 34], ["PLC/PRF/5 cells", "TREATMENT", 38, 53], ["HAV", "PROBLEM", 68, 71], ["HAV infection", "PROBLEM", 114, 127], ["HBsAg from hepatocytes harboring integrated HBV DNA sequences", "PROBLEM", 186, 247], ["HBsAg", "OBSERVATION", 18, 23], ["infection", "OBSERVATION", 118, 127]]], ["We also infected HepG2.2.15, which produces HBV virion or HepG2 cells, with the HAV HA11-1299 strain.", [["HepG2.2.15", "ANATOMY", 17, 27], ["virion", "ANATOMY", 48, 54], ["HepG2 cells", "ANATOMY", 58, 69], ["HA11-1299", "CHEMICAL", 84, 93], ["HepG2.2.15", "CELL", 17, 27], ["HBV", "ORGANISM", 44, 47], ["HepG2 cells", "CELL", 58, 69], ["HAV HA11-1299 strain", "ORGANISM", 80, 100], ["HepG2.2.15", "CELL_LINE", 17, 27], ["HepG2 cells", "CELL_LINE", 58, 69], ["HBV", "SPECIES", 44, 47], ["HAV HA11-1299", "SPECIES", 80, 93], ["infected HepG2", "TEST", 8, 22], ["HBV virion or HepG2 cells", "PROBLEM", 44, 69], ["the HAV HA11", "TEST", 76, 88], ["strain", "PROBLEM", 94, 100], ["HepG2 cells", "OBSERVATION", 58, 69]]], ["We demonstrated that the HAV replication is similar between HepG2.2.15 and HepG2, 96 h after HAV infection.", [["HepG2", "ANATOMY", 60, 65], ["HepG2", "ANATOMY", 75, 80], ["HAV infection", "DISEASE", 93, 106], ["HAV", "ORGANISM", 25, 28], ["HepG2", "CELL", 60, 65], ["HepG2", "CELL", 75, 80], ["HAV", "ORGANISM", 93, 96], ["HepG2", "CELL_LINE", 60, 65], ["HepG2", "CELL_LINE", 75, 80], ["HAV", "SPECIES", 25, 28], ["HAV", "SPECIES", 93, 96], ["the HAV replication", "PROBLEM", 21, 40], ["HAV infection", "PROBLEM", 93, 106], ["HAV replication", "OBSERVATION", 25, 40], ["HepG2", "ANATOMY", 75, 80], ["infection", "OBSERVATION", 97, 106]]], ["However, HBV replication is inhibited in HAV-infected HepG2.2.15, compared to HepG2.2.15 without HAV infection [73] .Coinfection of HAV with HBVWe also observed that the replication of both HAV and HBV is suppressed in human hepatocyte PXB cells superinfected with HAV and HBV, compared to those mono-infected with HAV or HBV [73] .", [["HepG2.2.15", "ANATOMY", 54, 64], ["HepG2", "ANATOMY", 78, 83], ["hepatocyte PXB cells", "ANATOMY", 225, 245], ["HAV infection", "DISEASE", 97, 110], ["HBV", "ORGANISM", 9, 12], ["HAV", "ORGANISM", 41, 44], ["HepG2.2.15", "CELL", 54, 64], ["HepG2", "CELL", 78, 83], ["HAV", "ORGANISM", 97, 100], ["HAV", "ORGANISM", 132, 135], ["HAV", "ORGANISM", 190, 193], ["HBV", "ORGANISM", 198, 201], ["human", "ORGANISM", 219, 224], ["hepatocyte PXB cells", "CELL", 225, 245], ["HAV", "ORGANISM", 265, 268], ["HBV", "ORGANISM", 273, 276], ["HAV", "ORGANISM", 315, 318], ["HBV", "ORGANISM", 322, 325], ["HepG2.2.15", "CELL_LINE", 54, 64], ["HepG2", "CELL_LINE", 78, 83], ["human hepatocyte PXB cells", "CELL_LINE", 219, 245], ["human", "SPECIES", 219, 224], ["HBV", "SPECIES", 9, 12], ["HAV", "SPECIES", 41, 44], ["HAV", "SPECIES", 97, 100], ["HAV", "SPECIES", 132, 135], ["HAV", "SPECIES", 190, 193], ["HBV", "SPECIES", 198, 201], ["human", "SPECIES", 219, 224], ["HAV", "SPECIES", 265, 268], ["HBV", "SPECIES", 273, 276], ["HAV", "SPECIES", 315, 318], ["HBV", "SPECIES", 322, 325], ["HBV replication", "PROBLEM", 9, 24], ["infected HepG2", "PROBLEM", 45, 59], ["HAV infection", "PROBLEM", 97, 110], ["Coinfection of HAV", "PROBLEM", 117, 135], ["both HAV", "PROBLEM", 185, 193], ["HBV", "PROBLEM", 198, 201], ["HAV", "PROBLEM", 265, 268], ["HBV", "PROBLEM", 273, 276], ["HBV", "PROBLEM", 322, 325], ["HBV", "OBSERVATION", 9, 12], ["infected", "OBSERVATION_MODIFIER", 45, 53], ["HepG2", "ANATOMY", 54, 59], ["HepG2", "ANATOMY", 78, 83], ["without", "UNCERTAINTY", 89, 96], ["HAV", "OBSERVATION_MODIFIER", 97, 100], ["infection", "OBSERVATION", 101, 110]]], ["Thus, HAV infection seems to inhibit HBV replication.", [["HAV infection", "DISEASE", 6, 19], ["HAV", "ORGANISM", 6, 9], ["HBV", "ORGANISM", 37, 40], ["HAV", "SPECIES", 6, 9], ["HBV", "SPECIES", 37, 40], ["HAV infection", "PROBLEM", 6, 19], ["HBV replication", "TREATMENT", 37, 52], ["infection", "OBSERVATION", 10, 19]]], ["Further studies are required to support this point, although it indicates that the existence of cirrhosis or advanced liver fibrosis should cause severe hepatitis in the superinfection of HAV in patients with HBV.Coinfection of HAV with HCVIn general, HCV is a rare cause of fulminant hepatitis or acute liver failure [74, 75] .", [["liver", "ANATOMY", 118, 123], ["liver", "ANATOMY", 304, 309], ["cirrhosis", "DISEASE", 96, 105], ["liver fibrosis", "DISEASE", 118, 132], ["hepatitis", "DISEASE", 153, 162], ["superinfection", "DISEASE", 170, 184], ["HAV", "DISEASE", 188, 191], ["HAV", "DISEASE", 228, 231], ["HCV", "DISEASE", 252, 255], ["hepatitis", "DISEASE", 285, 294], ["acute liver failure", "DISEASE", 298, 317], ["liver", "ORGAN", 118, 123], ["HAV", "ORGANISM", 188, 191], ["patients", "ORGANISM", 195, 203], ["HBV", "ORGANISM", 209, 212], ["HAV", "ORGANISM", 228, 231], ["HCV", "ORGANISM", 252, 255], ["liver", "ORGAN", 304, 309], ["patients", "SPECIES", 195, 203], ["HAV", "SPECIES", 188, 191], ["HBV", "SPECIES", 209, 212], ["HAV", "SPECIES", 228, 231], ["HCV", "SPECIES", 252, 255], ["Further studies", "TEST", 0, 15], ["cirrhosis", "PROBLEM", 96, 105], ["advanced liver fibrosis", "PROBLEM", 109, 132], ["severe hepatitis", "PROBLEM", 146, 162], ["the superinfection of HAV", "PROBLEM", 166, 191], ["HBV", "PROBLEM", 209, 212], ["HCV", "PROBLEM", 252, 255], ["fulminant hepatitis", "PROBLEM", 275, 294], ["acute liver failure", "PROBLEM", 298, 317], ["cirrhosis", "OBSERVATION", 96, 105], ["advanced", "OBSERVATION_MODIFIER", 109, 117], ["liver", "ANATOMY", 118, 123], ["fibrosis", "OBSERVATION", 124, 132], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["hepatitis", "OBSERVATION", 153, 162], ["superinfection", "OBSERVATION", 170, 184], ["fulminant", "OBSERVATION_MODIFIER", 275, 284], ["hepatitis", "OBSERVATION", 285, 294], ["acute", "OBSERVATION_MODIFIER", 298, 303], ["liver", "ANATOMY", 304, 309], ["failure", "OBSERVATION", 310, 317]]], ["We did not identify any cases of fulminant hepatitis with HCV RNA in 82 cases of fulminant hepatitis and late-onset hepatic failure from 1986 to 2001, which were examined at Chiba University School of Medicine, Japan [74] .", [["hepatic", "ANATOMY", 116, 123], ["hepatitis", "DISEASE", 43, 52], ["fulminant hepatitis", "DISEASE", 81, 100], ["hepatic failure", "DISEASE", 116, 131], ["HCV", "ORGANISM", 58, 61], ["hepatic", "ORGAN", 116, 123], ["HCV RNA", "RNA", 58, 65], ["HCV", "SPECIES", 58, 61], ["fulminant hepatitis", "PROBLEM", 33, 52], ["HCV RNA", "PROBLEM", 58, 65], ["fulminant hepatitis", "PROBLEM", 81, 100], ["late-onset hepatic failure", "PROBLEM", 105, 131], ["fulminant", "OBSERVATION_MODIFIER", 33, 42], ["hepatitis", "OBSERVATION", 43, 52], ["fulminant", "OBSERVATION_MODIFIER", 81, 90], ["hepatitis", "OBSERVATION", 91, 100], ["late", "OBSERVATION_MODIFIER", 105, 109], ["-onset", "OBSERVATION_MODIFIER", 109, 115], ["hepatic", "ANATOMY", 116, 123], ["failure", "OBSERVATION", 124, 131]]], ["There were several reports that HAV infection in patients with chronic hepatitis C is associated with increased mortality [9, 21, 22, 76] , although several contrary opinions exist [59, 77] ( Table 4 ).", [["HAV infection", "DISEASE", 32, 45], ["chronic hepatitis C", "DISEASE", 63, 82], ["HAV", "ORGANISM", 32, 35], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["HAV", "SPECIES", 32, 35], ["HAV infection", "PROBLEM", 32, 45], ["chronic hepatitis C", "PROBLEM", 63, 82], ["increased mortality", "PROBLEM", 102, 121], ["HAV", "OBSERVATION_MODIFIER", 32, 35], ["infection", "OBSERVATION", 36, 45], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["hepatitis", "OBSERVATION", 71, 80]]], ["Acute-on-chronic liver failure (ACLF) and/or the superinfection of hepatitis virus (HAV) in patients with hepatitis C virus (HCV).", [["liver", "ANATOMY", 17, 22], ["Acute-on-chronic liver failure", "DISEASE", 0, 30], ["ACLF", "DISEASE", 32, 36], ["superinfection of hepatitis virus", "DISEASE", 49, 82], ["HAV", "DISEASE", 84, 87], ["hepatitis C", "DISEASE", 106, 117], ["liver", "ORGAN", 17, 22], ["hepatitis virus", "ORGANISM", 67, 82], ["HAV", "ORGANISM", 84, 87], ["patients", "ORGANISM", 92, 100], ["hepatitis C virus", "ORGANISM", 106, 123], ["HCV", "ORGANISM", 125, 128], ["hepatitis virus", "SPECIES", 67, 82], ["patients", "SPECIES", 92, 100], ["hepatitis C virus", "SPECIES", 106, 123], ["hepatitis virus", "SPECIES", 67, 82], ["HAV", "SPECIES", 84, 87], ["hepatitis C virus", "SPECIES", 106, 123], ["HCV", "SPECIES", 125, 128], ["Acute-on-chronic liver failure", "PROBLEM", 0, 30], ["ACLF)", "PROBLEM", 32, 37], ["hepatitis virus", "PROBLEM", 67, 82], ["hepatitis C virus (HCV)", "PROBLEM", 106, 129], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["liver", "ANATOMY", 17, 22], ["failure", "OBSERVATION", 23, 30], ["ACLF", "OBSERVATION", 32, 36], ["superinfection", "OBSERVATION", 49, 63], ["hepatitis", "OBSERVATION", 67, 76], ["hepatitis", "OBSERVATION", 106, 115]]], ["Vento et al. reported that, among 17 patients with an acquired HAV superinfection with chronic hepatitis C, seven patients (41.2%) possessed fulminant hepatic failure, and six (85.7%) of those seven patients died [9] .", [["hepatic", "ANATOMY", 151, 158], ["HAV superinfection", "DISEASE", 63, 81], ["chronic hepatitis C", "DISEASE", 87, 106], ["fulminant hepatic failure", "DISEASE", 141, 166], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 114, 122], ["hepatic", "ORGAN", 151, 158], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 199, 207], ["an acquired HAV superinfection", "PROBLEM", 51, 81], ["chronic hepatitis C", "PROBLEM", 87, 106], ["fulminant hepatic failure", "PROBLEM", 141, 166], ["superinfection", "OBSERVATION", 67, 81], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["hepatitis", "OBSERVATION", 95, 104], ["fulminant", "OBSERVATION_MODIFIER", 141, 150], ["hepatic", "ANATOMY", 151, 158], ["failure", "OBSERVATION", 159, 166]]], ["It is interesting to note that antinuclear antibodies, anti-smooth-muscle antibodies, and/or anti-asialoglycoprotein receptor antibodies were detected in five of seven patients with fulminant hepatitis (71.4%) [9] .", [["fulminant hepatitis", "DISEASE", 182, 201], ["antinuclear antibodies", "GENE_OR_GENE_PRODUCT", 31, 53], ["anti-smooth-muscle antibodies", "GENE_OR_GENE_PRODUCT", 55, 84], ["anti-asialoglycoprotein receptor antibodies", "GENE_OR_GENE_PRODUCT", 93, 136], ["patients", "ORGANISM", 168, 176], ["antinuclear antibodies", "PROTEIN", 31, 53], ["anti-smooth-muscle antibodies", "PROTEIN", 55, 84], ["anti-asialoglycoprotein receptor antibodies", "PROTEIN", 93, 136], ["patients", "SPECIES", 168, 176], ["antinuclear antibodies", "TEST", 31, 53], ["anti-smooth-muscle antibodies", "TEST", 55, 84], ["anti-asialoglycoprotein receptor antibodies", "TEST", 93, 136], ["fulminant hepatitis", "PROBLEM", 182, 201], ["muscle", "ANATOMY", 67, 73], ["fulminant", "OBSERVATION_MODIFIER", 182, 191], ["hepatitis", "OBSERVATION", 192, 201]]], ["Moreover, six of these seven patients possessed chronic active hepatitis, and one patient recovered from fulminant hepatitis and was treated with methylprednisolone [9] .", [["chronic active hepatitis", "DISEASE", 48, 72], ["fulminant hepatitis", "DISEASE", 105, 124], ["methylprednisolone", "CHEMICAL", 146, 164], ["methylprednisolone", "CHEMICAL", 146, 164], ["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 82, 89], ["methylprednisolone", "SIMPLE_CHEMICAL", 146, 164], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 82, 89], ["chronic active hepatitis", "PROBLEM", 48, 72], ["fulminant hepatitis", "PROBLEM", 105, 124], ["methylprednisolone", "TREATMENT", 146, 164], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["active", "OBSERVATION_MODIFIER", 56, 62], ["hepatitis", "OBSERVATION", 63, 72], ["fulminant", "OBSERVATION_MODIFIER", 105, 114], ["hepatitis", "OBSERVATION", 115, 124]]], ["There are some reports indicating a higher fatality rate of HAV superinfection in patients with chronic HCV infection, not considering those with or without cirrhosis [21] .", [["HAV superinfection", "DISEASE", 60, 78], ["chronic HCV infection", "DISEASE", 96, 117], ["cirrhosis", "DISEASE", 157, 166], ["HAV", "ORGANISM", 60, 63], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["HAV", "SPECIES", 60, 63], ["HCV", "SPECIES", 104, 107], ["HAV superinfection", "PROBLEM", 60, 78], ["chronic HCV infection", "PROBLEM", 96, 117], ["cirrhosis", "PROBLEM", 157, 166], ["higher", "OBSERVATION_MODIFIER", 36, 42], ["HAV", "OBSERVATION_MODIFIER", 60, 63], ["superinfection", "OBSERVATION", 64, 78], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["HCV", "OBSERVATION_MODIFIER", 104, 107], ["infection", "OBSERVATION", 108, 117], ["cirrhosis", "OBSERVATION", 157, 166]]], ["However, it is unclear whether the high fatality rates were due to severe underlying liver damage or not [21, 22] .Authors (Year) [ReferencesIt was reported that the superinfection of HAV is associated with decreased HCV replication, which may lead to a clearance of HCV [77, 78] .", [["liver", "ANATOMY", 85, 90], ["liver damage", "DISEASE", 85, 97], ["superinfection", "DISEASE", 166, 180], ["HAV", "DISEASE", 184, 187], ["liver", "ORGAN", 85, 90], ["HAV", "ORGANISM", 184, 187], ["HCV", "ORGANISM", 217, 220], ["HCV", "ORGANISM", 267, 270], ["HAV", "SPECIES", 184, 187], ["HCV", "SPECIES", 217, 220], ["HCV", "SPECIES", 267, 270], ["the high fatality rates", "PROBLEM", 31, 54], ["severe underlying liver damage", "PROBLEM", 67, 97], ["the superinfection of HAV", "PROBLEM", 162, 187], ["decreased HCV replication", "PROBLEM", 207, 232], ["HCV", "PROBLEM", 267, 270], ["liver", "ANATOMY", 85, 90], ["damage", "OBSERVATION", 91, 97], ["superinfection", "OBSERVATION", 166, 180], ["HAV", "OBSERVATION", 184, 187], ["HCV", "OBSERVATION", 217, 220]]], ["Esser-Nobis et al. found that Huh7-Lunet cells supported HAV and HCV replication with similar efficacy and limited interference with each other [79] .Authors (Year) [ReferencesIn fact, as several severe hepatitis A cases have been observed in patients with chronic HCV infection, clinicians should pay attention to HAV infection in HCV-infected individuals [80] .", [["Huh7-Lunet cells", "ANATOMY", 30, 46], ["hepatitis A", "DISEASE", 203, 214], ["chronic HCV infection", "DISEASE", 257, 278], ["HAV infection", "DISEASE", 315, 328], ["HCV-infected", "DISEASE", 332, 344], ["Huh7-Lunet cells", "CELL", 30, 46], ["HAV", "ORGANISM", 57, 60], ["HCV", "ORGANISM", 65, 68], ["patients", "ORGANISM", 243, 251], ["HAV", "ORGANISM", 315, 318], ["HCV", "ORGANISM", 332, 335], ["Huh7", "CELL_LINE", 30, 34], ["Lunet cells", "CELL_LINE", 35, 46], ["patients", "SPECIES", 243, 251], ["HAV", "SPECIES", 57, 60], ["HCV", "SPECIES", 65, 68], ["HCV", "SPECIES", 265, 268], ["HAV", "SPECIES", 315, 318], ["HCV", "SPECIES", 332, 335], ["Huh7-Lunet cells", "TREATMENT", 30, 46], ["HAV", "PROBLEM", 57, 60], ["HCV replication", "TREATMENT", 65, 80], ["several severe hepatitis A cases", "PROBLEM", 188, 220], ["chronic HCV infection", "PROBLEM", 257, 278], ["HAV infection", "PROBLEM", 315, 328], ["HCV", "PROBLEM", 332, 335], ["infected individuals", "PROBLEM", 336, 356], ["Huh7", "OBSERVATION", 30, 34], ["Lunet cells", "OBSERVATION", 35, 46], ["HCV replication", "OBSERVATION", 65, 80], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["hepatitis", "OBSERVATION", 203, 212], ["chronic", "OBSERVATION_MODIFIER", 257, 264], ["HCV", "OBSERVATION", 265, 268], ["infection", "OBSERVATION", 319, 328]]], ["At present, although direct-acting antivirals against HCV can lead to a higher sustained virological response with less adverse events, no effective HCV vaccines are available.", [["HCV", "DISEASE", 54, 57], ["HCV", "ORGANISM", 54, 57], ["HCV", "ORGANISM", 149, 152], ["HCV", "SPECIES", 54, 57], ["HCV", "SPECIES", 149, 152], ["direct-acting antivirals", "TREATMENT", 21, 45], ["HCV", "PROBLEM", 54, 57], ["a higher sustained virological response", "PROBLEM", 70, 109], ["less adverse events", "PROBLEM", 115, 134], ["effective HCV vaccines", "TREATMENT", 139, 161]]], ["Thus, HAV vaccination should be considered for HCV-infected patients, especially those with cirrhosis or advanced fibrosis [81] [82] [83] [84] [85] [86] [87] [88] .HAV and Other Chronic Liver DiseasesIt was reported that a prospective study of 31 children in the age group of 1-16 years, who fulfilled the criteria for ACLF of the Asian Pacific Association for the Study of the Liver (APASL) 2008 consensus, found 13 ACLF cases of HAV as an acute insult and autoimmune hepatitis or Wilson disease as causes of chronic liver disease [15] .", [["Liver", "ANATOMY", 186, 191], ["Liver", "ANATOMY", 378, 383], ["liver", "ANATOMY", 518, 523], ["HCV-infected", "DISEASE", 47, 59], ["cirrhosis", "DISEASE", 92, 101], ["fibrosis", "DISEASE", 114, 122], ["HAV", "DISEASE", 164, 167], ["Chronic Liver Diseases", "DISEASE", 178, 200], ["ACLF", "DISEASE", 417, 421], ["HAV", "DISEASE", 431, 434], ["autoimmune hepatitis", "DISEASE", 458, 478], ["Wilson disease", "DISEASE", 482, 496], ["chronic liver disease", "DISEASE", 510, 531], ["HAV", "ORGANISM", 6, 9], ["HCV", "ORGANISM", 47, 50], ["patients", "ORGANISM", 60, 68], ["HAV", "ORGANISM", 164, 167], ["Liver", "ORGAN", 186, 191], ["children", "ORGANISM", 247, 255], ["Liver", "ORGAN", 378, 383], ["HAV", "ORGANISM", 431, 434], ["liver", "ORGAN", 518, 523], ["patients", "SPECIES", 60, 68], ["children", "SPECIES", 247, 255], ["HAV", "SPECIES", 6, 9], ["HCV", "SPECIES", 47, 50], ["HAV", "SPECIES", 164, 167], ["HAV", "SPECIES", 431, 434], ["HAV vaccination", "TREATMENT", 6, 21], ["HCV", "PROBLEM", 47, 50], ["cirrhosis", "PROBLEM", 92, 101], ["advanced fibrosis", "PROBLEM", 105, 122], ["HAV", "PROBLEM", 164, 167], ["Other Chronic Liver Diseases", "PROBLEM", 172, 200], ["a prospective study", "TEST", 221, 240], ["the Study", "TEST", 361, 370], ["HAV", "PROBLEM", 431, 434], ["an acute insult", "PROBLEM", 438, 453], ["autoimmune hepatitis", "PROBLEM", 458, 478], ["Wilson disease", "PROBLEM", 482, 496], ["chronic liver disease", "PROBLEM", 510, 531], ["cirrhosis", "OBSERVATION", 92, 101], ["fibrosis", "OBSERVATION", 114, 122], ["Chronic", "OBSERVATION_MODIFIER", 178, 185], ["Liver", "ANATOMY", 186, 191], ["Diseases", "OBSERVATION", 192, 200], ["Liver", "ANATOMY", 378, 383], ["acute", "OBSERVATION_MODIFIER", 441, 446], ["insult", "OBSERVATION", 447, 453], ["autoimmune hepatitis", "OBSERVATION", 458, 478], ["chronic", "OBSERVATION_MODIFIER", 510, 517], ["liver", "ANATOMY", 518, 523], ["disease", "OBSERVATION", 524, 531]]], ["In children, acute-on-chronic liver diseases, HEV, and HAV are more frequently causes of acute insults and Wilson disease, while autoimmune liver disease and primary sclerosing cholangitis are more frequently causes of chronic liver disease [12] .", [["liver", "ANATOMY", 30, 35], ["liver", "ANATOMY", 140, 145], ["primary sclerosing cholangitis", "ANATOMY", 158, 188], ["liver", "ANATOMY", 227, 232], ["chronic liver diseases", "DISEASE", 22, 44], ["HEV", "DISEASE", 46, 49], ["HAV", "DISEASE", 55, 58], ["Wilson disease", "DISEASE", 107, 121], ["autoimmune liver disease", "DISEASE", 129, 153], ["primary sclerosing cholangitis", "DISEASE", 158, 188], ["chronic liver disease", "DISEASE", 219, 240], ["children", "ORGANISM", 3, 11], ["liver", "ORGAN", 30, 35], ["HEV", "ORGANISM", 46, 49], ["liver", "ORGAN", 140, 145], ["liver", "ORGAN", 227, 232], ["children", "SPECIES", 3, 11], ["HEV", "SPECIES", 46, 49], ["HAV", "SPECIES", 55, 58], ["chronic liver diseases", "PROBLEM", 22, 44], ["HEV", "PROBLEM", 46, 49], ["HAV", "PROBLEM", 55, 58], ["acute insults", "PROBLEM", 89, 102], ["Wilson disease", "PROBLEM", 107, 121], ["autoimmune liver disease", "PROBLEM", 129, 153], ["primary sclerosing cholangitis", "PROBLEM", 158, 188], ["chronic liver disease", "PROBLEM", 219, 240], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["chronic", "OBSERVATION_MODIFIER", 22, 29], ["liver", "ANATOMY", 30, 35], ["diseases", "OBSERVATION", 36, 44], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["insults", "OBSERVATION", 95, 102], ["liver", "ANATOMY", 140, 145], ["primary", "OBSERVATION_MODIFIER", 158, 165], ["sclerosing", "OBSERVATION_MODIFIER", 166, 176], ["cholangitis", "OBSERVATION", 177, 188], ["chronic", "OBSERVATION_MODIFIER", 219, 226], ["liver", "ANATOMY", 227, 232], ["disease", "OBSERVATION", 233, 240]]], ["It is possible that HAV infection, as an acute insult, could result in ACLF in patients with any chronic liver disease, especially cirrhosis.", [["liver", "ANATOMY", 105, 110], ["HAV infection", "DISEASE", 20, 33], ["ACLF", "DISEASE", 71, 75], ["chronic liver disease", "DISEASE", 97, 118], ["cirrhosis", "DISEASE", 131, 140], ["HAV", "ORGANISM", 20, 23], ["ACLF", "CANCER", 71, 75], ["patients", "ORGANISM", 79, 87], ["liver", "ORGAN", 105, 110], ["patients", "SPECIES", 79, 87], ["HAV", "SPECIES", 20, 23], ["HAV infection", "PROBLEM", 20, 33], ["an acute insult", "PROBLEM", 38, 53], ["ACLF", "PROBLEM", 71, 75], ["any chronic liver disease", "PROBLEM", 93, 118], ["cirrhosis", "PROBLEM", 131, 140], ["possible that", "UNCERTAINTY", 6, 19], ["HAV", "OBSERVATION_MODIFIER", 20, 23], ["infection", "OBSERVATION", 24, 33], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["insult", "OBSERVATION", 47, 53], ["ACLF", "OBSERVATION", 71, 75], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["liver", "ANATOMY", 105, 110], ["disease", "OBSERVATION", 111, 118], ["cirrhosis", "OBSERVATION", 131, 140]]], ["Careful attention should also be paid to HAV infection in adults and children who have certain chronic liver diseases.Host Genetic Factors in HAV InfectionAcute insults in ACLF are different, depending on the country in which they are found [2] .", [["liver", "ANATOMY", 103, 108], ["HAV infection", "DISEASE", 41, 54], ["chronic liver diseases", "DISEASE", 95, 117], ["HAV InfectionAcute insults", "DISEASE", 142, 168], ["ACLF", "DISEASE", 172, 176], ["HAV", "ORGANISM", 41, 44], ["adults", "ORGANISM", 58, 64], ["children", "ORGANISM", 69, 77], ["liver", "ORGAN", 103, 108], ["HAV InfectionAcute", "ORGANISM", 142, 160], ["ACLF", "CANCER", 172, 176], ["children", "SPECIES", 69, 77], ["HAV", "SPECIES", 41, 44], ["HAV", "SPECIES", 142, 145], ["HAV infection", "PROBLEM", 41, 54], ["chronic liver diseases", "PROBLEM", 95, 117], ["HAV InfectionAcute insults", "PROBLEM", 142, 168], ["ACLF", "PROBLEM", 172, 176], ["infection", "OBSERVATION", 45, 54], ["liver", "ANATOMY", 103, 108], ["diseases", "OBSERVATION", 109, 117], ["ACLF", "OBSERVATION", 172, 176]]], ["In Asian countries, European countries, and the United States, hepatic, hepatic, and extrahepatic or infection (extrahepatic) causes, respectively, are representative acute insults in the definition of the APASL, EASL, and NACSELD ACLF guidelines [2, [89] [90] [91] .", [["hepatic", "ANATOMY", 63, 70], ["hepatic", "ANATOMY", 72, 79], ["extrahepatic", "ANATOMY", 85, 97], ["extrahepatic", "ANATOMY", 112, 124], ["hepatic, hepatic, and extrahepatic or infection", "DISEASE", 63, 110], ["hepatic", "MULTI-TISSUE_STRUCTURE", 63, 70], ["hepatic", "MULTI-TISSUE_STRUCTURE", 72, 79], ["extrahepatic", "ORGAN", 85, 97], ["extrahepatic", "ORGAN", 112, 124], ["hepatic, hepatic, and extrahepatic or infection (extrahepatic) causes", "PROBLEM", 63, 132], ["hepatic", "ANATOMY", 63, 70], ["hepatic", "ANATOMY", 72, 79], ["extrahepatic", "ANATOMY", 85, 97], ["infection", "OBSERVATION", 101, 110], ["extrahepatic", "ANATOMY", 112, 124], ["acute", "OBSERVATION_MODIFIER", 167, 172]]], ["Of course, not only a sanitary environment but also host genetic factors are different in these different regions.", [["different", "OBSERVATION_MODIFIER", 77, 86]]], ["Among Mexican Americans, transforming growth factor beta 1 (TGFB1) rs1800469 (adjusted odds ratio (OR), 1.38; 95% confidence interval (CI), 1.14-1.68; P value adjusted for false discovery rate (FDR-P) = 0.017) and X-ray repair cross complementing 1 (XRCC1) rs1799782 (OR, 1.57; 95% CI, 1.27-1.94; FDR-P = 0.0007) were associated with an increased risk of HAV infection [92] .", [["HAV infection", "DISEASE", 355, 368], ["transforming growth factor beta 1", "GENE_OR_GENE_PRODUCT", 25, 58], ["TGFB1) rs1800469", "GENE_OR_GENE_PRODUCT", 60, 76], ["X-ray repair cross complementing 1", "GENE_OR_GENE_PRODUCT", 214, 248], ["XRCC1", "GENE_OR_GENE_PRODUCT", 250, 255], ["HAV", "ORGANISM", 355, 358], ["transforming growth factor beta 1 (TGFB1) rs1800469", "DNA", 25, 76], ["HAV", "SPECIES", 355, 358], ["ratio", "TEST", 92, 97], ["CI", "TEST", 135, 137], ["P value", "TEST", 151, 158], ["false discovery rate", "TEST", 172, 192], ["FDR", "TEST", 194, 197], ["X-ray repair", "TREATMENT", 214, 226], ["CI", "TEST", 282, 284], ["FDR", "TEST", 297, 300], ["P", "TEST", 301, 302], ["HAV infection", "PROBLEM", 355, 368], ["increased", "OBSERVATION_MODIFIER", 337, 346], ["HAV", "OBSERVATION_MODIFIER", 355, 358], ["infection", "OBSERVATION", 359, 368]]], ["ATP-binding cassette subfamily B member 1 (ABCB1) rs1045642 (OR, 0.79; 95% CI, 0.71-0.89; FDR-P = 0.0007) was associated with a decreased risk [92] .", [["ATP", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 0, 3], ["ATP-binding cassette subfamily B member 1", "GENE_OR_GENE_PRODUCT", 0, 41], ["ABCB1", "GENE_OR_GENE_PRODUCT", 43, 48], ["ATP-binding cassette subfamily B member 1", "PROTEIN", 0, 41], ["ABCB1", "PROTEIN", 43, 48], ["CI", "TEST", 75, 77], ["FDR", "TEST", 90, 93], ["P", "TEST", 94, 95], ["a decreased risk", "PROBLEM", 126, 142]]], ["Host genetic factors may also play an important role in determining the differential susceptibility to HAV infection [92] [93] [94] .HAV VaccinationHAV vaccination may be important for patients with chronic liver diseases, especially those with cirrhosis [81] [82] [83] [84] [85] [86] [87] [88] .", [["liver", "ANATOMY", 207, 212], ["HAV infection", "DISEASE", 103, 116], ["chronic liver diseases", "DISEASE", 199, 221], ["cirrhosis", "DISEASE", 245, 254], ["HAV", "ORGANISM", 103, 106], ["HAV", "ORGANISM", 133, 136], ["patients", "ORGANISM", 185, 193], ["liver", "ORGAN", 207, 212], ["patients", "SPECIES", 185, 193], ["HAV", "SPECIES", 103, 106], ["HAV", "SPECIES", 133, 136], ["HAV infection", "PROBLEM", 103, 116], ["HAV VaccinationHAV vaccination", "TREATMENT", 133, 163], ["chronic liver diseases", "PROBLEM", 199, 221], ["cirrhosis", "PROBLEM", 245, 254], ["liver", "ANATOMY", 207, 212], ["diseases", "OBSERVATION", 213, 221]]], ["While a universal vaccination program against HAV seems to be the most effective solution for the prevention of HAV infection, it may be difficult to carry out this program worldwide due to the high costs of HAV vaccine production and its low effectiveness in certain countries in which the infection is endemic [88, 95] .", [["HAV", "DISEASE", 46, 49], ["HAV infection", "DISEASE", 112, 125], ["infection", "DISEASE", 291, 300], ["HAV", "ORGANISM", 46, 49], ["HAV", "ORGANISM", 112, 115], ["HAV", "ORGANISM", 208, 211], ["HAV", "SPECIES", 46, 49], ["HAV", "SPECIES", 112, 115], ["HAV", "SPECIES", 208, 211], ["a universal vaccination program", "TREATMENT", 6, 37], ["HAV", "PROBLEM", 46, 49], ["HAV infection", "PROBLEM", 112, 125], ["HAV vaccine production", "TREATMENT", 208, 230], ["the infection", "PROBLEM", 287, 300], ["infection", "OBSERVATION", 116, 125], ["low effectiveness", "OBSERVATION_MODIFIER", 239, 256], ["infection", "OBSERVATION", 291, 300]]], ["HAV vaccination targeting certain populations may also be effective and important in this regard [96] .", [["HAV", "ORGANISM", 0, 3], ["HAV", "SPECIES", 0, 3], ["HAV vaccination", "TREATMENT", 0, 15]]], ["Antivirals against HAV infection may also be needed (Figure 1 ).", [["HAV infection", "DISEASE", 19, 32], ["HAV", "ORGANISM", 19, 22], ["HAV", "SPECIES", 19, 22], ["Antivirals", "TREATMENT", 0, 10], ["HAV infection", "PROBLEM", 19, 32], ["infection", "OBSERVATION", 23, 32]]], ["The unknown causes for chronic injury constitute only 5-15% of cases of ACLF [2] .Japanese Rice-Koji Miso Extracts and Zinc Sulfates Could Inhibit HAV Replication with the Enhancement of GRP78 ExpressionJapanese rice-koji miso extracts enhanced GRP78 expression and inhibited HAV HA11-1299 genotype IIIA strain replication in the human hepatocytes, Huh7 and PXB cells [97] .", [["extracts", "ANATOMY", 227, 235], ["hepatocytes", "ANATOMY", 336, 347], ["Huh7", "ANATOMY", 349, 353], ["PXB cells", "ANATOMY", 358, 367], ["chronic injury", "DISEASE", 23, 37], ["ACLF", "DISEASE", 72, 76], ["Zinc Sulfates", "CHEMICAL", 119, 132], ["HA11-1299", "CHEMICAL", 280, 289], ["Zinc Sulfates", "CHEMICAL", 119, 132], ["Zinc Sulfates", "SIMPLE_CHEMICAL", 119, 132], ["HAV", "ORGANISM", 147, 150], ["GRP78", "GENE_OR_GENE_PRODUCT", 187, 192], ["extracts", "ORGANISM_SUBSTANCE", 227, 235], ["GRP78", "GENE_OR_GENE_PRODUCT", 245, 250], ["HAV", "ORGANISM", 276, 279], ["human", "ORGANISM", 330, 335], ["hepatocytes", "CELL", 336, 347], ["Huh7", "CELL", 349, 353], ["PXB cells", "CELL", 358, 367], ["GRP78", "PROTEIN", 187, 192], ["GRP78", "PROTEIN", 245, 250], ["human hepatocytes", "CELL_TYPE", 330, 347], ["Huh7", "CELL_LINE", 349, 353], ["PXB cells", "CELL_LINE", 358, 367], ["rice-koji", "SPECIES", 212, 221], ["human", "SPECIES", 330, 335], ["HAV", "SPECIES", 147, 150], ["Japanese rice-koji", "SPECIES", 203, 221], ["HAV HA11-1299", "SPECIES", 276, 289], ["human", "SPECIES", 330, 335], ["chronic injury", "PROBLEM", 23, 37], ["ACLF", "PROBLEM", 72, 76], ["Japanese Rice", "TREATMENT", 82, 95], ["Koji Miso Extracts", "TREATMENT", 96, 114], ["Zinc Sulfates", "TREATMENT", 119, 132], ["GRP78 expression", "TEST", 245, 261], ["HAV HA11", "TEST", 276, 284], ["genotype IIIA strain replication", "PROBLEM", 290, 322], ["the human hepatocytes", "TEST", 326, 347], ["Huh7 and PXB cells", "TEST", 349, 367], ["unknown causes for", "UNCERTAINTY", 4, 22], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["injury", "OBSERVATION", 31, 37], ["ACLF", "OBSERVATION", 72, 76], ["human hepatocytes", "ANATOMY", 330, 347], ["Huh7", "ANATOMY", 349, 353]]], ["We investigated the effect of miso extracts on virus replication in HepG2.2.15 cells infected with the HAV HA11-1299 strain [73] .", [["extracts", "ANATOMY", 35, 43], ["HepG2", "ANATOMY", 68, 73], ["2.15 cells", "ANATOMY", 74, 84], ["HAV HA11-1299", "CHEMICAL", 103, 116], ["miso extracts", "ORGANISM_SUBSTANCE", 30, 43], ["HepG2", "CELL", 68, 73], ["2.15 cells", "CELL", 74, 84], ["HAV HA11-1299", "ORGANISM", 103, 116], ["HepG2", "CELL_LINE", 68, 73], ["HAV HA11-1299 strain", "SPECIES", 103, 123], ["miso extracts", "TREATMENT", 30, 43], ["virus replication", "TREATMENT", 47, 64], ["the HAV HA11", "TEST", 99, 111], ["strain", "PROBLEM", 117, 123], ["infected", "OBSERVATION_MODIFIER", 85, 93]]], ["It is noteworthy that miso extracts have an inhibitory effect on HAV replication but no inhibitory effect on HBV replication.", [["extracts", "ANATOMY", 27, 35], ["miso extracts", "ORGANISM_SUBSTANCE", 22, 35], ["HAV", "ORGANISM", 65, 68], ["HBV", "ORGANISM", 109, 112], ["HAV", "SPECIES", 65, 68], ["HBV", "SPECIES", 109, 112], ["miso extracts", "TREATMENT", 22, 35], ["HAV replication", "TREATMENT", 65, 80], ["inhibitory effect", "PROBLEM", 88, 105], ["HBV replication", "TREATMENT", 109, 124]]], ["Japanese rice-koji miso extracts may have an inhibitory effect on HAV replication in patients superinfected with HAV and HBV.Japanese Rice-Koji Miso Extracts and Zinc Sulfates Could Inhibit HAV Replication with the Enhancement of GRP78 ExpressionThe zinc homeostasis pathway was identified as a key pathway of the antiviral activity of Japanese rice-koji miso against HAV infection using transcriptome-sequencing analysis [98] .", [["extracts", "ANATOMY", 24, 32], ["Japanese rice-koji miso", "CHEMICAL", 0, 23], ["Zinc Sulfates", "CHEMICAL", 162, 175], ["zinc", "CHEMICAL", 250, 254], ["Japanese rice-koji miso", "CHEMICAL", 336, 359], ["HAV infection", "DISEASE", 368, 381], ["Zinc Sulfates", "CHEMICAL", 162, 175], ["zinc", "CHEMICAL", 250, 254], ["koji miso extracts", "ORGANISM_SUBSTANCE", 14, 32], ["HAV", "ORGANISM", 66, 69], ["patients", "ORGANISM", 85, 93], ["HAV", "ORGANISM", 113, 116], ["HBV", "ORGANISM", 121, 124], ["Zinc Sulfates", "SIMPLE_CHEMICAL", 162, 175], ["HAV", "ORGANISM", 190, 193], ["GRP78", "GENE_OR_GENE_PRODUCT", 230, 235], ["zinc", "SIMPLE_CHEMICAL", 250, 254], ["Japanese", "ORGANISM", 336, 344], ["rice-koji miso", "ORGANISM", 345, 359], ["HAV", "ORGANISM", 368, 371], ["GRP78", "PROTEIN", 230, 235], ["rice-koji", "SPECIES", 9, 18], ["patients", "SPECIES", 85, 93], ["rice-koji", "SPECIES", 345, 354], ["Japanese rice-koji", "SPECIES", 0, 18], ["HAV", "SPECIES", 66, 69], ["HAV", "SPECIES", 113, 116], ["HBV", "SPECIES", 121, 124], ["HAV", "SPECIES", 190, 193], ["Japanese rice-koji", "SPECIES", 336, 354], ["HAV", "SPECIES", 368, 371], ["Japanese rice", "TREATMENT", 0, 13], ["koji miso extracts", "TREATMENT", 14, 32], ["HAV replication", "TREATMENT", 66, 81], ["HAV", "TREATMENT", 113, 116], ["HBV", "PROBLEM", 121, 124], ["Japanese Rice", "TREATMENT", 125, 138], ["Koji Miso Extracts", "TREATMENT", 139, 157], ["Zinc Sulfates", "TREATMENT", 162, 175], ["The zinc homeostasis pathway", "TREATMENT", 246, 274], ["Japanese rice", "TREATMENT", 336, 349], ["HAV infection", "PROBLEM", 368, 381], ["sequencing analysis", "TEST", 402, 421]]], ["We also demonstrated that zinc sulfate has an inhibitory effect on HAV HA11-1299 replication in human hepatocytes with the enhancement of GRP78 expression [98] .", [["hepatocytes", "ANATOMY", 102, 113], ["zinc sulfate", "CHEMICAL", 26, 38], ["HA11-1299", "CHEMICAL", 71, 80], ["zinc sulfate", "CHEMICAL", 26, 38], ["zinc sulfate", "SIMPLE_CHEMICAL", 26, 38], ["HAV", "ORGANISM", 67, 70], ["HA11-1299", "CELL", 71, 80], ["human", "ORGANISM", 96, 101], ["hepatocytes", "CELL", 102, 113], ["GRP78", "GENE_OR_GENE_PRODUCT", 138, 143], ["human hepatocytes", "CELL_TYPE", 96, 113], ["GRP78", "PROTEIN", 138, 143], ["human", "SPECIES", 96, 101], ["HAV HA11-1299", "SPECIES", 67, 80], ["human", "SPECIES", 96, 101], ["zinc sulfate", "TREATMENT", 26, 38], ["HAV HA11", "TEST", 67, 75], ["GRP78 expression", "TEST", 138, 154], ["hepatocytes", "ANATOMY", 102, 113]]], ["As Japanese miso soup and zinc sulfate are traditional foods and drugs, respectively, they induce GRP78 expression and are useful and safe antiviral compounds against HAV, with fewer adverse events.", [["zinc sulfate", "CHEMICAL", 26, 38], ["HAV", "DISEASE", 167, 170], ["zinc sulfate", "CHEMICAL", 26, 38], ["zinc sulfate", "SIMPLE_CHEMICAL", 26, 38], ["GRP78", "GENE_OR_GENE_PRODUCT", 98, 103], ["HAV", "ORGANISM", 167, 170], ["GRP78", "PROTEIN", 98, 103], ["HAV", "SPECIES", 167, 170], ["Japanese miso soup", "TREATMENT", 3, 21], ["zinc sulfate", "TREATMENT", 26, 38], ["drugs", "TREATMENT", 65, 70], ["safe antiviral compounds", "TREATMENT", 134, 158], ["fewer adverse events", "PROBLEM", 177, 197]]], ["Gut dysbiosis and increased permeability cause pathological bacterial translocation and endotoxemia, which play an important role in the development of ACLF [2] .", [["Gut", "ANATOMY", 0, 3], ["endotoxemia", "DISEASE", 88, 99], ["ACLF", "DISEASE", 152, 156], ["Gut", "MULTI-TISSUE_STRUCTURE", 0, 3], ["Gut dysbiosis", "PROBLEM", 0, 13], ["increased permeability", "PROBLEM", 18, 40], ["pathological bacterial translocation", "PROBLEM", 47, 83], ["endotoxemia", "PROBLEM", 88, 99], ["ACLF", "PROBLEM", 152, 156], ["dysbiosis", "OBSERVATION", 4, 13], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["permeability", "OBSERVATION_MODIFIER", 28, 40], ["bacterial translocation", "OBSERVATION", 60, 83], ["endotoxemia", "OBSERVATION", 88, 99], ["ACLF", "OBSERVATION", 152, 156]]], ["HAV infects the liver by the gut-portal vein-liver axis through fecal-oral routes.", [["liver", "ANATOMY", 16, 21], ["gut", "ANATOMY", 29, 32], ["portal vein", "ANATOMY", 33, 44], ["liver", "ANATOMY", 45, 50], ["oral", "ANATOMY", 70, 74], ["HAV infects the liver", "DISEASE", 0, 21], ["HAV", "ORGANISM", 0, 3], ["liver", "ORGAN", 16, 21], ["gut-portal vein", "MULTI-TISSUE_STRUCTURE", 29, 44], ["liver", "ORGAN", 45, 50], ["fecal", "ORGANISM_SUBSTANCE", 64, 69], ["oral", "ORGANISM_SUBDIVISION", 70, 74], ["HAV", "SPECIES", 0, 3], ["HAV infects the liver", "PROBLEM", 0, 21], ["infects", "OBSERVATION", 4, 11], ["liver", "ANATOMY", 16, 21], ["gut", "ANATOMY", 29, 32], ["portal vein", "ANATOMY", 33, 44], ["liver", "ANATOMY", 45, 50], ["axis", "ANATOMY_MODIFIER", 51, 55], ["fecal", "ANATOMY", 64, 69]]], ["The digestion and absorption of Japanese rice-koji miso extracts and zinc sulfate may be used through similar routes.Candidates of Antivirals against HAV in Chronic Liver DiseasesThe inhibitory effects of interferon-alpha, interferon-gamma, interferon-lambda, ribavirin, amantadine, sirtinol, and AZD1480 as host-targeting drugs and HAV 3C cysteine protease inhibitors, as well as small interfering RNAs against HAV, as antivirals that directly act on HAV replication, have been reported [11, 46, 99] .", [["extracts", "ANATOMY", 56, 64], ["Liver", "ANATOMY", 165, 170], ["Japanese rice-koji miso", "CHEMICAL", 32, 55], ["zinc sulfate", "CHEMICAL", 69, 81], ["HAV", "DISEASE", 150, 153], ["Chronic Liver Diseases", "DISEASE", 157, 179], ["interferon-gamma, interferon-lambda", "CHEMICAL", 223, 258], ["ribavirin", "CHEMICAL", 260, 269], ["amantadine", "CHEMICAL", 271, 281], ["sirtinol", "CHEMICAL", 283, 291], ["AZD1480", "CHEMICAL", 297, 304], ["HAV", "DISEASE", 412, 415], ["zinc sulfate", "CHEMICAL", 69, 81], ["ribavirin", "CHEMICAL", 260, 269], ["amantadine", "CHEMICAL", 271, 281], ["sirtinol", "CHEMICAL", 283, 291], ["AZD1480", "CHEMICAL", 297, 304], ["cysteine", "CHEMICAL", 340, 348], ["extracts", "ORGANISM_SUBSTANCE", 56, 64], ["zinc sulfate", "SIMPLE_CHEMICAL", 69, 81], ["HAV", "ORGANISM", 150, 153], ["Liver", "ORGAN", 165, 170], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 205, 221], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 223, 239], ["interferon-lambda", "GENE_OR_GENE_PRODUCT", 241, 258], ["ribavirin", "SIMPLE_CHEMICAL", 260, 269], ["amantadine", "SIMPLE_CHEMICAL", 271, 281], ["sirtinol", "SIMPLE_CHEMICAL", 283, 291], ["AZD1480", "SIMPLE_CHEMICAL", 297, 304], ["HAV 3C", "ORGANISM", 333, 339], ["HAV", "ORGANISM", 412, 415], ["HAV", "ORGANISM", 452, 455], ["interferon-alpha", "PROTEIN", 205, 221], ["interferon-gamma", "PROTEIN", 223, 239], ["interferon", "PROTEIN", 241, 251], ["small interfering RNAs", "RNA", 381, 403], ["rice-koji", "SPECIES", 41, 50], ["Japanese rice-koji", "SPECIES", 32, 50], ["HAV", "SPECIES", 150, 153], ["HAV", "SPECIES", 333, 336], ["HAV", "SPECIES", 412, 415], ["HAV", "SPECIES", 452, 455], ["The digestion", "PROBLEM", 0, 13], ["Japanese rice", "TREATMENT", 32, 45], ["koji miso extracts", "TREATMENT", 46, 64], ["zinc sulfate", "TREATMENT", 69, 81], ["Antivirals", "TREATMENT", 131, 141], ["Chronic Liver Diseases", "PROBLEM", 157, 179], ["interferon", "TREATMENT", 205, 215], ["alpha", "TREATMENT", 216, 221], ["interferon", "TREATMENT", 223, 233], ["gamma", "TREATMENT", 234, 239], ["interferon", "TREATMENT", 241, 251], ["lambda", "TREATMENT", 252, 258], ["ribavirin", "TREATMENT", 260, 269], ["amantadine", "TREATMENT", 271, 281], ["sirtinol", "TREATMENT", 283, 291], ["AZD1480", "TREATMENT", 297, 304], ["drugs", "TREATMENT", 323, 328], ["HAV 3C cysteine protease inhibitors", "TREATMENT", 333, 368], ["small interfering RNAs", "PROBLEM", 381, 403], ["HAV", "PROBLEM", 412, 415], ["antivirals", "TREATMENT", 420, 430], ["HAV replication", "TREATMENT", 452, 467], ["Chronic", "OBSERVATION_MODIFIER", 157, 164], ["Liver", "ANATOMY", 165, 170], ["Diseases", "OBSERVATION", 171, 179]]], ["Interferon has antiviral potential against HAV [100, 101] , but it is difficult to use interferon in patients with ACLF, as interferon generally has cytotoxicity.", [["Interferon", "CHEMICAL", 0, 10], ["HAV", "DISEASE", 43, 46], ["ACLF", "DISEASE", 115, 119], ["interferon", "CHEMICAL", 124, 134], ["Interferon", "GENE_OR_GENE_PRODUCT", 0, 10], ["HAV", "ORGANISM", 43, 46], ["interferon", "GENE_OR_GENE_PRODUCT", 87, 97], ["patients", "ORGANISM", 101, 109], ["ACLF", "CANCER", 115, 119], ["interferon", "GENE_OR_GENE_PRODUCT", 124, 134], ["Interferon", "PROTEIN", 0, 10], ["interferon", "PROTEIN", 87, 97], ["interferon", "PROTEIN", 124, 134], ["patients", "SPECIES", 101, 109], ["HAV", "SPECIES", 43, 46], ["Interferon", "TREATMENT", 0, 10], ["HAV", "PROBLEM", 43, 46], ["interferon", "TREATMENT", 87, 97], ["ACLF", "TREATMENT", 115, 119], ["interferon", "TREATMENT", 124, 134], ["cytotoxicity", "PROBLEM", 149, 161]]], ["Peginterferon-lambda has fewer side effects than peginterferon-alpha and may be useful in some patients with HAV infection.", [["Peginterferon-lambda", "CHEMICAL", 0, 20], ["peginterferon-alpha", "CHEMICAL", 49, 68], ["HAV infection", "DISEASE", 109, 122], ["Peginterferon-lambda", "GENE_OR_GENE_PRODUCT", 0, 20], ["peginterferon-alpha", "GENE_OR_GENE_PRODUCT", 49, 68], ["patients", "ORGANISM", 95, 103], ["HAV", "ORGANISM", 109, 112], ["peginterferon-alpha", "PROTEIN", 49, 68], ["patients", "SPECIES", 95, 103], ["HAV", "SPECIES", 109, 112], ["Peginterferon-lambda", "TREATMENT", 0, 20], ["fewer side effects", "PROBLEM", 25, 43], ["peginterferon", "TREATMENT", 49, 62], ["HAV infection", "PROBLEM", 109, 122], ["fewer side effects", "OBSERVATION_MODIFIER", 25, 43], ["infection", "OBSERVATION", 113, 122]]], ["Amantadine is a broad-spectrum antiviral and has an inhibitory effect on HAV replication through the targeting of HAV internal entry site (IRES) activity [100, 102, 103] .", [["Amantadine", "CHEMICAL", 0, 10], ["Amantadine", "CHEMICAL", 0, 10], ["Amantadine", "SIMPLE_CHEMICAL", 0, 10], ["HAV", "ORGANISM", 73, 76], ["HAV", "ORGANISM", 114, 117], ["HAV internal entry site", "DNA", 114, 137], ["IRES", "DNA", 139, 143], ["HAV", "SPECIES", 73, 76], ["HAV", "SPECIES", 114, 117], ["Amantadine", "TREATMENT", 0, 10], ["a broad-spectrum antiviral", "TREATMENT", 14, 40], ["an inhibitory effect", "TREATMENT", 49, 69], ["HAV replication", "TREATMENT", 73, 88]]], ["The sirtuin inhibitor, sirtinol, also inhibits HAV replication by inhibiting HAV IRES activity [104] .", [["sirtinol", "CHEMICAL", 23, 31], ["sirtinol", "CHEMICAL", 23, 31], ["sirtuin", "GENE_OR_GENE_PRODUCT", 4, 11], ["sirtinol", "SIMPLE_CHEMICAL", 23, 31], ["HAV", "ORGANISM", 47, 50], ["HAV", "ORGANISM", 77, 80], ["HAV IRES", "DNA", 77, 85], ["HAV", "SPECIES", 47, 50], ["HAV", "SPECIES", 77, 80], ["The sirtuin inhibitor", "TREATMENT", 0, 21], ["sirtinol", "TREATMENT", 23, 31], ["HAV replication", "TREATMENT", 47, 62]]], ["Further studies on the mechanism of the sirtuin inhibitor and JAK pathways in HAV replication are needed [104, 105] .", [["sirtuin", "GENE_OR_GENE_PRODUCT", 40, 47], ["JAK", "GENE_OR_GENE_PRODUCT", 62, 65], ["HAV", "ORGANISM", 78, 81], ["JAK", "PROTEIN", 62, 65], ["HAV", "SPECIES", 78, 81], ["Further studies", "TEST", 0, 15], ["the sirtuin inhibitor", "TREATMENT", 36, 57], ["JAK pathways", "TREATMENT", 62, 74], ["HAV replication", "TREATMENT", 78, 93]]], ["In patients with chronic liver diseases or ACLF, these drugs should be improved, and more safe drugs are needed and should be explored.", [["liver", "ANATOMY", 25, 30], ["chronic liver diseases", "DISEASE", 17, 39], ["ACLF", "DISEASE", 43, 47], ["patients", "ORGANISM", 3, 11], ["liver", "ORGAN", 25, 30], ["patients", "SPECIES", 3, 11], ["chronic liver diseases", "PROBLEM", 17, 39], ["ACLF", "PROBLEM", 43, 47], ["these drugs", "TREATMENT", 49, 60], ["safe drugs", "TREATMENT", 90, 100], ["chronic", "OBSERVATION_MODIFIER", 17, 24], ["liver", "ANATOMY", 25, 30], ["diseases", "OBSERVATION", 31, 39], ["ACLF", "OBSERVATION", 43, 47]]], ["It has been reported that HCV receptor candidates, such as HAV cellular receptor 1 (HAVcr-1), integrin \u03b21, and gangliosides, are the entryJapanese Rice-Koji Miso Extracts and Zinc Sulfates Could Inhibit HAV Replication with the Enhancement of GRP78 ExpressionJapanese rice-koji miso extracts enhanced GRP78 expression and inhibited HAV HA11-1299 genotype IIIA strain replication in the human hepatocytes, Huh7 and PXB cells [97] .", [["extracts", "ANATOMY", 283, 291], ["hepatocytes", "ANATOMY", 392, 403], ["Huh7", "ANATOMY", 405, 409], ["PXB cells", "ANATOMY", 414, 423], ["Zinc Sulfates", "CHEMICAL", 175, 188], ["HA11-1299", "CHEMICAL", 336, 345], ["Zinc Sulfates", "CHEMICAL", 175, 188], ["HAV cellular receptor 1", "GENE_OR_GENE_PRODUCT", 59, 82], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 84, 91], ["integrin \u03b21", "GENE_OR_GENE_PRODUCT", 94, 105], ["gangliosides", "GENE_OR_GENE_PRODUCT", 111, 123], ["Zinc Sulfates", "SIMPLE_CHEMICAL", 175, 188], ["HAV", "ORGANISM", 203, 206], ["GRP78", "GENE_OR_GENE_PRODUCT", 243, 248], ["extracts", "ORGANISM_SUBSTANCE", 283, 291], ["GRP78", "GENE_OR_GENE_PRODUCT", 301, 306], ["HAV", "ORGANISM", 332, 335], ["human", "ORGANISM", 386, 391], ["hepatocytes", "CELL", 392, 403], ["Huh7", "CELL", 405, 409], ["PXB cells", "CELL", 414, 423], ["HCV receptor candidates", "PROTEIN", 26, 49], ["HAV cellular receptor 1", "PROTEIN", 59, 82], ["HAVcr", "PROTEIN", 84, 89], ["integrin \u03b21", "PROTEIN", 94, 105], ["GRP78", "PROTEIN", 243, 248], ["GRP78", "PROTEIN", 301, 306], ["human hepatocytes", "CELL_TYPE", 386, 403], ["Huh7", "CELL_LINE", 405, 409], ["PXB cells", "CELL_LINE", 414, 423], ["rice-koji", "SPECIES", 268, 277], ["human", "SPECIES", 386, 391], ["HCV", "SPECIES", 26, 29], ["HAV", "SPECIES", 59, 62], ["HAV", "SPECIES", 203, 206], ["Japanese rice-koji", "SPECIES", 259, 277], ["HAV HA11-1299", "SPECIES", 332, 345], ["human", "SPECIES", 386, 391], ["HCV receptor candidates", "TREATMENT", 26, 49], ["HAV cellular receptor", "TREATMENT", 59, 80], ["HAVcr", "TEST", 84, 89], ["integrin \u03b21", "TREATMENT", 94, 105], ["gangliosides", "TREATMENT", 111, 123], ["the entryJapanese Rice", "TREATMENT", 129, 151], ["Koji Miso Extracts", "TREATMENT", 152, 170], ["Zinc Sulfates", "TREATMENT", 175, 188], ["GRP78 expression", "TEST", 301, 317], ["HAV HA11", "TEST", 332, 340], ["genotype IIIA strain replication", "PROBLEM", 346, 378], ["the human hepatocytes", "TEST", 382, 403], ["Huh7 and PXB cells", "TEST", 405, 423], ["gangliosides", "ANATOMY", 111, 123], ["human hepatocytes", "ANATOMY", 386, 403], ["Huh7", "ANATOMY", 405, 409]]], ["We investigated the effect of miso extracts on virus replication in HepG2.2.15 cells infected with the HAV HA11-1299 strain [73] .", [["extracts", "ANATOMY", 35, 43], ["HepG2", "ANATOMY", 68, 73], ["2.15 cells", "ANATOMY", 74, 84], ["HAV HA11-1299", "CHEMICAL", 103, 116], ["miso extracts", "ORGANISM_SUBSTANCE", 30, 43], ["HepG2", "CELL", 68, 73], ["2.15 cells", "CELL", 74, 84], ["HAV HA11-1299", "ORGANISM", 103, 116], ["HepG2", "CELL_LINE", 68, 73], ["HAV HA11-1299 strain", "SPECIES", 103, 123], ["miso extracts", "TREATMENT", 30, 43], ["virus replication", "TREATMENT", 47, 64], ["the HAV HA11", "TEST", 99, 111], ["strain", "PROBLEM", 117, 123], ["infected", "OBSERVATION_MODIFIER", 85, 93]]], ["It is noteworthy that miso extracts have an inhibitory effect on HAV replication but no inhibitory effect on HBV replication.", [["extracts", "ANATOMY", 27, 35], ["miso extracts", "ORGANISM_SUBSTANCE", 22, 35], ["HAV", "ORGANISM", 65, 68], ["HBV", "ORGANISM", 109, 112], ["HAV", "SPECIES", 65, 68], ["HBV", "SPECIES", 109, 112], ["miso extracts", "TREATMENT", 22, 35], ["HAV replication", "TREATMENT", 65, 80], ["inhibitory effect", "PROBLEM", 88, 105], ["HBV replication", "TREATMENT", 109, 124]]], ["Japanese rice-koji miso extracts may have an inhibitory effect on HAV replication in patients superinfected with HAV and HBV.Japanese Rice-Koji Miso Extracts and Zinc Sulfates Could Inhibit HAV Replication with the Enhancement of GRP78 ExpressionThe zinc homeostasis pathway was identified as a key pathway of the antiviral activity of Japanese rice-koji miso against HAV infection using transcriptome-sequencing analysis [98] .", [["extracts", "ANATOMY", 24, 32], ["Japanese rice-koji miso", "CHEMICAL", 0, 23], ["Zinc Sulfates", "CHEMICAL", 162, 175], ["zinc", "CHEMICAL", 250, 254], ["Japanese rice-koji miso", "CHEMICAL", 336, 359], ["HAV infection", "DISEASE", 368, 381], ["Zinc Sulfates", "CHEMICAL", 162, 175], ["zinc", "CHEMICAL", 250, 254], ["koji miso extracts", "ORGANISM_SUBSTANCE", 14, 32], ["HAV", "ORGANISM", 66, 69], ["patients", "ORGANISM", 85, 93], ["HAV", "ORGANISM", 113, 116], ["HBV", "ORGANISM", 121, 124], ["Zinc Sulfates", "SIMPLE_CHEMICAL", 162, 175], ["HAV", "ORGANISM", 190, 193], ["GRP78", "GENE_OR_GENE_PRODUCT", 230, 235], ["zinc", "SIMPLE_CHEMICAL", 250, 254], ["Japanese", "ORGANISM", 336, 344], ["rice-koji miso", "ORGANISM", 345, 359], ["HAV", "ORGANISM", 368, 371], ["GRP78", "PROTEIN", 230, 235], ["rice-koji", "SPECIES", 9, 18], ["patients", "SPECIES", 85, 93], ["rice-koji", "SPECIES", 345, 354], ["Japanese rice-koji", "SPECIES", 0, 18], ["HAV", "SPECIES", 66, 69], ["HAV", "SPECIES", 113, 116], ["HBV", "SPECIES", 121, 124], ["HAV", "SPECIES", 190, 193], ["Japanese rice-koji", "SPECIES", 336, 354], ["HAV", "SPECIES", 368, 371], ["Japanese rice", "TREATMENT", 0, 13], ["koji miso extracts", "TREATMENT", 14, 32], ["HAV replication", "TREATMENT", 66, 81], ["HAV", "TREATMENT", 113, 116], ["HBV", "PROBLEM", 121, 124], ["Japanese Rice", "TREATMENT", 125, 138], ["Koji Miso Extracts", "TREATMENT", 139, 157], ["Zinc Sulfates", "TREATMENT", 162, 175], ["The zinc homeostasis pathway", "TREATMENT", 246, 274], ["Japanese rice", "TREATMENT", 336, 349], ["HAV infection", "PROBLEM", 368, 381], ["sequencing analysis", "TEST", 402, 421]]], ["We also demonstrated that zinc sulfate has an inhibitory effect on HAV HA11-1299 replication in human hepatocytes with the enhancement of GRP78 expression [98] .", [["hepatocytes", "ANATOMY", 102, 113], ["zinc sulfate", "CHEMICAL", 26, 38], ["HA11-1299", "CHEMICAL", 71, 80], ["zinc sulfate", "CHEMICAL", 26, 38], ["zinc sulfate", "SIMPLE_CHEMICAL", 26, 38], ["HAV", "ORGANISM", 67, 70], ["HA11-1299", "CELL", 71, 80], ["human", "ORGANISM", 96, 101], ["hepatocytes", "CELL", 102, 113], ["GRP78", "GENE_OR_GENE_PRODUCT", 138, 143], ["human hepatocytes", "CELL_TYPE", 96, 113], ["GRP78", "PROTEIN", 138, 143], ["human", "SPECIES", 96, 101], ["HAV HA11-1299", "SPECIES", 67, 80], ["human", "SPECIES", 96, 101], ["zinc sulfate", "TREATMENT", 26, 38], ["HAV HA11", "TEST", 67, 75], ["GRP78 expression", "TEST", 138, 154], ["hepatocytes", "ANATOMY", 102, 113]]], ["As Japanese miso soup and zinc sulfate are traditional foods and drugs, respectively, they induce GRP78 expression and are useful and safe antiviral compounds against HAV, with fewer adverse events.", [["zinc sulfate", "CHEMICAL", 26, 38], ["HAV", "DISEASE", 167, 170], ["zinc sulfate", "CHEMICAL", 26, 38], ["zinc sulfate", "SIMPLE_CHEMICAL", 26, 38], ["GRP78", "GENE_OR_GENE_PRODUCT", 98, 103], ["HAV", "ORGANISM", 167, 170], ["GRP78", "PROTEIN", 98, 103], ["HAV", "SPECIES", 167, 170], ["Japanese miso soup", "TREATMENT", 3, 21], ["zinc sulfate", "TREATMENT", 26, 38], ["drugs", "TREATMENT", 65, 70], ["safe antiviral compounds", "TREATMENT", 134, 158], ["fewer adverse events", "PROBLEM", 177, 197]]], ["Gut dysbiosis and increased permeability cause pathological bacterial translocation and endotoxemia, which play an important role in the development of ACLF [2] .", [["Gut", "ANATOMY", 0, 3], ["endotoxemia", "DISEASE", 88, 99], ["ACLF", "DISEASE", 152, 156], ["Gut", "MULTI-TISSUE_STRUCTURE", 0, 3], ["Gut dysbiosis", "PROBLEM", 0, 13], ["increased permeability", "PROBLEM", 18, 40], ["pathological bacterial translocation", "PROBLEM", 47, 83], ["endotoxemia", "PROBLEM", 88, 99], ["ACLF", "PROBLEM", 152, 156], ["dysbiosis", "OBSERVATION", 4, 13], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["permeability", "OBSERVATION_MODIFIER", 28, 40], ["bacterial translocation", "OBSERVATION", 60, 83], ["endotoxemia", "OBSERVATION", 88, 99], ["ACLF", "OBSERVATION", 152, 156]]], ["HAV infects the liver by the gut-portal vein-liver axis through fecal-oral routes.", [["liver", "ANATOMY", 16, 21], ["gut", "ANATOMY", 29, 32], ["portal vein", "ANATOMY", 33, 44], ["liver", "ANATOMY", 45, 50], ["oral", "ANATOMY", 70, 74], ["HAV infects the liver", "DISEASE", 0, 21], ["HAV", "ORGANISM", 0, 3], ["liver", "ORGAN", 16, 21], ["gut-portal vein", "MULTI-TISSUE_STRUCTURE", 29, 44], ["liver", "ORGAN", 45, 50], ["fecal", "ORGANISM_SUBSTANCE", 64, 69], ["oral", "ORGANISM_SUBDIVISION", 70, 74], ["HAV", "SPECIES", 0, 3], ["HAV infects the liver", "PROBLEM", 0, 21], ["infects", "OBSERVATION", 4, 11], ["liver", "ANATOMY", 16, 21], ["gut", "ANATOMY", 29, 32], ["portal vein", "ANATOMY", 33, 44], ["liver", "ANATOMY", 45, 50], ["axis", "ANATOMY_MODIFIER", 51, 55], ["fecal", "ANATOMY", 64, 69]]], ["The digestion and absorption of Japanese rice-koji miso extracts and zinc sulfate may be used through similar routes.Candidates of Antivirals against HAV in Chronic Liver DiseasesThe inhibitory effects of interferon-alpha, interferon-gamma, interferon-lambda, ribavirin, amantadine, sirtinol, and AZD1480 as host-targeting drugs and HAV 3C cysteine protease inhibitors, as well as small interfering RNAs against HAV, as antivirals that directly act on HAV replication, have been reported [11, 46, 99] .", [["extracts", "ANATOMY", 56, 64], ["Liver", "ANATOMY", 165, 170], ["Japanese rice-koji miso", "CHEMICAL", 32, 55], ["zinc sulfate", "CHEMICAL", 69, 81], ["HAV", "DISEASE", 150, 153], ["Chronic Liver Diseases", "DISEASE", 157, 179], ["interferon-gamma, interferon-lambda", "CHEMICAL", 223, 258], ["ribavirin", "CHEMICAL", 260, 269], ["amantadine", "CHEMICAL", 271, 281], ["sirtinol", "CHEMICAL", 283, 291], ["AZD1480", "CHEMICAL", 297, 304], ["HAV", "DISEASE", 412, 415], ["zinc sulfate", "CHEMICAL", 69, 81], ["ribavirin", "CHEMICAL", 260, 269], ["amantadine", "CHEMICAL", 271, 281], ["sirtinol", "CHEMICAL", 283, 291], ["AZD1480", "CHEMICAL", 297, 304], ["cysteine", "CHEMICAL", 340, 348], ["extracts", "ORGANISM_SUBSTANCE", 56, 64], ["zinc sulfate", "SIMPLE_CHEMICAL", 69, 81], ["HAV", "ORGANISM", 150, 153], ["Liver", "ORGAN", 165, 170], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 205, 221], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 223, 239], ["interferon-lambda", "GENE_OR_GENE_PRODUCT", 241, 258], ["ribavirin", "SIMPLE_CHEMICAL", 260, 269], ["amantadine", "SIMPLE_CHEMICAL", 271, 281], ["sirtinol", "SIMPLE_CHEMICAL", 283, 291], ["AZD1480", "SIMPLE_CHEMICAL", 297, 304], ["HAV 3C", "ORGANISM", 333, 339], ["HAV", "ORGANISM", 412, 415], ["HAV", "ORGANISM", 452, 455], ["interferon-alpha", "PROTEIN", 205, 221], ["interferon-gamma", "PROTEIN", 223, 239], ["interferon", "PROTEIN", 241, 251], ["small interfering RNAs", "RNA", 381, 403], ["rice-koji", "SPECIES", 41, 50], ["Japanese rice-koji", "SPECIES", 32, 50], ["HAV", "SPECIES", 150, 153], ["HAV", "SPECIES", 333, 336], ["HAV", "SPECIES", 412, 415], ["HAV", "SPECIES", 452, 455], ["The digestion", "PROBLEM", 0, 13], ["Japanese rice", "TREATMENT", 32, 45], ["koji miso extracts", "TREATMENT", 46, 64], ["zinc sulfate", "TREATMENT", 69, 81], ["Antivirals", "TREATMENT", 131, 141], ["Chronic Liver Diseases", "PROBLEM", 157, 179], ["interferon", "TREATMENT", 205, 215], ["alpha", "TREATMENT", 216, 221], ["interferon", "TREATMENT", 223, 233], ["gamma", "TREATMENT", 234, 239], ["interferon", "TREATMENT", 241, 251], ["lambda", "TREATMENT", 252, 258], ["ribavirin", "TREATMENT", 260, 269], ["amantadine", "TREATMENT", 271, 281], ["sirtinol", "TREATMENT", 283, 291], ["AZD1480", "TREATMENT", 297, 304], ["drugs", "TREATMENT", 323, 328], ["HAV 3C cysteine protease inhibitors", "TREATMENT", 333, 368], ["small interfering RNAs", "PROBLEM", 381, 403], ["HAV", "PROBLEM", 412, 415], ["antivirals", "TREATMENT", 420, 430], ["HAV replication", "TREATMENT", 452, 467], ["Chronic", "OBSERVATION_MODIFIER", 157, 164], ["Liver", "ANATOMY", 165, 170], ["Diseases", "OBSERVATION", 171, 179]]], ["Interferon has antiviral potential against HAV [100, 101] , but it is difficult to use interferon in patients with ACLF, as interferon generally has cytotoxicity.", [["Interferon", "CHEMICAL", 0, 10], ["HAV", "DISEASE", 43, 46], ["ACLF", "DISEASE", 115, 119], ["interferon", "CHEMICAL", 124, 134], ["Interferon", "GENE_OR_GENE_PRODUCT", 0, 10], ["HAV", "ORGANISM", 43, 46], ["interferon", "GENE_OR_GENE_PRODUCT", 87, 97], ["patients", "ORGANISM", 101, 109], ["ACLF", "CANCER", 115, 119], ["interferon", "GENE_OR_GENE_PRODUCT", 124, 134], ["Interferon", "PROTEIN", 0, 10], ["interferon", "PROTEIN", 87, 97], ["interferon", "PROTEIN", 124, 134], ["patients", "SPECIES", 101, 109], ["HAV", "SPECIES", 43, 46], ["Interferon", "TREATMENT", 0, 10], ["HAV", "PROBLEM", 43, 46], ["interferon", "TREATMENT", 87, 97], ["ACLF", "TREATMENT", 115, 119], ["interferon", "TREATMENT", 124, 134], ["cytotoxicity", "PROBLEM", 149, 161]]], ["Peginterferon-lambda has fewer side effects than peginterferon-alpha and may be useful in some patients with HAV infection.", [["Peginterferon-lambda", "CHEMICAL", 0, 20], ["peginterferon-alpha", "CHEMICAL", 49, 68], ["HAV infection", "DISEASE", 109, 122], ["Peginterferon-lambda", "GENE_OR_GENE_PRODUCT", 0, 20], ["peginterferon-alpha", "GENE_OR_GENE_PRODUCT", 49, 68], ["patients", "ORGANISM", 95, 103], ["HAV", "ORGANISM", 109, 112], ["peginterferon-alpha", "PROTEIN", 49, 68], ["patients", "SPECIES", 95, 103], ["HAV", "SPECIES", 109, 112], ["Peginterferon-lambda", "TREATMENT", 0, 20], ["fewer side effects", "PROBLEM", 25, 43], ["peginterferon", "TREATMENT", 49, 62], ["HAV infection", "PROBLEM", 109, 122], ["fewer side effects", "OBSERVATION_MODIFIER", 25, 43], ["infection", "OBSERVATION", 113, 122]]], ["Amantadine is a broad-spectrum antiviral and has an inhibitory effect on HAV replication through the targeting of HAV internal entry site (IRES) activity [100, 102, 103] .", [["Amantadine", "CHEMICAL", 0, 10], ["Amantadine", "CHEMICAL", 0, 10], ["Amantadine", "SIMPLE_CHEMICAL", 0, 10], ["HAV", "ORGANISM", 73, 76], ["HAV", "ORGANISM", 114, 117], ["HAV internal entry site", "DNA", 114, 137], ["IRES", "DNA", 139, 143], ["HAV", "SPECIES", 73, 76], ["HAV", "SPECIES", 114, 117], ["Amantadine", "TREATMENT", 0, 10], ["a broad-spectrum antiviral", "TREATMENT", 14, 40], ["an inhibitory effect", "TREATMENT", 49, 69], ["HAV replication", "TREATMENT", 73, 88]]], ["The sirtuin inhibitor, sirtinol, also inhibits HAV replication by inhibiting HAV IRES activity [104] .", [["sirtinol", "CHEMICAL", 23, 31], ["sirtinol", "CHEMICAL", 23, 31], ["sirtuin", "GENE_OR_GENE_PRODUCT", 4, 11], ["sirtinol", "SIMPLE_CHEMICAL", 23, 31], ["HAV", "ORGANISM", 47, 50], ["HAV", "ORGANISM", 77, 80], ["HAV IRES", "DNA", 77, 85], ["HAV", "SPECIES", 47, 50], ["HAV", "SPECIES", 77, 80], ["The sirtuin inhibitor", "TREATMENT", 0, 21], ["sirtinol", "TREATMENT", 23, 31], ["HAV replication", "TREATMENT", 47, 62]]], ["Further studies on the mechanism of the sirtuin inhibitor and JAK pathways in HAV replication are needed [104, 105] .", [["sirtuin", "GENE_OR_GENE_PRODUCT", 40, 47], ["JAK", "GENE_OR_GENE_PRODUCT", 62, 65], ["HAV", "ORGANISM", 78, 81], ["JAK", "PROTEIN", 62, 65], ["HAV", "SPECIES", 78, 81], ["Further studies", "TEST", 0, 15], ["the sirtuin inhibitor", "TREATMENT", 36, 57], ["JAK pathways", "TREATMENT", 62, 74], ["HAV replication", "TREATMENT", 78, 93]]], ["In patients with chronic liver diseases or ACLF, these drugs should be improved, and more safe drugs are needed and should be explored.", [["liver", "ANATOMY", 25, 30], ["chronic liver diseases", "DISEASE", 17, 39], ["ACLF", "DISEASE", 43, 47], ["patients", "ORGANISM", 3, 11], ["liver", "ORGAN", 25, 30], ["patients", "SPECIES", 3, 11], ["chronic liver diseases", "PROBLEM", 17, 39], ["ACLF", "PROBLEM", 43, 47], ["these drugs", "TREATMENT", 49, 60], ["safe drugs", "TREATMENT", 90, 100], ["chronic", "OBSERVATION_MODIFIER", 17, 24], ["liver", "ANATOMY", 25, 30], ["diseases", "OBSERVATION", 31, 39], ["ACLF", "OBSERVATION", 43, 47]]], ["It has been reported that HCV receptor candidates, such as HAV cellular receptor 1 (HAVcr-1), integrin \u03b21, and gangliosides, are the entry receptor candidates for HAV.", [["HAV", "DISEASE", 163, 166], ["HCV receptor", "GENE_OR_GENE_PRODUCT", 26, 38], ["HAV cellular receptor 1", "GENE_OR_GENE_PRODUCT", 59, 82], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 84, 91], ["integrin \u03b21", "GENE_OR_GENE_PRODUCT", 94, 105], ["gangliosides", "GENE_OR_GENE_PRODUCT", 111, 123], ["HAV", "ORGANISM", 163, 166], ["HCV receptor candidates", "PROTEIN", 26, 49], ["HAV cellular receptor 1", "PROTEIN", 59, 82], ["HAVcr", "PROTEIN", 84, 89], ["integrin \u03b21", "PROTEIN", 94, 105], ["HCV", "SPECIES", 26, 29], ["HAV", "SPECIES", 59, 62], ["HAV", "SPECIES", 163, 166], ["HCV receptor candidates", "TREATMENT", 26, 49], ["HAV cellular receptor", "TREATMENT", 59, 80], ["integrin \u03b21", "TREATMENT", 94, 105], ["gangliosides", "TREATMENT", 111, 123], ["HAV", "PROBLEM", 163, 166]]], ["Further studies in this vein are needed [106] [107] [108] .", [["vein", "ANATOMY", 24, 28], ["vein", "MULTI-TISSUE_STRUCTURE", 24, 28], ["Further studies", "TEST", 0, 15], ["vein", "ANATOMY", 24, 28]]], ["Gangliosides seem to function as endosome receptors for infection using both naked and quasi-enveloped HAV virions [108] .", [["endosome", "ANATOMY", 33, 41], ["infection", "DISEASE", 56, 65], ["Gangliosides", "GENE_OR_GENE_PRODUCT", 0, 12], ["endosome", "CELLULAR_COMPONENT", 33, 41], ["HAV", "ORGANISM", 103, 106], ["endosome receptors", "PROTEIN", 33, 51], ["Gangliosides", "TREATMENT", 0, 12], ["infection", "PROBLEM", 56, 65]]], ["Blocking the cellular entry of HAV is also an attractive drug target for combating HAV infection.HAV Infection Is Associated with the Activation of the Host Immune System and Severe Systemic InflammationAcute hepatitis A usually exhibits more severe inflammation, such as a higher fever and higher C-reactive protein levels, compared to acute hepatitis due to other hepatitis viruses [109] [110] [111] .", [["cellular", "ANATOMY", 13, 21], ["HAV infection", "DISEASE", 83, 96], ["HAV Infection", "DISEASE", 97, 110], ["Systemic InflammationAcute hepatitis A", "DISEASE", 182, 220], ["inflammation", "DISEASE", 250, 262], ["fever", "DISEASE", 281, 286], ["hepatitis", "DISEASE", 343, 352], ["hepatitis viruses", "DISEASE", 366, 383], ["cellular", "CELL", 13, 21], ["HAV", "ORGANISM", 31, 34], ["HAV", "ORGANISM", 83, 86], ["HAV", "ORGANISM", 97, 100], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 298, 316], ["C-reactive protein", "PROTEIN", 298, 316], ["HAV", "SPECIES", 31, 34], ["HAV", "SPECIES", 83, 86], ["HAV", "SPECIES", 97, 100], ["combating HAV infection", "PROBLEM", 73, 96], ["HAV Infection", "PROBLEM", 97, 110], ["the Host Immune System", "TREATMENT", 148, 170], ["Severe Systemic InflammationAcute hepatitis", "PROBLEM", 175, 218], ["more severe inflammation", "PROBLEM", 238, 262], ["a higher fever", "PROBLEM", 272, 286], ["higher C-reactive protein levels", "PROBLEM", 291, 323], ["acute hepatitis", "PROBLEM", 337, 352], ["other hepatitis viruses", "PROBLEM", 360, 383], ["infection", "OBSERVATION", 87, 96], ["Infection", "OBSERVATION", 101, 110], ["Host Immune", "OBSERVATION", 152, 163], ["Severe", "OBSERVATION_MODIFIER", 175, 181], ["Systemic", "OBSERVATION_MODIFIER", 182, 190], ["InflammationAcute hepatitis", "OBSERVATION", 191, 218], ["more severe", "OBSERVATION_MODIFIER", 238, 249], ["inflammation", "OBSERVATION", 250, 262], ["higher", "OBSERVATION_MODIFIER", 274, 280], ["fever", "OBSERVATION", 281, 286], ["acute", "OBSERVATION_MODIFIER", 337, 342], ["hepatitis", "OBSERVATION", 343, 352], ["hepatitis", "OBSERVATION", 366, 375]]], ["Some cases of acute HAV infection present acute renal failure [112] [113] [114] .", [["renal", "ANATOMY", 48, 53], ["HAV infection", "DISEASE", 20, 33], ["acute renal failure", "DISEASE", 42, 61], ["HAV", "ORGANISM", 20, 23], ["renal", "ORGAN", 48, 53], ["HAV", "SPECIES", 20, 23], ["acute HAV infection", "PROBLEM", 14, 33], ["acute renal failure", "PROBLEM", 42, 61], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["HAV", "OBSERVATION_MODIFIER", 20, 23], ["infection", "OBSERVATION", 24, 33], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["renal", "ANATOMY", 48, 53], ["failure", "OBSERVATION", 54, 61]]], ["These results suggest that HAV infection activates human immune systems and induces cytokines [115] [116] [117] [118] [119] .", [["HAV infection", "DISEASE", 27, 40], ["HAV", "ORGANISM", 27, 30], ["human", "ORGANISM", 51, 56], ["cytokines", "PROTEIN", 84, 93], ["human", "SPECIES", 51, 56], ["HAV", "SPECIES", 27, 30], ["human", "SPECIES", 51, 56], ["HAV infection", "PROBLEM", 27, 40], ["cytokines", "TEST", 84, 93], ["infection", "OBSERVATION", 31, 40]]], ["Innate immunity also seems to be involved in the pathogenesis of hepatitis A [120, 121] .", [["hepatitis A", "DISEASE", 65, 76], ["hepatitis A", "ORGANISM", 65, 76], ["hepatitis A", "SPECIES", 65, 76], ["hepatitis A", "PROBLEM", 65, 76], ["seems to be", "UNCERTAINTY", 21, 32], ["hepatitis", "OBSERVATION", 65, 74]]], ["Hypergammaglobulinemia and a high occurrence of autoantibodies are observed in HAV infection [122, 123] .", [["Hypergammaglobulinemia", "DISEASE", 0, 22], ["HAV infection", "DISEASE", 79, 92], ["HAV", "ORGANISM", 79, 82], ["autoantibodies", "PROTEIN", 48, 62], ["HAV", "SPECIES", 79, 82], ["Hypergammaglobulinemia", "PROBLEM", 0, 22], ["autoantibodies", "PROBLEM", 48, 62], ["HAV infection", "PROBLEM", 79, 92], ["high occurrence", "OBSERVATION_MODIFIER", 29, 44], ["autoantibodies", "OBSERVATION", 48, 62], ["infection", "OBSERVATION", 83, 92]]], ["Moreover, the higher gammaglobulinemia in fulminant HAV suggests the existence of a more aggressive immunological reaction in severe hepatitis A [123] .HAV Infection Is Associated with the Activation of the Host Immune System and Severe Systemic InflammationSevere systemic inflammation can affect the functions of somatic cells in tissue and modify the clinical manifestation of cirrhosis and ACLF [124, 125] .", [["somatic cells", "ANATOMY", 315, 328], ["tissue", "ANATOMY", 332, 338], ["gammaglobulinemia", "DISEASE", 21, 38], ["HAV", "DISEASE", 52, 55], ["hepatitis", "DISEASE", 133, 142], ["systemic inflammation", "DISEASE", 265, 286], ["cirrhosis", "DISEASE", 380, 389], ["ACLF", "DISEASE", 394, 398], ["HAV", "ORGANISM", 52, 55], ["HAV", "ORGANISM", 152, 155], ["somatic cells", "CELL", 315, 328], ["tissue", "TISSUE", 332, 338], ["somatic cells", "CELL_TYPE", 315, 328], ["HAV", "SPECIES", 52, 55], ["HAV", "SPECIES", 152, 155], ["the higher gammaglobulinemia in fulminant HAV", "PROBLEM", 10, 55], ["a more aggressive immunological reaction", "PROBLEM", 82, 122], ["severe hepatitis A", "PROBLEM", 126, 144], ["HAV Infection", "PROBLEM", 152, 165], ["the Host Immune System", "TREATMENT", 203, 225], ["Severe Systemic Inflammation", "PROBLEM", 230, 258], ["Severe systemic inflammation", "PROBLEM", 258, 286], ["somatic cells in tissue", "PROBLEM", 315, 338], ["cirrhosis", "PROBLEM", 380, 389], ["ACLF", "PROBLEM", 394, 398], ["fulminant", "OBSERVATION", 42, 51], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["hepatitis", "OBSERVATION", 133, 142], ["Infection", "OBSERVATION", 156, 165], ["Severe", "OBSERVATION_MODIFIER", 230, 236], ["Systemic", "OBSERVATION_MODIFIER", 237, 245], ["Inflammation", "OBSERVATION", 246, 258], ["Severe", "OBSERVATION_MODIFIER", 258, 264], ["systemic", "OBSERVATION_MODIFIER", 265, 273], ["inflammation", "OBSERVATION", 274, 286], ["somatic cells", "OBSERVATION", 315, 328], ["cirrhosis", "OBSERVATION", 380, 389]]], ["Patients with acute liver failure or ACLF are susceptible to infection, and early transplant-free survival is poor [126] [127] [128] [129] .", [["liver", "ANATOMY", 20, 25], ["ACLF", "ANATOMY", 37, 41], ["acute liver failure", "DISEASE", 14, 33], ["ACLF", "DISEASE", 37, 41], ["infection", "DISEASE", 61, 70], ["Patients", "ORGANISM", 0, 8], ["liver", "ORGAN", 20, 25], ["ACLF", "CANCER", 37, 41], ["Patients", "SPECIES", 0, 8], ["acute liver failure", "PROBLEM", 14, 33], ["ACLF", "PROBLEM", 37, 41], ["infection", "PROBLEM", 61, 70], ["early transplant", "TREATMENT", 76, 92], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["liver", "ANATOMY", 20, 25], ["failure", "OBSERVATION", 26, 33], ["ACLF", "OBSERVATION", 37, 41], ["infection", "OBSERVATION", 61, 70]]], ["In liver transplantation for patients with ACLF, the role of the timing, bridging, and management of liver transplantation is important [130, 131] .Recent Outbreak of HAV Infection in MSMIt has recently been reported that HAV susceptibility parallels the high COVID-19 mortality [132] .", [["liver", "ANATOMY", 3, 8], ["liver", "ANATOMY", 101, 106], ["ACLF", "DISEASE", 43, 47], ["HAV Infection", "DISEASE", 167, 180], ["HAV", "DISEASE", 222, 225], ["liver", "ORGAN", 3, 8], ["patients", "ORGANISM", 29, 37], ["ACLF", "CANCER", 43, 47], ["liver", "ORGAN", 101, 106], ["HAV", "ORGANISM", 167, 170], ["HAV", "ORGANISM", 222, 225], ["patients", "SPECIES", 29, 37], ["HAV", "SPECIES", 167, 170], ["HAV", "SPECIES", 222, 225], ["liver transplantation", "TREATMENT", 3, 24], ["ACLF", "PROBLEM", 43, 47], ["liver transplantation", "TREATMENT", 101, 122], ["HAV Infection", "PROBLEM", 167, 180], ["HAV susceptibility parallels", "PROBLEM", 222, 250], ["liver", "ANATOMY", 3, 8], ["transplantation", "OBSERVATION", 9, 24], ["ACLF", "OBSERVATION", 43, 47], ["liver", "ANATOMY", 101, 106], ["transplantation", "OBSERVATION", 107, 122], ["HAV", "OBSERVATION_MODIFIER", 167, 170], ["Infection", "OBSERVATION", 171, 180]]], ["The 2019 coronavirus disease (COVID-19) has been observed in Japan, where the HAV susceptibility of the general population is high [34, 35] .", [["coronavirus disease", "DISEASE", 9, 28], ["HAV", "DISEASE", 78, 81], ["2019 coronavirus", "ORGANISM", 4, 20], ["HAV", "ORGANISM", 78, 81], ["coronavirus", "SPECIES", 9, 20], ["HAV", "SPECIES", 78, 81], ["The 2019 coronavirus disease", "PROBLEM", 0, 28], ["COVID", "TEST", 30, 35], ["coronavirus disease", "OBSERVATION", 9, 28]]], ["An HAV vaccination program is urgently required for individuals with or without HIV infection in this area.", [["HIV infection", "DISEASE", 80, 93], ["HAV", "ORGANISM", 3, 6], ["HIV", "ORGANISM", 80, 83], ["HIV", "SPECIES", 80, 83], ["HAV", "SPECIES", 3, 6], ["HIV", "SPECIES", 80, 83], ["An HAV vaccination program", "TREATMENT", 0, 26], ["HIV infection in this area", "PROBLEM", 80, 106], ["infection", "OBSERVATION", 84, 93]]], ["HAV infection is an imported infection, like novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [133] .", [["HAV infection", "DISEASE", 0, 13], ["infection", "DISEASE", 29, 38], ["acute respiratory syndrome coronavirus", "DISEASE", 58, 96], ["infection", "DISEASE", 112, 121], ["HAV", "ORGANISM", 0, 3], ["SARS-CoV-2", "ORGANISM", 100, 110], ["HAV", "SPECIES", 0, 3], ["severe acute respiratory syndrome coronavirus", "SPECIES", 51, 96], ["SARS-CoV-2", "SPECIES", 100, 110], ["HAV infection", "PROBLEM", 0, 13], ["an imported infection", "PROBLEM", 17, 38], ["novel severe acute respiratory syndrome coronavirus", "PROBLEM", 45, 96], ["SARS", "TEST", 100, 104], ["CoV", "TEST", 105, 108], ["infection", "PROBLEM", 112, 121], ["infection", "OBSERVATION", 4, 13], ["infection", "OBSERVATION", 29, 38], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory syndrome coronavirus", "OBSERVATION", 64, 96]]], ["In the era of COVID-19, attention should also be paid to dual infection with HAV and SARS-CoV-2.Recent Outbreak of HAV Infection in MSMAn outbreak of HAV infection in MSM has been observed worldwide.", [["infection", "DISEASE", 62, 71], ["HAV", "DISEASE", 77, 80], ["SARS", "DISEASE", 85, 89], ["HAV Infection", "DISEASE", 115, 128], ["HAV infection", "DISEASE", 150, 163], ["HAV", "ORGANISM", 77, 80], ["SARS-CoV-2", "ORGANISM", 85, 95], ["HAV", "ORGANISM", 115, 118], ["HAV", "ORGANISM", 150, 153], ["HAV", "SPECIES", 77, 80], ["SARS-CoV", "SPECIES", 85, 93], ["HAV", "SPECIES", 115, 118], ["HAV", "SPECIES", 150, 153], ["COVID", "TEST", 14, 19], ["dual infection", "PROBLEM", 57, 71], ["HAV Infection", "PROBLEM", 115, 128], ["HAV infection", "PROBLEM", 150, 163], ["HAV", "OBSERVATION_MODIFIER", 115, 118], ["Infection", "OBSERVATION", 119, 128], ["HAV", "OBSERVATION_MODIFIER", 150, 153], ["infection", "OBSERVATION", 154, 163]]], ["An outbreak of acute HAV infection among HIV-coinfected MSM in Taiwan was observed from June 2015 to September 2017 [50, 134, 135] .", [["HAV infection", "DISEASE", 21, 34], ["HIV-coinfected", "DISEASE", 41, 55], ["HAV", "ORGANISM", 21, 24], ["HIV", "ORGANISM", 41, 44], ["MSM", "ORGANISM", 56, 59], ["HIV-coinfected", "SPECIES", 41, 55], ["HAV", "SPECIES", 21, 24], ["HIV", "SPECIES", 41, 44], ["acute HAV infection", "PROBLEM", 15, 34], ["outbreak", "OBSERVATION_MODIFIER", 3, 11], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["HAV", "OBSERVATION_MODIFIER", 21, 24], ["infection", "OBSERVATION", 25, 34]]], ["Between July 2016 and February 2017, 48 male cases of HAV infection were found in the Netherlands [48] .", [["HAV infection", "DISEASE", 54, 67], ["HAV", "ORGANISM", 54, 57], ["HAV", "SPECIES", 54, 57], ["HAV infection", "PROBLEM", 54, 67], ["infection", "OBSERVATION", 58, 67]]], ["A total of 17 of them were MSM.", [["MSM", "CHEMICAL", 27, 30]]], ["This strain is identical to a strain causing a large outbreak among MSM in Taiwan [48] .", [["a strain", "PROBLEM", 28, 36], ["large", "OBSERVATION_MODIFIER", 47, 52], ["outbreak", "OBSERVATION_MODIFIER", 53, 61]]], ["In the United States, HAV infections also increased among MSM from 2016 to 2018 [54, 136, 137] .", [["HAV infections", "DISEASE", 22, 36], ["HAV", "ORGANISM", 22, 25], ["HAV", "SPECIES", 22, 25], ["HAV infections", "PROBLEM", 22, 36], ["infections", "OBSERVATION", 26, 36], ["increased", "OBSERVATION_MODIFIER", 42, 51]]], ["Since 2017, HAV infection has increased among MSM in Japan [34, 37, 52] .", [["HAV infection", "DISEASE", 12, 25], ["HAV", "ORGANISM", 12, 15], ["HAV", "SPECIES", 12, 15], ["HAV infection", "PROBLEM", 12, 25], ["infection", "OBSERVATION", 16, 25], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["RIVM-HAV16-090-like hepatitis A virus strains, which were >99.6% identical to the 66 reported strains isolated from Taiwan and European countries from 2015 to 2017, were also recovered from Japanese MSM [52] .", [["RIVM-HAV16-090", "CHEMICAL", 0, 14], ["hepatitis A", "DISEASE", 20, 31], ["RIVM-HAV16-090-like hepatitis A virus", "ORGANISM", 0, 37], ["hepatitis A virus", "SPECIES", 20, 37], ["hepatitis A virus", "SPECIES", 20, 37], ["RIVM", "TEST", 0, 4], ["HAV16", "TEST", 5, 10], ["hepatitis A virus strains", "PROBLEM", 20, 45], ["hepatitis", "OBSERVATION", 20, 29]]], ["A recent outbreak of HAV infection was also reported in various countries, such as Brazil, Spain, and Italy [53, [138] [139] [140] .Possible Molecular Mechanism of the Development of ACLF in Patients with HAV InfectionThe molecular mechanism of the development of ACLF in patients with HAV infection is not fully understood.", [["ACLF", "ANATOMY", 264, 268], ["HAV infection", "DISEASE", 21, 34], ["ACLF", "DISEASE", 183, 187], ["HAV Infection", "DISEASE", 205, 218], ["ACLF", "DISEASE", 264, 268], ["HAV infection", "DISEASE", 286, 299], ["HAV", "ORGANISM", 21, 24], ["ACLF", "CANCER", 183, 187], ["Patients", "ORGANISM", 191, 199], ["HAV", "ORGANISM", 205, 208], ["ACLF", "CANCER", 264, 268], ["patients", "ORGANISM", 272, 280], ["HAV", "ORGANISM", 286, 289], ["Patients", "SPECIES", 191, 199], ["patients", "SPECIES", 272, 280], ["HAV", "SPECIES", 21, 24], ["HAV", "SPECIES", 205, 208], ["HAV", "SPECIES", 286, 289], ["HAV infection", "PROBLEM", 21, 34], ["ACLF", "PROBLEM", 183, 187], ["HAV Infection", "PROBLEM", 205, 218], ["ACLF", "PROBLEM", 264, 268], ["HAV infection", "PROBLEM", 286, 299], ["outbreak", "OBSERVATION_MODIFIER", 9, 17], ["HAV", "OBSERVATION_MODIFIER", 21, 24], ["infection", "OBSERVATION", 25, 34], ["ACLF", "OBSERVATION", 183, 187], ["Infection", "OBSERVATION", 209, 218], ["ACLF", "OBSERVATION", 264, 268], ["infection", "OBSERVATION", 290, 299]]], ["The possible mechanisms of the development of liver failure in the presence of coinfection with HCV and HAV are as follows.", [["liver", "ANATOMY", 46, 51], ["liver failure", "DISEASE", 46, 59], ["coinfection", "DISEASE", 79, 90], ["HCV", "DISEASE", 96, 99], ["HAV", "DISEASE", 104, 107], ["liver", "ORGAN", 46, 51], ["HCV", "ORGANISM", 96, 99], ["HAV", "ORGANISM", 104, 107], ["HCV", "SPECIES", 96, 99], ["HAV", "SPECIES", 104, 107], ["liver failure", "PROBLEM", 46, 59], ["coinfection", "PROBLEM", 79, 90], ["HCV and HAV", "PROBLEM", 96, 107], ["possible", "UNCERTAINTY", 4, 12], ["liver", "ANATOMY", 46, 51], ["failure", "OBSERVATION", 52, 59], ["coinfection", "OBSERVATION", 79, 90], ["HCV", "OBSERVATION", 96, 99]]], ["HAV is a virus that is generally sensitive to interferon [100] [101] [102] .", [["HAV", "DISEASE", 0, 3], ["HAV", "ORGANISM", 0, 3], ["HAV", "SPECIES", 0, 3], ["a virus", "PROBLEM", 7, 14], ["interferon", "TREATMENT", 46, 56], ["virus", "OBSERVATION", 9, 14]]], ["In comparison with HCV, HAV induces a limited production of type I interferon when HAV infects chimpanzees [141] .", [["HAV", "DISEASE", 24, 27], ["HCV", "ORGANISM", 19, 22], ["HAV", "ORGANISM", 24, 27], ["type I interferon", "GENE_OR_GENE_PRODUCT", 60, 77], ["HAV", "ORGANISM", 83, 86], ["chimpanzees", "ORGANISM", 95, 106], ["type I interferon", "PROTEIN", 60, 77], ["HCV", "SPECIES", 19, 22], ["HAV", "SPECIES", 24, 27], ["HAV", "SPECIES", 83, 86], ["type I interferon", "TREATMENT", 60, 77], ["HAV infects chimpanzees", "PROBLEM", 83, 106]]], ["Compared with HBV and HCV, HAV weakly induced the activation of NF-\u03baB signaling pathways in human hepatocytes [142, 143] .", [["hepatocytes", "ANATOMY", 98, 109], ["HBV", "ORGANISM", 14, 17], ["HCV", "ORGANISM", 22, 25], ["HAV", "ORGANISM", 27, 30], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 64, 69], ["human", "ORGANISM", 92, 97], ["hepatocytes", "CELL", 98, 109], ["NF-\u03baB", "PROTEIN", 64, 69], ["human hepatocytes", "CELL_TYPE", 92, 109], ["human", "SPECIES", 92, 97], ["HBV", "SPECIES", 14, 17], ["HCV", "SPECIES", 22, 25], ["HAV", "SPECIES", 27, 30], ["human", "SPECIES", 92, 97], ["HBV", "PROBLEM", 14, 17], ["HCV", "PROBLEM", 22, 25], ["NF", "TEST", 64, 66], ["human hepatocytes", "TEST", 92, 109], ["hepatocytes", "ANATOMY", 98, 109]]], ["While HAV VP3 activates cell growth signaling [143] , HAV VP1/2A reduces cell viabilities in HCV sub-genomic replicon cells [144] .Possible Molecular Mechanism of the Development of ACLF in Patients with HAV InfectionHAV is usually a non-cytopathic virus, and HAV inhibits double-stranded (dsRNA)-induced interferon-beta gene expression by influencing the interferon-beta enhanceosome, as well as dsRNA-induced apoptosis [145] .", [["cell", "ANATOMY", 24, 28], ["cell", "ANATOMY", 73, 77], ["cells", "ANATOMY", 118, 123], ["ACLF", "DISEASE", 182, 186], ["HAV InfectionHAV", "DISEASE", 204, 220], ["HAV VP3", "ORGANISM", 6, 13], ["cell", "CELL", 24, 28], ["HAV VP1", "ORGANISM", 54, 61], ["cell", "CELL", 73, 77], ["cells", "CELL", 118, 123], ["ACLF", "CANCER", 182, 186], ["Patients", "ORGANISM", 190, 198], ["HAV", "ORGANISM", 204, 207], ["HAV", "ORGANISM", 260, 263], ["interferon-beta", "GENE_OR_GENE_PRODUCT", 305, 320], ["interferon-beta", "GENE_OR_GENE_PRODUCT", 356, 371], ["HAV VP3", "PROTEIN", 6, 13], ["HAV VP1/2A", "PROTEIN", 54, 64], ["HCV sub-genomic replicon cells", "CELL_LINE", 93, 123], ["interferon-beta gene", "DNA", 305, 325], ["interferon-beta enhanceosome", "PROTEIN", 356, 384], ["Patients", "SPECIES", 190, 198], ["HAV", "SPECIES", 6, 9], ["HCV", "SPECIES", 93, 96], ["HAV", "SPECIES", 204, 207], ["HAV", "SPECIES", 260, 263], ["cell growth signaling", "TEST", 24, 45], ["HAV VP1", "TEST", 54, 61], ["cell viabilities", "TEST", 73, 89], ["HCV sub", "TEST", 93, 100], ["ACLF", "PROBLEM", 182, 186], ["HAV InfectionHAV", "PROBLEM", 204, 220], ["a non-cytopathic virus", "PROBLEM", 232, 254], ["HAV inhibits", "PROBLEM", 260, 272], ["double-stranded (dsRNA)", "TREATMENT", 273, 296], ["interferon", "TREATMENT", 305, 315], ["beta gene expression", "TREATMENT", 316, 336], ["the interferon-beta enhanceosome", "TREATMENT", 352, 384], ["cell viabilities", "OBSERVATION", 73, 89], ["replicon cells", "OBSERVATION", 109, 123], ["ACLF", "OBSERVATION", 182, 186], ["non-cytopathic virus", "OBSERVATION", 234, 254]]], ["Compared with HBV and HCV, HAV could evade mitochondrial antiviral signaling protein (MAVS)-mediated type I interferon responses [146] .", [["mitochondrial", "ANATOMY", 43, 56], ["HBV", "ORGANISM", 14, 17], ["HCV", "ORGANISM", 22, 25], ["HAV", "ORGANISM", 27, 30], ["mitochondrial antiviral signaling protein", "GENE_OR_GENE_PRODUCT", 43, 84], ["MAVS", "GENE_OR_GENE_PRODUCT", 86, 90], ["type I interferon", "GENE_OR_GENE_PRODUCT", 101, 118], ["mitochondrial antiviral signaling protein", "PROTEIN", 43, 84], ["MAVS", "PROTEIN", 86, 90], ["type I interferon", "PROTEIN", 101, 118], ["HBV", "SPECIES", 14, 17], ["HCV", "SPECIES", 22, 25], ["HAV", "SPECIES", 27, 30], ["HBV", "PROBLEM", 14, 17], ["HCV", "PROBLEM", 22, 25], ["mitochondrial antiviral signaling protein", "PROBLEM", 43, 84], ["mitochondrial antiviral", "OBSERVATION", 43, 66]]], ["HAV 3ABC is capable of MAVS cleavage, like HCV NS3/4A, which cleaves MAVS and disrupts interferon signaling [147] .", [["HAV 3ABC", "ORGANISM", 0, 8], ["MAVS", "GENE_OR_GENE_PRODUCT", 23, 27], ["HCV NS3/4A", "ORGANISM", 43, 53], ["MAVS", "GENE_OR_GENE_PRODUCT", 69, 73], ["interferon", "GENE_OR_GENE_PRODUCT", 87, 97], ["HAV 3ABC", "PROTEIN", 0, 8], ["MAVS", "PROTEIN", 23, 27], ["HCV NS3/4A", "PROTEIN", 43, 53], ["MAVS", "PROTEIN", 69, 73], ["interferon", "PROTEIN", 87, 97], ["HAV", "SPECIES", 0, 3], ["HCV", "SPECIES", 43, 46], ["MAVS cleavage", "PROBLEM", 23, 36], ["HCV NS3", "TREATMENT", 43, 50]]], ["HAV 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein [148] .", [["HAV 3C", "ORGANISM", 0, 6], ["HAV", "ORGANISM", 16, 19], ["polypyrimidine tract-binding protein", "GENE_OR_GENE_PRODUCT", 63, 99], ["HAV 3C", "PROTEIN", 0, 6], ["HAV IRES", "DNA", 16, 24], ["polypyrimidine tract-binding protein", "PROTEIN", 63, 99], ["HAV 3C", "SPECIES", 0, 6], ["HAV", "SPECIES", 16, 19], ["HAV IRES", "TREATMENT", 16, 24], ["dependent translation", "TREATMENT", 25, 46], ["the polypyrimidine tract", "TEST", 59, 83], ["binding protein", "TEST", 84, 99]]], ["HCV induces interferon-beta signaling pathways in human hepatocytes [149] .", [["hepatocytes", "ANATOMY", 56, 67], ["HCV", "ORGANISM", 0, 3], ["interferon-beta", "GENE_OR_GENE_PRODUCT", 12, 27], ["human", "ORGANISM", 50, 55], ["hepatocytes [149]", "CELL", 56, 73], ["interferon-beta", "PROTEIN", 12, 27], ["human hepatocytes", "CELL_TYPE", 50, 67], ["human", "SPECIES", 50, 55], ["HCV", "SPECIES", 0, 3], ["human", "SPECIES", 50, 55], ["HCV", "PROBLEM", 0, 3], ["interferon", "TREATMENT", 12, 22], ["beta signaling pathways in human hepatocytes", "PROBLEM", 23, 67], ["interferon", "OBSERVATION", 12, 22], ["hepatocytes", "ANATOMY", 56, 67]]], ["Controlling the effects of interferon signaling may determine the prognosis of patients coinfected with HCV and HAV (Figure 2 ).", [["HCV", "DISEASE", 104, 107], ["HAV", "DISEASE", 112, 115], ["interferon", "GENE_OR_GENE_PRODUCT", 27, 37], ["patients", "ORGANISM", 79, 87], ["HCV", "ORGANISM", 104, 107], ["interferon", "PROTEIN", 27, 37], ["patients", "SPECIES", 79, 87], ["HCV", "SPECIES", 104, 107], ["HAV", "SPECIES", 112, 115], ["interferon signaling", "TREATMENT", 27, 47], ["HCV", "PROBLEM", 104, 107]]], ["HCV induces interferon-beta signaling pathways in human hepatocytes [149] .", [["hepatocytes", "ANATOMY", 56, 67], ["HCV", "ORGANISM", 0, 3], ["interferon-beta", "GENE_OR_GENE_PRODUCT", 12, 27], ["human", "ORGANISM", 50, 55], ["hepatocytes [149]", "CELL", 56, 73], ["interferon-beta", "PROTEIN", 12, 27], ["human hepatocytes", "CELL_TYPE", 50, 67], ["human", "SPECIES", 50, 55], ["HCV", "SPECIES", 0, 3], ["human", "SPECIES", 50, 55], ["HCV", "PROBLEM", 0, 3], ["interferon", "TREATMENT", 12, 22], ["beta signaling pathways in human hepatocytes", "PROBLEM", 23, 67], ["interferon", "OBSERVATION", 12, 22], ["hepatocytes", "ANATOMY", 56, 67]]], ["Controlling the effects of interferon signaling may determine the prognosis of patients coinfected with HCV and HAV (Figure 2 ).", [["HCV", "DISEASE", 104, 107], ["HAV", "DISEASE", 112, 115], ["interferon", "GENE_OR_GENE_PRODUCT", 27, 37], ["patients", "ORGANISM", 79, 87], ["HCV", "ORGANISM", 104, 107], ["interferon", "PROTEIN", 27, 37], ["patients", "SPECIES", 79, 87], ["HCV", "SPECIES", 104, 107], ["HAV", "SPECIES", 112, 115], ["interferon signaling", "TREATMENT", 27, 47], ["HCV", "PROBLEM", 104, 107]]], ["HBV is a stealth virus which efficiently infects humans without alerting the innate immune system, although HCV strongly induces but cunningly evades the innate immune response [150] .", [["HBV", "ORGANISM", 0, 3], ["humans", "ORGANISM", 49, 55], ["immune system", "ANATOMICAL_SYSTEM", 84, 97], ["HCV", "ORGANISM", 108, 111], ["humans", "SPECIES", 49, 55], ["HBV", "SPECIES", 0, 3], ["humans", "SPECIES", 49, 55], ["HCV", "SPECIES", 108, 111], ["HBV", "PROBLEM", 0, 3], ["a stealth virus", "PROBLEM", 7, 22], ["stealth virus", "OBSERVATION", 9, 22]]], ["The high glucose and fat deposition of hepatocytes seem to induce a chaperon-mediated autophagy (CMA) [151] .", [["fat", "ANATOMY", 21, 24], ["hepatocytes", "ANATOMY", 39, 50], ["glucose", "CHEMICAL", 9, 16], ["glucose", "CHEMICAL", 9, 16], ["glucose", "SIMPLE_CHEMICAL", 9, 16], ["fat", "TISSUE", 21, 24], ["hepatocytes", "CELL", 39, 50], ["hepatocytes", "CELL_TYPE", 39, 50], ["The high glucose and fat deposition of hepatocytes", "PROBLEM", 0, 50], ["hepatocytes", "ANATOMY", 39, 50]]], ["CMA targets interferon-alpha receptor chain-1 for degradation, dampens hepatic innate immunity, and disrupts interferon signaling pathways [151] .", [["hepatic", "ANATOMY", 71, 78], ["CMA", "CHEMICAL", 0, 3], ["CMA", "SIMPLE_CHEMICAL", 0, 3], ["interferon-alpha receptor chain-1", "GENE_OR_GENE_PRODUCT", 12, 45], ["hepatic", "ORGAN", 71, 78], ["interferon", "GENE_OR_GENE_PRODUCT", 109, 119], ["interferon-alpha receptor chain-1", "PROTEIN", 12, 45], ["interferon", "PROTEIN", 109, 119], ["CMA", "TEST", 0, 3], ["interferon", "TEST", 12, 22], ["alpha receptor chain", "TREATMENT", 23, 43], ["degradation", "PROBLEM", 50, 61], ["hepatic", "ANATOMY", 71, 78]]], ["CMA is also observed in patients with ALD or MAFLD [152, 153] .", [["ALD", "DISEASE", 38, 41], ["MAFLD", "DISEASE", 45, 50], ["CMA", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["Altering interferon signaling may contribute to ALF-associated acute HAV infection.", [["ALF", "DISEASE", 48, 51], ["HAV infection", "DISEASE", 69, 82], ["ALF", "CHEMICAL", 48, 51], ["interferon", "GENE_OR_GENE_PRODUCT", 9, 19], ["ALF", "GENE_OR_GENE_PRODUCT", 48, 51], ["HAV", "ORGANISM", 69, 72], ["interferon", "PROTEIN", 9, 19], ["HAV", "SPECIES", 69, 72], ["Altering interferon signaling", "PROBLEM", 0, 29], ["ALF", "PROBLEM", 48, 51], ["acute HAV infection", "PROBLEM", 63, 82], ["may contribute to", "UNCERTAINTY", 30, 47], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["HAV", "OBSERVATION_MODIFIER", 69, 72], ["infection", "OBSERVATION", 73, 82]]], ["However, further studies are needed.", [["further studies", "TEST", 9, 24]]], ["Among HIV-positive patients with acute HAV infection, lower peaks in total bilirubin, AST, and ALT levels were observed in comparison with HIV- HBV is a stealth virus which efficiently infects humans without alerting the innate immune system, although HCV strongly induces but cunningly evades the innate immune response [150] .", [["HIV-positive", "DISEASE", 6, 18], ["HAV infection", "DISEASE", 39, 52], ["bilirubin", "CHEMICAL", 75, 84], ["bilirubin", "CHEMICAL", 75, 84], ["HIV", "ORGANISM", 6, 9], ["patients", "ORGANISM", 19, 27], ["HAV", "ORGANISM", 39, 42], ["bilirubin", "GENE_OR_GENE_PRODUCT", 75, 84], ["AST", "SIMPLE_CHEMICAL", 86, 89], ["ALT", "SIMPLE_CHEMICAL", 95, 98], ["HIV- HBV", "ORGANISM", 139, 147], ["humans", "ORGANISM", 193, 199], ["immune system", "ANATOMICAL_SYSTEM", 228, 241], ["HCV", "ORGANISM", 252, 255], ["AST", "PROTEIN", 86, 89], ["ALT", "PROTEIN", 95, 98], ["HIV", "SPECIES", 6, 9], ["patients", "SPECIES", 19, 27], ["HIV- HBV", "SPECIES", 139, 147], ["humans", "SPECIES", 193, 199], ["HIV", "SPECIES", 6, 9], ["HAV", "SPECIES", 39, 42], ["HIV- HBV", "SPECIES", 139, 147], ["humans", "SPECIES", 193, 199], ["HCV", "SPECIES", 252, 255], ["acute HAV infection", "PROBLEM", 33, 52], ["lower peaks", "PROBLEM", 54, 65], ["total bilirubin", "TEST", 69, 84], ["AST", "TEST", 86, 89], ["ALT levels", "TEST", 95, 105], ["HIV", "PROBLEM", 139, 142], ["HBV", "PROBLEM", 144, 147], ["a stealth virus", "PROBLEM", 151, 166], ["HCV strongly", "PROBLEM", 252, 264], ["positive patients", "OBSERVATION_MODIFIER", 10, 27], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["HAV", "OBSERVATION_MODIFIER", 39, 42], ["infection", "OBSERVATION", 43, 52], ["lower peaks", "OBSERVATION_MODIFIER", 54, 65]]], ["The high glucose and fat deposition of hepatocytes seem to induce a chaperon-mediated autophagy (CMA) [151] .", [["fat", "ANATOMY", 21, 24], ["hepatocytes", "ANATOMY", 39, 50], ["glucose", "CHEMICAL", 9, 16], ["glucose", "CHEMICAL", 9, 16], ["glucose", "SIMPLE_CHEMICAL", 9, 16], ["fat", "TISSUE", 21, 24], ["hepatocytes", "CELL", 39, 50], ["hepatocytes", "CELL_TYPE", 39, 50], ["The high glucose and fat deposition of hepatocytes", "PROBLEM", 0, 50], ["hepatocytes", "ANATOMY", 39, 50]]], ["CMA targets interferon-alpha receptor chain-1 for degradation, dampens hepatic innate immunity, and disrupts interferon signaling pathways [151] .", [["hepatic", "ANATOMY", 71, 78], ["CMA", "CHEMICAL", 0, 3], ["CMA", "SIMPLE_CHEMICAL", 0, 3], ["interferon-alpha receptor chain-1", "GENE_OR_GENE_PRODUCT", 12, 45], ["hepatic", "ORGAN", 71, 78], ["interferon", "GENE_OR_GENE_PRODUCT", 109, 119], ["interferon-alpha receptor chain-1", "PROTEIN", 12, 45], ["interferon", "PROTEIN", 109, 119], ["CMA", "TEST", 0, 3], ["interferon", "TEST", 12, 22], ["alpha receptor chain", "TREATMENT", 23, 43], ["degradation", "PROBLEM", 50, 61], ["hepatic", "ANATOMY", 71, 78]]], ["CMA is also observed in patients with ALD or MAFLD [152, 153] .", [["ALD", "DISEASE", 38, 41], ["MAFLD", "DISEASE", 45, 50], ["CMA", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["Altering interferon signaling may contribute to ALF-associated acute HAV infection.", [["ALF", "DISEASE", 48, 51], ["HAV infection", "DISEASE", 69, 82], ["ALF", "CHEMICAL", 48, 51], ["interferon", "GENE_OR_GENE_PRODUCT", 9, 19], ["ALF", "GENE_OR_GENE_PRODUCT", 48, 51], ["HAV", "ORGANISM", 69, 72], ["interferon", "PROTEIN", 9, 19], ["HAV", "SPECIES", 69, 72], ["Altering interferon signaling", "PROBLEM", 0, 29], ["ALF", "PROBLEM", 48, 51], ["acute HAV infection", "PROBLEM", 63, 82], ["may contribute to", "UNCERTAINTY", 30, 47], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["HAV", "OBSERVATION_MODIFIER", 69, 72], ["infection", "OBSERVATION", 73, 82]]], ["However, further studies are needed.", [["further studies", "TEST", 9, 24]]], ["Among HIV-positive patients with acute HAV infection, lower peaks in total bilirubin, AST, and ALT levels were observed in comparison with HIV-negative patients with acute HAV infection [154] , suggesting that weaker immune responses occur in HIV-positive patients.", [["HIV-positive", "DISEASE", 6, 18], ["HAV infection", "DISEASE", 39, 52], ["bilirubin", "CHEMICAL", 75, 84], ["HAV infection", "DISEASE", 172, 185], ["HIV-positive", "DISEASE", 243, 255], ["bilirubin", "CHEMICAL", 75, 84], ["HIV", "ORGANISM", 6, 9], ["patients", "ORGANISM", 19, 27], ["HAV", "ORGANISM", 39, 42], ["bilirubin", "GENE_OR_GENE_PRODUCT", 75, 84], ["AST", "SIMPLE_CHEMICAL", 86, 89], ["ALT", "SIMPLE_CHEMICAL", 95, 98], ["HIV", "ORGANISM", 139, 142], ["patients", "ORGANISM", 152, 160], ["HAV", "ORGANISM", 172, 175], ["HIV", "ORGANISM", 243, 246], ["patients", "ORGANISM", 256, 264], ["AST", "PROTEIN", 86, 89], ["ALT", "PROTEIN", 95, 98], ["HIV", "SPECIES", 6, 9], ["patients", "SPECIES", 19, 27], ["HIV", "SPECIES", 139, 142], ["patients", "SPECIES", 152, 160], ["HIV", "SPECIES", 243, 246], ["patients", "SPECIES", 256, 264], ["HIV", "SPECIES", 6, 9], ["HAV", "SPECIES", 39, 42], ["HIV", "SPECIES", 139, 142], ["HAV", "SPECIES", 172, 175], ["HIV", "SPECIES", 243, 246], ["acute HAV infection", "PROBLEM", 33, 52], ["lower peaks", "PROBLEM", 54, 65], ["total bilirubin", "TEST", 69, 84], ["AST", "TEST", 86, 89], ["ALT levels", "TEST", 95, 105], ["HIV", "TEST", 139, 142], ["acute HAV infection", "PROBLEM", 166, 185], ["weaker immune responses", "PROBLEM", 210, 233], ["positive patients", "OBSERVATION_MODIFIER", 10, 27], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["HAV", "OBSERVATION_MODIFIER", 39, 42], ["infection", "OBSERVATION", 43, 52], ["lower peaks", "OBSERVATION_MODIFIER", 54, 65], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["infection", "OBSERVATION", 176, 185]]], ["These immune responses could enhance HAV replication and modify the pathogenesis in HIV-positive patients with acute hepatitis A [155] .ConclusionsWe reviewed the literature concerning HAV infection in patients with chronic liver diseases.", [["liver", "ANATOMY", 224, 229], ["HIV-positive", "DISEASE", 84, 96], ["acute hepatitis A", "DISEASE", 111, 128], ["HAV infection", "DISEASE", 185, 198], ["chronic liver diseases", "DISEASE", 216, 238], ["HAV", "ORGANISM", 37, 40], ["HIV", "ORGANISM", 84, 87], ["patients", "ORGANISM", 97, 105], ["HAV", "ORGANISM", 185, 188], ["patients", "ORGANISM", 202, 210], ["liver", "ORGAN", 224, 229], ["HIV", "SPECIES", 84, 87], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 202, 210], ["HAV", "SPECIES", 37, 40], ["HIV", "SPECIES", 84, 87], ["HAV", "SPECIES", 185, 188], ["HAV replication", "TREATMENT", 37, 52], ["acute hepatitis A", "PROBLEM", 111, 128], ["HAV infection", "PROBLEM", 185, 198], ["chronic liver diseases", "PROBLEM", 216, 238], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["hepatitis", "OBSERVATION", 117, 126], ["infection", "OBSERVATION", 189, 198], ["chronic", "OBSERVATION_MODIFIER", 216, 223], ["liver", "ANATOMY", 224, 229], ["diseases", "OBSERVATION", 230, 238]]], ["In patients with chronic liver diseases, HAV infection can occasionally lead to a critical condition, such as acute liver failure.", [["liver", "ANATOMY", 25, 30], ["liver", "ANATOMY", 116, 121], ["chronic liver diseases", "DISEASE", 17, 39], ["HAV infection", "DISEASE", 41, 54], ["acute liver failure", "DISEASE", 110, 129], ["patients", "ORGANISM", 3, 11], ["liver", "ORGAN", 25, 30], ["HAV", "ORGANISM", 41, 44], ["liver", "ORGAN", 116, 121], ["patients", "SPECIES", 3, 11], ["HAV", "SPECIES", 41, 44], ["chronic liver diseases", "PROBLEM", 17, 39], ["HAV infection", "PROBLEM", 41, 54], ["a critical condition", "PROBLEM", 80, 100], ["acute liver failure", "PROBLEM", 110, 129], ["chronic", "OBSERVATION_MODIFIER", 17, 24], ["liver", "ANATOMY", 25, 30], ["diseases", "OBSERVATION", 31, 39], ["infection", "OBSERVATION", 45, 54], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["liver", "ANATOMY", 116, 121], ["failure", "OBSERVATION", 122, 129]]], ["There seems to be no etiological association between liver failure and HAV infection, but there is a significant correlation between the severity of liver disease and the degree to which the liver has already been damaged.", [["liver", "ANATOMY", 53, 58], ["liver", "ANATOMY", 149, 154], ["liver", "ANATOMY", 191, 196], ["liver failure", "DISEASE", 53, 66], ["HAV infection", "DISEASE", 71, 84], ["liver disease", "DISEASE", 149, 162], ["liver", "ORGAN", 53, 58], ["HAV", "ORGANISM", 71, 74], ["liver", "ORGAN", 149, 154], ["liver", "ORGAN", 191, 196], ["HAV", "SPECIES", 71, 74], ["liver failure", "PROBLEM", 53, 66], ["HAV infection", "PROBLEM", 71, 84], ["liver disease", "PROBLEM", 149, 162], ["seems to be no", "UNCERTAINTY", 6, 20], ["liver", "ANATOMY", 53, 58], ["failure", "OBSERVATION", 59, 66], ["HAV", "OBSERVATION_MODIFIER", 71, 74], ["infection", "OBSERVATION", 75, 84], ["significant", "OBSERVATION_MODIFIER", 101, 112], ["liver", "ANATOMY", 149, 154], ["disease", "OBSERVATION", 155, 162], ["degree", "OBSERVATION_MODIFIER", 171, 177], ["liver", "ANATOMY", 191, 196], ["damaged", "OBSERVATION", 214, 221]]], ["While there are effective HAV vaccines currently in existence, antivirals against HAV should be further explored.", [["HAV", "DISEASE", 82, 85], ["HAV", "ORGANISM", 26, 29], ["HAV", "ORGANISM", 82, 85], ["HAV", "SPECIES", 26, 29], ["HAV", "SPECIES", 82, 85], ["effective HAV vaccines", "TREATMENT", 16, 38], ["antivirals", "TREATMENT", 63, 73], ["HAV", "TREATMENT", 82, 85]]], ["The latter is urgent given that the lives of patients with HAV infection and a chronic liver disease of another etiology may be at immediate risk.Conflicts of Interest:The authors declare no conflict of interest.", [["liver", "ANATOMY", 87, 92], ["HAV infection", "DISEASE", 59, 72], ["chronic liver disease", "DISEASE", 79, 100], ["patients", "ORGANISM", 45, 53], ["HAV", "ORGANISM", 59, 62], ["liver", "ORGAN", 87, 92], ["patients", "SPECIES", 45, 53], ["HAV", "SPECIES", 59, 62], ["HAV infection", "PROBLEM", 59, 72], ["a chronic liver disease", "PROBLEM", 77, 100], ["infection", "OBSERVATION", 63, 72], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["liver", "ANATOMY", 87, 92], ["disease", "OBSERVATION", 93, 100]]], ["The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.", [["the study", "TEST", 41, 50]]]], "4caaed0a895de3081811e4c7888209e1920ea42f": [["INTRODUCTIONThe pulmonary transition from intrauterine environment to normal postnatal air breathing is vulnerable and may cause a multitude of pulmonary complications that are increasingly prevalent with decreasing gestational age of the newborn infant.", [["pulmonary", "ANATOMY", 16, 25], ["intrauterine", "ANATOMY", 42, 54], ["pulmonary", "ANATOMY", 144, 153], ["pulmonary complications", "DISEASE", 144, 167], ["pulmonary", "ORGAN", 16, 25], ["pulmonary", "ORGAN", 144, 153], ["infant", "ORGANISM", 247, 253], ["infant", "SPECIES", 247, 253], ["The pulmonary transition", "PROBLEM", 12, 36], ["intrauterine environment", "PROBLEM", 42, 66], ["pulmonary complications", "PROBLEM", 144, 167], ["pulmonary", "ANATOMY", 16, 25], ["intrauterine", "OBSERVATION", 42, 54], ["air breathing", "OBSERVATION", 87, 100], ["may cause", "UNCERTAINTY", 119, 128], ["pulmonary", "ANATOMY", 144, 153], ["complications", "OBSERVATION", 154, 167]]], ["Abnormal pulmonary aeration is common in neonatal lung diseases.", [["pulmonary", "ANATOMY", 9, 18], ["lung", "ANATOMY", 50, 54], ["neonatal lung diseases", "DISEASE", 41, 63], ["pulmonary", "ORGAN", 9, 18], ["lung", "ORGAN", 50, 54], ["Abnormal pulmonary aeration", "PROBLEM", 0, 27], ["neonatal lung diseases", "PROBLEM", 41, 63], ["pulmonary", "ANATOMY", 9, 18], ["aeration", "OBSERVATION", 19, 27], ["neonatal", "OBSERVATION_MODIFIER", 41, 49], ["lung", "ANATOMY", 50, 54], ["diseases", "OBSERVATION", 55, 63]]], ["Despite modern synchronized respiratory support methods or minimally invasive surfactant therapy, there is still a risk of life-threatening complications such as pneumothorax, 1 and bronchopulmonary dysplasia remains a major problem and a long-term consequence of the acutely ill preterm lung.", [["respiratory", "ANATOMY", 28, 39], ["bronchopulmonary dysplasia", "ANATOMY", 182, 208], ["lung", "ANATOMY", 288, 292], ["pneumothorax", "DISEASE", 162, 174], ["bronchopulmonary dysplasia", "DISEASE", 182, 208], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 182, 208], ["lung", "ORGAN", 288, 292], ["modern synchronized respiratory support methods", "TREATMENT", 8, 55], ["minimally invasive surfactant therapy", "TREATMENT", 59, 96], ["life-threatening complications", "PROBLEM", 123, 153], ["pneumothorax", "PROBLEM", 162, 174], ["bronchopulmonary dysplasia", "PROBLEM", 182, 208], ["a major problem", "PROBLEM", 217, 232], ["the acutely ill preterm lung", "PROBLEM", 264, 292], ["respiratory support", "OBSERVATION", 28, 47], ["minimally", "OBSERVATION_MODIFIER", 59, 68], ["invasive", "OBSERVATION_MODIFIER", 69, 77], ["surfactant therapy", "OBSERVATION", 78, 96], ["pneumothorax", "OBSERVATION", 162, 174], ["bronchopulmonary", "ANATOMY", 182, 198], ["dysplasia", "OBSERVATION", 199, 208], ["long-term", "OBSERVATION_MODIFIER", 239, 248], ["acutely", "OBSERVATION_MODIFIER", 268, 275], ["ill", "OBSERVATION_MODIFIER", 276, 279], ["preterm", "OBSERVATION", 280, 287], ["lung", "ANATOMY", 288, 292]]], ["2 Thereby, a continuous measure of lung aeration may be useful for improving the precision of ventilatory support and detection of air leaks or inadequately ventilated regions of the lung.INTRODUCTIONPresently, most lung problems are diagnosed with pulmonary X-ray, which only gives a snapshot of the current condition and causes harmful radiation, increasing the risk of malignancy development later in life.", [["lung", "ANATOMY", 35, 39], ["lung", "ANATOMY", 183, 187], ["lung", "ANATOMY", 216, 220], ["pulmonary", "ANATOMY", 249, 258], ["air leaks", "DISEASE", 131, 140], ["lung problems", "DISEASE", 216, 229], ["malignancy", "DISEASE", 372, 382], ["lung", "ORGAN", 35, 39], ["lung", "ORGAN", 183, 187], ["lung", "ORGAN", 216, 220], ["malignancy", "CANCER", 372, 382], ["lung aeration", "TREATMENT", 35, 48], ["ventilatory support", "TREATMENT", 94, 113], ["air leaks", "PROBLEM", 131, 140], ["inadequately ventilated regions of the lung", "PROBLEM", 144, 187], ["most lung problems", "PROBLEM", 211, 229], ["pulmonary X-ray", "TEST", 249, 264], ["harmful radiation", "TREATMENT", 330, 347], ["malignancy development", "PROBLEM", 372, 394], ["lung", "ANATOMY", 35, 39], ["aeration", "OBSERVATION", 40, 48], ["ventilatory support", "OBSERVATION", 94, 113], ["air leaks", "OBSERVATION", 131, 140], ["inadequately", "OBSERVATION_MODIFIER", 144, 156], ["ventilated", "OBSERVATION", 157, 167], ["lung", "ANATOMY", 183, 187], ["lung", "ANATOMY", 216, 220], ["problems", "OBSERVATION", 221, 229], ["pulmonary", "ANATOMY", 249, 258], ["harmful", "OBSERVATION_MODIFIER", 330, 337], ["radiation", "OBSERVATION", 338, 347], ["malignancy", "OBSERVATION", 372, 382]]], ["3, 4 Research efforts have been directed towards the development of noninvasive alternatives to X-ray imaging.", [["X-ray imaging", "TEST", 96, 109]]], ["Currently, lung ultrasound imaging 5 can be used for the detection of pneumothorax, consolidated lung parts and pleural effusions (e.g. blood).", [["lung", "ANATOMY", 11, 15], ["lung parts", "ANATOMY", 97, 107], ["pleural effusions", "ANATOMY", 112, 129], ["blood", "ANATOMY", 136, 141], ["pneumothorax", "DISEASE", 70, 82], ["pleural effusions", "DISEASE", 112, 129], ["lung", "ORGAN", 11, 15], ["lung parts", "MULTI-TISSUE_STRUCTURE", 97, 107], ["pleural effusions", "CANCER", 112, 129], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["lung ultrasound imaging", "TEST", 11, 34], ["the detection", "TEST", 53, 66], ["pneumothorax", "PROBLEM", 70, 82], ["consolidated lung parts", "PROBLEM", 84, 107], ["pleural effusions", "PROBLEM", 112, 129], ["lung", "ANATOMY", 11, 15], ["pneumothorax", "OBSERVATION", 70, 82], ["consolidated", "OBSERVATION", 84, 96], ["lung", "ANATOMY", 97, 101], ["parts", "ANATOMY_MODIFIER", 102, 107], ["pleural", "ANATOMY", 112, 119], ["effusions", "OBSERVATION", 120, 129]]], ["However, since nearly 100% of the ultrasound pulses are reflected by gas, the amount of air in the lungs cannot be estimated.", [["lungs", "ANATOMY", 99, 104], ["lungs", "ORGAN", 99, 104], ["the ultrasound pulses", "TEST", 30, 51], ["air in the lungs", "PROBLEM", 88, 104], ["gas", "OBSERVATION", 69, 72], ["amount", "OBSERVATION_MODIFIER", 78, 84], ["air", "OBSERVATION", 88, 91], ["lungs", "ANATOMY", 99, 104], ["cannot be", "UNCERTAINTY", 105, 114]]], ["The technique is emerging as an alternative to chest X-ray, 6 but it is user-dependent and provides only momentary information.INTRODUCTIONA new optical technique called gas in scattering media absorption spectroscopy (GASMAS), 7 based on tunable diode laser absorption spectroscopy (TDLAS), detects gas concentration by free gas absorption in cavities surrounded by multiple light scattering media.", [["chest X-ray", "TEST", 47, 58], ["scattering media absorption spectroscopy", "TEST", 177, 217], ["tunable diode laser absorption spectroscopy", "TREATMENT", 239, 282], ["gas concentration", "TEST", 300, 317], ["free gas absorption in cavities", "PROBLEM", 321, 352], ["multiple light scattering media", "PROBLEM", 367, 398], ["chest", "ANATOMY", 47, 52], ["free", "OBSERVATION_MODIFIER", 321, 325], ["gas absorption", "OBSERVATION", 326, 340], ["cavities", "ANATOMY_MODIFIER", 344, 352], ["multiple", "OBSERVATION_MODIFIER", 367, 375], ["light", "OBSERVATION_MODIFIER", 376, 381], ["scattering media", "OBSERVATION", 382, 398]]], ["8 The high-resolution spectroscopic technique detects spectrally narrow gas absorption features in the surrounding wide band absorption of the tissue.", [["tissue", "ANATOMY", 143, 149], ["tissue", "TISSUE", 143, 149], ["spectrally narrow gas absorption features", "PROBLEM", 54, 95], ["the surrounding wide band absorption of the tissue", "PROBLEM", 99, 149], ["narrow", "OBSERVATION_MODIFIER", 65, 71], ["gas absorption", "OBSERVATION", 72, 86], ["wide", "OBSERVATION_MODIFIER", 115, 119], ["band absorption", "OBSERVATION", 120, 135], ["tissue", "ANATOMY", 143, 149]]], ["We have applied this technique on phantoms of newborn lung 9-11 and on healthy newborn infants 12 and showed that pulmonary O 2 content could be detected.", [["lung", "ANATOMY", 54, 58], ["pulmonary", "ANATOMY", 114, 123], ["O 2", "CHEMICAL", 124, 127], ["lung", "ORGAN", 54, 58], ["infants", "ORGANISM", 87, 94], ["pulmonary O 2", "SIMPLE_CHEMICAL", 114, 127], ["infants", "SPECIES", 87, 94], ["this technique on phantoms of newborn lung", "TREATMENT", 16, 58], ["lung", "ANATOMY", 54, 58], ["pulmonary", "ANATOMY", 114, 123]]], ["13 In addition, the method allows determination of water vapor (H 2 O) absorption path length, which enables evaluation of lung volume and pulmonary O 2 concentration.", [["lung", "ANATOMY", 123, 127], ["pulmonary", "ANATOMY", 139, 148], ["H 2 O", "CHEMICAL", 64, 69], ["O 2", "CHEMICAL", 149, 152], ["water", "SIMPLE_CHEMICAL", 51, 56], ["lung", "ORGAN", 123, 127], ["water vapor (H 2 O) absorption path length", "TREATMENT", 51, 93], ["evaluation of lung volume", "TEST", 109, 134], ["lung", "ANATOMY", 123, 127], ["volume", "OBSERVATION", 128, 134], ["pulmonary", "ANATOMY", 139, 148]]], ["10, 13 A challenge when using optical methods in biological tissues is the strong light scattering and absorption leading to considerable attenuation of detectable light and weak signals.", [["tissues", "ANATOMY", 60, 67], ["tissues", "TISSUE", 60, 67], ["A challenge", "TREATMENT", 7, 18], ["optical methods", "TREATMENT", 30, 45], ["considerable attenuation of detectable light and weak signals", "PROBLEM", 125, 186]]], ["Much of the light emitted through the skin is scattered, and only a small portion of the light reaches the detector.", [["skin", "ANATOMY", 38, 42], ["skin", "ORGAN", 38, 42], ["skin", "ANATOMY", 38, 42], ["scattered", "OBSERVATION_MODIFIER", 46, 55], ["small", "OBSERVATION_MODIFIER", 68, 73]]], ["The approach with internal illumination would increase the amount of light reaching the detector.", [["The approach", "TREATMENT", 0, 12], ["internal illumination", "TREATMENT", 18, 39], ["amount", "OBSERVATION_MODIFIER", 59, 65]]], ["This approach has successfully been used in our phantom studies.", [["This approach", "TREATMENT", 0, 13], ["our phantom studies", "TEST", 44, 63]]], ["14 We hypothesized that the GASMAS method with an external as well as an internal light source probe would detect changes in pulmonary O 2 gas concentration, including responses to induced local lung pathologies in newborn piglets.Animal preparation and monitoringDanish Landrace newborn piglets underwent routine care at the farm together with siblings until transported to the animal facilities of Copenhagen University.", [["pulmonary", "ANATOMY", 125, 134], ["lung", "ANATOMY", 195, 199], ["lung pathologies", "DISEASE", 195, 211], ["O 2", "CHEMICAL", 135, 138], ["lung", "ORGAN", 195, 199], ["piglets", "ORGANISM", 223, 230], ["piglets", "ORGANISM", 288, 295], ["piglets", "SPECIES", 223, 230], ["piglets", "SPECIES", 288, 295], ["Landrace", "SPECIES", 271, 279], ["the GASMAS method", "TEST", 24, 41], ["changes in pulmonary O 2 gas concentration", "PROBLEM", 114, 156], ["induced local lung pathologies", "PROBLEM", 181, 211], ["Animal preparation", "TREATMENT", 231, 249], ["routine care", "TREATMENT", 306, 318], ["pulmonary", "ANATOMY", 125, 134], ["lung", "ANATOMY", 195, 199], ["pathologies", "OBSERVATION", 200, 211], ["newborn piglets", "OBSERVATION", 215, 230]]], ["The Danish Animal Experiments Inspectorate approved the study protocol (2018-15-0201-01403).", [["the study protocol", "TEST", 52, 70]]], ["All responsible researchers had current animal handling certificate and the experiments were performed according to FELASA (Federation of Laboratory Animal Science Associations) guidelines and national regulations.Animal preparation and monitoringFive healthy piglets, at a mean age of 14 days (range 13 \u221215 days) and a median weight of 3.2 kg (range 3.1-3.3 kg), were used.", [["piglets", "ORGANISM", 260, 267], ["piglets", "SPECIES", 260, 267], ["Animal preparation", "TREATMENT", 214, 232], ["a median weight", "TEST", 318, 333]]], ["Anesthesia was induced by an intramuscular injection of 1 ml/kg Zoletil (tiletamine 25 mg/ml, zolazepam 25 mg/ml, xylazine 25 mg/ml, ketamine 25 mg/ml, methadone 4 mg/ml, buthorphanol 4 mg/ml) and was maintained by infusion of propofol (15 mg/ kg/h) and fentanyl (7 \u00b5g/kg/h).", [["intramuscular", "ANATOMY", 29, 42], ["Zoletil", "CHEMICAL", 64, 71], ["tiletamine", "CHEMICAL", 73, 83], ["zolazepam", "CHEMICAL", 94, 103], ["xylazine", "CHEMICAL", 114, 122], ["ketamine", "CHEMICAL", 133, 141], ["methadone", "CHEMICAL", 152, 161], ["buthorphanol", "CHEMICAL", 171, 183], ["propofol", "CHEMICAL", 227, 235], ["fentanyl", "CHEMICAL", 254, 262], ["Zoletil", "CHEMICAL", 64, 71], ["tiletamine", "CHEMICAL", 73, 83], ["zolazepam", "CHEMICAL", 94, 103], ["xylazine", "CHEMICAL", 114, 122], ["ketamine", "CHEMICAL", 133, 141], ["methadone", "CHEMICAL", 152, 161], ["buthorphanol", "CHEMICAL", 171, 183], ["propofol", "CHEMICAL", 227, 235], ["fentanyl", "CHEMICAL", 254, 262], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 42], ["Zoletil", "SIMPLE_CHEMICAL", 64, 71], ["tiletamine", "SIMPLE_CHEMICAL", 73, 83], ["zolazepam", "SIMPLE_CHEMICAL", 94, 103], ["xylazine", "SIMPLE_CHEMICAL", 114, 122], ["ketamine", "SIMPLE_CHEMICAL", 133, 141], ["buthorphanol", "SIMPLE_CHEMICAL", 171, 183], ["propofol", "SIMPLE_CHEMICAL", 227, 235], ["fentanyl", "SIMPLE_CHEMICAL", 254, 262], ["Anesthesia", "TREATMENT", 0, 10], ["an intramuscular injection", "TREATMENT", 26, 52], ["Zoletil", "TREATMENT", 64, 71], ["tiletamine", "TREATMENT", 73, 83], ["zolazepam", "TREATMENT", 94, 103], ["xylazine", "TREATMENT", 114, 122], ["ketamine", "TREATMENT", 133, 141], ["methadone", "TREATMENT", 152, 161], ["buthorphanol", "TREATMENT", 171, 183], ["propofol", "TREATMENT", 227, 235], ["fentanyl", "TREATMENT", 254, 262]]], ["After sedation, the piglets were endotracheally intubated and connected to a pressure-controlled ventilator.", [["piglets", "ORGANISM", 20, 27], ["piglets", "SPECIES", 20, 27], ["sedation", "TREATMENT", 6, 14], ["the piglets", "TREATMENT", 16, 27], ["a pressure-controlled ventilator", "TREATMENT", 75, 107]]], ["At 3 h after initiation of anesthesia, 1 ml/kg Zoletil was administered intravenously, and at any signs of distress or poor sedation additional dose of 0.1 ml Zoletil was given.", [["intravenously", "ANATOMY", 72, 85], ["Zoletil", "CHEMICAL", 47, 54], ["Zoletil", "CHEMICAL", 159, 166], ["Zoletil", "CHEMICAL", 47, 54], ["Zoletil", "CHEMICAL", 159, 166], ["Zoletil", "SIMPLE_CHEMICAL", 47, 54], ["Zoletil", "SIMPLE_CHEMICAL", 159, 166], ["anesthesia", "TREATMENT", 27, 37], ["Zoletil", "TREATMENT", 47, 54], ["distress", "PROBLEM", 107, 115], ["poor sedation", "TREATMENT", 119, 132], ["0.1 ml Zoletil", "TREATMENT", 152, 166]]], ["Arterial CO 2 was kept between 4.5 and 6.5 kPa and arterial saturation above 95%.", [["Arterial", "ANATOMY", 0, 8], ["arterial", "ANATOMY", 51, 59], ["CO 2", "CHEMICAL", 9, 13], ["Arterial", "MULTI-TISSUE_STRUCTURE", 0, 8], ["arterial", "MULTI-TISSUE_STRUCTURE", 51, 59], ["Arterial CO", "TEST", 0, 11], ["arterial saturation", "TEST", 51, 70], ["arterial", "ANATOMY", 51, 59]]], ["A heat moister exchanger (Humid-vent\u00ae mini, Teleflex, Morrisville, North Carolina) was connected between the ventilator and the endotracheal tube.", [["endotracheal tube", "ANATOMY", 128, 145], ["endotracheal tube", "TISSUE", 128, 145], ["A heat moister exchanger", "TREATMENT", 0, 24], ["Humid-vent\u00ae mini", "TREATMENT", 26, 42], ["the ventilator", "TREATMENT", 105, 119], ["the endotracheal tube", "TREATMENT", 124, 145], ["ventilator", "ANATOMY", 109, 119], ["endotracheal tube", "OBSERVATION", 128, 145]]], ["Arterial saturation was continuously monitored by pulse oximetry on the foreleg (Radical 7 \u00ae , Massimo, Irvine, Canada).", [["Arterial", "ANATOMY", 0, 8], ["Arterial", "MULTI-TISSUE_STRUCTURE", 0, 8], ["Arterial saturation", "TEST", 0, 19], ["pulse oximetry", "TEST", 50, 64], ["Radical", "TREATMENT", 81, 88]]], ["Normal rectal temperature was maintained (38.5 \u221239.5\u00b0C) by a heating pad.", [["rectal", "ANATOMY", 7, 13], ["rectal", "ORGAN", 7, 13], ["a heating pad", "TREATMENT", 59, 72], ["rectal", "ANATOMY", 7, 13]]], ["The femoral artery was cannulated for continuous invasive monitoring of mean arterial blood pressure and heart rate.", [["femoral artery", "ANATOMY", 4, 18], ["arterial", "ANATOMY", 77, 85], ["blood", "ANATOMY", 86, 91], ["heart", "ANATOMY", 105, 110], ["femoral artery", "MULTI-TISSUE_STRUCTURE", 4, 18], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 77, 91], ["heart", "ORGAN", 105, 110], ["continuous invasive monitoring", "TEST", 38, 68], ["mean arterial blood pressure", "TEST", 72, 100], ["heart rate", "TEST", 105, 115], ["femoral artery", "ANATOMY", 4, 18], ["heart", "ANATOMY", 105, 110]]], ["Both ear veins were cannulated for infusion of propofol, fentanyl and saline 0.9%.", [["ear veins", "ANATOMY", 5, 14], ["propofol", "CHEMICAL", 47, 55], ["fentanyl", "CHEMICAL", 57, 65], ["propofol", "CHEMICAL", 47, 55], ["fentanyl", "CHEMICAL", 57, 65], ["ear veins", "MULTI-TISSUE_STRUCTURE", 5, 14], ["propofol", "SIMPLE_CHEMICAL", 47, 55], ["fentanyl", "SIMPLE_CHEMICAL", 57, 65], ["saline", "SIMPLE_CHEMICAL", 70, 76], ["propofol", "TREATMENT", 47, 55], ["fentanyl", "TREATMENT", 57, 65], ["saline", "TREATMENT", 70, 76], ["ear veins", "ANATOMY", 5, 14]]], ["The piglet recovered for 1 h after the surgical preparation before the experiment.", [["piglet", "ANATOMY", 4, 10], ["piglet", "ORGANISM", 4, 10], ["piglet", "SPECIES", 4, 10], ["the surgical preparation", "TREATMENT", 35, 59], ["piglet", "OBSERVATION_MODIFIER", 4, 10]]], ["Arterial blood gases and blood glucose were measured after the surgical preparation and during the experimental study.", [["Arterial blood", "ANATOMY", 0, 14], ["blood", "ANATOMY", 25, 30], ["glucose", "CHEMICAL", 31, 38], ["glucose", "CHEMICAL", 31, 38], ["Arterial", "ORGANISM_SUBSTANCE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["glucose", "SIMPLE_CHEMICAL", 31, 38], ["Arterial blood gases", "TEST", 0, 20], ["blood glucose", "TEST", 25, 38], ["the surgical preparation", "TREATMENT", 59, 83], ["the experimental study", "TEST", 95, 117]]], ["At the end of the study, the piglet was euthanized with 100 mg/kg pentobarbital.Experimental designWe conducted three interventions ( Fig. 1 ) with a dermal detector probe and two different light source probes, one applied to the skin, and one internal probe located in the esophagus.", [["piglet", "ANATOMY", 29, 35], ["dermal", "ANATOMY", 150, 156], ["skin", "ANATOMY", 230, 234], ["esophagus", "ANATOMY", 274, 283], ["pentobarbital", "CHEMICAL", 66, 79], ["pentobarbital", "CHEMICAL", 66, 79], ["piglet", "ORGANISM", 29, 35], ["pentobarbital", "SIMPLE_CHEMICAL", 66, 79], ["dermal", "TISSUE", 150, 156], ["skin", "ORGAN", 230, 234], ["esophagus", "ORGAN", 274, 283], ["piglet", "SPECIES", 29, 35], ["the study", "TEST", 14, 23], ["pentobarbital", "TREATMENT", 66, 79], ["a dermal detector probe", "TREATMENT", 148, 171], ["skin", "ANATOMY", 230, 234], ["esophagus", "ANATOMY", 274, 283]]], ["The internal optical fiber probe was positioned in the esophagus at a distance of 21 cm from the snout.", [["esophagus", "ANATOMY", 55, 64], ["snout", "ANATOMY", 97, 102], ["esophagus", "ORGAN", 55, 64], ["snout", "ORGANISM_SUBDIVISION", 97, 102], ["The internal optical fiber probe", "TREATMENT", 0, 32], ["internal", "OBSERVATION_MODIFIER", 4, 12], ["optical", "OBSERVATION_MODIFIER", 13, 20], ["fiber probe", "OBSERVATION", 21, 32], ["esophagus", "ANATOMY", 55, 64], ["21 cm", "OBSERVATION_MODIFIER", 82, 87]]], ["The localization corresponded to a position at the heart level, which was confirmed by fluoroscopy X-ray in the first two piglets (Fig. 2 ).", [["heart", "ANATOMY", 51, 56], ["heart", "ORGAN", 51, 56], ["piglets", "ORGANISM", 122, 129], ["fluoroscopy", "TEST", 87, 98], ["heart", "ANATOMY", 51, 56]]], ["This position was kept for all the following piglets as they had similar size and weight.", [["piglets", "ORGANISM", 45, 52], ["weight", "TEST", 82, 88], ["size", "OBSERVATION_MODIFIER", 73, 77]]], ["The detector probe was placed in the right axillary line, approximately 2 cm below the foreleg.", [["right axillary line", "ANATOMY", 37, 56], ["foreleg", "ANATOMY", 87, 94], ["The detector probe", "TREATMENT", 0, 18], ["right", "ANATOMY_MODIFIER", 37, 42], ["axillary", "ANATOMY", 43, 51], ["line", "ANATOMY_MODIFIER", 52, 56], ["approximately", "OBSERVATION_MODIFIER", 58, 71], ["2 cm", "OBSERVATION_MODIFIER", 72, 76], ["foreleg", "ANATOMY", 87, 94]]], ["The dermal light source probe was placed in the midclavicular line on the right side of the thorax with at least 3 cm distance to the detector.", [["dermal", "ANATOMY", 4, 10], ["midclavicular line", "ANATOMY", 48, 66], ["thorax", "ANATOMY", 92, 98], ["dermal", "TISSUE", 4, 10], ["midclavicular line", "CELL", 48, 66], ["thorax", "ORGAN", 92, 98], ["The dermal light source probe", "TREATMENT", 0, 29], ["dermal", "OBSERVATION_MODIFIER", 4, 10], ["light", "OBSERVATION_MODIFIER", 11, 16], ["source probe", "OBSERVATION", 17, 29], ["midclavicular", "ANATOMY", 48, 61], ["line", "OBSERVATION", 62, 66], ["right", "ANATOMY_MODIFIER", 74, 79], ["thorax", "ANATOMY", 92, 98], ["at least 3 cm", "OBSERVATION_MODIFIER", 104, 117]]], ["The source and detector probes were fixed with elastic black nylon straps that also prevented light dispersion from the dermal laser source.Experimental designThe initial procedure was a stepwise increase and decrease in inspired oxygen fraction (FiO 2 ) in the ventilator settings with the light source on the skin and thereafter repeated in duplicate with the light source in the esophagus (Fig. 1a) .", [["dermal", "ANATOMY", 120, 126], ["skin", "ANATOMY", 311, 315], ["esophagus", "ANATOMY", 382, 391], ["oxygen", "CHEMICAL", 230, 236], ["oxygen", "CHEMICAL", 230, 236], ["dermal", "TISSUE", 120, 126], ["oxygen", "SIMPLE_CHEMICAL", 230, 236], ["skin", "ORGAN", 311, 315], ["esophagus", "ORGAN", 382, 391], ["detector probes", "TREATMENT", 15, 30], ["elastic black nylon straps", "TREATMENT", 47, 73], ["the dermal laser source", "PROBLEM", 116, 139], ["The initial procedure", "TREATMENT", 159, 180], ["inspired oxygen fraction", "TREATMENT", 221, 245], ["FiO", "TREATMENT", 247, 250], ["the ventilator settings", "TREATMENT", 258, 281], ["nylon straps", "OBSERVATION", 61, 73], ["light dispersion", "OBSERVATION_MODIFIER", 94, 110], ["dermal", "ANATOMY", 120, 126], ["laser source", "OBSERVATION", 127, 139], ["increase", "OBSERVATION_MODIFIER", 196, 204], ["decrease", "OBSERVATION_MODIFIER", 209, 217], ["oxygen fraction", "OBSERVATION", 230, 245], ["skin", "ANATOMY", 311, 315], ["esophagus", "ANATOMY", 382, 391]]], ["The absorption of O 2 and H 2 O vapor was measured by the GASMAS system with O 2 (FaO 2 ).", [["O 2 and H 2 O", "CHEMICAL", 18, 31], ["O 2", "CHEMICAL", 18, 21], ["H 2 O", "CHEMICAL", 26, 31], ["O 2", "CHEMICAL", 77, 80], ["FaO 2 )", "CHEMICAL", 82, 89], ["O 2", "SIMPLE_CHEMICAL", 18, 21], ["H 2 O", "SIMPLE_CHEMICAL", 26, 31]]], ["At each FiO 2 setting, the measured O 2 and H 2 O absorption signals were averaged over 10 s and sampled ten times.", [["O 2", "CHEMICAL", 36, 39], ["H 2 O", "CHEMICAL", 44, 49], ["H 2 O", "SIMPLE_CHEMICAL", 44, 49], ["absorption signals", "TEST", 50, 68]]], ["After the measurement at FiO 2 1.0, a pulmonary recruitment procedure was done by increasing the inspiration pressure, to reduce the risk of resorption atelectasis.", [["pulmonary", "ANATOMY", 38, 47], ["atelectasis", "DISEASE", 152, 163], ["pulmonary", "ORGAN", 38, 47], ["FiO", "TEST", 25, 28], ["a pulmonary recruitment procedure", "TREATMENT", 36, 69], ["the inspiration pressure", "TREATMENT", 93, 117], ["resorption atelectasis", "PROBLEM", 141, 163], ["pulmonary", "ANATOMY", 38, 47], ["recruitment", "OBSERVATION", 48, 59], ["resorption", "OBSERVATION_MODIFIER", 141, 151], ["atelectasis", "OBSERVATION", 152, 163]]], ["15 Recruitment was deemed successful when tidal volumes were the same as before starting the experiment.", [["tidal volumes", "TEST", 42, 55]]], ["The detector probe position, fixation and the stepwise changes of FiO 2 were the same in the dermal and esophageal measurements (Fig. 2) .", [["dermal", "ANATOMY", 93, 99], ["esophageal", "ANATOMY", 104, 114], ["FiO 2", "CHEMICAL", 66, 71], ["FiO 2", "GENE_OR_GENE_PRODUCT", 66, 71], ["dermal", "TISSUE", 93, 99], ["esophageal", "ORGAN", 104, 114], ["The detector probe position", "TREATMENT", 0, 27], ["fixation", "TREATMENT", 29, 37], ["the stepwise changes of FiO 2", "TREATMENT", 42, 71], ["dermal", "ANATOMY", 93, 99], ["esophageal", "ANATOMY", 104, 114]]], ["We then performed a partial pulmonary atelectasis with the esophageal light probe in place (Fig. 1b) .", [["pulmonary", "ANATOMY", 28, 37], ["esophageal", "ANATOMY", 59, 69], ["atelectasis", "DISEASE", 38, 49], ["pulmonary", "ORGAN", 28, 37], ["esophageal", "ORGAN", 59, 69], ["a partial pulmonary atelectasis", "PROBLEM", 18, 49], ["the esophageal light probe", "TREATMENT", 55, 81], ["partial", "OBSERVATION_MODIFIER", 20, 27], ["pulmonary", "ANATOMY", 28, 37], ["atelectasis", "OBSERVATION", 38, 49], ["esophageal", "ANATOMY", 59, 69], ["light probe", "OBSERVATION", 70, 81]]], ["The FiO 2 was set to 0.30.", [["The FiO 2", "TREATMENT", 0, 9]]], ["A 4 Fr embolectomy catheter with a balloon at its tip (LeMaitre\u00ae Vascular, Sulzbach, Germany) was inserted into the trachea parallel to the endotracheal tube into the right main bronchus (Fig. 1b) .", [["trachea", "ANATOMY", 116, 123], ["endotracheal tube", "ANATOMY", 140, 157], ["right main bronchus", "ANATOMY", 167, 186], ["Vascular", "MULTI-TISSUE_STRUCTURE", 65, 73], ["trachea", "ORGAN", 116, 123], ["endotracheal tube", "TISSUE", 140, 157], ["bronchus", "ORGAN", 178, 186], ["A 4 Fr embolectomy catheter", "TREATMENT", 0, 27], ["a balloon at its tip (LeMaitre\u00ae Vascular, Sulzbach, Germany)", "TREATMENT", 33, 93], ["embolectomy", "OBSERVATION_MODIFIER", 7, 18], ["catheter", "OBSERVATION", 19, 27], ["balloon", "OBSERVATION", 35, 42], ["tip", "OBSERVATION_MODIFIER", 50, 53], ["Vascular", "ANATOMY", 65, 73], ["trachea", "ANATOMY", 116, 123], ["endotracheal tube", "OBSERVATION", 140, 157], ["right main bronchus", "ANATOMY", 167, 186]]], ["In two piglets, the position was verified by fluoroscopy X-ray.", [["piglets", "ORGANISM", 7, 14], ["piglets", "SPECIES", 7, 14], ["fluoroscopy X-ray", "TEST", 45, 62]]], ["Partial obstruction of the distal airways was considered confirmed when the end-tidal CO 2 had decreased by 50% after balloon inflation.", [["distal airways", "ANATOMY", 27, 41], ["balloon", "ANATOMY", 118, 125], ["obstruction of the distal airways", "DISEASE", 8, 41], ["CO 2", "CHEMICAL", 86, 90], ["airways", "MULTI-TISSUE_STRUCTURE", 34, 41], ["Partial obstruction of the distal airways", "PROBLEM", 0, 41], ["the end-tidal CO", "TEST", 72, 88], ["balloon inflation", "TREATMENT", 118, 135], ["obstruction", "OBSERVATION", 8, 19], ["distal", "ANATOMY_MODIFIER", 27, 33], ["airways", "ANATOMY", 34, 41], ["balloon inflation", "OBSERVATION", 118, 135]]], ["The balloon was deflated after approximately 1.5 min or if the piglet became circulatory unstable.", [["piglet", "ANATOMY", 63, 69], ["piglet", "ORGANISM", 63, 69], ["The balloon", "TREATMENT", 0, 11], ["circulatory unstable", "PROBLEM", 77, 97], ["balloon", "OBSERVATION", 4, 11], ["deflated", "OBSERVATION", 16, 24], ["circulatory unstable", "OBSERVATION", 77, 97]]], ["Oxygen signals were continuously measured during the procedure, which was repeated three times.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen signals", "TEST", 0, 14], ["the procedure", "TREATMENT", 49, 62]]], ["Between each atelectasis, mechanical recruitment of pulmonary volume was performed.Experimental designAfter the piglet had recovered from atelectasis, a small thoracostomy was prepared in the right axillary line, 1 cm below the dermal detector probe, and a drainage tube was placed and fixated with sutures.", [["pulmonary", "ANATOMY", 52, 61], ["piglet", "ANATOMY", 112, 118], ["right axillary line", "ANATOMY", 192, 211], ["dermal", "ANATOMY", 228, 234], ["atelectasis", "DISEASE", 13, 24], ["atelectasis", "DISEASE", 138, 149], ["pulmonary", "ORGAN", 52, 61], ["piglet", "ORGANISM", 112, 118], ["dermal", "TISSUE", 228, 234], ["tube", "TISSUE", 266, 270], ["piglet", "SPECIES", 112, 118], ["each atelectasis", "PROBLEM", 8, 24], ["mechanical recruitment of pulmonary volume", "TEST", 26, 68], ["atelectasis", "PROBLEM", 138, 149], ["a small thoracostomy", "TREATMENT", 151, 171], ["the dermal detector probe", "TREATMENT", 224, 249], ["a drainage tube", "TREATMENT", 255, 270], ["sutures", "TREATMENT", 299, 306], ["atelectasis", "OBSERVATION", 13, 24], ["mechanical", "OBSERVATION_MODIFIER", 26, 36], ["recruitment", "OBSERVATION_MODIFIER", 37, 48], ["pulmonary", "ANATOMY", 52, 61], ["atelectasis", "OBSERVATION", 138, 149], ["small", "OBSERVATION_MODIFIER", 153, 158], ["thoracostomy", "OBSERVATION", 159, 171], ["right", "ANATOMY_MODIFIER", 192, 197], ["axillary", "ANATOMY", 198, 206], ["line", "ANATOMY_MODIFIER", 207, 211], ["1 cm", "OBSERVATION_MODIFIER", 213, 217], ["dermal", "ANATOMY", 228, 234], ["detector probe", "OBSERVATION", 235, 249], ["drainage tube", "OBSERVATION", 257, 270], ["sutures", "OBSERVATION", 299, 306]]], ["The piglet was ventilated with FiO 2 1.0 while 100 ml of ambient air (FiO 2 0.21) was injected into the pleural space through the tube (Fig. 1c) .", [["piglet", "ANATOMY", 4, 10], ["pleural space", "ANATOMY", 104, 117], ["FiO 2 1.0", "CHEMICAL", 31, 40], ["FiO 2 0.21", "CHEMICAL", 70, 80], ["FiO 2", "CHEMICAL", 31, 36], ["piglet", "ORGANISM", 4, 10], ["pleural space", "MULTI-TISSUE_STRUCTURE", 104, 117], ["tube", "TISSUE", 130, 134], ["piglet", "SPECIES", 4, 10], ["FiO", "TREATMENT", 31, 34], ["ambient air (FiO", "TREATMENT", 57, 73], ["the tube", "TREATMENT", 126, 134], ["piglet", "OBSERVATION_MODIFIER", 4, 10], ["ventilated", "OBSERVATION", 15, 25], ["pleural", "ANATOMY", 104, 111], ["tube", "OBSERVATION", 130, 134]]], ["In two piglets, we confirmed the pneumothorax with fluoroscopy X-ray.", [["pneumothorax", "DISEASE", 33, 45], ["piglets", "ORGANISM", 7, 14], ["piglets", "SPECIES", 7, 14], ["the pneumothorax", "PROBLEM", 29, 45], ["fluoroscopy X-ray", "TEST", 51, 68], ["pneumothorax", "OBSERVATION", 33, 45]]], ["Oxygen signals were continuously measured during the pneumothorax phase.", [["pneumothorax", "DISEASE", 53, 65], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen signals", "TEST", 0, 14], ["the pneumothorax phase", "PROBLEM", 49, 71], ["pneumothorax", "OBSERVATION", 53, 65]]], ["Approximately 2 min after induction, the air was withdrawn from the pleural cavity and pulmonary recruitment followed.", [["pleural cavity", "ANATOMY", 68, 82], ["pulmonary", "ANATOMY", 87, 96], ["pleural cavity", "MULTI-TISSUE_STRUCTURE", 68, 82], ["pulmonary", "ORGAN", 87, 96], ["the air", "PROBLEM", 37, 44], ["pulmonary recruitment", "TREATMENT", 87, 108], ["air", "OBSERVATION", 41, 44], ["pleural", "ANATOMY", 68, 75], ["cavity", "ANATOMY_MODIFIER", 76, 82], ["pulmonary", "ANATOMY", 87, 96], ["recruitment", "OBSERVATION", 97, 108]]], ["The procedure was repeated three times.Experimental designOptical experimental setup The GASMAS system (GPX Medical AB, Sweden) measured gas absorption at two wavelengths, 764 nm for O 2 gas absorption and 820 nm for H 2 O vapor absorption.", [["H 2 O", "CHEMICAL", 217, 222], ["O 2", "CHEMICAL", 183, 186], ["H 2 O", "CHEMICAL", 217, 222], ["H 2 O vapor", "SIMPLE_CHEMICAL", 217, 228], ["The procedure", "TREATMENT", 0, 13]]], ["The measured gas absorption is expressed in a dimension of [%m] which is the product of the relative gas concentration [%] and the absorption path length [m].", [["The measured gas absorption", "PROBLEM", 0, 27], ["the relative gas concentration", "TEST", 88, 118], ["gas absorption", "OBSERVATION", 13, 27], ["gas concentration", "OBSERVATION", 101, 118]]], ["13 The instrument was calibrated using known concentrations and absorption path lengths.", [["The instrument", "TREATMENT", 3, 17], ["known concentrations and absorption path lengths", "PROBLEM", 39, 87]]], ["The relative humidity in the lung is approximately 100%, and together with the knowledge of tissue temperature and air pressure, the H 2 O vapor gas concentration can numerically be estimated.", [["lung", "ANATOMY", 29, 33], ["tissue", "ANATOMY", 92, 98], ["H 2 O", "CHEMICAL", 133, 138], ["lung", "ORGAN", 29, 33], ["tissue", "TISSUE", 92, 98], ["H 2 O", "SIMPLE_CHEMICAL", 133, 138], ["tissue temperature", "PROBLEM", 92, 110], ["air pressure", "TEST", 115, 127], ["the H 2 O vapor gas concentration", "TREATMENT", 129, 162], ["relative", "OBSERVATION_MODIFIER", 4, 12], ["humidity", "OBSERVATION_MODIFIER", 13, 21], ["lung", "ANATOMY", 29, 33], ["approximately", "OBSERVATION_MODIFIER", 37, 50], ["100%", "OBSERVATION_MODIFIER", 51, 55], ["air pressure", "OBSERVATION", 115, 127]]], ["16 The measured H 2 O vapor gas absorption in [%m] thus provides the absorption path length in [m] for light at 820 nm.", [["H 2 O", "CHEMICAL", 16, 21], ["H 2 O", "CHEMICAL", 16, 21], ["H 2 O", "SIMPLE_CHEMICAL", 16, 21], ["vapor gas absorption", "TEST", 22, 42]]], ["Assuming that the light at 764 nm travels the same average distance in the gas volume, the measured O 2 gas absorption in [%m] then provides the O 2 concentration in [%].Experimental designThe two diode lasers providing light at 764 and 820 nm, respectively, were focused into an optical fiber (core diameter 400 \u00b5m), which provided an output power at the tissue interface of 25 and 8.1 mW, respectively.", [["tissue", "ANATOMY", 356, 362], ["O 2", "CHEMICAL", 100, 103], ["O 2", "CHEMICAL", 145, 148], ["O 2", "SIMPLE_CHEMICAL", 145, 148], ["tissue", "TISSUE", 356, 362], ["the gas volume", "TEST", 71, 85], ["The two diode lasers", "TREATMENT", 189, 209], ["an output power", "TEST", 333, 348], ["gas volume", "OBSERVATION", 75, 85]]], ["The diode lasers and the light combining optics were enclosed in a nitrogen-filled box to eliminate offsets in the absorption signal due to ambient air.Experimental designThe gas absorption signal was obtained by sequentially scanning the wavelength of the lasers, at a rate of 1 kHz, over one of the absorption lines of the O 2 molecule at 764 nm and of H 2 O at 820 nm.", [["nitrogen", "CHEMICAL", 67, 75], ["O 2", "CHEMICAL", 325, 328], ["H 2 O", "CHEMICAL", 355, 360], ["O 2 molecule", "PROTEIN", 325, 337], ["The diode lasers", "TREATMENT", 0, 16], ["the light combining optics", "TREATMENT", 21, 47], ["a nitrogen-filled box", "TREATMENT", 65, 86], ["the absorption signal", "TEST", 111, 132], ["ambient air", "PROBLEM", 140, 151], ["The gas absorption signal", "TEST", 171, 196], ["the lasers", "TREATMENT", 253, 263], ["diode lasers", "OBSERVATION", 4, 16], ["ambient air", "OBSERVATION", 140, 151], ["absorption lines", "OBSERVATION", 301, 317]]], ["The two gases were measured in sequence with a measurement time of 100 s before switching.Experimental designOptical fibers with two different light distributions at the distal end were employed for skin and esophageal light administration, respectively.", [["designOptical fibers", "ANATOMY", 103, 123], ["skin", "ANATOMY", 199, 203], ["esophageal", "ANATOMY", 208, 218], ["skin", "ORGAN", 199, 203], ["esophageal", "ORGAN", 208, 218], ["The two gases", "TEST", 0, 13], ["a measurement time", "TEST", 45, 63], ["Experimental designOptical fibers", "TREATMENT", 90, 123], ["skin and esophageal light administration", "TREATMENT", 199, 239], ["two", "OBSERVATION_MODIFIER", 129, 132], ["different", "OBSERVATION_MODIFIER", 133, 142], ["light distributions", "OBSERVATION", 143, 162], ["distal", "ANATOMY_MODIFIER", 170, 176], ["skin", "ANATOMY", 199, 203], ["esophageal", "ANATOMY", 208, 218]]], ["The rationale for using internal light illumination is the fact that when light is applied on the skin and detected from the skin surface, theoretically, only 1% of the light that reaches lung tissue would reach the detector.", [["skin", "ANATOMY", 98, 102], ["skin surface", "ANATOMY", 125, 137], ["lung tissue", "ANATOMY", 188, 199], ["skin", "ORGAN", 98, 102], ["skin surface", "MULTI-TISSUE_STRUCTURE", 125, 137], ["lung tissue", "TISSUE", 188, 199], ["internal light illumination", "TREATMENT", 24, 51], ["skin", "ANATOMY", 98, 102], ["skin", "ANATOMY", 125, 129], ["surface", "ANATOMY_MODIFIER", 130, 137], ["lung", "ANATOMY", 188, 192], ["tissue", "OBSERVATION", 193, 199]]], ["If the light source is placed internally, e.g. through a nasogastric feeding tube or an endotracheal tube, the light travels through the air-filled lung with a shorter path through solid tissue before reaching the skin surface, thereby theoretically leading to higher light intensity at the detector with a larger portion of photons subjected to gas absorption.", [["endotracheal tube", "ANATOMY", 88, 105], ["lung", "ANATOMY", 148, 152], ["solid tissue", "ANATOMY", 181, 193], ["skin surface", "ANATOMY", 214, 226], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 88, 105], ["lung", "ORGAN", 148, 152], ["solid tissue", "TISSUE", 181, 193], ["skin surface", "TISSUE", 214, 226], ["a nasogastric feeding tube", "TREATMENT", 55, 81], ["an endotracheal tube", "TREATMENT", 85, 105], ["a shorter path through solid tissue", "TREATMENT", 158, 193], ["feeding tube", "OBSERVATION", 69, 81], ["endotracheal tube", "OBSERVATION", 88, 105], ["air-filled", "ANATOMY_MODIFIER", 137, 147], ["lung", "ANATOMY", 148, 152], ["solid tissue", "OBSERVATION", 181, 193], ["skin", "ANATOMY", 214, 218], ["surface", "ANATOMY_MODIFIER", 219, 226], ["higher", "OBSERVATION_MODIFIER", 261, 267], ["light intensity", "OBSERVATION_MODIFIER", 268, 283], ["larger", "OBSERVATION_MODIFIER", 307, 313], ["gas absorption", "OBSERVATION", 346, 360]]], ["Taking as an example if 1% of the light emitted at the surface would reach the lung tissue and then be scattered back after interacting with the gas, again only 1% of that light would reach a detector on the surface.", [["surface", "ANATOMY", 55, 62], ["lung tissue", "ANATOMY", 79, 90], ["surface", "ANATOMY", 208, 215], ["surface", "CELLULAR_COMPONENT", 55, 62], ["lung tissue", "TISSUE", 79, 90], ["surface", "CELLULAR_COMPONENT", 208, 215], ["the gas", "TEST", 141, 148], ["lung tissue", "ANATOMY", 79, 90], ["scattered", "OBSERVATION_MODIFIER", 103, 112]]], ["Also, by internal illumination, a larger fraction of the detected light would have passed through the gas-bearing lung tissue, laying between the light injection point and the detector.", [["lung tissue", "ANATOMY", 114, 125], ["lung tissue", "TISSUE", 114, 125], ["internal", "OBSERVATION_MODIFIER", 9, 17], ["illumination", "OBSERVATION_MODIFIER", 18, 30], ["larger", "OBSERVATION_MODIFIER", 34, 40], ["fraction", "OBSERVATION_MODIFIER", 41, 49], ["gas", "OBSERVATION", 102, 105], ["bearing", "ANATOMY_MODIFIER", 106, 113], ["lung", "ANATOMY", 114, 118], ["tissue", "OBSERVATION", 119, 125]]], ["For skin light administration, a diffusing cylindrical object was used to create a homogeneous emission over an area of 1 cm 2 with an irradiance of 25 mW/cm 2 and 8.1 mW/cm 2 for 764 and 820 nm, respectively.", [["skin", "ANATOMY", 4, 8], ["skin", "ORGAN", 4, 8], ["skin light administration", "TREATMENT", 4, 29], ["a diffusing cylindrical object", "TREATMENT", 31, 61], ["an irradiance", "TEST", 132, 145], ["skin", "ANATOMY", 4, 8], ["cylindrical object", "OBSERVATION", 43, 61], ["homogeneous", "OBSERVATION_MODIFIER", 83, 94], ["emission", "OBSERVATION_MODIFIER", 95, 103], ["1 cm", "OBSERVATION_MODIFIER", 120, 124]]], ["For the internal light administration, the end of the fiber was diffusing over a longitudinal distance of 10 mm with an outer diameter of 0.9 mm, giving an irradiance of 88 and 29 mW/cm 2 for 764 and 820 nm, respectively.", [["fiber", "ANATOMY", 54, 59], ["fiber", "CELLULAR_COMPONENT", 54, 59], ["the internal light administration", "TREATMENT", 4, 37], ["an irradiance", "TEST", 153, 166], ["fiber", "OBSERVATION_MODIFIER", 54, 59], ["10 mm", "OBSERVATION_MODIFIER", 106, 111], ["outer", "OBSERVATION_MODIFIER", 120, 125], ["diameter", "OBSERVATION_MODIFIER", 126, 134], ["0.9 mm", "OBSERVATION_MODIFIER", 138, 144]]], ["Due to the diffuse emission and low light intensities, both fiber probe designs are eye-safe (Laser Class I, IEC 60825-1:2014) and no significant tissue heating is expected as the irradiance is kept below 150 mW/cm 2 .", [["tissue", "ANATOMY", 146, 152], ["tissue", "TISSUE", 146, 152], ["the diffuse emission and low light intensities", "PROBLEM", 7, 53], ["IEC", "TEST", 109, 112], ["significant tissue heating", "PROBLEM", 134, 160], ["diffuse", "OBSERVATION_MODIFIER", 11, 18], ["emission", "OBSERVATION", 19, 27], ["low light intensities", "OBSERVATION_MODIFIER", 32, 53], ["no", "UNCERTAINTY", 131, 133], ["significant tissue", "OBSERVATION_MODIFIER", 134, 152], ["heating", "OBSERVATION", 153, 160]]], ["17 After propagating through the tissue, the transmitted light was detected by a photodiode (active area 10 mm \u00d7 10 mm) incorporated into a detector probe attached to the skin.", [["tissue", "ANATOMY", 33, 39], ["skin", "ANATOMY", 171, 175], ["tissue", "TISSUE", 33, 39], ["skin", "ORGAN", 171, 175], ["a photodiode (active area", "TREATMENT", 79, 104], ["a detector probe", "TREATMENT", 138, 154], ["skin", "ANATOMY", 171, 175]]], ["The detector probe area was covered with a layer of ultrasonic gel in order to reduce offsets in the absorption signal.", [["The detector probe area", "TREATMENT", 0, 23], ["a layer of ultrasonic gel", "TREATMENT", 41, 66], ["the absorption signal", "TEST", 97, 118]]], ["The detected absorption signal was intensity normalized and frequency filtered by the electronic platform, which acquires the absorption magnitude through proprietary algorithms.Statistical analysisThe oxygen concentration, X O2 , was evaluated assuming that the absorption path length of water vapor L H2O \u00f0 \u00de and oxygen L O2 \u00f0 \u00de is equal.", [["oxygen", "CHEMICAL", 202, 208], ["O2", "CHEMICAL", 226, 228], ["H2O", "CHEMICAL", 303, 306], ["oxygen", "CHEMICAL", 315, 321], ["oxygen", "CHEMICAL", 202, 208], ["O2", "CHEMICAL", 226, 228], ["H2O", "CHEMICAL", 303, 306], ["oxygen", "CHEMICAL", 315, 321], ["O2", "CHEMICAL", 324, 326], ["oxygen", "SIMPLE_CHEMICAL", 202, 208], ["X O2", "SIMPLE_CHEMICAL", 224, 228], ["oxygen L O2", "SIMPLE_CHEMICAL", 315, 326], ["Statistical analysis", "TEST", 178, 198], ["The oxygen concentration", "TREATMENT", 198, 222], ["X O2", "TREATMENT", 224, 228], ["the absorption path length of water vapor L H2O", "TREATMENT", 259, 306], ["oxygen L O2", "TREATMENT", 315, 326], ["oxygen concentration", "OBSERVATION", 202, 222], ["equal", "OBSERVATION", 334, 339]]], ["L H2O was obtained from the absorption signal of water vapor (A H2O ) and by calculating the temperature-dependent water vapor concentration X H2O .", [["H2O", "CHEMICAL", 2, 5], ["H2O", "CHEMICAL", 64, 67], ["H2O", "CHEMICAL", 143, 146], ["H2O", "CHEMICAL", 2, 5], ["H2O", "CHEMICAL", 64, 67], ["H2O", "CHEMICAL", 143, 146], ["L H2O", "SIMPLE_CHEMICAL", 0, 5], ["L H2O", "TREATMENT", 0, 5], ["water vapor", "TREATMENT", 49, 60], ["A H2O )", "TREATMENT", 62, 69], ["the temperature-dependent water vapor concentration", "TREATMENT", 89, 140], ["H2O", "OBSERVATION", 2, 5]]], ["18Statistical analysisFor each measurement series, i.e. a set value of inspired oxygen, the A O2 and A H2O were sequentially obtained, as described above.", [["oxygen", "CHEMICAL", 80, 86], ["O2", "CHEMICAL", 94, 96], ["H2O", "CHEMICAL", 103, 106], ["oxygen", "CHEMICAL", 80, 86], ["O2", "CHEMICAL", 94, 96], ["H2O", "CHEMICAL", 103, 106], ["oxygen", "SIMPLE_CHEMICAL", 80, 86], ["A O2", "SIMPLE_CHEMICAL", 92, 96], ["A H2O", "SIMPLE_CHEMICAL", 101, 106], ["18Statistical analysis", "TEST", 0, 22], ["each measurement series", "TEST", 26, 49], ["inspired oxygen", "TREATMENT", 71, 86], ["the A O2", "TREATMENT", 88, 96], ["A H2O", "TREATMENT", 101, 106]]], ["The oxygen concentration in the equation was determined by using the measured oxygen absorption and the median value of the water vapor absorption.", [["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 78, 84], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 78, 84], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 78, 84], ["water", "SIMPLE_CHEMICAL", 124, 129], ["The oxygen concentration", "TREATMENT", 0, 24], ["the measured oxygen absorption", "TREATMENT", 65, 95], ["the water vapor absorption", "TREATMENT", 120, 146], ["oxygen concentration", "OBSERVATION", 4, 24]]], ["Every measurement series yielded between 8 and 12 data points and the FiO 2 was repeated between two and five times for each piglet, with the exception for piglet number 3, where the FiO 2 challenge was done only once.", [["piglet", "ANATOMY", 125, 131], ["FiO 2", "CHEMICAL", 183, 188], ["piglet", "ORGANISM", 125, 131], ["Every measurement series", "TEST", 0, 24], ["the FiO 2", "TEST", 66, 75], ["the FiO 2 challenge", "TREATMENT", 179, 198]]], ["For statistical analyses, a one-way ANOVA test was performed.Determination of oxygen and water vapor absorptionWith the internal light probe placed in the esophagus, the detected absorption signal was roughly one order of magnitude larger compared to the measurements with the dermal light source (Fig. 3) .", [["esophagus", "ANATOMY", 155, 164], ["dermal", "ANATOMY", 277, 283], ["oxygen", "CHEMICAL", 78, 84], ["oxygen", "CHEMICAL", 78, 84], ["oxygen", "SIMPLE_CHEMICAL", 78, 84], ["water", "SIMPLE_CHEMICAL", 89, 94], ["esophagus", "ORGAN", 155, 164], ["a one-way ANOVA test", "TEST", 26, 46], ["oxygen", "TREATMENT", 78, 84], ["water vapor", "TREATMENT", 89, 100], ["the internal light probe", "TREATMENT", 116, 140], ["oxygen", "OBSERVATION_MODIFIER", 78, 84], ["esophagus", "ANATOMY", 155, 164]]], ["Water vapor absorption was variably detected when using the skin light source (Fig. 3b) .", [["skin", "ANATOMY", 60, 64], ["skin", "ORGAN", 60, 64], ["Water vapor absorption", "TREATMENT", 0, 22], ["skin", "ANATOMY", 60, 64]]], ["As the evaluation of O 2 concentration is dependent on the absorption of both O 2 and H 2 O, determination was not possible for all piglets.", [["O 2", "CHEMICAL", 21, 24], ["O 2", "CHEMICAL", 78, 81], ["H 2 O", "CHEMICAL", 86, 91], ["O 2", "SIMPLE_CHEMICAL", 21, 24], ["O 2", "SIMPLE_CHEMICAL", 78, 81], ["H 2 O", "SIMPLE_CHEMICAL", 86, 91], ["piglets", "ORGANISM", 132, 139], ["the evaluation", "TEST", 3, 17]]], ["When using the internal light source, the signals from both O 2 and H 2 O were clearly detectable, and the absorption values changed with the set value of FiO 2 (Fig. 3c, d) .", [["O 2", "CHEMICAL", 60, 63], ["H 2 O", "CHEMICAL", 68, 73], ["FiO 2", "CHEMICAL", 155, 160], ["H 2 O", "SIMPLE_CHEMICAL", 68, 73], ["the absorption values", "TEST", 103, 124], ["FiO", "TEST", 155, 158]]], ["The calculated O 2 concentrations, using the internal light source, are shown in Fig. 4Atelectasis and pneumothoraxAtelectasis was induced in four piglets while continuously monitoring the O 2 absorption and light transmission using the internal light source.", [["4Atelectasis", "CHEMICAL", 86, 98], ["pneumothorax", "DISEASE", 103, 115], ["O 2", "CHEMICAL", 15, 18], ["O 2", "CHEMICAL", 189, 192], ["piglets", "ORGANISM", 147, 154], ["piglets", "SPECIES", 147, 154], ["4Atelectasis", "PROBLEM", 86, 98], ["pneumothorax", "PROBLEM", 103, 115], ["Atelectasis", "PROBLEM", 115, 126], ["light transmission", "TEST", 208, 226], ["pneumothorax", "OBSERVATION", 103, 115], ["Atelectasis", "OBSERVATION", 115, 126]]], ["During the atelectasis, the O 2 absorption signal and the light transmission were both observed to decrease over a time scale of 10\u221230 s (Fig. 5) .", [["atelectasis", "DISEASE", 11, 22], ["O 2", "CHEMICAL", 28, 31], ["the atelectasis", "PROBLEM", 7, 22], ["the light transmission", "TEST", 54, 76], ["atelectasis", "OBSERVATION", 11, 22]]], ["When the balloon was deflated, the absorption and light transmission returned in most cases to the initial value before atelectasis.", [["atelectasis", "DISEASE", 120, 131], ["the balloon", "TREATMENT", 5, 16], ["light transmission", "TEST", 50, 68], ["atelectasis", "PROBLEM", 120, 131], ["balloon", "OBSERVATION", 9, 16], ["deflated", "OBSERVATION", 21, 29], ["atelectasis", "OBSERVATION", 120, 131]]], ["The continuously monitored O 2 absorption decreased rapidly when the pneumothorax was induced and simultaneously the light transmission increased (Fig. 6a) .", [["pneumothorax", "DISEASE", 69, 81], ["O 2", "CHEMICAL", 27, 30], ["O 2", "SIMPLE_CHEMICAL", 27, 30], ["the pneumothorax", "PROBLEM", 65, 81], ["pneumothorax", "OBSERVATION", 69, 81]]], ["When the air was removed from the pleural space, the O 2 absorption and the light transmission returned to their initial values.", [["pleural space", "ANATOMY", 34, 47], ["O 2", "CHEMICAL", 53, 56], ["pleural space", "MULTI-TISSUE_STRUCTURE", 34, 47], ["the light transmission", "TEST", 72, 94], ["air", "OBSERVATION", 9, 12], ["pleural", "ANATOMY", 34, 41]]], ["Using an optical measurement exposure time of 0.333 s in one piglet during the pneumothorax, the variation in transmission and absorption followed each breath provided by the ventilator (Fig. 6b) .DISCUSSIONIn this study, for the first time, we have successfully determined pulmonary O 2 concentration using an internal laser light source.", [["piglet", "ANATOMY", 61, 67], ["pulmonary", "ANATOMY", 274, 283], ["pneumothorax", "DISEASE", 79, 91], ["O 2", "CHEMICAL", 284, 287], ["piglet", "ORGANISM", 61, 67], ["an optical measurement exposure", "TEST", 6, 37], ["the pneumothorax", "PROBLEM", 75, 91], ["the ventilator", "TREATMENT", 171, 185], ["this study", "TEST", 210, 220], ["an internal laser light source", "TREATMENT", 308, 338], ["pneumothorax", "OBSERVATION", 79, 91], ["variation", "OBSERVATION_MODIFIER", 97, 106], ["pulmonary", "ANATOMY", 274, 283]]], ["We show here that the detected amount of O 2 in the lungs correlated with inhaled O 2 concentrations and that the pathophysiological changes of aeration produced in the experimental setting were detectable by the GASMAS system.", [["lungs", "ANATOMY", 52, 57], ["O 2", "CHEMICAL", 41, 44], ["O 2", "CHEMICAL", 82, 85], ["O 2", "GENE_OR_GENE_PRODUCT", 41, 44], ["lungs", "ORGAN", 52, 57], ["O 2", "PROTEIN", 41, 44], ["the pathophysiological changes of aeration", "PROBLEM", 110, 152], ["amount", "OBSERVATION_MODIFIER", 31, 37], ["lungs", "ANATOMY", 52, 57], ["aeration", "OBSERVATION", 144, 152]]], ["We were not able to estimate O 2 concentrations when using a dermal light source, due to too weak H 2 O absorption signal.DISCUSSIONUsing the internal light source placed in the esophagus, we detected distinct and prompt changes in absorption and transmission signals in response to stepwise changes in FiO 2 , as well as to induced pneumothorax.", [["dermal", "ANATOMY", 61, 67], ["esophagus", "ANATOMY", 178, 187], ["pneumothorax", "DISEASE", 333, 345], ["O 2", "CHEMICAL", 29, 32], ["H 2 O", "CHEMICAL", 98, 103], ["FiO 2", "CHEMICAL", 303, 308], ["H 2 O", "SIMPLE_CHEMICAL", 98, 103], ["esophagus", "ORGAN", 178, 187], ["FiO 2", "GENE_OR_GENE_PRODUCT", 303, 308], ["a dermal light source", "PROBLEM", 59, 80], ["too weak H 2 O absorption signal", "PROBLEM", 89, 121], ["prompt changes in absorption", "PROBLEM", 214, 242], ["transmission signals", "TEST", 247, 267], ["stepwise changes in FiO 2", "TREATMENT", 283, 308], ["pneumothorax", "PROBLEM", 333, 345], ["esophagus", "ANATOMY", 178, 187], ["distinct", "OBSERVATION_MODIFIER", 201, 209], ["pneumothorax", "OBSERVATION", 333, 345]]], ["Interestingly, a breath-related change was observed both in O 2 absorption and light transmission during pneumothorax.", [["pneumothorax", "DISEASE", 105, 117], ["O 2", "CHEMICAL", 60, 63], ["a breath-related change", "PROBLEM", 15, 38], ["pneumothorax", "PROBLEM", 105, 117], ["pneumothorax", "OBSERVATION", 105, 117]]], ["The observed decrease in O 2 absorption during atelectasis was less robust with variations between piglets.DISCUSSIONThe rapid decrease in O 2 absorption signal during the pneumothorax can be explained by the collapse of the lung enabling the light to predominately travel through a hollow, nonstructured pleural cavity.", [["lung", "ANATOMY", 225, 229], ["pleural cavity", "ANATOMY", 305, 319], ["atelectasis", "DISEASE", 47, 58], ["pneumothorax", "DISEASE", 172, 184], ["O 2", "CHEMICAL", 25, 28], ["O 2", "CHEMICAL", 139, 142], ["O 2", "SIMPLE_CHEMICAL", 25, 28], ["piglets", "ORGANISM", 99, 106], ["O 2", "GENE_OR_GENE_PRODUCT", 139, 142], ["lung", "ORGAN", 225, 229], ["pleural cavity", "MULTI-TISSUE_STRUCTURE", 305, 319], ["piglets", "SPECIES", 99, 106], ["atelectasis", "PROBLEM", 47, 58], ["The rapid decrease in O 2 absorption signal", "PROBLEM", 117, 160], ["the pneumothorax", "PROBLEM", 168, 184], ["the collapse of the lung", "PROBLEM", 205, 229], ["a hollow, nonstructured pleural cavity", "PROBLEM", 281, 319], ["decrease", "OBSERVATION_MODIFIER", 13, 21], ["atelectasis", "OBSERVATION", 47, 58], ["rapid", "OBSERVATION_MODIFIER", 121, 126], ["decrease", "OBSERVATION_MODIFIER", 127, 135], ["O 2 absorption", "OBSERVATION_MODIFIER", 139, 153], ["pneumothorax", "OBSERVATION", 172, 184], ["can be explained", "UNCERTAINTY", 185, 201], ["collapse", "OBSERVATION", 209, 217], ["lung", "ANATOMY", 225, 229], ["hollow", "OBSERVATION_MODIFIER", 283, 289], ["pleural", "ANATOMY", 305, 312], ["cavity", "OBSERVATION", 313, 319]]], ["The FiO 2 was 1.0, and upon lung collapse, the remaining absorption signal equivalents the O 2 content in ambient air injected into the pleural cavity.", [["lung", "ANATOMY", 28, 32], ["pleural cavity", "ANATOMY", 136, 150], ["FiO 2", "CHEMICAL", 4, 9], ["O 2", "CHEMICAL", 91, 94], ["FiO 2", "GENE_OR_GENE_PRODUCT", 4, 9], ["lung", "ORGAN", 28, 32], ["pleural cavity", "MULTI-TISSUE_STRUCTURE", 136, 150], ["The FiO", "TEST", 0, 7], ["lung collapse", "PROBLEM", 28, 41], ["ambient air", "TREATMENT", 106, 117], ["lung", "ANATOMY", 28, 32], ["collapse", "OBSERVATION", 33, 41], ["pleural", "ANATOMY", 136, 143], ["cavity", "ANATOMY_MODIFIER", 144, 150]]], ["Conversely, when removing the air, the incremental absorption signal can be explained by the lung gradually regaining its original gas-filled form.", [["lung", "ANATOMY", 93, 97], ["lung", "ORGAN", 93, 97], ["the incremental absorption signal", "PROBLEM", 35, 68], ["air", "OBSERVATION", 30, 33], ["lung", "ANATOMY", 93, 97]]], ["The O 2 absorption decrease during atelectasis may be related to O 2 consumption and induced physical change of the lung structure resulting in a reduced absorption path length, i.e. smaller gas volume in a denser lung.", [["lung", "ANATOMY", 116, 120], ["lung", "ANATOMY", 214, 218], ["atelectasis", "DISEASE", 35, 46], ["O 2", "CHEMICAL", 4, 7], ["O 2", "CHEMICAL", 65, 68], ["O 2", "SIMPLE_CHEMICAL", 4, 7], ["lung", "ORGAN", 116, 120], ["lung", "ORGAN", 214, 218], ["atelectasis", "PROBLEM", 35, 46], ["induced physical change of the lung structure", "PROBLEM", 85, 130], ["a reduced absorption path length", "PROBLEM", 144, 176], ["smaller gas volume in a denser lung", "PROBLEM", 183, 218], ["atelectasis", "OBSERVATION", 35, 46], ["lung", "ANATOMY", 116, 120], ["reduced", "OBSERVATION_MODIFIER", 146, 153], ["absorption", "OBSERVATION_MODIFIER", 154, 164], ["path", "OBSERVATION_MODIFIER", 165, 169], ["length", "OBSERVATION_MODIFIER", 170, 176], ["smaller", "OBSERVATION_MODIFIER", 183, 190], ["gas volume", "OBSERVATION", 191, 201], ["denser", "ANATOMY_MODIFIER", 207, 213], ["lung", "ANATOMY", 214, 218]]], ["This pathophysiologic difference between pneumothorax and atelectasis explains the patterns of absorption changes.", [["pneumothorax", "DISEASE", 41, 53], ["atelectasis", "DISEASE", 58, 69], ["pneumothorax", "PROBLEM", 41, 53], ["atelectasis", "PROBLEM", 58, 69], ["absorption changes", "PROBLEM", 95, 113], ["difference", "OBSERVATION_MODIFIER", 22, 32], ["pneumothorax", "OBSERVATION", 41, 53], ["atelectasis", "OBSERVATION", 58, 69], ["absorption changes", "OBSERVATION", 95, 113]]], ["Thus, this experimental study provides a proof of concept that the GASMAS technique has the potential to detect neonatal life-threatening pulmonary complications.DISCUSSIONThe incidence of pneumothorax is up to 5\u22127% in infants with a birth weight less than 1500 g treated in ventilators 19 and it carries a risk of mortality.", [["pulmonary", "ANATOMY", 138, 147], ["pulmonary complications", "DISEASE", 138, 161], ["pneumothorax", "DISEASE", 189, 201], ["pulmonary", "ORGAN", 138, 147], ["infants", "ORGANISM", 219, 226], ["infants", "SPECIES", 219, 226], ["this experimental study", "TEST", 6, 29], ["the GASMAS technique", "TEST", 63, 83], ["neonatal life-threatening pulmonary complications", "PROBLEM", 112, 161], ["pneumothorax", "PROBLEM", 189, 201], ["a birth weight", "TEST", 232, 246], ["ventilators", "TREATMENT", 275, 286], ["pulmonary", "ANATOMY", 138, 147], ["complications", "OBSERVATION", 148, 161], ["pneumothorax", "OBSERVATION", 189, 201]]], ["Continuous monitoring of pulmonary oxygen (Fig. 3c, d) .", [["pulmonary", "ANATOMY", 25, 34], ["oxygen", "CHEMICAL", 35, 41], ["oxygen", "CHEMICAL", 35, 41], ["pulmonary", "ORGAN", 25, 34], ["oxygen", "SIMPLE_CHEMICAL", 35, 41], ["Continuous monitoring", "TEST", 0, 21], ["pulmonary", "ANATOMY", 25, 34], ["oxygen", "ANATOMY_MODIFIER", 35, 41]]], ["The median and the 25th and 75th quartiles are shown.DISCUSSIONChanges in pulmonary oxygen content are detectable with laser absorption. . .", [["pulmonary", "ANATOMY", 74, 83], ["oxygen", "CHEMICAL", 84, 90], ["oxygen", "CHEMICAL", 84, 90], ["pulmonary", "ORGAN", 74, 83], ["oxygen", "SIMPLE_CHEMICAL", 84, 90], ["pulmonary", "ANATOMY", 74, 83], ["oxygen content", "OBSERVATION", 84, 98]]], ["EK Svanberg et al. content could possibly reduce the time from onset of pneumothorax until diagnosis and intervention.", [["pneumothorax", "DISEASE", 72, 84], ["pneumothorax", "PROBLEM", 72, 84], ["intervention", "TREATMENT", 105, 117], ["pneumothorax", "OBSERVATION", 72, 84]]], ["The GASMAS technique, if applied with an indwelling probe in the nasogastric tube, is not more invasive than the routinely used NAVA-ventilation, and according to one study no adverse effects of the NAVA catheter were observed.", [["nasogastric tube", "ANATOMY", 65, 81], ["nasogastric tube", "TISSUE", 65, 81], ["The GASMAS technique", "TREATMENT", 0, 20], ["an indwelling probe in the nasogastric tube", "TREATMENT", 38, 81], ["NAVA-ventilation", "TREATMENT", 128, 144], ["one study", "TEST", 163, 172], ["the NAVA catheter", "TREATMENT", 195, 212], ["indwelling", "OBSERVATION", 41, 51], ["nasogastric tube", "OBSERVATION", 65, 81], ["not more", "UNCERTAINTY", 86, 94], ["invasive", "OBSERVATION_MODIFIER", 95, 103], ["NAVA catheter", "OBSERVATION", 199, 212]]], ["20 We envision that the technique could be developed into a surveillance for preterm infants in need of respiration support.", [["infants", "ORGANISM", 85, 92], ["infants", "SPECIES", 85, 92], ["the technique", "TREATMENT", 20, 33], ["respiration support", "TREATMENT", 104, 123]]], ["Pulmonary pathophysiology has been subject to investigation with a range of noninvasive techniques with continuous monitoring.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary", "ORGAN", 0, 9], ["continuous monitoring", "TEST", 104, 125]]], ["21 In general, newer techniques, such as electromagnetic inductance plethysmography and electrical impedance tomography, provide clinically useful data, including the detection of pneumothoraxes.", [["pneumothoraxes", "DISEASE", 180, 194], ["pneumothoraxes", "CANCER", 180, 194], ["electromagnetic inductance plethysmography", "TEST", 41, 83], ["electrical impedance tomography", "TEST", 88, 119], ["pneumothoraxes", "PROBLEM", 180, 194], ["pneumothoraxes", "OBSERVATION", 180, 194]]], ["22 The techniques, however, are restricted in the applicability due to difficulties in electrode placement on the tested subjects, especially in infants with very low birth weight.", [["infants", "ORGANISM", 145, 152], ["infants", "SPECIES", 145, 152], ["difficulties in electrode placement", "TREATMENT", 71, 106], ["very low birth weight", "PROBLEM", 158, 179]]], ["23 Optoelectronic plethysmography is a noninvasive 3D motion capture method, measuring chest wall movements, estimating lung volumes.", [["chest wall", "ANATOMY", 87, 97], ["lung", "ANATOMY", 120, 124], ["chest wall", "MULTI-TISSUE_STRUCTURE", 87, 97], ["lung", "ORGAN", 120, 124], ["Optoelectronic plethysmography", "TEST", 3, 33], ["measuring chest wall movements", "TEST", 77, 107], ["estimating lung volumes", "TEST", 109, 132], ["chest", "ANATOMY", 87, 92], ["wall", "ANATOMY_MODIFIER", 93, 97], ["movements", "OBSERVATION", 98, 107], ["lung", "ANATOMY", 120, 124], ["volumes", "ANATOMY_MODIFIER", 125, 132]]], ["The technique reconstructs the chest wall surface by using up to 89 surface markers (24 can be used in the infant setting) and 8 infrared cameras, mounted in the room.", [["chest wall surface", "ANATOMY", 31, 49], ["surface", "ANATOMY", 68, 75], ["chest wall surface", "MULTI-TISSUE_STRUCTURE", 31, 49], ["The technique", "TREATMENT", 0, 13], ["chest", "ANATOMY", 31, 36], ["wall", "ANATOMY_MODIFIER", 37, 41]]], ["This is a promising research technique for lung volume assessment, but not feasible for clinical bed-side continuous monitoring, nor can it provide information on oxygen distribution throughout the lungs.", [["lung", "ANATOMY", 43, 47], ["lungs", "ANATOMY", 198, 203], ["oxygen", "CHEMICAL", 163, 169], ["oxygen", "CHEMICAL", 163, 169], ["lung", "ORGAN", 43, 47], ["oxygen", "SIMPLE_CHEMICAL", 163, 169], ["lungs", "ORGAN", 198, 203], ["lung volume assessment", "TEST", 43, 65], ["side continuous monitoring", "TEST", 101, 127], ["lung", "ANATOMY", 43, 47], ["volume", "OBSERVATION", 48, 54], ["oxygen distribution", "OBSERVATION", 163, 182], ["lungs", "ANATOMY", 198, 203]]], ["24 Electrical impedance tomography 25, 26 gives information on global and regional changes in lung impedance correlating with intrathoracic changes in air content and thereby lung volume.", [["lung", "ANATOMY", 94, 98], ["intrathoracic", "ANATOMY", 126, 139], ["lung", "ANATOMY", 175, 179], ["lung", "ORGAN", 94, 98], ["lung", "ORGAN", 175, 179], ["Electrical impedance tomography", "TEST", 3, 34], ["global and regional changes in lung impedance", "PROBLEM", 63, 108], ["intrathoracic changes in air content", "PROBLEM", 126, 162], ["thereby lung volume", "PROBLEM", 167, 186], ["lung", "ANATOMY", 94, 98], ["intrathoracic", "ANATOMY", 126, 139], ["air content", "OBSERVATION", 151, 162], ["lung", "ANATOMY", 175, 179], ["volume", "OBSERVATION_MODIFIER", 180, 186]]], ["However, this technique only gives information on a transversal \"slice\" of the lung and does not provide any information on O 2 content.DISCUSSIONLung ultrasound is another noninvasive technique used in intensive care units to detect e.g. atelectasis 5 ; however, it is highly user-dependent, gives no information on oxygen distribution, and does not allow for continuous surveillance.", [["lung", "ANATOMY", 79, 83], ["atelectasis", "DISEASE", 239, 250], ["oxygen", "CHEMICAL", 317, 323], ["O 2", "CHEMICAL", 124, 127], ["oxygen", "CHEMICAL", 317, 323], ["lung", "ORGAN", 79, 83], ["O 2", "SIMPLE_CHEMICAL", 124, 127], ["oxygen", "SIMPLE_CHEMICAL", 317, 323], ["ultrasound", "TEST", 151, 161], ["another noninvasive technique", "TEST", 165, 194], ["atelectasis", "PROBLEM", 239, 250], ["continuous surveillance", "TEST", 361, 384], ["lung", "ANATOMY", 79, 83], ["atelectasis", "OBSERVATION", 239, 250]]], ["In comparison to the above mentioned, the GASMAS technique enables continuous monitoring of the oxygen concentration in the lung as well as an indication of changes in gas volume with one light probe (preferably internal) and one or several detection probes.DISCUSSIONConventional pulse oximetry is routinely used for arterial oxygen saturation monitoring, and in the newborn infant information about pre-and postductal differences in oxygen saturation can be obtained.", [["lung", "ANATOMY", 124, 128], ["arterial", "ANATOMY", 318, 326], ["postductal", "ANATOMY", 409, 419], ["oxygen", "CHEMICAL", 96, 102], ["oxygen", "CHEMICAL", 327, 333], ["oxygen", "CHEMICAL", 435, 441], ["oxygen", "CHEMICAL", 96, 102], ["oxygen", "CHEMICAL", 327, 333], ["oxygen", "CHEMICAL", 435, 441], ["oxygen", "SIMPLE_CHEMICAL", 96, 102], ["lung", "ORGAN", 124, 128], ["arterial", "MULTI-TISSUE_STRUCTURE", 318, 326], ["oxygen", "SIMPLE_CHEMICAL", 327, 333], ["oxygen", "SIMPLE_CHEMICAL", 435, 441], ["the GASMAS technique", "TEST", 38, 58], ["the oxygen concentration", "TREATMENT", 92, 116], ["changes in gas volume", "PROBLEM", 157, 178], ["DISCUSSIONConventional pulse oximetry", "TEST", 258, 295], ["arterial oxygen saturation monitoring", "TEST", 318, 355], ["oxygen saturation", "TEST", 435, 452], ["oxygen concentration", "OBSERVATION", 96, 116], ["lung", "ANATOMY", 124, 128], ["gas volume", "OBSERVATION", 168, 178]]], ["The proposed technique in the present study should be considered as a complement to pulse oximetry as it has the ability to detect lung pathologies quickly, most probably before changes in arterial oxygenation occur.DISCUSSIONA considerable signal variation in the absorption signal between the piglets during the induced atelectasis was observed.", [["lung", "ANATOMY", 131, 135], ["arterial", "ANATOMY", 189, 197], ["lung pathologies", "DISEASE", 131, 147], ["atelectasis", "DISEASE", 322, 333], ["lung", "ORGAN", 131, 135], ["arterial", "MULTI-TISSUE_STRUCTURE", 189, 197], ["piglets", "ORGANISM", 295, 302], ["pulse oximetry", "TEST", 84, 98], ["lung pathologies", "PROBLEM", 131, 147], ["arterial oxygenation", "TEST", 189, 209], ["considerable signal variation in the absorption signal", "PROBLEM", 228, 282], ["the induced atelectasis", "PROBLEM", 310, 333], ["lung", "ANATOMY", 131, 135], ["pathologies", "OBSERVATION", 136, 147], ["most probably", "UNCERTAINTY", 157, 170], ["arterial oxygenation", "OBSERVATION", 189, 209], ["variation", "OBSERVATION_MODIFIER", 248, 257], ["atelectasis", "OBSERVATION", 322, 333]]], ["However, the decrease in transmission observed in all piglets was consistent.", [["piglets", "ORGANISM", 54, 61], ["piglets", "SPECIES", 54, 61], ["the decrease in transmission", "PROBLEM", 9, 37], ["decrease", "OBSERVATION_MODIFIER", 13, 21]]], ["This is physiologically well understood, since the induced atelectasis leads to distal lung parenchyma collapse, resulting in concomitant decreased transmission of light.", [["lung parenchyma", "ANATOMY", 87, 102], ["atelectasis", "DISEASE", 59, 70], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 87, 102], ["the induced atelectasis", "PROBLEM", 47, 70], ["distal lung parenchyma collapse", "PROBLEM", 80, 111], ["concomitant decreased transmission of light", "PROBLEM", 126, 169], ["atelectasis", "OBSERVATION", 59, 70], ["distal", "ANATOMY_MODIFIER", 80, 86], ["lung", "ANATOMY", 87, 91], ["parenchyma", "ANATOMY_MODIFIER", 92, 102], ["collapse", "OBSERVATION", 103, 111], ["concomitant", "OBSERVATION_MODIFIER", 126, 137], ["decreased", "OBSERVATION_MODIFIER", 138, 147], ["transmission", "OBSERVATION_MODIFIER", 148, 160]]], ["This needs to be further investigated, focusing on the transmission variation as a response to varying degrees of atelectasis.DISCUSSIONDue to too weak H 2 O signal with dermal light administration, the pulmonary O 2 concentration could not be estimated.", [["dermal", "ANATOMY", 170, 176], ["pulmonary", "ANATOMY", 203, 212], ["atelectasis", "DISEASE", 114, 125], ["H 2 O", "CHEMICAL", 152, 157], ["O 2", "CHEMICAL", 213, 216], ["H 2 O", "SIMPLE_CHEMICAL", 152, 157], ["atelectasis", "PROBLEM", 114, 125], ["dermal light administration", "TREATMENT", 170, 197], ["atelectasis", "OBSERVATION", 114, 125], ["pulmonary", "ANATOMY", 203, 212]]], ["Piglets have an elongated and narrow thorax compared to human infants and the front leg makes the apical part of the thorax less accessible.", [["thorax", "ANATOMY", 37, 43], ["front leg", "ANATOMY", 78, 87], ["apical part", "ANATOMY", 98, 109], ["thorax", "ANATOMY", 117, 123], ["Piglets", "ORGANISM", 0, 7], ["thorax", "ORGAN", 37, 43], ["human", "ORGANISM", 56, 61], ["infants", "ORGANISM", 62, 69], ["leg", "ORGANISM_SUBDIVISION", 84, 87], ["apical part", "MULTI-TISSUE_STRUCTURE", 98, 109], ["thorax", "ORGAN", 117, 123], ["Piglets", "SPECIES", 0, 7], ["human", "SPECIES", 56, 61], ["infants", "SPECIES", 62, 69], ["human", "SPECIES", 56, 61], ["an elongated and narrow thorax", "PROBLEM", 13, 43], ["elongated", "OBSERVATION_MODIFIER", 16, 25], ["narrow", "OBSERVATION_MODIFIER", 30, 36], ["thorax", "ANATOMY", 37, 43], ["front", "ANATOMY_MODIFIER", 78, 83], ["leg", "ANATOMY", 84, 87], ["apical", "ANATOMY_MODIFIER", 98, 104], ["thorax", "ANATOMY", 117, 123]]], ["This disturbs the required balance between the need for a minimum light source-detector distance and proximity to lung tissue with volumes large enough for the light not to travel through extra-pulmonary tissue (e.g. trachea, mediastinum, and abdominal organs).", [["lung tissue", "ANATOMY", 114, 125], ["extra-pulmonary tissue", "ANATOMY", 188, 210], ["trachea", "ANATOMY", 217, 224], ["mediastinum", "ANATOMY", 226, 237], ["abdominal organs", "ANATOMY", 243, 259], ["lung tissue", "TISSUE", 114, 125], ["extra-pulmonary tissue", "TISSUE", 188, 210], ["trachea", "MULTI-TISSUE_STRUCTURE", 217, 224], ["mediastinum", "ORGAN", 226, 237], ["abdominal organs", "ORGAN", 243, 259], ["extra-pulmonary tissue (e.g. trachea, mediastinum, and abdominal organs", "PROBLEM", 188, 259], ["lung", "ANATOMY", 114, 118], ["tissue", "OBSERVATION", 119, 125], ["extra-pulmonary tissue", "ANATOMY", 188, 210], ["trachea", "ANATOMY", 217, 224], ["mediastinum", "ANATOMY", 226, 237], ["abdominal organs", "ANATOMY", 243, 259]]], ["Light from a dermal light source will theoretically scatter more at entrance to the lungs than from an internal source.", [["dermal", "ANATOMY", 13, 19], ["lungs", "ANATOMY", 84, 89], ["lungs", "ORGAN", 84, 89], ["lungs", "ANATOMY", 84, 89], ["internal", "OBSERVATION_MODIFIER", 103, 111], ["source", "OBSERVATION", 112, 118]]], ["Moreover, the characteristics of the skin of the piglet differ from preterm infants and thereby piglets may not be the optimal model to mimic human infants, when evaluating the dermal light source.", [["skin", "ANATOMY", 37, 41], ["piglet", "ANATOMY", 49, 55], ["dermal", "ANATOMY", 177, 183], ["skin", "ORGAN", 37, 41], ["piglet", "ORGANISM", 49, 55], ["infants", "ORGANISM", 76, 83], ["piglets", "ORGANISM", 96, 103], ["human", "ORGANISM", 142, 147], ["infants", "ORGANISM", 148, 155], ["dermal", "TISSUE", 177, 183], ["piglet", "SPECIES", 49, 55], ["infants", "SPECIES", 76, 83], ["piglets", "SPECIES", 96, 103], ["human", "SPECIES", 142, 147], ["infants", "SPECIES", 148, 155], ["human", "SPECIES", 142, 147], ["skin", "ANATOMY", 37, 41]]], ["However, using internal light administration, we obtained clear signal changes in response to the right-sided pneumothorax, suggesting robust signal conductance from source to detector.", [["pneumothorax", "DISEASE", 110, 122], ["internal light administration", "TREATMENT", 15, 44], ["clear signal changes", "PROBLEM", 58, 78], ["the right-sided pneumothorax", "PROBLEM", 94, 122], ["robust signal conductance", "PROBLEM", 135, 160], ["right", "ANATOMY_MODIFIER", 98, 103], ["sided", "ANATOMY_MODIFIER", 104, 109], ["pneumothorax", "OBSERVATION", 110, 122], ["suggesting", "UNCERTAINTY", 124, 134], ["robust", "OBSERVATION_MODIFIER", 135, 141], ["signal conductance", "OBSERVATION", 142, 160]]], ["In previous studies, we have obtained strong O 2 absorption signals in healthy full-term infants with a dermal light source.", [["dermal", "ANATOMY", 104, 110], ["O 2", "CHEMICAL", 45, 48], ["infants", "ORGANISM", 89, 96], ["dermal", "TISSUE", 104, 110], ["infants", "SPECIES", 89, 96], ["previous studies", "TEST", 3, 19]]], ["13 In the present study, when delivering the light internally, reliable pulmonary O 2 concentrations could, for the first time in an experimental animal, be determined using the H 2 O absorption signal.", [["pulmonary", "ANATOMY", 72, 81], ["O 2", "CHEMICAL", 82, 85], ["H 2 O", "CHEMICAL", 178, 183], ["pulmonary", "ANATOMY", 72, 81]]], ["Likewise, calculations of oxygen concentrations were possible on a 3D phantom of a newborn infant\u00b4s torso, when applying the light source internally.", [["oxygen", "CHEMICAL", 26, 32], ["oxygen", "CHEMICAL", 26, 32], ["oxygen", "SIMPLE_CHEMICAL", 26, 32], ["torso", "ORGANISM_SUBDIVISION", 100, 105], ["calculations of oxygen concentrations", "TREATMENT", 10, 47], ["a newborn infant\u00b4s torso", "TREATMENT", 81, 105], ["oxygen concentrations", "OBSERVATION", 26, 47], ["torso", "ANATOMY", 100, 105]]], ["14 Autopsy of one piglet did not reveal any visually detected damage to the esophagus.", [["piglet", "ANATOMY", 18, 24], ["esophagus", "ANATOMY", 76, 85], ["damage to the esophagus", "DISEASE", 62, 85], ["piglet", "ORGANISM", 18, 24], ["esophagus", "ORGAN", 76, 85], ["piglet", "SPECIES", 18, 24], ["any visually detected damage to the esophagus", "PROBLEM", 40, 85], ["damage", "OBSERVATION", 62, 68], ["esophagus", "ANATOMY", 76, 85]]], ["However, we did not study the possible microscopic damages to the tissue from slight Changes in pulmonary oxygen content are detectable with laser absorption. . .", [["tissue", "ANATOMY", 66, 72], ["pulmonary", "ANATOMY", 96, 105], ["oxygen", "CHEMICAL", 106, 112], ["oxygen", "CHEMICAL", 106, 112], ["tissue", "TISSUE", 66, 72], ["pulmonary", "ORGAN", 96, 105], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["microscopic damages to the tissue", "PROBLEM", 39, 72], ["slight Changes in pulmonary oxygen content", "PROBLEM", 78, 120], ["slight", "OBSERVATION_MODIFIER", 78, 84], ["Changes", "OBSERVATION", 85, 92], ["pulmonary", "ANATOMY", 96, 105], ["oxygen content", "OBSERVATION", 106, 120]]], ["EK Svanberg et al. temperature increases or physical damage from the optical fiber probe.", [["temperature increases", "PROBLEM", 19, 40], ["physical damage", "PROBLEM", 44, 59], ["the optical fiber probe", "TREATMENT", 65, 88], ["physical", "OBSERVATION_MODIFIER", 44, 52], ["damage", "OBSERVATION", 53, 59]]], ["The diffuse light emission was significantly lower than the maximum irradiance allowed, 150 mW/cm 2 , which when exposed on the skin would generate a maximum temperature increase of 2\u00b0C. 17 Whether this local increase in temperature of the nasogastric tube could have any adverse effects on neonatal esophagus needs to be investigated.", [["skin", "ANATOMY", 128, 132], ["nasogastric tube", "ANATOMY", 240, 256], ["neonatal esophagus", "ANATOMY", 291, 309], ["skin", "ORGAN", 128, 132], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 240, 256], ["esophagus", "ORGAN", 300, 309], ["The diffuse light emission", "PROBLEM", 0, 26], ["the nasogastric tube", "TREATMENT", 236, 256], ["any adverse effects on neonatal esophagus", "PROBLEM", 268, 309], ["diffuse", "OBSERVATION_MODIFIER", 4, 11], ["significantly", "OBSERVATION_MODIFIER", 31, 44], ["lower", "OBSERVATION_MODIFIER", 45, 50], ["skin", "ANATOMY", 128, 132], ["increase", "OBSERVATION_MODIFIER", 209, 217], ["nasogastric tube", "OBSERVATION", 240, 256], ["esophagus", "ANATOMY", 300, 309]]], ["We envision that for clinical investigations to avoid contact with esophagus, the light probe would be inserted into or embedded in a nasogastric tube, and could even be used together with NAVA ventilation.", [["esophagus", "ANATOMY", 67, 76], ["nasogastric tube", "ANATOMY", 134, 150], ["esophagus", "ORGAN", 67, 76], ["nasogastric tube", "TISSUE", 134, 150], ["NAVA", "SIMPLE_CHEMICAL", 189, 193], ["clinical investigations", "TEST", 21, 44], ["the light probe", "TREATMENT", 78, 93], ["a nasogastric tube", "TREATMENT", 132, 150], ["NAVA ventilation", "TREATMENT", 189, 205], ["esophagus", "ANATOMY", 67, 76], ["nasogastric tube", "OBSERVATION", 134, 150]]], ["Future studies of the GASMAS technique should focus on the reliability and accuracy of the measurements in sufficient number of subjects with an improved equipment developed from the prototype used in this study.", [["Future studies", "TEST", 0, 14], ["the GASMAS technique", "TEST", 18, 38], ["the measurements", "TEST", 87, 103], ["this study", "TEST", 201, 211]]], ["Further, the applicability of the technique to detect changes in lung volume parameters (e.g. tidal volume) can be studied by changing ventilator settings in the experimental model, as indicated by the possibility to follow each breath.", [["lung", "ANATOMY", 65, 69], ["lung", "ORGAN", 65, 69], ["tidal", "ORGANISM_SUBDIVISION", 94, 99], ["the technique", "TEST", 30, 43], ["changes in lung volume parameters", "PROBLEM", 54, 87], ["tidal volume", "TEST", 94, 106], ["lung", "ANATOMY", 65, 69], ["volume", "OBSERVATION", 70, 76]]], ["Before clinical studies in newborn infants can be designed, the safety aspects of the technique, such as heating effects, must be assessed.", [["infants", "ORGANISM", 35, 42], ["infants", "SPECIES", 35, 42], ["clinical studies", "TEST", 7, 23], ["the technique", "TREATMENT", 82, 95]]], ["Also, ensuring a simple and robust applicability with well-designed light probes and detectors suitable for fragile preterm infants is essential for the technique to be investigated in the neonatal intensive care unit environment.CONCLUSIONGASMAS enables measurement of pulmonary O 2 concentration using an internal light probe along with distinct signal changes during pneumothorax in a neonatal piglet model.", [["pulmonary", "ANATOMY", 270, 279], ["piglet", "ANATOMY", 397, 403], ["pneumothorax", "DISEASE", 370, 382], ["O 2", "CHEMICAL", 280, 283], ["infants", "ORGANISM", 124, 131], ["pulmonary O 2", "CELL", 270, 283], ["piglet", "ORGAN", 397, 403], ["infants", "SPECIES", 124, 131], ["light probes and detectors", "TREATMENT", 68, 94], ["fragile preterm infants", "TREATMENT", 108, 131], ["the technique", "TREATMENT", 149, 162], ["an internal light probe", "TREATMENT", 304, 327], ["distinct signal changes", "PROBLEM", 339, 362], ["pneumothorax", "PROBLEM", 370, 382], ["a neonatal piglet model", "TREATMENT", 386, 409], ["pulmonary", "ANATOMY", 270, 279], ["distinct", "OBSERVATION_MODIFIER", 339, 347], ["signal changes", "OBSERVATION", 348, 362], ["pneumothorax", "OBSERVATION", 370, 382]]], ["Compared to electric impedance and ultrasound, GASMAS has the advantage to detect oxygen content and lung volume changes of each breath.", [["lung", "ANATOMY", 101, 105], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["lung", "ORGAN", 101, 105], ["electric impedance", "TEST", 12, 30], ["ultrasound", "TEST", 35, 45], ["oxygen content", "TEST", 82, 96], ["lung volume changes of each breath", "PROBLEM", 101, 135], ["oxygen content", "OBSERVATION", 82, 96], ["lung", "ANATOMY", 101, 105], ["volume", "OBSERVATION", 106, 112]]], ["We were not able to reliably detect pulmonary O 2 content using a dermal light probe.", [["pulmonary", "ANATOMY", 36, 45], ["dermal", "ANATOMY", 66, 72], ["O 2", "CHEMICAL", 46, 49], ["a dermal light probe", "TREATMENT", 64, 84], ["pulmonary", "ANATOMY", 36, 45]]], ["Future studies should focus on the accuracy and reliability along with safety of this method.", [["Future studies", "TEST", 0, 14], ["the accuracy", "TEST", 31, 43], ["this method", "TREATMENT", 81, 92]]]], "PMC7437951": [["INTRODUCTIONThe ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by a novel coronavirusknown as SARS-CoV-2 iterates an important question about how viruses are transmitted throughnatural respiratory activities such as breath, talk, speech, cough, and sneeze (e.g., Mittal et al., 2020; Bourouiba, 2020; and Asadiet al., 2020).", [["respiratory", "ANATOMY", 198, 209], ["Coronavirus Disease", "DISEASE", 24, 43], ["COVID-19", "CHEMICAL", 50, 58], ["SARS", "DISEASE", 107, 111], ["cough", "DISEASE", 251, 256], ["sneeze", "DISEASE", 262, 268], ["SARS-CoV-2", "ORGANISM", 107, 117], ["Coronavirus Disease 2019 (COVID-19", "SPECIES", 24, 58], ["SARS-CoV", "SPECIES", 107, 115], ["ongoing Coronavirus Disease", "PROBLEM", 16, 43], ["COVID", "TEST", 50, 55], ["pandemic", "PROBLEM", 60, 68], ["cough", "PROBLEM", 251, 256], ["Coronavirus Disease", "OBSERVATION", 24, 43]]], ["The dynamics of virus transmission is not wellunderstood, with one challenge being the complicated fluid and flow characteristics involvedin the fate and transport of virus, including source dynamics (e.g., exhale velocity andtemperature, droplet sizes, virus load, and droplet\u2013virus correlations), ambient conditions(e.g., mean and turbulent flows, temperature, and humidity), and virus dynamics (e.g., virusviability and infectious rate) (e.g., Lindsley etal., 2015; Feng et al.,2020; Dbouk and Drikakis, 2020a; and Mittal et al., 2020).", [["fluid", "ANATOMY", 99, 104], ["the complicated fluid", "PROBLEM", 83, 104], ["virus", "PROBLEM", 167, 172], ["source dynamics", "TEST", 184, 199], ["exhale velocity andtemperature", "TEST", 207, 237], ["droplet sizes", "PROBLEM", 239, 252], ["virus load", "TREATMENT", 254, 264], ["droplet\u2013virus correlations", "TEST", 270, 296], ["ambient conditions", "PROBLEM", 299, 317], ["mean", "TEST", 324, 328], ["temperature", "TEST", 350, 361], ["virus dynamics", "PROBLEM", 382, 396], ["virusviability", "PROBLEM", 404, 418], ["infectious rate", "TEST", 423, 438], ["complicated", "OBSERVATION_MODIFIER", 87, 98], ["fluid", "OBSERVATION", 99, 104], ["turbulent flows", "OBSERVATION", 333, 348]]], ["Understanding thefundamental fluid dynamics of expiratory virus-laden droplets is critical to the predictionof the transport and fate of droplets and associated potential threats of infectious diseasetransmission and will provide quantitative guidance for making a public health policy fordisease mitigation, e.g., decisions on social distancing and face covering in various indoorand outdoor environments (Dbouk and Drikakis, 2020b;Verma et al., 2020).INTRODUCTIONHuman respiratory activities produce droplets with a wide range of sizes, depending on thetype of activities and physical and health conditions of individuals.", [["fluid", "ANATOMY", 29, 34], ["diseasetransmission", "DISEASE", 193, 212], ["expiratory virus", "PROBLEM", 47, 63], ["infectious diseasetransmission", "PROBLEM", 182, 212], ["infectious", "OBSERVATION", 182, 192], ["sizes", "OBSERVATION_MODIFIER", 532, 537]]], ["The typical sizes ofhuman expiratory droplets are in the range of 10\u22121\u03bcm\u2013103\u03bcm (e.g., Duguid, 1945; Yang et al., 2007; Chao et al., 2009; Xieet al., 2009; Han etal., 2013; and Asadi etal., 2019).", [["The typical sizes ofhuman expiratory droplets", "TEST", 0, 45], ["typical", "OBSERVATION_MODIFIER", 4, 11], ["sizes", "OBSERVATION_MODIFIER", 12, 17], ["ofhuman", "OBSERVATION_MODIFIER", 18, 25], ["expiratory droplets", "OBSERVATION", 26, 45]]], ["This wide range of droplet sizes results in variousflow-following capabilities and falling speeds in the respiratory flows.", [["respiratory", "ANATOMY", 105, 116], ["falling speeds", "PROBLEM", 83, 97], ["droplet sizes", "OBSERVATION", 19, 32], ["respiratory flows", "OBSERVATION", 105, 122]]], ["For instance, a 10\u03bcm droplet has the terminal velocity of 3 mm/s, whereas a 1000\u03bcm droplet has the terminal velocity of 3.86 m/s.", [["a 10\u03bcm droplet", "TEST", 14, 28], ["the terminal velocity", "TEST", 33, 54], ["a 1000\u03bcm droplet", "TEST", 74, 90], ["the terminal velocity", "TEST", 95, 116], ["terminal", "OBSERVATION_MODIFIER", 37, 45], ["velocity", "OBSERVATION_MODIFIER", 46, 54], ["terminal", "OBSERVATION_MODIFIER", 99, 107], ["velocity", "OBSERVATION_MODIFIER", 108, 116]]], ["In the meantime, theparticle relaxation time of a 10 \u03bcm and a 1000 \u03bcm dropletis 0.0003 s and 0.39 s, respectively.", [["a 1000 \u03bcm dropletis", "TREATMENT", 60, 79]]], ["Given their sizes, the Stokes number for 1000\u03bcm droplets is one order of magnitude higher than that of 10\u03bcm droplets in the same air velocity.", [["sizes", "OBSERVATION_MODIFIER", 12, 17], ["air velocity", "OBSERVATION", 129, 141]]], ["Hence, the air flow has much weakerimpact on the 1000 \u03bcm droplet (i.e., stronger inertia effect) than the 10\u03bcm droplet.", [["the air flow", "TEST", 7, 19], ["the 1000 \u03bcm droplet", "TREATMENT", 45, 64], ["the 10\u03bcm droplet", "TREATMENT", 102, 118], ["air flow", "OBSERVATION", 11, 19]]], ["Because the human expiratory droplets span a wide size rangeeven in a single event, the transport of these droplets has significant temporal and spatialvariability in air flows from the perspective of fluid kinematics, let alone various timescales of the concurrent thermodynamic processes.INTRODUCTIONRespiratory infectious illness can be transmitted by viruses that are passed along fromhosts to recipients through the dispersal of virus-laden droplets in the normal respiratoryactivities (Milton et al., 2013;Gralton et al., 2013; and Zhou et al., 2018).", [["fluid", "ANATOMY", 201, 206], ["infectious illness", "DISEASE", 314, 332], ["human", "ORGANISM", 12, 17], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["the human expiratory droplets", "TEST", 8, 37], ["these droplets", "TEST", 101, 115], ["significant temporal and spatialvariability in air flows", "PROBLEM", 120, 176], ["fluid kinematics", "PROBLEM", 201, 217], ["INTRODUCTIONRespiratory infectious illness", "PROBLEM", 290, 332], ["viruses", "PROBLEM", 355, 362], ["wide", "OBSERVATION_MODIFIER", 45, 49], ["size", "OBSERVATION_MODIFIER", 50, 54], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["temporal", "OBSERVATION_MODIFIER", 132, 140], ["spatialvariability", "OBSERVATION", 145, 163], ["air flows", "OBSERVATION", 167, 176], ["fluid kinematics", "OBSERVATION", 201, 217], ["thermodynamic processes", "OBSERVATION", 266, 289], ["infectious", "OBSERVATION", 314, 324], ["viruses", "OBSERVATION", 355, 362], ["normal respiratoryactivities", "OBSERVATION", 462, 490]]], ["Violent expiratoryevents such as coughing and sneezing have high initial velocity (\u223c10 m/s) and can spreaddroplets within 2 m\u20133 m (Bourouiba et al.,2014), which can be extended up to 7 m\u20138 m due to strong turbulence and buoyanteffects (Bourouiba, 2020).", [["coughing", "DISEASE", 33, 41], ["sneezing", "DISEASE", 46, 54], ["Violent expiratoryevents", "PROBLEM", 0, 24], ["coughing", "PROBLEM", 33, 41], ["sneezing", "PROBLEM", 46, 54], ["turbulence", "OBSERVATION", 205, 215]]], ["Many studies have reportedviable viruses in human respiratory activities and virus detection in air samples away frompatients (e.g., Bischoff et al.,2013; Lindsley et al., 2012;and 2015).", [["respiratory", "ANATOMY", 50, 61], ["human", "ORGANISM", 44, 49], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["Many studies", "TEST", 0, 12], ["reportedviable viruses in human respiratory activities", "PROBLEM", 18, 72], ["virus detection", "TEST", 77, 92], ["viruses", "OBSERVATION", 33, 40], ["respiratory activities", "OBSERVATION", 50, 72]]], ["Despite no well-constrained dynamics ofairborne virus transmission, it is apparent that the transport of droplets through humanrespiratory activities plays a key role in the transmission of respiratory infectiousdiseases.INTRODUCTIONExhaled droplets are transported away from the source (i.e., nose and mouth) in respiratoryactivities, following flow patterns with the expiratory event controlled time and velocityscales and their interaction with ambient air flows.", [["respiratory", "ANATOMY", 190, 201], ["nose", "ANATOMY", 294, 298], ["mouth", "ANATOMY", 303, 308], ["respiratory infectiousdiseases", "DISEASE", 190, 220], ["ofairborne virus", "ORGANISM", 37, 53], ["nose", "ORGANISM_SUBDIVISION", 294, 298], ["mouth", "ORGANISM_SUBDIVISION", 303, 308], ["respiratory infectiousdiseases", "PROBLEM", 190, 220], ["INTRODUCTIONExhaled droplets", "TREATMENT", 221, 249], ["ambient air flows", "TREATMENT", 448, 465], ["respiratory infectiousdiseases", "OBSERVATION", 190, 220], ["nose", "ANATOMY", 294, 298], ["mouth", "ANATOMY", 303, 308]]], ["Human cough generates a maximal initialvelocity on the scale of \u223c10 m/s (Chao etal., 2009; Tang et al.,2008; VanSciver et al.,2011; Kwon et al., 2012;and Zhu et al., 2006) within atypical time scale of 0.5 s (Gupta et al.,2009).", [["cough", "DISEASE", 6, 11], ["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human cough", "PROBLEM", 0, 11], ["maximal", "OBSERVATION_MODIFIER", 24, 31]]], ["Yang et al. (2007)found a positive correlation between cough flow rate and droplet population.", [["cough flow rate", "TEST", 55, 70], ["droplet population", "TREATMENT", 75, 93], ["droplet population", "OBSERVATION", 75, 93]]], ["Theseproperties of respiratory flows and associated droplets provide necessary information todetermine the evolving droplet dynamics within a rapid physical process in the near field ofthe source before the end of the respiratory activities.", [["respiratory", "ANATOMY", 19, 30], ["respiratory", "ANATOMY", 218, 229], ["respiratory flows", "PROBLEM", 19, 36], ["the evolving droplet dynamics", "PROBLEM", 103, 132], ["a rapid physical process", "PROBLEM", 140, 164], ["respiratory flows", "OBSERVATION", 19, 36], ["droplet dynamics", "OBSERVATION", 116, 132], ["rapid", "OBSERVATION_MODIFIER", 142, 147], ["respiratory activities", "OBSERVATION", 218, 240]]], ["The droplet dynamics in the nearfield determines where, when, and which droplets would settle on the solid surface (e.g.,ground and table) as a potential infectious source for fomite transmission (Lindsley et al., 2010; Wei and Li, 2016).", [["solid surface", "ANATOMY", 101, 114], ["droplet dynamics", "OBSERVATION", 4, 20], ["infectious", "OBSERVATION", 154, 164]]], ["This near field dynamics also servesas the initial condition and can be coupled with far field transport by ambient air flowsand turbulence (e.g., Wei and Li, 2016; Zhu et al., 2006; Thatiparti et al., 2017; and Dbouk and Drikakis, 2020a).INTRODUCTIONBoth droplet properties and flow characteristics play a key role in the transport ofdroplets and transmission of associated infectious diseases.", [["infectious diseases", "DISEASE", 375, 394], ["INTRODUCTIONBoth droplet properties", "TREATMENT", 239, 274], ["associated infectious diseases", "PROBLEM", 364, 394], ["infectious", "OBSERVATION", 375, 385]]], ["Xie et al. (2007) demonstrates the evaporation time and settlingtime as a function of droplet diameter, known as the Wells-curve (Wells, 1934).", [["the evaporation time", "TREATMENT", 31, 51]]], ["They added an additional curve that illustrates thedroplets escaping from cough jets.", [["cough", "DISEASE", 74, 79], ["thedroplets", "SIMPLE_CHEMICAL", 48, 59], ["an additional curve", "TREATMENT", 11, 30], ["cough jets", "PROBLEM", 74, 84], ["cough jets", "OBSERVATION", 74, 84]]], ["In their analyses, the influence of turbulence was notincluded, and hence, the conclusion is limited for practical purposes.", [["turbulence", "PROBLEM", 36, 46]]], ["Wei and Li (2015) applied a discrete random walk (DRW) model to simulatethe turbulent transport of droplets in a cough jet, providing better predictions of droplettransports in the lateral direction of the cough jet.", [["Li", "CHEMICAL", 8, 10], ["cough", "DISEASE", 113, 118], ["cough", "DISEASE", 206, 211], ["a discrete random walk (DRW)", "TREATMENT", 26, 54], ["a cough jet", "PROBLEM", 111, 122], ["droplettransports", "TREATMENT", 156, 173], ["the cough jet", "PROBLEM", 202, 215], ["lateral", "ANATOMY_MODIFIER", 181, 188], ["cough jet", "OBSERVATION", 206, 215]]], ["A critical information from the modelresult is that the median-sized droplets (30 \u03bcm\u201350 \u03bcm intheir simulation) are sensitive to ambient humidity.", [["the median-sized droplets", "TREATMENT", 52, 77], ["ambient humidity", "TREATMENT", 128, 144], ["sized", "OBSERVATION_MODIFIER", 63, 68], ["droplets", "OBSERVATION", 69, 77], ["ambient humidity", "OBSERVATION", 128, 144]]], ["When ambient air is dry, themedian-sized droplets can shrink to adequately small sizes within the cough jet and wouldnot escape the jet.", [["cough", "DISEASE", 98, 103], ["themedian-sized droplets", "TREATMENT", 25, 49], ["the cough jet", "PROBLEM", 94, 107], ["sized", "OBSERVATION_MODIFIER", 35, 40], ["droplets", "OBSERVATION", 41, 49], ["small", "OBSERVATION_MODIFIER", 75, 80], ["sizes", "OBSERVATION_MODIFIER", 81, 86], ["cough jet", "OBSERVATION", 98, 107], ["jet", "OBSERVATION", 132, 135]]], ["In humid air, the suppressed shrinkage of droplet sizes due tosuppressed evaporation can maintain adequate inertia so that these droplets are able toleave the cough jet.", [["cough", "DISEASE", 159, 164], ["the suppressed shrinkage of droplet sizes", "TREATMENT", 14, 55], ["tosuppressed evaporation", "TREATMENT", 60, 84], ["these droplets", "TREATMENT", 123, 137], ["the cough jet", "PROBLEM", 155, 168], ["humid air", "OBSERVATION", 3, 12], ["suppressed", "OBSERVATION_MODIFIER", 18, 28], ["shrinkage", "OBSERVATION_MODIFIER", 29, 38], ["droplet sizes", "OBSERVATION", 42, 55], ["cough", "OBSERVATION", 159, 164]]], ["One limitation of their model is that DRW is not a good representationof the continuously correlated turbulent fluctuations as it uses a discrete random walkalgorithm.", [["a discrete random walkalgorithm", "TREATMENT", 135, 166], ["turbulent fluctuations", "OBSERVATION", 101, 123]]], ["The random process is only imposed when the time scale is larger than theparticle\u2013flow interaction time scale, defined based on the particle relaxation time and eddylifetime.", [["the particle relaxation time", "TREATMENT", 128, 156], ["larger", "OBSERVATION_MODIFIER", 58, 64]]], ["Wei and Li (2015) acknowledged thislimitation and pointed out that their model does not perform well for median-weightedparticles (87 \u03bcm corn pollen in their validation).", [["pollen", "ANATOMY", 142, 148], ["Li", "CHEMICAL", 8, 10], ["corn", "SPECIES", 137, 141]]], ["Note that the cornpollen has approximately the same relaxation time as the expiratory droplets with the samesizes.", [["cornpollen", "CHEMICAL", 14, 24]]], ["Hence, the limitation in predicting median-weighted particles may induce considerableerrors in predicting the transport of virus-laden droplets in human respiratory flows.INTRODUCTIONTo address the above shortcomings in predicting human respiratory flows and associatedtransport of droplets, here, we present a droplet transport and fate model to improve theprediction of spreading of median-sized droplets, which are sensitive to ambient environmentand critical to the decision of public health responses.", [["respiratory", "ANATOMY", 153, 164], ["respiratory", "ANATOMY", 237, 248], ["human", "ORGANISM", 147, 152], ["human", "ORGANISM", 231, 236], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 231, 236], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 231, 236], ["virus-laden droplets", "TREATMENT", 123, 143], ["a droplet transport", "TREATMENT", 309, 328], ["median-sized droplets", "TREATMENT", 385, 406], ["laden droplets", "OBSERVATION", 129, 143], ["respiratory flows", "OBSERVATION", 153, 170], ["respiratory flows", "OBSERVATION", 237, 254], ["sized", "OBSERVATION_MODIFIER", 392, 397], ["droplets", "OBSERVATION", 398, 406]]], ["In our model, we use a continuousrandom walk (CRW) algorithm, an approach designed to simulate the continuous andauto-correlated nature of turbulent fluctuations (Bockselland Loth, 2001; Mofakham and Ahmadi, 2019;and 2020) and mathematically represented by astochastic differential equation (SDE) and its numerical form.", [["a continuousrandom walk (CRW) algorithm", "TREATMENT", 21, 60], ["turbulent fluctuations", "PROBLEM", 139, 161], ["turbulent", "OBSERVATION", 139, 148]]], ["The CRW model and the equations ofthe cough jet are also presented in Sec.", [["The CRW model", "TEST", 0, 13], ["the equations ofthe cough jet", "PROBLEM", 18, 47]]], ["II.", [["II", "CHEMICAL", 0, 2]]], ["In Sec.IV, with various applications of the model, weillustrate the behavior of the human expiratory droplets in a set of idealized scenarios inindoor environments.", [["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["the human expiratory droplets", "TREATMENT", 80, 109]]], ["V, we discuss limitationsof the model and caveats to the presented study.", [["V", "GENE_OR_GENE_PRODUCT", 0, 1], ["the presented study", "TEST", 53, 72]]], ["VI.Lagrangian particle model ::: METHODSThe Lagrangian particle model (LPM) computes the aerodynamic and thermodynamic propertiesof individual particles, where the particles are predefined by their type and properties(i.e., density, size, temperature, and hu).", [["VI", "GENE_OR_GENE_PRODUCT", 0, 2], ["thermodynamic propertiesof", "OBSERVATION", 105, 131], ["particles", "OBSERVATION_MODIFIER", 164, 173], ["density", "OBSERVATION", 224, 231], ["size", "OBSERVATION_MODIFIER", 233, 237]]], ["The location(xi, i = 1, 2, 3, whereindices 1 and 2 represent the horizontal directions and 3 represents the verticaldirection in the Cartesian coordinate system) and velocity(up,i) of each particleare calculated along its path based on the governing equation (Wei and Li, 2015; Chao and Wan,2006),dxidt=up,i,(1)dup,idt=3\u03c1gCd4dp\u03c1p(ui\u2212up,i)|ui\u2212up,i|+gi,(2)where\u03c1p and \u03c1 are the densityof the particle and ambient air, respectively,dp is the particle diameter,Cd is the drag coefficient,ui is the instantaneous air velocity thatconsists of a mean and a turbulent component, and g3 = \u22129.81m/s2 is the gravitational acceleration.", [["Cd", "CHEMICAL", 457, 459], ["Cd", "CHEMICAL", 457, 459], ["Cd", "SIMPLE_CHEMICAL", 457, 459], ["\u03c1", "PROTEIN", 366, 367], ["velocity", "TEST", 166, 174], ["the instantaneous air velocity", "TEST", 490, 520], ["a turbulent component", "PROBLEM", 548, 569], ["g3", "TEST", 575, 577], ["the gravitational acceleration", "PROBLEM", 593, 623], ["velocity", "OBSERVATION_MODIFIER", 166, 174], ["gi", "ANATOMY", 348, 350], ["particle", "OBSERVATION_MODIFIER", 390, 398], ["ambient air", "OBSERVATION", 403, 414], ["particle", "OBSERVATION_MODIFIER", 439, 447], ["diameter", "OBSERVATION_MODIFIER", 448, 456], ["Cd", "OBSERVATION", 457, 459], ["instantaneous", "OBSERVATION_MODIFIER", 494, 507], ["air velocity", "OBSERVATION", 508, 520], ["turbulent", "OBSERVATION_MODIFIER", 550, 559], ["component", "OBSERVATION_MODIFIER", 560, 569], ["gravitational acceleration", "OBSERVATION", 597, 623]]], ["The drag coefficientCd is calculated (Wei and Li, 2015; Goossens,2019),Cd=24Re, Re\u2264124Re(1+0.15Re0.687), 1<Re\u226410000.44, Re>1000,(3)where the Reynolds number is defined asRe =dp|ui\u2212 up,i|/\u03bdwith \u03bd being the kinematic viscosity of air.Lagrangian particle model ::: METHODSIn respiratory flows, the mass and temperature of each droplet are calculated accordingto mass and heat transfer equations, following a series of developments in dropletevaporation and condensation processes (Kukkonenet al., 1989; Walton,2004).", [["respiratory", "ANATOMY", 272, 283], ["Cd", "CHEMICAL", 71, 73], ["Cd", "CHEMICAL", 71, 73], ["24Re", "CHEMICAL", 74, 78], ["Re", "CHEMICAL", 80, 82], ["Re", "CHEMICAL", 107, 109], ["Re", "CHEMICAL", 120, 122], ["METHODSIn respiratory flows", "TEST", 262, 289], ["the mass", "PROBLEM", 291, 299], ["each droplet", "TEST", 319, 331], ["kinematic viscosity", "OBSERVATION", 205, 224], ["air", "OBSERVATION", 228, 231], ["flows", "OBSERVATION_MODIFIER", 284, 289], ["mass", "OBSERVATION", 295, 299], ["mass", "OBSERVATION", 359, 363]]], ["Mass transfer occurs at the droplet surface due to the diffusive flux ofvapor (Iv =\u2212dmp/dt),dmpdt=2\u03c0dppMpCTD\u221eShRT\u221eln1\u2212pv,p/p1\u2212pv,\u221e/p,(4)whereMp is the molecular weight of thedroplet, p is the total pressure, D\u221e is theambient binary diffusion coefficient, R is the universal gas constant,T\u221e is the ambient temperature with unit of Kelvin, andpv,p andpv,\u221e are the vapor pressure at the droplet surface andin the ambient, respectively.", [["droplet surface", "ANATOMY", 28, 43], ["thedroplet", "CHEMICAL", 171, 181], ["droplet surface", "CELLULAR_COMPONENT", 28, 43], ["thedroplet", "SIMPLE_CHEMICAL", 171, 181], ["Mass transfer", "PROBLEM", 0, 13], ["the diffusive flux ofvapor", "PROBLEM", 51, 77], ["the total pressure", "TEST", 188, 206], ["Kelvin", "TREATMENT", 330, 336], ["the vapor pressure", "TREATMENT", 358, 376]]], ["The factor CTaccounts for the temperature dependence of the diffusion coefficient, definedasCT=T\u221e\u2212TpT\u221e\u03bb\u221212\u2212\u03bbT\u221e2\u2212\u03bb\u2212Tp2\u2212\u03bb,(5)with a coefficient \u03bbspecified for droplets (Kukkonen et al.,1989).Lagrangian particle model ::: METHODSIn Eq.", [["T\u221e", "PROTEIN", 95, 97], ["the temperature dependence", "PROBLEM", 26, 52], ["the diffusion coefficient", "TEST", 56, 81], ["definedasCT", "TEST", 83, 94], ["T\u221e", "TEST", 95, 97], ["\u2212", "TEST", 103, 104], ["T", "TEST", 108, 109], ["\u221e", "TEST", 109, 110], ["\u03bb", "TEST", 112, 113], ["Tp2", "TEST", 114, 117], ["\u2212\u03bb", "TEST", 117, 119], ["a coefficient", "TEST", 128, 141], ["droplets", "TEST", 157, 165]]], ["(4), the Sherwood number accountsfor enhanced mass transfer in the turbulent boundary layer of the droplet surface,calculated by Sh = 1 +0.3Re1/2Sc1/3 with Schmidtnumber Sc =\u03bd/D\u221e.", [["droplet surface", "ANATOMY", 99, 114], ["droplet surface", "CELLULAR_COMPONENT", 99, 114], ["enhanced mass", "PROBLEM", 37, 50], ["mass", "OBSERVATION", 46, 50], ["turbulent", "OBSERVATION_MODIFIER", 67, 76], ["boundary", "OBSERVATION_MODIFIER", 77, 85], ["layer", "OBSERVATION_MODIFIER", 86, 91], ["droplet surface", "OBSERVATION", 99, 114]]], ["When the droplet isat rest, Sh = 1 and mass transfer is entirely controlled by the molecularbinary diffusion process.Lagrangian particle model ::: METHODSThe temperature of the droplet is calculated (Wei and Li,2015),cpmpdTpdt=2\u03c0dpKg(T\u221e\u2212Tp)Nu\u2212LvIv\u2212\u03c0dp2\u0393(Tp4\u2212T\u221e4),(6)wherecp is the specific heat capacity of thedroplet, Kg is the thermal conductivity ofair, Lv is the latent heat of droplet vapor, and \u0393 is theStefan\u2013Boltzmann constant.Lagrangian particle model ::: METHODSThe three terms on the right-hand side in Eq.", [["right-hand", "ANATOMY", 495, 505], ["2\u03c0dpKg(T\u221e\u2212Tp)Nu\u2212LvIv\u2212\u03c0dp2\u0393", "CHEMICAL", 227, 253], ["Tp4\u2212T\u221e4)", "CHEMICAL", 254, 262], ["thedroplet", "SIMPLE_CHEMICAL", 307, 317], ["the droplet isat rest", "TREATMENT", 5, 26], ["mass transfer", "PROBLEM", 39, 52], ["the molecularbinary diffusion process", "PROBLEM", 79, 116], ["METHODSThe temperature", "TEST", 147, 169], ["the droplet", "TEST", 173, 184], ["cpmpdTpdt", "TEST", 217, 226], ["2\u03c0dpKg(T\u221e\u2212Tp)Nu\u2212LvIv\u2212\u03c0dp2\u0393(Tp4\u2212T\u221e", "TREATMENT", 227, 260], ["the thermal conductivity ofair", "TREATMENT", 325, 355], ["droplet vapor", "TREATMENT", 382, 395], ["mass", "OBSERVATION", 39, 43], ["Lv", "ANATOMY", 357, 359], ["latent", "OBSERVATION_MODIFIER", 367, 373], ["droplet vapor", "OBSERVATION", 382, 395], ["right", "ANATOMY_MODIFIER", 495, 500], ["hand", "ANATOMY", 501, 505]]], ["(6) are thermal conduction, evaporation, and thermal radiation.", [["thermal conduction", "TREATMENT", 8, 26], ["evaporation", "TREATMENT", 28, 39], ["thermal radiation", "TREATMENT", 45, 62]]], ["Similar to masstransfer, enhanced thermal conduction in turbulent flow should be considered, given by thefactor of Nusselt number Nu = 1 +0.3Re1/2Pr1/3 with Prandtlnumber Pr =c\u03bc/Kg (cand \u03bc are the specific heat and dynamic viscosity of ambient air).Lagrangian particle model ::: METHODSDroplets have various compositions (e.g., salt, protein, and surfactant), which vary fordifferent individuals, their health conditions, and the respiratory activities (i.e.,breath, talk, cough, and sneeze) (Vejerano and Marr,2018).", [["respiratory", "ANATOMY", 430, 441], ["cough", "DISEASE", 473, 478], ["salt", "SIMPLE_CHEMICAL", 328, 332], ["surfactant", "SIMPLE_CHEMICAL", 347, 357], ["cand \u03bc", "PROTEIN", 182, 188], ["enhanced thermal conduction in turbulent flow", "PROBLEM", 25, 70], ["Prandtlnumber Pr", "TREATMENT", 157, 173], ["METHODSDroplets", "TREATMENT", 279, 294], ["various compositions", "TREATMENT", 300, 320], ["salt, protein", "TREATMENT", 328, 341], ["surfactant", "TREATMENT", 347, 357], ["cough", "PROBLEM", 473, 478], ["turbulent flow", "OBSERVATION", 56, 70]]], ["A simplified treatment is to decompose the droplet to liquid and solidphases, where the solid phase is contributed by NaCl (Xieet al., 2007; Wei and Li,2015).", [["NaCl", "CHEMICAL", 118, 122], ["NaCl", "CHEMICAL", 118, 122], ["solidphases", "SIMPLE_CHEMICAL", 65, 76], ["A simplified treatment", "TREATMENT", 0, 22], ["the droplet to liquid and solidphases", "TREATMENT", 39, 76]]], ["Hence, thecpmpin Eq.", [["thecpmpin", "TREATMENT", 7, 16]]], ["(6) can be written asclml+csms,where the subscripts l and s represent the liquid andsolid phases, respectively.Lagrangian particle model ::: METHODSWe follow Wei and Li (2015) to include the effectof the surface curvature of the droplet and the solid phase on the vapor pressure of thedroplet, namely, Kelvin effect.", [["surface", "ANATOMY", 204, 211], ["thedroplet", "SIMPLE_CHEMICAL", 282, 292], ["asclml", "PROTEIN", 19, 25], ["the vapor pressure of thedroplet", "TREATMENT", 260, 292]]], ["This correction considers the concentration of NaCl andits influence on the final nucleus sizes when the droplets lose all of the liquidcontent.Lagrangian particle model ::: METHODSWhen the air flow field is given, i.e., instantaneous air velocityui at any location is known, the ordinarydifferential equation (ODE) system [Eqs.", [["nucleus", "ANATOMY", 82, 89], ["NaCl", "CHEMICAL", 47, 51], ["NaCl", "CHEMICAL", 47, 51], ["NaCl", "SIMPLE_CHEMICAL", 47, 51], ["NaCl andits influence", "TREATMENT", 47, 68], ["the air flow field", "TEST", 186, 204], ["instantaneous air velocityui", "PROBLEM", 221, 249], ["sizes", "OBSERVATION_MODIFIER", 90, 95], ["air flow", "OBSERVATION", 190, 198], ["air velocityui", "OBSERVATION", 235, 249]]], ["(1), (2), (4), and (6)] can be solved to track the location, velocity, mass (used to calculate thedroplet diameter), and temperature of each droplet.", [["mass", "PROBLEM", 71, 75], ["mass", "OBSERVATION", 71, 75]]], ["In almost any natural and indoorenvironments, turbulence exists and helps spread particles in air flow, which needsadditional treatment.Modeling of turbulent fluctuation ::: METHODSWe apply a continuous random walk (CRW) model to simulate the turbulent fluctuatingvelocity in air.", [["turbulence", "PROBLEM", 46, 56], ["needsadditional treatment", "TREATMENT", 110, 135], ["a continuous random walk (CRW) model", "TREATMENT", 190, 226], ["the turbulent fluctuatingvelocity in air", "PROBLEM", 239, 279], ["turbulence", "OBSERVATION", 46, 56], ["spread", "OBSERVATION_MODIFIER", 74, 80], ["particles", "OBSERVATION_MODIFIER", 81, 90], ["air flow", "OBSERVATION", 94, 102], ["turbulent fluctuation", "OBSERVATION", 148, 169], ["turbulent", "OBSERVATION_MODIFIER", 243, 252], ["fluctuatingvelocity", "OBSERVATION", 253, 272], ["air", "OBSERVATION", 276, 279]]], ["A stochastic differential equation (SDE) is used to simulateinstantaneous air fluctuating velocity, known as the Langevin equation,dui\u2032dt=\u2212\u03b1ui\u2032+\u03b2\u03bei,(7)where ui\u2032 is the fluctuating velocity component of air,\u03bei is a Gaussian white noise, and\u03b1 and \u03b2 are coefficients that determine the stochasticnature of the turbulent process.", [["ui\u2032", "PROTEIN", 157, 160], ["and\u03b1", "PROTEIN", 236, 240], ["\u03b2", "PROTEIN", 245, 246], ["A stochastic differential equation", "TEST", 0, 34], ["simulateinstantaneous air fluctuating velocity", "PROBLEM", 52, 98], ["the Langevin equation", "TEST", 109, 130], ["dui\u2032dt", "TEST", 131, 137], ["a Gaussian white noise", "PROBLEM", 212, 234], ["fluctuating", "OBSERVATION_MODIFIER", 168, 179], ["velocity", "OBSERVATION_MODIFIER", 180, 188], ["component", "OBSERVATION_MODIFIER", 189, 198], ["air", "OBSERVATION", 202, 205], ["turbulent process", "OBSERVATION", 307, 324]]], ["The magnitude of \u03b1 represents theautocorrelation of flow fluctuation, and the magnitude of \u03b2 representsthe relative importance of the random process with respect to the velocity correlations.Legg and Raupach (1982) showed \u03b1= 1/\u03c4i and \u03b2=\u03c3i(2/\u03c4i)0.5, with \u03c4i beingthe Lagrangian time scale and \u03c3i being theroot-mean-square (rms) of velocity fluctuations at each direction.Modeling of turbulent fluctuation ::: METHODSA discrete format of Eq.", [["\u03b1", "PROTEIN", 17, 18], ["\u03b2", "PROTEIN", 91, 92], ["flow fluctuation", "PROBLEM", 52, 68], ["the velocity correlations", "TEST", 165, 190], ["Legg", "TEST", 191, 195], ["Raupach", "TEST", 200, 207], ["\u03b1", "TEST", 222, 223], ["\u03c4i", "TEST", 227, 229], ["\u03b2", "TEST", 234, 235], ["\u03c3i", "TEST", 292, 294], ["theroot", "TEST", 301, 308], ["velocity fluctuations at each direction", "PROBLEM", 330, 369], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["flow fluctuation", "OBSERVATION", 52, 68], ["velocity fluctuations", "OBSERVATION", 330, 351], ["turbulent fluctuation", "OBSERVATION", 382, 403]]], ["(7) is equivalentto the Markov chain equation, which has been used in Bocksell and Loth (2001) for CRW modeling,ui\u2032(t+\u0394t)=ui\u2032(t)exp(\u2212\u0394t/\u03c4i)+\u03c3i(1\u2212exp(\u22122\u0394t/\u03c4i))1/2\u03bei.(8)Modeling of turbulent fluctuation ::: METHODSThe advantage of CRW is its inherent nature of considering both successive velocitycorrelation and continuously stochastic behavior.", [["\u0394t", "TEST", 133, 135], ["\u03c3i", "TEST", 140, 142], ["turbulent fluctuation", "TEST", 179, 200], ["turbulent fluctuation", "OBSERVATION", 179, 200]]], ["This is a better representation ofturbulence than DRW because DRW only considers the stochastic behavior discretely at eacheddy interaction time scale and neglects the correlation of successive velocities.", [["velocities", "OBSERVATION_MODIFIER", 194, 204]]], ["Figure 1(a) demonstrates an example of DRW vs CRW inpredicting turbulent fluctuations (u0\u2032 = 0.1 m/s, \u03c3 = 0.1 m/s,\u0394t = 10\u22125 s, \u03c4 = 10\u22124 s).", [["DRW", "PROBLEM", 39, 42], ["CRW", "TEST", 46, 49], ["turbulent fluctuations", "PROBLEM", 63, 85], ["\u03c3", "TEST", 102, 103], ["\u0394t", "TEST", 114, 116]]], ["Thisexample shows a continuously varying velocity signal with the behavior of a Markov chain(not a completely white noise signal) in CRW, compared to the discrete velocity signal inDRW.", [["Markov chain", "PROTEIN", 80, 92], ["CRW", "CELL_LINE", 133, 136], ["inDRW", "PROTEIN", 179, 184], ["a continuously varying velocity signal", "PROBLEM", 18, 56], ["a completely white noise signal", "PROBLEM", 97, 128], ["CRW", "TEST", 133, 136], ["continuously", "OBSERVATION_MODIFIER", 20, 32], ["varying", "OBSERVATION_MODIFIER", 33, 40], ["velocity", "OBSERVATION_MODIFIER", 41, 49], ["signal", "OBSERVATION_MODIFIER", 50, 56], ["behavior", "OBSERVATION_MODIFIER", 66, 74], ["Markov chain", "OBSERVATION", 80, 92], ["discrete", "OBSERVATION_MODIFIER", 154, 162], ["velocity", "OBSERVATION_MODIFIER", 163, 171]]], ["The plot of the autocorrelation function [Fig.1(b)] shows that the velocity maintains its \u201cmemory\u201d beyond the time scale ofeddy interaction in CRW, whereas the velocity autocorrelation in DRW drops to zero afterthe eddy interaction time scale.Modeling of jet ::: METHODSStrong respiratory flows such as coughing and sneezing can be treated as buoyant jets dueto their violent initial velocity and temperature difference between exhaled fluids andambient air (Bourouiba et al.,2014).", [["respiratory", "ANATOMY", 277, 288], ["coughing", "DISEASE", 303, 311], ["sneezing", "DISEASE", 316, 324], ["CRW", "CELL_LINE", 143, 146], ["DRW", "PROTEIN", 188, 191], ["the autocorrelation function", "TEST", 12, 40], ["the velocity", "TEST", 63, 75], ["CRW", "TEST", 143, 146], ["the velocity autocorrelation", "TEST", 156, 184], ["DRW drops", "TREATMENT", 188, 197], ["METHODSStrong respiratory flows", "TREATMENT", 263, 294], ["coughing", "PROBLEM", 303, 311], ["sneezing", "PROBLEM", 316, 324], ["temperature difference", "PROBLEM", 397, 419], ["velocity", "OBSERVATION_MODIFIER", 67, 75], ["velocity", "OBSERVATION_MODIFIER", 160, 168], ["jet", "OBSERVATION_MODIFIER", 255, 258], ["respiratory flows", "OBSERVATION", 277, 294]]], ["For pure jets with no buoyancy, streamwise velocity is assumed to maintainits initial velocity within a short distance known as zone-of-flow-establishment (ZFE),typically 5\u201312 source diameter D (i.e., mouth opening in coughing andsneezing).", [["mouth", "ANATOMY", 201, 206], ["mouth", "ORGANISM_SUBDIVISION", 201, 206], ["coughing", "PROBLEM", 218, 226], ["jets", "OBSERVATION", 9, 13], ["no", "UNCERTAINTY", 19, 21], ["buoyancy", "OBSERVATION_MODIFIER", 22, 30], ["streamwise velocity", "OBSERVATION", 32, 51], ["velocity", "OBSERVATION_MODIFIER", 86, 94], ["short", "OBSERVATION_MODIFIER", 104, 109], ["zone", "OBSERVATION_MODIFIER", 128, 132], ["flow", "OBSERVATION", 136, 140], ["diameter", "OBSERVATION_MODIFIER", 183, 191]]], ["In our model, we take ZFE = 6.2D for round jets (Lee and Chu, 2003).", [["ZFE", "TEST", 22, 25]]], ["It is typically assumed that radialvelocity is zero and no turbulence is present in the ZFE.", [["ZFE", "DNA", 88, 91], ["turbulence", "PROBLEM", 59, 69], ["radialvelocity", "OBSERVATION", 29, 43], ["no", "UNCERTAINTY", 56, 58], ["turbulence", "OBSERVATION", 59, 69]]], ["Beyond the ZFE, the meanstreamwise velocity decreases linearly with increasing distance away from the sourcewithin a well-defined flow region known as zone-of-established-flow (ZEF): (1) thestreamwise velocity follows a Gaussian distribution in the cross section of the jet and(2) the radial velocity is much smaller in the jet, and its value at the jet boundary isknown as entrainment velocity.", [["ZFE", "DNA", 11, 14], ["the meanstreamwise velocity", "TEST", 16, 43], ["thestreamwise velocity", "TEST", 187, 209], ["the radial velocity", "TEST", 281, 300], ["velocity", "OBSERVATION_MODIFIER", 35, 43], ["decreases", "OBSERVATION_MODIFIER", 44, 53], ["linearly", "OBSERVATION_MODIFIER", 54, 62], ["increasing", "OBSERVATION_MODIFIER", 68, 78], ["distance", "OBSERVATION_MODIFIER", 79, 87], ["well-defined", "OBSERVATION_MODIFIER", 117, 129], ["flow", "OBSERVATION", 130, 134], ["zone", "OBSERVATION_MODIFIER", 151, 155], ["flow", "OBSERVATION", 171, 175], ["Gaussian distribution", "OBSERVATION", 220, 241], ["jet", "OBSERVATION_MODIFIER", 270, 273], ["radial", "ANATOMY_MODIFIER", 285, 291], ["velocity", "OBSERVATION_MODIFIER", 292, 300], ["much", "OBSERVATION_MODIFIER", 304, 308], ["smaller", "OBSERVATION_MODIFIER", 309, 316], ["jet", "OBSERVATION_MODIFIER", 324, 327], ["jet", "OBSERVATION_MODIFIER", 350, 353], ["boundary", "OBSERVATION_MODIFIER", 354, 362], ["entrainment velocity", "OBSERVATION", 374, 394]]], ["The streamwise(Ur) and radial(Vr) velocities are written as (Lee and Chu, 2003; Weiand Li, 2015)Ur=Uc\u2061exp(\u2212r2/bg2),(9)Vr=\u03b1jUc1\u2212exp(\u2212r2/bg2)\u2212(\u03b2j/\u03b1j)(r2/bg2)exp(\u2212r2/bg2)r/bg,(10)where centerline velocityUc =6.2U0(D/x), jetentrainment coefficient \u03b1j = 0.057, jet widthgrowth rate \u03b2j = 0.114 (Wei and Li, 2015), and bgis the Gaussian jet half-width that defines the boundary of the jet.Modeling of jet ::: METHODSEquations (9) and (10) define the mean flow field of the air jetin coughing and sneezing.", [["sneezing", "DISEASE", 489, 497], ["\u03b2j", "PROTEIN", 141, 143], ["Li", "TEST", 87, 89], ["Ur", "TEST", 96, 98], ["Uc\u2061exp", "TEST", 99, 105], ["bg2", "TEST", 110, 113], ["Vr=\u03b1jUc1\u2212exp(\u2212r2/bg2", "TEST", 118, 138], ["\u03b2j", "TEST", 141, 143], ["\u03b1j", "TEST", 144, 146], ["bg", "TEST", 151, 153], ["exp", "TEST", 155, 158], ["\u2212r2", "TEST", 159, 162], ["bg", "TEST", 163, 165], ["r/bg", "TEST", 167, 171], ["centerline velocityUc", "TEST", 182, 203], ["jetentrainment", "TEST", 217, 231], ["\u03b1j", "TEST", 244, 246], ["jet widthgrowth rate \u03b2j", "TEST", 256, 279], ["Li", "TEST", 297, 299], ["the mean flow field", "TEST", 439, 458], ["the air jetin coughing", "PROBLEM", 462, 484], ["sneezing", "PROBLEM", 489, 497], ["radial", "ANATOMY_MODIFIER", 23, 29], ["Gaussian jet", "OBSERVATION", 321, 333], ["width", "OBSERVATION_MODIFIER", 339, 344], ["jet", "OBSERVATION_MODIFIER", 378, 381], ["jet", "OBSERVATION_MODIFIER", 394, 397], ["air jetin", "OBSERVATION", 466, 475], ["sneezing", "OBSERVATION", 489, 497]]], ["In addition, turbulent statistics in the jet is needed to definenecessary parameters for random walk [i.e., \u03b1 and \u03b2 inEq.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 108, 109], ["\u03b2 inEq", "GENE_OR_GENE_PRODUCT", 114, 120], ["\u03b1", "PROTEIN", 108, 109], ["inEq", "PROTEIN", 116, 120], ["turbulent", "OBSERVATION_MODIFIER", 13, 22]]], ["In the model of Wei and Li (2015), the equations for rms velocityfluctuation and turbulent dissipation rate are fitted to the simulation data of acomputational fluid dynamics (CFD) modeling of a sediment-laden jet in water (Chan et al., 2014).", [["the equations", "TEST", 35, 48], ["rms velocityfluctuation", "PROBLEM", 53, 76], ["turbulent dissipation rate", "PROBLEM", 81, 107], ["acomputational fluid dynamics", "PROBLEM", 145, 174], ["a sediment", "PROBLEM", 193, 203], ["turbulent", "OBSERVATION_MODIFIER", 81, 90], ["fluid dynamics", "OBSERVATION", 160, 174], ["sediment", "OBSERVATION", 195, 203], ["laden", "OBSERVATION_MODIFIER", 204, 209], ["jet", "OBSERVATION_MODIFIER", 210, 213]]], ["In this paper, weuse the experimental data from an air jet with a source Reynolds number ofRej =U0D/\u03bd = 1.4 \u00d7105 (Darisse et al.,2015).", [["an air jet", "PROBLEM", 48, 58], ["Rej", "TEST", 91, 94], ["air jet", "OBSERVATION", 51, 58]]], ["Following a similar formula in Chanet al. (2014), we define the profile of turbulent kineticenergy and dissipation rate as follows:k=Uc2c1exp(\u2212c2(r/bg\u2212c3)2)+exp(\u2212c2(r/bg+c3)2),(11)\u03b5=Uc3/bgc4exp(\u2212c5(r/bg\u2212c6)2)+exp(\u2212c5(r/bg+c6)2),(12)with fitted coefficientsc1 = 0.0667, c2 = 1.079,c3 = 0.6853, c4 = 0.0178,c5 = 1.963, c6 = 0.6126 to thereported data in Darisse et al.(2015).", [["dissipation rate", "TEST", 103, 119], ["k", "TEST", 131, 132], ["Uc2c1exp", "TEST", 133, 141], ["\u2212c2", "TEST", 142, 145], ["\u2212c", "TEST", 194, 196], ["exp", "TEST", 209, 212], ["\u2212c", "TEST", 213, 215], ["r/bg+c", "TEST", 217, 223], ["fitted coefficientsc1", "TEST", 237, 258], ["c2", "TEST", 269, 271], ["c3", "TEST", 280, 282], ["c4", "TEST", 293, 295], ["c6", "TEST", 317, 319]]], ["A schematic presentation of the jet is given in Fig. 2, where all parameters in Eqs.", [["the jet", "PROBLEM", 28, 35]]], ["(9)\u2013(12) are plotted.", [["\u2013(12)", "SIMPLE_CHEMICAL", 3, 8]]], ["Note that the radial profiles ofturbulent fields (k and \u03b5) are different from those inChan et al. (2014) [used in Wei and Li (2015)].Model framework ::: METHODSThe model is coded in open-source language Python with the scientific computing library\u201cSciPy\u201d and package \u201csdeint\u201d for solving the ODE and SDE systems.", [["radial", "ANATOMY_MODIFIER", 14, 20]]], ["The model solves forlocation (xi), velocity(up,i), mass(mp), temperature(Tp), and turbulent fluctuating velocity(ui\u2032) in each time step.", [["velocity", "TEST", 35, 43], ["mass", "PROBLEM", 51, 55], ["temperature", "TEST", 61, 72], ["turbulent fluctuating velocity", "PROBLEM", 82, 112], ["mass", "OBSERVATION", 51, 55], ["turbulent", "OBSERVATION_MODIFIER", 82, 91], ["fluctuating", "OBSERVATION_MODIFIER", 92, 103], ["velocity", "OBSERVATION_MODIFIER", 104, 112]]], ["We apply a fifth order integrator usingadaptive time steps with an absolute tolerance parameter of 10\u22128 to obtain thesub-micron accuracy.", [["an absolute tolerance parameter", "TREATMENT", 64, 95]]], ["The model has several separated modules to compute mean flow velocity(Ui) and properties of particles and air.We follow the equations in Kukkonen etal.", [["several", "OBSERVATION_MODIFIER", 14, 21], ["separated", "OBSERVATION_MODIFIER", 22, 31], ["modules", "OBSERVATION", 32, 39], ["flow velocity", "OBSERVATION", 56, 69], ["particles", "OBSERVATION_MODIFIER", 92, 101], ["air", "OBSERVATION", 106, 109]]], ["(1989) (see their Appendix) to calculate the thermodynamicproperties of the liquid droplet, vapor, and air.", [["the liquid droplet", "TREATMENT", 72, 90], ["liquid droplet", "OBSERVATION", 76, 90], ["air", "ANATOMY", 103, 106]]], ["The mean flow and the turbulent statistics are calculatedbased on the initial condition given in the simulation.", [["The mean flow", "TEST", 0, 13], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["flow", "OBSERVATION_MODIFIER", 9, 13], ["turbulent", "OBSERVATION_MODIFIER", 22, 31]]], ["These parameters are used in theODE and SDE solver until a model termination criterion (settle-on-ground or dry-out) issatisfied.MODEL VALIDATIONThe model is validated to measurement data and is compared with other modeling work in theliterature.", [["a model termination criterion", "TEST", 57, 86], ["measurement data", "TEST", 171, 187]]], ["First, we validate the evaporation of a droplet in the condition of at-rest anduniform flow.", [["the evaporation", "TREATMENT", 19, 34], ["a droplet", "TREATMENT", 38, 47]]], ["Ranz and Marshall (1952) measured the shrinkage of awater drop (dp = 1.1 mm,Tp = 282 K) in dry air[Ta = 298 K, relative humidity (RH) = 0%].Smolik et al. (2001) measured theshrinkage of a drop (dp = 1.2 mm,Tp = 287 K) in a constant air stream(Ua = 0.203 m/s,Ta = 297 K, RH = 35%).", [["dp", "TEST", 64, 66], ["Tp", "TEST", 76, 78], ["K", "TEST", 85, 86], ["dry air", "TEST", 91, 98], ["Ta", "TEST", 99, 101], ["K", "TEST", 108, 109], ["relative humidity (RH", "TEST", 111, 132], ["dp", "TEST", 194, 196], ["Tp", "TEST", 206, 208], ["K", "TEST", 215, 216], ["a constant air stream", "TEST", 221, 242], ["Ua", "TEST", 243, 245], ["Ta", "TEST", 258, 260], ["K", "TEST", 267, 268], ["RH", "TEST", 270, 272]]], ["Themeasurement-modeling comparison of droplet shrinkage as a function of time is shown in Fig. 3.", [["droplet shrinkage", "PROBLEM", 38, 55], ["droplet shrinkage", "OBSERVATION", 38, 55]]], ["Our modeling and Xie et al. (2007) show almost identical results because the sameset of mass and heat transfer equations were used.", [["mass", "PROBLEM", 88, 92], ["heat transfer equations", "TREATMENT", 97, 120], ["mass", "OBSERVATION", 88, 92]]], ["The slight difference in model results islikely due to the numerical schemes.", [["The slight difference in model results", "PROBLEM", 0, 38], ["the numerical schemes", "PROBLEM", 55, 76], ["slight", "OBSERVATION_MODIFIER", 4, 10], ["difference", "OBSERVATION_MODIFIER", 11, 21]]], ["(2007) used fourth-order Runge\u2013Kutta and we applied the fifth orderSciPy ODE integrator based on the variable-coefficient ODE (VODE) with backwarddifferentiation formulas (BDFs) for stiff problems.", [["Runge\u2013Kutta", "TREATMENT", 25, 36], ["the fifth orderSciPy ODE integrator", "TREATMENT", 52, 87], ["the variable-coefficient ODE (VODE)", "TREATMENT", 97, 132], ["backwarddifferentiation formulas", "TREATMENT", 138, 170], ["stiff problems", "PROBLEM", 182, 196]]], ["The comparison shows that the modelresults generally follow the data with an overestimate of shrinkage in the at-rest condition(R2 = 0.866) and underestimate of shrinkage in the uniformflow condition (R2 = 0.827).", [["the data", "TEST", 60, 68], ["shrinkage", "PROBLEM", 93, 102], ["R2", "TEST", 128, 130], ["shrinkage in the uniformflow condition", "PROBLEM", 161, 199], ["R2", "TEST", 201, 203], ["shrinkage", "OBSERVATION", 93, 102], ["shrinkage", "OBSERVATION", 161, 170]]], ["(2001) suggests the need for a better representation of theturbulent transfer of mass and heat in future studies.MODEL VALIDATIONTo validate the model prediction of particle spreading in air flow, we compare our modelresults with the measurements of dispersion of four different inert particle types (seeTable I) in a grid-generated turbulence field(Snyder and Lumley, 1971).", [["seeTable I", "PROTEIN", 301, 311], ["mass", "PROBLEM", 81, 85], ["heat in future studies", "TEST", 90, 112], ["mass", "OBSERVATION", 81, 85], ["air flow", "OBSERVATION", 187, 195]]], ["The mean flow in theexperiment is upward with a velocity of Wa =6.5 m/s.", [["The mean flow", "TEST", 0, 13], ["a velocity", "TEST", 46, 56], ["Wa", "TEST", 60, 62], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["flow", "OBSERVATION", 9, 13], ["upward", "OBSERVATION_MODIFIER", 34, 40], ["velocity", "OBSERVATION_MODIFIER", 48, 56]]], ["The turbulent fluctuations were measured in the experiment and were used to derivethe turbulent kinetic energy and dissipation rate (Bockselland Loth, 2001),k=Wa22142.4(z/M\u221216)+239.4(z/M\u221212),(13)\u03b5=Wa32M142.4(z/M\u221216)2+239.4(z/M\u221212)2,(14)where z is the verticaldistance to the grid and M = 0.0254 m is the grid spacing.MODEL VALIDATIONThe measurement-modeling comparison of the particle spreading is shown in Fig. 4.", [["The turbulent fluctuations", "PROBLEM", 0, 26], ["dissipation rate", "TEST", 115, 131], ["k", "TEST", 157, 158], ["z", "TEST", 169, 170], ["z/M\u2212", "TEST", 183, 187], ["z/M\u2212", "TEST", 208, 212], ["z/M\u2212", "TEST", 223, 227], ["the grid spacing", "PROBLEM", 300, 316], ["The measurement", "TEST", 333, 348], ["turbulent", "OBSERVATION_MODIFIER", 4, 13], ["fluctuations", "OBSERVATION_MODIFIER", 14, 26], ["kinetic energy", "OBSERVATION", 96, 110], ["grid spacing", "OBSERVATION", 304, 316], ["particle", "OBSERVATION_MODIFIER", 376, 384]]], ["Snyder and Lumley(1971) showed that the turbulent flow in the test region (68 <z/M < 168) is nearly isotropic and the spreadingperpendicular to the mean flow direction is nearly homogeneous.", [["the turbulent flow in the test region", "TEST", 36, 73], ["z/M", "TEST", 79, 82], ["turbulent", "OBSERVATION_MODIFIER", 40, 49], ["flow", "OBSERVATION", 50, 54], ["isotropic", "OBSERVATION_MODIFIER", 100, 109], ["mean flow", "OBSERVATION", 148, 157], ["nearly", "OBSERVATION_MODIFIER", 171, 177], ["homogeneous", "OBSERVATION", 178, 189]]], ["The measurement data showthat the lightest particles (hollow glass) spread about 450 mm2 and the heaviestparticles (copper) spread about 120 mm2 within 0.4 s\u20130.5 s after the particlespass the first measurement station.", [["copper", "CHEMICAL", 116, 122], ["copper", "CHEMICAL", 116, 122], ["copper", "SIMPLE_CHEMICAL", 116, 122], ["The measurement data", "TEST", 0, 20], ["hollow glass", "OBSERVATION", 54, 66], ["450 mm2", "OBSERVATION_MODIFIER", 81, 88]]], ["Glass has a similar particle relaxation time as copperand hence has a similar spreading area due to similar particle\u2013eddy interactions.", [["similar", "OBSERVATION_MODIFIER", 12, 19], ["particle relaxation", "OBSERVATION", 20, 39]]], ["The cornpollen is a median-weighted particle and has an intermediate spreading as a result ofintermediate particle properties.MODEL VALIDATIONWei and Li (2015) validated their cough jet modelusing this dataset with a DRW approach (shown as dashed lines in Fig. 4).", [["cornpollen", "CHEMICAL", 4, 14], ["cornpollen", "SIMPLE_CHEMICAL", 4, 14], ["lines", "CELL", 247, 252], ["a DRW approach", "TREATMENT", 215, 229]]], ["They pointed out that the DRW model has difficulties inpredicting median-weighted particles (corn pollen).", [["pollen", "ANATOMY", 98, 104], ["corn", "ORGANISM_SUBDIVISION", 93, 97], ["pollen", "ORGANISM_SUBDIVISION", 98, 104], ["corn", "SPECIES", 93, 97], ["corn", "SPECIES", 93, 97]]], ["Our comparison shows a generalimprovement of particle spreading simulation using CRW.", [["CRW", "PROTEIN", 81, 84], ["particle", "OBSERVATION_MODIFIER", 45, 53], ["spreading", "OBSERVATION_MODIFIER", 54, 63]]], ["The improvement is more profound forpredicting median-weighted particles, corn pollen.", [["pollen", "ANATOMY", 79, 85], ["corn", "SPECIES", 74, 78], ["corn", "SPECIES", 74, 78], ["improvement", "OBSERVATION_MODIFIER", 4, 15], ["more", "OBSERVATION_MODIFIER", 19, 23], ["profound", "OBSERVATION_MODIFIER", 24, 32]]], ["The R2 valueof model-measurement comparison for corn pollen increases from 0.49 (DRW) to 0.97 (CRW), analmost 100% improvement.", [["corn", "SPECIES", 48, 52], ["corn", "SPECIES", 48, 52], ["The R2 valueof model", "TEST", 0, 20], ["corn pollen", "PROBLEM", 48, 59]]], ["The corn pollen tested in this experiment has the same density asthe water droplet and has a diameter of 87 \u03bcm, which is corresponding tothe peak range of human respiratory flows (Han etal., 2013).", [["respiratory", "ANATOMY", 161, 172], ["human", "ORGANISM", 155, 160], ["corn", "SPECIES", 4, 8], ["human", "SPECIES", 155, 160], ["corn", "SPECIES", 4, 8], ["human", "SPECIES", 155, 160], ["The corn pollen", "TREATMENT", 0, 15], ["diameter", "OBSERVATION_MODIFIER", 93, 101], ["87 \u03bcm", "OBSERVATION_MODIFIER", 105, 110], ["respiratory flows", "OBSERVATION", 161, 178]]], ["Hence, this improvement of modeling in this particle rangeis important in simulating particle dynamics in respiratory flows.MODEL VALIDATIONFurther model validation combines the droplet evaporation and location in a simulated coughjet flow.", [["respiratory", "ANATOMY", 106, 117], ["the droplet evaporation", "TREATMENT", 174, 197], ["respiratory flows", "OBSERVATION", 106, 123]]], ["We simulate the experiment of Chao and Wan(2006)\u2014an upward injection of droplets with a duration of 1 s in an environment ofTa = 21 \u00b0C and RH = 55%.", [["upward injection of droplets", "TREATMENT", 52, 80], ["Ta", "TEST", 124, 126], ["RH", "TEST", 139, 141]]], ["The experimentaldata showed the droplets with diameters of 87.5 \u03bcm and 137.5\u03bcm settled on the ground, whereas the droplets with diameters of 28\u03bcm and 45 \u03bcm completely dried out in air (see Fig. 5).", [["droplets", "ANATOMY", 32, 40], ["droplets", "ANATOMY", 114, 122], ["diameters", "TEST", 46, 55], ["diameters", "TEST", 128, 137], ["droplets", "OBSERVATION", 32, 40], ["diameters", "OBSERVATION_MODIFIER", 46, 55], ["diameters", "OBSERVATION_MODIFIER", 128, 137], ["air", "ANATOMY", 180, 183]]], ["We select droplets with diameters in the range of 1 \u03bcm\u20131000\u03bcm, the primary range of droplet sizes in the human respiratory flows(Han et al., 2013).", [["respiratory", "ANATOMY", 111, 122], ["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["diameters", "TEST", 24, 33], ["droplets", "OBSERVATION_MODIFIER", 10, 18], ["diameters", "OBSERVATION_MODIFIER", 24, 33], ["droplet sizes", "OBSERVATION", 84, 97], ["respiratory flows", "OBSERVATION", 111, 128]]], ["Dropletssmaller than 1 \u03bcm evaporate quickly in typical indoor and outdoorenvironments (except for suppressed evaporation in extremely humid environments orcondensation due to rapid droplet cooling).", [["suppressed evaporation", "TREATMENT", 98, 120], ["rapid droplet cooling", "TREATMENT", 175, 196]]], ["(2007) used 0.3 \u03bcm as the criterion of nucleiformation, which is also used in this simulation.Free-fall droplets ::: MODEL APPLICATIONSThis simulation is similar to what has been done in Xieet al. (2007), who showed settling or dry-out of afree-falling droplet up to 200 \u03bcm(Tp = 33 \u00b0C) from 2 m with an ambienttemperature of Ta = 18 \u00b0C. We adjust themodel parameter to the initial height of 1.6 m, typical height of the human mouth, and theinitial droplet temperature of 37 \u00b0C, typical body temperature of a healthy person.", [["mouth", "ANATOMY", 426, 431], ["body", "ANATOMY", 486, 490], ["human", "ORGANISM", 420, 425], ["mouth", "ORGANISM_SUBDIVISION", 426, 431], ["body", "ORGANISM_SUBDIVISION", 486, 490], ["human", "SPECIES", 420, 425], ["person", "SPECIES", 516, 522], ["human", "SPECIES", 420, 425], ["fall droplets", "PROBLEM", 99, 112], ["falling droplet", "PROBLEM", 245, 260], ["Tp", "TEST", 274, 276], ["themodel parameter", "TEST", 347, 365], ["the initial height", "TEST", 369, 387], ["theinitial droplet temperature", "TEST", 437, 467], ["fall droplets", "OBSERVATION", 99, 112], ["human mouth", "ANATOMY", 420, 431]]], ["Withthese conditions, we examine the droplet properties in the ambient temperature range of 5\u00b0C\u201335 \u00b0C (interval of 1 \u00b0C) and relative humidity of RH = 0%\u201395% (interval of 5%).Free-fall droplets ::: MODEL APPLICATIONSFigure 6 shows an example of airborne lifetime oftwo droplets (dp = 50 \u03bcm and100 \u03bcm) as a function of relative humidity at an ambient temperature of22 \u00b0C. For the 100 \u03bcm droplet, the maximum lifetime oftl = 11.6 s occurs at RH = 40% in thetested RH range.", [["RH", "TEST", 146, 148], ["dp", "TEST", 279, 281], ["an ambient temperature", "TREATMENT", 339, 361], ["the maximum lifetime oftl", "TEST", 395, 420], ["RH", "TEST", 440, 442]]], ["The maximum tl correspondsto the coincident moment between the droplet settling on the ground and completely dryingout. tl is shorter in either less (dry-outbefore settled) or more (settled before dry-out) humid conditions.", [["maximum", "OBSERVATION_MODIFIER", 4, 11], ["tl", "OBSERVATION_MODIFIER", 12, 14], ["coincident", "OBSERVATION_MODIFIER", 33, 43], ["moment", "OBSERVATION_MODIFIER", 44, 50], ["droplet", "OBSERVATION_MODIFIER", 63, 70], ["settling", "OBSERVATION_MODIFIER", 71, 79], ["shorter", "OBSERVATION_MODIFIER", 126, 133]]], ["When air iscompletely dry (RH = 0%), the 50 \u03bcm droplet evaporates within 1.7 s andthe 100 \u03bcm droplet evaporates within 6.2 s, slightly shorter than themodel result of 2.0 s and 7.2 s, respectively, in Xieet al. (2007) in the condition ofTa = 18 \u00b0C andz0 = 2 m.", [["RH", "TEST", 27, 29], ["the 50 \u03bcm droplet evaporates", "TREATMENT", 37, 65], ["droplet evaporates", "TEST", 93, 111], ["Ta", "TEST", 237, 239]]], ["It should be emphasized that the humidity canextend the airborne lifetime of a 50 \u03bcm droplet by more than 23 timesfrom RH = 0%\u201395%.", [["a 50 \u03bcm droplet", "TREATMENT", 77, 92]]], ["This suggests that the airborne transport of median-sized droplets isextremely sensitive to the humidity.Free-fall droplets ::: MODEL APPLICATIONSAmbient temperature also affects the lifetime of a droplet because the temperaturestrongly influences the thermodynamic properties of the droplets and associated vaporthrough heat exchange between droplets/vapor and the ambient air.", [["median-sized droplets", "TREATMENT", 45, 66], ["the humidity", "TREATMENT", 92, 104], ["the droplets", "TREATMENT", 280, 292], ["associated vaporthrough heat exchange", "TREATMENT", 297, 334], ["droplets/vapor", "TREATMENT", 343, 357], ["the ambient air", "TREATMENT", 362, 377], ["sized", "OBSERVATION_MODIFIER", 52, 57], ["droplets", "OBSERVATION", 58, 66], ["fall droplets", "OBSERVATION", 110, 123]]], ["Figure 7 shows an example of the lifetime curve of a 100\u03bcm droplet as a function of RH and temperature.", [["a 100\u03bcm droplet", "TREATMENT", 51, 66]]], ["This result shows howthe maximum airborne lifetime shifts from humid toward dry air conditions when temperaturedecreases.", [["dry air conditions", "PROBLEM", 76, 94], ["airborne lifetime", "OBSERVATION", 33, 50], ["air conditions", "OBSERVATION", 80, 94]]], ["In very humid air, decreasing temperature shortens the airborne lifetime due toslower evaporation if the droplet eventually settles on the ground.", [["decreasing temperature", "PROBLEM", 19, 41], ["toslower evaporation", "TREATMENT", 77, 97], ["very", "OBSERVATION_MODIFIER", 3, 7], ["humid air", "OBSERVATION", 8, 17], ["decreasing", "OBSERVATION_MODIFIER", 19, 29]]], ["On the other hand,decreasing temperature in dry air would generally increase the airborne lifetime due toslower evaporation that slows down the dry-out process of the droplet.", [["decreasing temperature in dry air", "PROBLEM", 18, 51], ["toslower evaporation", "TREATMENT", 103, 123], ["decreasing", "OBSERVATION_MODIFIER", 18, 28]]], ["In most of indoorconditions, the combination of temperature and humidity lies in the middle range of thetested values, where the droplets with different sizes would have different and sensitiveevaporation-settling dynamics.", [["temperature and humidity", "TREATMENT", 48, 72], ["middle", "ANATOMY_MODIFIER", 85, 91]]], ["Hence, evaluating the interaction of individual expiratorydroplets with the ambient environment is critical to understanding the fate and transportof virus-laden droplets.Free-fall droplets ::: MODEL APPLICATIONSThe settling height of a droplet, defined as the final vertical location when dry-out orsettle-to-ground occurs, is an intrinsic droplet property during evaporation in thefree-falling condition.", [["individual expiratorydroplets", "TREATMENT", 37, 66], ["transportof virus-laden droplets", "TREATMENT", 138, 170], ["fall droplets", "OBSERVATION", 176, 189], ["settling", "OBSERVATION_MODIFIER", 216, 224], ["droplet property", "OBSERVATION", 341, 357]]], ["Similar to the airborne lifetime, it is a function of temperatureand humidity for each droplet size.", [["size", "OBSERVATION_MODIFIER", 95, 99]]], ["Figure 8 shows adata map of the settling height along with the lifetime for droplets of 50\u03bcm and 100 \u03bcm.", [["Figure", "TEST", 0, 6], ["adata map", "TEST", 15, 24]]], ["For the 50 \u03bcm droplet,the settling height spans the range of 1.56 m (only 4 cm away from the initial height) to0 (ground), with the lifetime in the range of 1.15 s\u201343.5 s.", [["the settling height", "TEST", 22, 41], ["settling", "OBSERVATION_MODIFIER", 26, 34], ["height", "OBSERVATION_MODIFIER", 35, 41]]], ["From the data map, a 50\u03bcm droplet is likely to evaporate completely before it falls to theground under the free-fall condition in the majority of the indoor environments.", [["the data map", "TEST", 5, 17]]], ["Thesettling height of the droplet higher than 1 m (i.e., less than 0.6 m falling distance)occupies 87.4% of the total combinations of temperature and humidity.", [["the droplet", "TEST", 22, 33], ["temperature and humidity", "TREATMENT", 134, 158], ["droplet", "OBSERVATION_MODIFIER", 26, 33]]], ["Thetemperature-humidity map for the 100 \u03bcm droplet shows a clear boundarybetween settle-to-ground and dry-out.", [["Thetemperature", "TEST", 0, 14], ["humidity map", "TEST", 15, 27], ["the 100 \u03bcm droplet", "TEST", 32, 50]]], ["The longest and the shortest lifetime are 12.3 s and4.1 s, respectively.", [["longest", "OBSERVATION_MODIFIER", 4, 11]]], ["The shortest lifetime corresponds to the fastest evaporation at ahigh temperature and dry air condition, resulting in the final settling height of 1.07 m,equivalent to 53 cm falling distance.", [["the fastest evaporation", "TREATMENT", 37, 60], ["dry air condition", "PROBLEM", 86, 103], ["fastest", "OBSERVATION_MODIFIER", 41, 48], ["evaporation", "OBSERVATION_MODIFIER", 49, 60], ["dry", "OBSERVATION_MODIFIER", 86, 89], ["air condition", "OBSERVATION", 90, 103], ["final", "OBSERVATION_MODIFIER", 122, 127], ["settling", "OBSERVATION_MODIFIER", 128, 136], ["height", "OBSERVATION_MODIFIER", 137, 143], ["53 cm", "OBSERVATION_MODIFIER", 168, 173]]], ["The model result shows that a 100\u03bcm droplet would settle to the ground for 62.6% of the combinations oftemperature and humidity in the tested range.Droplet dynamics in a \u201ccontinuous\u201d cough jet ::: MODEL APPLICATIONSWe further apply the model to simulate an idealized case of human cough generated flows.Human cough can be treated as a momentum jet immediately after the flow being expelled.When the temperature of the expiratory fluid is higher than ambient air, a buoyancy drivenplume effect would lift the flow upward, enhancing the upwelling of the droplets andleading to longer transport time in air (Bourouibaet al., 2014).Droplet dynamics in a \u201ccontinuous\u201d cough jet ::: MODEL APPLICATIONSTo initialize the jet modeling, the exit velocity is a critical parameter that determinesall mean and turbulent properties in the jet and the flow associated interactive termssuch as turbulent enhanced mass and heat transfers.", [["cough", "DISEASE", 183, 188], ["cough", "DISEASE", 281, 286], ["cough", "DISEASE", 309, 314], ["cough", "DISEASE", 663, 668], ["human", "ORGANISM", 275, 280], ["Human", "ORGANISM", 303, 308], ["human", "SPECIES", 275, 280], ["Human", "SPECIES", 303, 308], ["human", "SPECIES", 275, 280], ["Human", "SPECIES", 303, 308], ["a 100\u03bcm droplet", "TREATMENT", 28, 43], ["humidity", "TREATMENT", 119, 127], ["Droplet dynamics", "PROBLEM", 148, 164], ["human cough", "PROBLEM", 275, 286], ["Human cough", "PROBLEM", 303, 314], ["a momentum jet", "TREATMENT", 333, 347], ["the expiratory fluid", "TEST", 414, 434], ["a buoyancy drivenplume effect", "TREATMENT", 463, 492], ["Droplet dynamics", "PROBLEM", 628, 644], ["the exit velocity", "TEST", 727, 744], ["turbulent enhanced mass", "PROBLEM", 878, 901], ["heat transfers", "TREATMENT", 906, 920], ["higher", "OBSERVATION_MODIFIER", 438, 444], ["flow", "OBSERVATION_MODIFIER", 508, 512], ["upward", "OBSERVATION_MODIFIER", 513, 519], ["jet", "OBSERVATION_MODIFIER", 713, 716], ["exit velocity", "OBSERVATION", 731, 744], ["turbulent", "OBSERVATION_MODIFIER", 797, 806], ["properties", "OBSERVATION_MODIFIER", 807, 817], ["jet", "OBSERVATION_MODIFIER", 825, 828], ["flow", "OBSERVATION_MODIFIER", 837, 841], ["turbulent", "OBSERVATION_MODIFIER", 878, 887], ["enhanced", "OBSERVATION_MODIFIER", 888, 896], ["mass", "OBSERVATION", 897, 901]]], ["In this study, we use initial jetvelocity U0 = 10 m/s, as the same value as used in the modelof Wei and Li (2015).", [["this study", "TEST", 3, 13], ["initial jetvelocity U0", "TREATMENT", 22, 44]]], ["This velocity is close to theliterature reported values in human coughing flows (Chaoet al., 2009; Kwon etal., 2012).", [["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["This velocity", "TEST", 0, 13]]], ["We apply the mouth opening diameter of 2 cm according tothe measured mouth opening area in Gupta etal.", [["mouth", "ANATOMY", 13, 18], ["mouth", "ANATOMY", 69, 74], ["mouth", "ORGANISM_SUBDIVISION", 13, 18], ["mouth", "ORGANISM_SUBDIVISION", 69, 74], ["the mouth opening diameter", "TREATMENT", 9, 35], ["mouth", "ANATOMY", 13, 18], ["diameter", "OBSERVATION_MODIFIER", 27, 35], ["2 cm", "OBSERVATION_MODIFIER", 39, 43], ["mouth", "ANATOMY", 69, 74], ["Gupta etal", "OBSERVATION", 91, 101]]], ["(2009), which was later used in the modeling in Wei and Li (2015).Droplet dynamics in a \u201ccontinuous\u201d cough jet ::: MODEL APPLICATIONSA key feature of our model is using CRW to better simulate turbulent velocities, whichare critical to the spreading of the droplets in the near field of cough jets (Wei and Li, 2015).", [["cough", "DISEASE", 101, 106], ["cough", "DISEASE", 286, 291], ["Droplet dynamics", "PROBLEM", 66, 82], ["CRW", "TREATMENT", 169, 172], ["cough jets", "PROBLEM", 286, 296], ["turbulent", "OBSERVATION", 192, 201], ["droplets", "OBSERVATION", 256, 264]]], ["To demonstrate the performance ofCRW in cough jets, we simulate an isothermal jet by releasing 100 droplets with the samediameter (two cases: 50 \u03bcm and 100 \u03bcm) one by one at atime interval of 0.1 s.", [["cough", "DISEASE", 40, 45], ["cough jets", "PROBLEM", 40, 50], ["an isothermal jet", "TREATMENT", 64, 81]]], ["We assume that there is no ambient flow and turn off theevaporation by defining RH = 100%.", [["ambient flow", "TREATMENT", 27, 39], ["RH", "TEST", 80, 82], ["no", "UNCERTAINTY", 24, 26], ["ambient flow", "OBSERVATION", 27, 39]]], ["Droplet trajectories show that majority of the 50\u03bcm droplets are retained in the jet region and some droplets reach 4 m(see Fig. 9).", [["Droplet trajectories", "TEST", 0, 20], ["jet", "OBSERVATION_MODIFIER", 81, 84], ["droplets", "OBSERVATION_MODIFIER", 101, 109]]], ["Alldroplets travel within 2.5 m in the streamwise direction.Droplet dynamics in a \u201ccontinuous\u201d cough jet ::: MODEL APPLICATIONSFrom Fig. 9, we observe that most of the dropletsare bounded within the Gaussian width of the jet(2bg withbg = 0.114x).", [["cough", "DISEASE", 95, 100], ["Droplet dynamics", "PROBLEM", 60, 76], ["bg withbg", "TEST", 226, 235]]], ["Our resultshows smaller spreading than that reported in Wei and Li(2015) using DRW.", [["smaller", "OBSERVATION_MODIFIER", 16, 23], ["spreading", "OBSERVATION_MODIFIER", 24, 33]]], ["The boundary of particle trajectories in the DRW model trackscloser to the top-hat jet width 2bt withbt=2bg (Wei and Li, 2015),which likely overestimates the droplet spreading since DRW may inaccurately capture theflow\u2013particle interactions for expiratory droplets (see Fig.4).Droplet dynamics in a \u201ccontinuous\u201d cough jet ::: MODEL APPLICATIONSTo test the influence of relative humidity on the droplet spreading, we release 1000equal-diameter droplets (two cases: 50 \u03bcm and 100 \u03bcm)and track their dispersion in the cough jet for 10 s at two relative humidity conditions(RH = 50% and 100%).", [["cough", "DISEASE", 312, 317], ["cough", "DISEASE", 515, 520], ["DRW", "SIMPLE_CHEMICAL", 182, 185], ["the droplet spreading", "PROBLEM", 154, 175], ["DRW", "TREATMENT", 182, 185], ["expiratory droplets", "TEST", 245, 264], ["Droplet dynamics", "PROBLEM", 277, 293], ["the droplet spreading", "TREATMENT", 390, 411], ["the cough jet", "TREATMENT", 511, 524], ["RH", "TEST", 570, 572], ["particle trajectories", "OBSERVATION", 16, 37], ["droplet spreading", "OBSERVATION", 158, 175]]], ["Due to the strong initial velocity, all droplets reach 0.5 m(i.e., probability = 1).", [["strong", "OBSERVATION_MODIFIER", 11, 17], ["initial", "OBSERVATION_MODIFIER", 18, 25], ["velocity", "OBSERVATION_MODIFIER", 26, 34], ["droplets", "OBSERVATION_MODIFIER", 40, 48]]], ["Some droplets settle to the ground within 1 m distance, leadingto the decrease in reaching probability at further streamwise distances.", [["Some droplets", "PROBLEM", 0, 13], ["the decrease", "PROBLEM", 66, 78], ["droplets", "OBSERVATION", 5, 13], ["decrease", "OBSERVATION_MODIFIER", 70, 78]]], ["At RH = 100%, all100 \u03bcm droplets settle to the ground within 2.7 m, whereas some 50\u03bcm droplets reach 5 m.", [["RH", "TEST", 3, 5]]], ["Half population of the droplets reach 1.03 m and2.62 m for 50 \u03bcm and 100 \u03bcm, respectively.Droplet dynamics in a \u201ccontinuous\u201d cough jet ::: MODEL APPLICATIONSWhen RH = 50%, droplets shrink during the airborne travel, leading to the modification ofthe reaching probability curve.", [["cough", "DISEASE", 125, 130], ["Droplet dynamics", "PROBLEM", 90, 106]]], ["The model results show that the effect of relativehumidity is profound for 50 \u03bcm droplets but not as significant as for 100\u03bcm droplets.", [["50 \u03bcm droplets", "PROBLEM", 75, 89], ["profound", "OBSERVATION_MODIFIER", 62, 70]]], ["At RH = 50%, no droplets reach 3.5 m with the initialdiameter of 50 \u03bcm, reducing the maximum reaching distance by 34.6%.", [["RH", "TEST", 3, 5]]], ["Inthe meantime, reducing RH also increases the likelihood of the droplet transport in theshorter region.", [["the droplet transport in theshorter region", "TREATMENT", 61, 103], ["droplet", "OBSERVATION", 65, 72]]], ["For instance, the reaching probability at x = 2 mincreases from 68.1% to 82.5% when RH decreases from 100% to 50%.", [["RH", "TEST", 84, 86], ["decreases", "OBSERVATION_MODIFIER", 87, 96]]], ["This suggests that 50\u03bcm droplets tend to accumulate within a narrower range in thestreamwise direction when RH decreases to 50%.", [["50\u03bcm droplets", "ANATOMY", 19, 32], ["50\u03bcm droplets", "PROBLEM", 19, 32], ["narrower", "OBSERVATION_MODIFIER", 61, 69], ["decreases", "OBSERVATION_MODIFIER", 111, 120]]], ["At RH = 100%, the middle 60% of thedroplets are within the 1.56 m\u20133.7 m range, and this range becomes 2.05 m\u20132.66 m at RH =50%.Droplet dynamics in a \u201ccontinuous\u201d cough jet ::: MODEL APPLICATIONSDifferent from the decrease in the maximum reaching distance for 50 \u03bcmdroplets, decreasing RH to 50% increases the maximum reaching distance by 29.6% for 100\u03bcm, from 2.7 m to 3.5 m.", [["cough", "DISEASE", 162, 167], ["thedroplets", "CANCER", 32, 43], ["RH", "TEST", 3, 5], ["RH", "TEST", 119, 121], ["Droplet dynamics", "PROBLEM", 127, 143], ["MODEL APPLICATIONSDifferent", "TREATMENT", 176, 203], ["middle", "OBSERVATION_MODIFIER", 18, 24], ["decrease", "OBSERVATION_MODIFIER", 213, 221]]], ["For the shorter regime (within 1 m), theprobability curve almost does not respond to the change of RH from 100% to 50%, givingonly 50% of the droplets reaching 1 m.", [["theprobability curve", "PROBLEM", 37, 57], ["the droplets", "TREATMENT", 138, 150]]], ["The sensitivity of droplet transport in cough jetsbetween different diameters in response to the RH changes varies significantly due to thenon-linearly correlated dynamics in the processes of mass and heat transfer and thekinematics of droplets.Droplet dynamics in a \u201cpulsating\u201d cough jet ::: MODEL APPLICATIONSIn a single coughing event, the cough jet is more like a pulsating flow with stronginitial velocity, which rapidly decays to the normal breath condition.", [["cough", "DISEASE", 40, 45], ["cough", "DISEASE", 279, 284], ["cough", "DISEASE", 343, 348], ["droplet transport", "TREATMENT", 19, 36], ["cough", "PROBLEM", 40, 45], ["the RH changes", "PROBLEM", 93, 107], ["mass", "PROBLEM", 192, 196], ["heat transfer", "TREATMENT", 201, 214], ["thekinematics of droplets", "TREATMENT", 219, 244], ["Droplet dynamics", "PROBLEM", 245, 261], ["a single coughing event", "PROBLEM", 314, 337], ["the cough jet", "PROBLEM", 339, 352], ["a pulsating flow with stronginitial velocity", "PROBLEM", 366, 410], ["diameters", "OBSERVATION_MODIFIER", 68, 77], ["mass", "OBSERVATION", 192, 196], ["pulsating flow", "OBSERVATION", 368, 382], ["stronginitial velocity", "OBSERVATION", 388, 410], ["normal", "OBSERVATION_MODIFIER", 440, 446], ["breath condition", "OBSERVATION", 447, 463]]], ["The duration ofpulsating cough flow is typically 0.5 s (Gupta etal., 2009).", [["cough", "DISEASE", 25, 30], ["The duration ofpulsating cough flow", "PROBLEM", 0, 35]]], ["Wei and Li (2017)conducted an experiment by releasing particle-laden jets in water to simulate the coughjet using a constant velocity, a sinusoidal profile, and a profile of the gammadistribution function in a duration of 2 s.", [["Li", "CHEMICAL", 8, 10], ["a constant velocity", "TEST", 114, 133], ["a sinusoidal profile", "TEST", 135, 155]]], ["Here, we simulate a similar pulsating coughjet to track the particle trajectory and its shrinkage, using a constant exit velocityU0 = 10 m/s for 1 s.", [["a similar pulsating coughjet", "PROBLEM", 18, 46], ["a constant exit velocityU0", "TREATMENT", 105, 131], ["particle", "OBSERVATION_MODIFIER", 60, 68], ["trajectory", "OBSERVATION_MODIFIER", 69, 79], ["shrinkage", "OBSERVATION_MODIFIER", 88, 97]]], ["After 1 s, we stop the jet and letparticles to settle in three different conditions: (1) no flow, (2) an upward flow withW = 0.1 m/s, and (3) a downward flow with W = \u22120.1m/s.", [["the jet and letparticles", "TREATMENT", 19, 43], ["an upward flow", "TEST", 102, 116], ["a downward flow", "TEST", 142, 157], ["W", "TEST", 163, 164]]], ["To simplify the physical process of droplets after the cough, we did not consider theinfluence of ambient turbulence, i.e., the droplets would be only advected by the ambientflow with their velocities determined at the end of the cough.Droplet dynamics in a \u201cpulsating\u201d cough jet ::: MODEL APPLICATIONSThe model takes a log-normal distribution of droplet diameters within the range of 1\u03bcm\u20131000 \u03bcm and randomly draws 1000 samples from thedistribution [see \u201cinitial\u201d in Fig. 11(a)].", [["cough", "DISEASE", 55, 60], ["cough", "DISEASE", 230, 235], ["cough", "DISEASE", 270, 275], ["the cough", "PROBLEM", 51, 60], ["the cough", "PROBLEM", 226, 235], ["Droplet dynamics", "PROBLEM", 236, 252], ["cough", "OBSERVATION", 230, 235], ["droplet diameters", "OBSERVATION", 347, 364]]], ["Themodeled droplet size distribution is similar to the measured distribution in real coughs(Xie et al., 2009).", [["real coughs", "PROBLEM", 80, 91], ["droplet", "OBSERVATION_MODIFIER", 11, 18], ["size", "OBSERVATION_MODIFIER", 19, 23], ["distribution", "OBSERVATION_MODIFIER", 24, 36], ["similar", "OBSERVATION_MODIFIER", 40, 47], ["distribution", "OBSERVATION_MODIFIER", 64, 76], ["coughs", "OBSERVATION", 85, 91]]], ["Our modeleddata have a median droplet diameter of 51.3 \u03bcm, a mean diameter of 85.9\u03bcm, and a standard derivation of 111.3 \u03bcm.", [["a median droplet diameter", "TEST", 21, 46], ["a mean diameter", "TEST", 59, 74], ["a standard derivation", "TEST", 90, 111], ["median", "OBSERVATION_MODIFIER", 23, 29], ["droplet", "OBSERVATION_MODIFIER", 30, 37], ["diameter", "OBSERVATION_MODIFIER", 38, 46], ["51.3 \u03bcm", "OBSERVATION_MODIFIER", 50, 57], ["mean diameter", "OBSERVATION_MODIFIER", 61, 74], ["85.9\u03bcm", "OBSERVATION_MODIFIER", 78, 84]]], ["Theevolution of the droplet locations and sizes at four tested humidity conditions isprovided in the supplementarymaterial.Droplet dynamics in a \u201cpulsating\u201d cough jet ::: MODEL APPLICATIONSFirst, we examine the total population changes of droplets that remain airborne after 1 scough.", [["cough", "DISEASE", 157, 162], ["the droplet locations", "TREATMENT", 16, 37], ["four tested humidity conditions", "TREATMENT", 51, 82], ["Droplet dynamics", "PROBLEM", 123, 139], ["the total population changes of droplets", "TREATMENT", 207, 247], ["droplet", "OBSERVATION_MODIFIER", 20, 27], ["sizes", "OBSERVATION_MODIFIER", 42, 47]]], ["Figure 11(a) shows the histogram plot ofdroplets that neither settle on the ground nor completely dry out.", [["the histogram plot ofdroplets", "TEST", 19, 48]]], ["Large-sized dropletssettle to the ground for all RH conditions.", [["-sized", "OBSERVATION_MODIFIER", 5, 11], ["dropletssettle", "OBSERVATION", 12, 26]]], ["The number of droplets in the diameter rangeof 10 \u03bcm\u2013100 \u03bcm decreases more dramatically withdecreasing RH than other size ranges.", [["number", "OBSERVATION_MODIFIER", 4, 10], ["droplets", "OBSERVATION_MODIFIER", 14, 22], ["diameter", "OBSERVATION_MODIFIER", 30, 38], ["dramatically", "OBSERVATION_MODIFIER", 75, 87], ["size", "OBSERVATION_MODIFIER", 117, 121]]], ["This suggests that this size range is mostlysensitive to humidity.", [["size", "OBSERVATION_MODIFIER", 24, 28]]], ["This result is also shown in the plot of the final-to-initialvolume ratio in each droplet size bin [Fig.11(b)].Droplet dynamics in a \u201cpulsating\u201d cough jet ::: MODEL APPLICATIONSFigure 12 plots the percentage of numbers andvolume of airborne droplets compared to the initial condition after 1 s cough at differentRH conditions.", [["cough", "DISEASE", 145, 150], ["cough", "DISEASE", 294, 299], ["Fig", "TEST", 100, 103], ["Droplet dynamics", "PROBLEM", 111, 127], ["airborne droplets", "TREATMENT", 232, 249], ["1 s cough at differentRH conditions", "PROBLEM", 290, 325]]], ["The model results show that about 85.1% of the droplets remain airborneafter 1 s at RH = 90%.", [["the droplets", "TEST", 43, 55]]], ["14.9% of the droplets either settle to the ground (2.6%) orcompletely evaporate (12.3%) within 1 s.", [["the droplets", "TEST", 9, 21], ["orcompletely evaporate", "TEST", 57, 79]]], ["When RH decreases, more droplets evaporatecompletely within 1 s, resulting in a significant decrease of airborne droplets (74.4% and65.8% for RH = 50% and 25%, respectively).", [["a significant decrease of airborne droplets", "PROBLEM", 78, 121], ["RH", "TEST", 142, 144], ["decreases", "OBSERVATION_MODIFIER", 8, 17], ["significant", "OBSERVATION_MODIFIER", 80, 91], ["decrease", "OBSERVATION_MODIFIER", 92, 100], ["airborne droplets", "OBSERVATION", 104, 121]]], ["Despite the dramatic change in airborne dropletnumbers, the total volume of airborne droplets does not change drastically due to the weakcontribution to the volume from small droplets.", [["the dramatic change in airborne dropletnumbers", "PROBLEM", 8, 54], ["the total volume of airborne droplets", "TREATMENT", 56, 93], ["the weakcontribution", "PROBLEM", 129, 149], ["small droplets", "PROBLEM", 169, 183], ["dramatic", "OBSERVATION_MODIFIER", 12, 20], ["change", "OBSERVATION_MODIFIER", 21, 27], ["airborne dropletnumbers", "OBSERVATION", 31, 54], ["airborne droplets", "OBSERVATION", 76, 93], ["small droplets", "OBSERVATION", 169, 183]]], ["The airborne droplets only occupy about30% of the initial volume, which remains almost unchanged during 1 s cough throughout thetested humidity range.", [["cough", "DISEASE", 108, 113], ["The airborne droplets", "PROBLEM", 0, 21], ["the initial volume", "TEST", 46, 64], ["airborne droplets", "OBSERVATION", 4, 21], ["volume", "OBSERVATION_MODIFIER", 58, 64], ["almost", "OBSERVATION_MODIFIER", 80, 86], ["unchanged", "OBSERVATION_MODIFIER", 87, 96]]], ["This suggests that the majority of the volume is contributed bythose droplets that settle to the ground during the cough.", [["cough", "DISEASE", 115, 120], ["bythose droplets", "PROBLEM", 61, 77], ["the cough", "PROBLEM", 111, 120], ["majority", "OBSERVATION_MODIFIER", 23, 31], ["volume", "OBSERVATION", 39, 45], ["cough", "OBSERVATION", 115, 120]]], ["For instance, at RH = 90%,82.5% of the dry-out droplets only occupy 0.0004% of the total volume.", [["RH", "TEST", 17, 19], ["the dry-out droplets", "TREATMENT", 35, 55]]], ["If the virus loadassociated with the droplets is proportional to the volume, almost 70% of the virus woulddeposit on the ground during the cough.", [["cough", "DISEASE", 139, 144], ["the virus loadassociated", "PROBLEM", 3, 27], ["the volume", "TEST", 65, 75], ["the cough", "PROBLEM", 135, 144], ["virus", "OBSERVATION", 7, 12], ["cough", "OBSERVATION", 139, 144]]], ["Hence, maintaining physical distance wouldsignificantly remediate the spreading of respiratory infectious diseases through reducingdirect deposition of droplets onto people within short distances and through reducing theprobability of inhalation of high concentration aerosols near the source.Droplet dynamics in a \u201cpulsating\u201d cough jet ::: MODEL APPLICATIONSWhen coughing occurs in the environment with ambient flows, the droplet airborne time andthe droplet transport will be modified by additional dispersion depending on the strengthof the mean and turbulent velocities.", [["respiratory infectious diseases", "DISEASE", 83, 114], ["cough", "DISEASE", 327, 332], ["people", "SPECIES", 166, 172], ["respiratory infectious diseases", "PROBLEM", 83, 114], ["reducingdirect deposition of droplets", "TREATMENT", 123, 160], ["high concentration aerosols", "PROBLEM", 249, 276], ["Droplet dynamics", "PROBLEM", 293, 309], ["coughing", "PROBLEM", 364, 372], ["ambient flows", "TREATMENT", 404, 417], ["the droplet airborne time", "TREATMENT", 419, 444], ["droplet transport", "TREATMENT", 452, 469], ["respiratory", "ANATOMY", 83, 94], ["infectious", "OBSERVATION", 95, 105], ["coughing", "OBSERVATION", 364, 372], ["turbulent velocities", "OBSERVATION", 553, 573]]], ["Figure 13illustrates the modification of droplet airborne time by the mean flow.", [["droplet airborne", "OBSERVATION", 41, 57], ["mean flow", "OBSERVATION", 70, 79]]], ["Here, we calculatethe droplet vertical location as a function of time under downward flow, no flow, andupward flow conditions.", [["downward flow", "TEST", 76, 89], ["downward flow", "OBSERVATION", 76, 89], ["no", "UNCERTAINTY", 91, 93], ["flow", "OBSERVATION", 94, 98], ["flow conditions", "OBSERVATION", 110, 125]]], ["The process is simplified by not accounting for turbulentfluctuations in ambient flows, assuming no horizontal velocities, and only applying theambient flows after the completion of the cough.", [["cough", "DISEASE", 186, 191], ["turbulentfluctuations in ambient flows", "PROBLEM", 48, 86], ["horizontal velocities", "PROBLEM", 100, 121], ["theambient flows", "TREATMENT", 141, 157], ["the cough", "PROBLEM", 182, 191], ["not accounting for", "UNCERTAINTY", 29, 47], ["ambient flows", "OBSERVATION", 73, 86], ["no", "UNCERTAINTY", 97, 99], ["horizontal", "OBSERVATION_MODIFIER", 100, 110], ["velocities", "OBSERVATION_MODIFIER", 111, 121], ["cough", "OBSERVATION", 186, 191]]], ["Note that such idealized flows do notexist in real indoor and outdoor environments but provide valuable quantitativeinformation about how the dynamics of coughing droplets can be modified by simpleadvection of mean velocities.Droplet dynamics in a \u201cpulsating\u201d cough jet ::: MODEL APPLICATIONSThe model results show that the longest droplet airborne time is 13.4 s with no ambientflow.", [["coughing", "DISEASE", 154, 162], ["cough", "DISEASE", 260, 265], ["coughing droplets", "PROBLEM", 154, 171], ["Droplet dynamics", "PROBLEM", 226, 242], ["ambientflow", "TREATMENT", 372, 383], ["mean velocities", "OBSERVATION", 210, 225]]], ["This duration would be reduced by 28% (9.6 s) with the downward velocity of 0.1 m/sand increased by 38% (18.5 s) with the upward velocity of 0.1 m/s, respectively.", [["the downward velocity", "TEST", 51, 72], ["the upward velocity", "TEST", 118, 137], ["reduced", "OBSERVATION_MODIFIER", 23, 30], ["downward", "OBSERVATION_MODIFIER", 55, 63], ["velocity", "OBSERVATION_MODIFIER", 64, 72], ["upward", "OBSERVATION_MODIFIER", 122, 128], ["velocity", "OBSERVATION_MODIFIER", 129, 137]]], ["Becausethe droplets undergo a continuous shrinkage during their transport in air, themodification of their airborne time would change their temporal and spatial distributionsand hence would affect the transmission of respiratory diseases if the droplets carryinfectious viruses.", [["respiratory", "ANATOMY", 217, 228], ["respiratory diseases", "DISEASE", 217, 237], ["a continuous shrinkage", "TREATMENT", 28, 50], ["respiratory diseases", "PROBLEM", 217, 237], ["the droplets carryinfectious viruses", "PROBLEM", 241, 277], ["respiratory diseases", "OBSERVATION", 217, 237]]], ["Figure 14 shows the finalvertical locations of each droplet (zl) asthe function of their fate (i.e., the maximal airborne lifetime,tl).", [["Figure", "TEST", 0, 6]]], ["When there is no ambient flow, 25.0%of the droplets settle before they completely evaporate in the air (occupying 72.6% of theinitial total volume).", [["ambient flow", "TEST", 17, 29], ["no", "UNCERTAINTY", 14, 16], ["ambient", "OBSERVATION_MODIFIER", 17, 24], ["flow", "OBSERVATION", 25, 29], ["air", "ANATOMY", 99, 102]]], ["The percentage ofsettled droplets is modified by the ambient flow with a decrease of 5.7% and an increaseof 7.1% in the upward (19.3% in population, occupying 72.2% of the initial total volume)and downward (32.1% in population, occupying 73.3% of the initial total volume) flowconditions, respectively.", [["The percentage ofsettled droplets", "TREATMENT", 0, 33], ["the ambient flow", "TEST", 49, 65], ["an increaseof", "TEST", 94, 107], ["population", "TEST", 216, 226], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["ofsettled droplets", "OBSERVATION", 15, 33], ["decrease", "OBSERVATION_MODIFIER", 73, 81], ["upward", "OBSERVATION_MODIFIER", 120, 126], ["downward", "OBSERVATION_MODIFIER", 197, 205]]], ["When the droplets are associated with infectious viruses, thesettled droplets could result in fomite transmission and the completely evaporateddroplets may cause airborne transmission of the respiratory infectious diseases throughtheir nuclei that are further transported by air flows.Droplet dynamics in a \u201cpulsating\u201d cough jet ::: MODEL APPLICATIONSThe airborne time, maximal reaching height, and percentage of airborne and settleddroplets can be modified by the ambient conditions such as temperature and humidity.", [["droplets", "ANATOMY", 9, 17], ["evaporateddroplets", "DISEASE", 133, 151], ["respiratory infectious diseases", "DISEASE", 191, 222], ["cough", "DISEASE", 319, 324], ["infectious viruses", "PROBLEM", 38, 56], ["thesettled droplets", "PROBLEM", 58, 77], ["the respiratory infectious diseases throughtheir nuclei", "PROBLEM", 187, 242], ["Droplet dynamics", "PROBLEM", 285, 301], ["settleddroplets", "TREATMENT", 426, 441], ["associated with", "UNCERTAINTY", 22, 37], ["infectious", "OBSERVATION_MODIFIER", 38, 48], ["respiratory", "ANATOMY", 191, 202], ["infectious", "OBSERVATION", 203, 213], ["air flows", "OBSERVATION", 275, 284], ["airborne", "OBSERVATION_MODIFIER", 355, 363]]], ["Table II summarizes the calculation for four differentrelative humidity and three flow conditions.", [["the calculation", "TEST", 20, 35], ["four differentrelative humidity", "TREATMENT", 40, 71], ["three flow conditions", "TREATMENT", 76, 97]]], ["Taking two extreme conditions (RH = 25% and90%), the maximal airborne time can be extended in humid air by 194%, 343%, and 77% underno flow, upward flow, and downward flow, respectively.", [["RH", "TEST", 31, 33], ["upward flow", "OBSERVATION", 141, 152], ["downward flow", "OBSERVATION", 158, 171]]], ["The change in maximal reachingheight is only noticeable in the upward flow condition from 1.87 m to 3.2 m when changingRH from 25% to 90%.", [["change", "OBSERVATION_MODIFIER", 4, 10], ["maximal reachingheight", "OBSERVATION", 14, 36], ["noticeable", "OBSERVATION_MODIFIER", 45, 55], ["upward", "OBSERVATION_MODIFIER", 63, 69], ["flow", "OBSERVATION", 70, 74]]], ["The droplets that reach high are those having small to median sizesbecause they can be easily carried by background flows and concurrently have adequatelifetime.", [["droplets", "OBSERVATION", 4, 12]]], ["Rising RH from 25% to 90% approximately doubles the percentage of settleddroplets in all flow conditions.", [["Rising RH", "PROBLEM", 0, 9]]], ["The droplets that settle to the ground are large ones,which contribute to the majority of the total volume.", [["droplets", "ANATOMY", 4, 12], ["The droplets", "TREATMENT", 0, 12], ["droplets", "OBSERVATION", 4, 12], ["large", "OBSERVATION", 43, 48]]], ["Even under the upward flow and thedriest condition, the settled droplets occupy 97.8% of the total volume.MODEL LIMITATIONSSeveral assumptions or simplification is used in the current model and study.", [["the current model and study", "TEST", 172, 199], ["upward flow", "OBSERVATION", 15, 26]]], ["First, inviolent expiratory events, droplets are generated from the source and then undergo acontinuous breakup/coalescence process under strong shear.", [["inviolent expiratory events", "PROBLEM", 7, 34], ["acontinuous breakup", "PROBLEM", 92, 111], ["coalescence process", "PROBLEM", 112, 131], ["coalescence", "OBSERVATION", 112, 123], ["strong shear", "OBSERVATION_MODIFIER", 138, 150]]], ["The non-Newtonian nature ofdroplets makes the droplet cascade a complex process and further affects the final dropletsizes in the downstream of the expiratory flows (Scharfmanet al., 2016).", [["non-Newtonian", "OBSERVATION_MODIFIER", 4, 17], ["expiratory flows", "OBSERVATION", 148, 164]]], ["In the current model, we assume that the initialdroplet size distribution is the final converged distribution and neglect theparticle\u2013particle interactions.", [["neglect theparticle\u2013particle interactions", "PROBLEM", 114, 155], ["size", "OBSERVATION_MODIFIER", 56, 60], ["neglect theparticle\u2013particle", "OBSERVATION", 114, 142]]], ["Second, the flow in human respiratory events is puff andinvolves time-varying velocity at the source.", [["respiratory", "ANATOMY", 26, 37], ["human", "ORGANISM", 20, 25], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["the flow in human respiratory events", "PROBLEM", 8, 44], ["flow", "OBSERVATION", 12, 16], ["respiratory events", "OBSERVATION", 26, 44], ["varying", "OBSERVATION_MODIFIER", 70, 77], ["velocity", "OBSERVATION_MODIFIER", 78, 86]]], ["The present study simplifies the flow as a jetand applies a constant initial velocity in the modeled cough event.", [["cough", "DISEASE", 101, 106], ["The present study", "TEST", 0, 17], ["the modeled cough event", "PROBLEM", 89, 112], ["constant", "OBSERVATION_MODIFIER", 60, 68], ["initial", "OBSERVATION_MODIFIER", 69, 76], ["velocity", "OBSERVATION_MODIFIER", 77, 85], ["modeled", "OBSERVATION_MODIFIER", 93, 100], ["cough", "OBSERVATION", 101, 106]]], ["The adjustment can bemade by employing a time-varying ambient flow field and adding the buoyancy effect due tothe temperature difference between the exhaled fluid and ambient air.", [["varying ambient flow field", "TREATMENT", 46, 72], ["the buoyancy effect", "TREATMENT", 84, 103], ["tothe temperature difference", "PROBLEM", 108, 136], ["the exhaled fluid", "TREATMENT", 145, 162], ["exhaled fluid", "OBSERVATION", 149, 162]]], ["Finally, theevaporation of droplets near the source would induce a localized humidity increase, whichcould potentially delay the evaporation of the droplets.", [["droplets", "TREATMENT", 27, 35], ["a localized humidity increase", "PROBLEM", 65, 94], ["the droplets", "PROBLEM", 144, 156], ["localized", "OBSERVATION_MODIFIER", 67, 76], ["humidity", "OBSERVATION_MODIFIER", 77, 85], ["increase", "OBSERVATION_MODIFIER", 86, 94]]], ["Neglecting this effect couldoverestimate the droplet shrinkage, particularly for the high concentration, small sizerange droplets.", [["the droplet shrinkage", "PROBLEM", 41, 62], ["small sizerange droplets", "PROBLEM", 105, 129], ["droplet shrinkage", "OBSERVATION", 45, 62], ["small", "OBSERVATION_MODIFIER", 105, 110], ["sizerange droplets", "OBSERVATION", 111, 129]]], ["These model limitations and caveats to the study are subject to futureinvestigations.CONCLUSION AND OUTLOOKIn this paper, we present a numerical model to quantify the dynamics of droplets from humanexpiratory events that are related to the transmission of respiratory infectious diseases.We apply a CRW model to improve the current shortcomings in predicting the spreading ofmedian-sized droplets in DRW models.", [["respiratory infectious diseases", "DISEASE", 256, 287], ["the study", "TEST", 39, 48], ["respiratory infectious diseases", "PROBLEM", 256, 287], ["a CRW model", "TREATMENT", 297, 308], ["respiratory", "ANATOMY", 256, 267], ["infectious", "OBSERVATION", 268, 278], ["sized", "OBSERVATION_MODIFIER", 382, 387], ["droplets", "OBSERVATION", 388, 396]]], ["Our validation data show a nearly 100% improvement inpredicting the spreading of droplets with environment-sensitive sizes.CONCLUSION AND OUTLOOKWe show the behavior of free-falling droplets in different temperature and humidityenvironments.", [["Our validation data", "TEST", 0, 19], ["falling droplets", "PROBLEM", 174, 190], ["humidityenvironments", "TREATMENT", 220, 240], ["sizes", "OBSERVATION_MODIFIER", 117, 122], ["different temperature", "OBSERVATION_MODIFIER", 194, 215]]], ["A 50 \u03bcm droplet has a large range of airborne lifetime (1.15s\u201343.5 s) and settling heights (0 m\u20131.56 m), which originated at 1.6 m height at thetemperature of 5 \u00b0C\u201335 \u00b0C and relative humidity of RH = 0%\u201395%.", [["relative humidity", "TEST", 174, 191], ["RH", "TEST", 195, 197], ["large", "OBSERVATION_MODIFIER", 22, 27], ["range", "OBSERVATION_MODIFIER", 28, 33]]], ["In the same combination oftemperature and humidity, a 100 \u03bcm droplet has a much narrower lifetimerange (4.1 s\u201312.3 s), resulting in a narrower range of settling heights (0 m\u20131.07 m).CONCLUSION AND OUTLOOKSimulating a continuous cough jet further illustrates the sensitivity of median-sizeddroplets to the ambient environment.", [["a continuous cough jet", "TREATMENT", 215, 237], ["median-sizeddroplets", "TREATMENT", 277, 297], ["narrower", "OBSERVATION_MODIFIER", 134, 142], ["settling", "OBSERVATION_MODIFIER", 152, 160], ["heights", "OBSERVATION_MODIFIER", 161, 168]]], ["The reaching probability of50 \u03bcm droplets is reshaped by the humidity, leading to a narrowed range inthe streamwise direction as a result of enhanced evaporation.CONCLUSION AND OUTLOOKTaking a realistic droplet size distribution and the duration of a cough jet, we show that14.9% of the droplet population either settles to the ground (2.6%) or completely evaporates(12.3%) at RH = 90% within the coughing event (1 s).", [["cough", "DISEASE", 251, 256], ["a narrowed range inthe streamwise direction", "PROBLEM", 82, 125], ["enhanced evaporation", "TREATMENT", 141, 161], ["a cough jet", "PROBLEM", 249, 260], ["the droplet population", "TEST", 283, 305], ["RH", "TEST", 377, 379], ["the coughing event", "PROBLEM", 393, 411], ["narrowed", "OBSERVATION", 84, 92], ["droplet", "OBSERVATION_MODIFIER", 203, 210], ["size", "OBSERVATION_MODIFIER", 211, 215], ["coughing", "OBSERVATION", 397, 405]]], ["85.1% of the droplet population remainsin air and will be further transported by ambient flows.", [["the droplet population remainsin air", "TREATMENT", 9, 45], ["air", "OBSERVATION", 42, 45]]], ["This remaining percentage decreasesto 74.4% and 65.8% for RH = 50% and 25%, respectively.", [["This remaining percentage decreasesto", "TEST", 0, 37], ["RH", "TEST", 58, 60], ["percentage", "OBSERVATION_MODIFIER", 15, 25]]], ["However, they only occupy about 30%of the total volume with negligible variations in the tested humidity range (RH = 25%\u201390%).Ambient flow further changes the transport and dynamics through modifying the settling,airborne travel, and dry-out of the droplets.", [["the total volume", "TEST", 38, 54], ["negligible variations", "PROBLEM", 60, 81], ["RH", "TEST", 112, 114], ["Ambient flow", "TREATMENT", 126, 138], ["the transport", "TREATMENT", 155, 168], ["the droplets", "TREATMENT", 245, 257], ["negligible", "OBSERVATION_MODIFIER", 60, 70], ["variations", "OBSERVATION", 71, 81]]], ["Different combinations of ambient environmentsand flows result in different droplet airborne time and transport distances, as well asdifferent percentages of droplets that could be the sources of airborne or fomitetransmissions.", [["ambient environmentsand flows", "TREATMENT", 26, 55], ["droplets", "TREATMENT", 158, 166], ["ambient environmentsand", "OBSERVATION", 26, 49], ["different", "OBSERVATION_MODIFIER", 66, 75], ["droplet airborne", "OBSERVATION", 76, 92]]], ["In the tested parameter range, the droplets occupying the majority of theinitial volume would eventually settle on the ground rather than completely evaporating inthe air.CONCLUSION AND OUTLOOKThe model we developed from this study will better our understanding of the mechanisms forairborne pathogens, e.g., influenza.", [["influenza", "DISEASE", 309, 318], ["the droplets", "PROBLEM", 31, 43], ["this study", "TEST", 221, 231], ["the mechanisms forairborne pathogens", "PROBLEM", 265, 301], ["influenza", "PROBLEM", 309, 318], ["majority", "OBSERVATION_MODIFIER", 58, 66], ["theinitial volume", "OBSERVATION", 70, 87], ["air", "OBSERVATION", 167, 170]]], ["Previous studies suggested that influenza viruses arepresent in both fine and coarse aerosol particles exhaled by influenza patients, includingthose with sizes <5 \u03bcm or >5 \u03bcm (Milton et al., 2013; Gralton et al., 2013; Lednicky and Loeb, 2013; and Lindsley et al., 2015).", [["influenza viruses", "DISEASE", 32, 49], ["influenza", "DISEASE", 114, 123], ["influenza viruses", "ORGANISM", 32, 49], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["Previous studies", "TEST", 0, 16], ["influenza viruses arepresent", "PROBLEM", 32, 60], ["influenza", "PROBLEM", 114, 123], ["influenza viruses", "OBSERVATION", 32, 49]]], ["These studies suggestedvariation of particle sizes in influenza carrying particles; however, none of these studieshave determined roles of particle sizes more than 50 \u03bcm (Milton et al., 2013).", [["influenza", "DISEASE", 54, 63], ["These studies", "TEST", 0, 13], ["particle sizes in influenza carrying particles", "PROBLEM", 36, 82], ["these studieshave", "TEST", 101, 118], ["particle", "OBSERVATION_MODIFIER", 36, 44], ["sizes", "OBSERVATION_MODIFIER", 45, 50], ["influenza carrying particles", "OBSERVATION", 54, 82]]], ["Thus, this studyhighlighted the importance of evaluating the transport and fate of various sizes of dropletsin aerosol transmission of airborne pathogens, such as influenza.", [["influenza", "DISEASE", 163, 172], ["dropletsin aerosol", "TREATMENT", 100, 118], ["airborne pathogens", "PROBLEM", 135, 153], ["influenza", "PROBLEM", 163, 172], ["airborne pathogens", "OBSERVATION", 135, 153]]], ["As a future study, we planto apply the model to study both fine and coarse droplets in influenza transmission.DATA AVAILABILITYThe data that support the findings of this study are available from the correspondingauthor upon reasonable request.", [["influenza transmission", "DISEASE", 87, 109], ["a future study", "TEST", 3, 17], ["influenza transmission", "PROBLEM", 87, 109], ["this study", "TEST", 165, 175]]]], "PMC7105280": [["METHODSWe performed a search on March 12, 2020, at the clinicaltrials. gov database, with the descriptor [coronavirus] in the simple search field \u201cconditions or disease\u201d search, without restrictions on languages, disease conditions, results, or locations.", [["coronavirus", "PROBLEM", 106, 117], ["disease", "PROBLEM", 161, 168], ["disease conditions", "PROBLEM", 213, 231]]], ["The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the study period; describe the patient\u2019s clinical conditions; and interventions utilize medicines already studied or approved for any other disease in patients with COVID-19.", [["patient", "ORGANISM", 181, 188], ["patients", "ORGANISM", 301, 309], ["participants", "SPECIES", 133, 145], ["patient", "SPECIES", 181, 188], ["patients", "SPECIES", 301, 309], ["the retrieved studies", "TEST", 29, 50], ["interventions", "TREATMENT", 216, 229], ["medicines", "TREATMENT", 238, 247], ["any other disease", "PROBLEM", 280, 297], ["COVID", "TEST", 315, 320]]], ["ClinicalTrials.gov is a resource from the US National Library of Medicine, and it contains clinical studies conducted by 209 countries.RESULTS AND DISCUSSIONWe identified 24 clinical trials (Table 1), in which 19 studies were at clinical phases 2, 3, or 4.", [["clinical studies", "TEST", 91, 107]]], ["The pharmaceutical interventions found for COVID-19 treatment include human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, oseltamivir, favipiravir, carrimycin, methylprednisolone, bevacizumab, thalidomide, vitamin C, pirfenidone, bromhexine, fingolimod, danoprevir, ritonavir, darunavir, cobicistat, lopinavir, xiyanping, and traditional Chinese medicines (TCM).RESULTS AND DISCUSSIONChloroquine and hydroxychloroquine are antimalarial drugs.", [["COVID-19", "CHEMICAL", 43, 51], ["chloroquine", "CHEMICAL", 105, 116], ["hydroxychloroquine", "CHEMICAL", 118, 136], ["arbidol", "CHEMICAL", 138, 145], ["remdesivir", "CHEMICAL", 147, 157], ["oseltamivir", "CHEMICAL", 159, 170], ["favipiravir", "CHEMICAL", 172, 183], ["carrimycin", "CHEMICAL", 185, 195], ["methylprednisolone", "CHEMICAL", 197, 215], ["bevacizumab", "CHEMICAL", 217, 228], ["thalidomide", "CHEMICAL", 230, 241], ["vitamin C", "CHEMICAL", 243, 252], ["pirfenidone", "CHEMICAL", 254, 265], ["bromhexine", "CHEMICAL", 267, 277], ["fingolimod", "CHEMICAL", 279, 289], ["danoprevir", "CHEMICAL", 291, 301], ["ritonavir", "CHEMICAL", 303, 312], ["darunavir", "CHEMICAL", 314, 323], ["cobicistat", "CHEMICAL", 325, 335], ["lopinavir", "CHEMICAL", 337, 346], ["xiyanping", "CHEMICAL", 348, 357], ["hydroxychloroquine", "CHEMICAL", 437, 455], ["COVID-19", "CHEMICAL", 43, 51], ["chloroquine", "CHEMICAL", 105, 116], ["hydroxychloroquine", "CHEMICAL", 118, 136], ["arbidol", "CHEMICAL", 138, 145], ["remdesivir", "CHEMICAL", 147, 157], ["oseltamivir", "CHEMICAL", 159, 170], ["favipiravir", "CHEMICAL", 172, 183], ["carrimycin", "CHEMICAL", 185, 195], ["methylprednisolone", "CHEMICAL", 197, 215], ["bevacizumab", "CHEMICAL", 217, 228], ["thalidomide", "CHEMICAL", 230, 241], ["vitamin C", "CHEMICAL", 243, 252], ["pirfenidone", "CHEMICAL", 254, 265], ["bromhexine", "CHEMICAL", 267, 277], ["fingolimod", "CHEMICAL", 279, 289], ["danoprevir", "CHEMICAL", 291, 301], ["ritonavir", "CHEMICAL", 303, 312], ["darunavir", "CHEMICAL", 314, 323], ["cobicistat", "CHEMICAL", 325, 335], ["lopinavir", "CHEMICAL", 337, 346], ["xiyanping", "CHEMICAL", 348, 357], ["DISCUSSIONChloroquine", "CHEMICAL", 411, 432], ["hydroxychloroquine", "CHEMICAL", 437, 455], ["human", "ORGANISM", 70, 75], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 76, 90], ["interferons", "GENE_OR_GENE_PRODUCT", 92, 103], ["chloroquine", "SIMPLE_CHEMICAL", 105, 116], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 118, 136], ["arbidol", "SIMPLE_CHEMICAL", 138, 145], ["remdesivir", "SIMPLE_CHEMICAL", 147, 157], ["oseltamivir", "SIMPLE_CHEMICAL", 159, 170], ["favipiravir", "SIMPLE_CHEMICAL", 172, 183], ["carrimycin", "SIMPLE_CHEMICAL", 185, 195], ["methylprednisolone", "SIMPLE_CHEMICAL", 197, 215], ["bevacizumab", "SIMPLE_CHEMICAL", 217, 228], ["thalidomide", "SIMPLE_CHEMICAL", 230, 241], ["vitamin C", "SIMPLE_CHEMICAL", 243, 252], ["pirfenidone", "SIMPLE_CHEMICAL", 254, 265], ["bromhexine", "SIMPLE_CHEMICAL", 267, 277], ["fingolimod", "SIMPLE_CHEMICAL", 279, 289], ["danoprevir", "SIMPLE_CHEMICAL", 291, 301], ["ritonavir", "SIMPLE_CHEMICAL", 303, 312], ["darunavir", "SIMPLE_CHEMICAL", 314, 323], ["cobicistat", "SIMPLE_CHEMICAL", 325, 335], ["lopinavir", "SIMPLE_CHEMICAL", 337, 346], ["xiyanping", "SIMPLE_CHEMICAL", 348, 357], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 437, 455], ["human immunoglobulin", "PROTEIN", 70, 90], ["interferons", "PROTEIN", 92, 103], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["The pharmaceutical interventions", "TREATMENT", 0, 32], ["COVID", "TEST", 43, 48], ["treatment", "TREATMENT", 52, 61], ["human immunoglobulin", "TREATMENT", 70, 90], ["interferons", "TREATMENT", 92, 103], ["chloroquine", "TREATMENT", 105, 116], ["hydroxychloroquine", "TREATMENT", 118, 136], ["arbidol", "TREATMENT", 138, 145], ["remdesivir", "TREATMENT", 147, 157], ["oseltamivir", "TREATMENT", 159, 170], ["favipiravir", "TREATMENT", 172, 183], ["carrimycin", "TREATMENT", 185, 195], ["methylprednisolone", "TREATMENT", 197, 215], ["bevacizumab", "TREATMENT", 217, 228], ["thalidomide", "TREATMENT", 230, 241], ["vitamin C", "TREATMENT", 243, 252], ["pirfenidone", "TREATMENT", 254, 265], ["bromhexine", "TREATMENT", 267, 277], ["fingolimod", "TREATMENT", 279, 289], ["danoprevir", "TREATMENT", 291, 301], ["ritonavir", "TREATMENT", 303, 312], ["darunavir", "TREATMENT", 314, 323], ["cobicistat", "TREATMENT", 325, 335], ["lopinavir", "TREATMENT", 337, 346], ["xiyanping", "TREATMENT", 348, 357], ["traditional Chinese medicines", "TREATMENT", 363, 392], ["DISCUSSIONChloroquine", "TREATMENT", 411, 432], ["hydroxychloroquine", "TREATMENT", 437, 455], ["antimalarial drugs", "TREATMENT", 460, 478]]], ["They have antiviral effects against human immuno-deficiency virus (HIV), namely by inhibiting virus entry into host cells.", [["cells", "ANATOMY", 116, 121], ["immuno-deficiency virus (HIV)", "DISEASE", 42, 71], ["human immuno-deficiency virus", "ORGANISM", 36, 65], ["HIV", "ORGANISM", 67, 70], ["host cells", "CELL", 111, 121], ["host cells", "CELL_TYPE", 111, 121], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["HIV", "SPECIES", 67, 70], ["antiviral effects", "TREATMENT", 10, 27], ["human immuno-deficiency virus", "PROBLEM", 36, 65], ["HIV", "PROBLEM", 67, 70], ["host cells", "OBSERVATION", 111, 121]]], ["Another antiviral mechanism is related to the post-translation alteration of newly synthesized proteins via glycosylation inhibition (12).", [["Another antiviral mechanism", "PROBLEM", 0, 27], ["newly synthesized proteins via glycosylation inhibition", "TREATMENT", 77, 132], ["antiviral", "OBSERVATION", 8, 17]]], ["Hydroxychloroquine is already being used in clinical trials on acquired immune deficiency syndrome (AIDS) treatment (13).", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["immune deficiency syndrome", "DISEASE", 72, 98], ["AIDS", "DISEASE", 100, 104], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["acquired immune deficiency syndrome", "PROBLEM", 63, 98], ["AIDS) treatment", "TREATMENT", 100, 115]]], ["In a recent trial with patients on COVID-19 treatment (14), 100% of patients treated with hydroxychloroquine in combination with the macrolide antibiotic azithromycin were virologically cured comparing with 57.1% in patients treated with hydroxychloroquine alone, and 12.5% in the control group.", [["COVID-19", "CHEMICAL", 35, 43], ["hydroxychloroquine", "CHEMICAL", 90, 108], ["macrolide", "CHEMICAL", 133, 142], ["azithromycin", "CHEMICAL", 154, 166], ["hydroxychloroquine", "CHEMICAL", 238, 256], ["COVID-19", "CHEMICAL", 35, 43], ["hydroxychloroquine", "CHEMICAL", 90, 108], ["macrolide", "CHEMICAL", 133, 142], ["azithromycin", "CHEMICAL", 154, 166], ["hydroxychloroquine", "CHEMICAL", 238, 256], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 68, 76], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 90, 108], ["macrolide", "SIMPLE_CHEMICAL", 133, 142], ["azithromycin", "SIMPLE_CHEMICAL", 154, 166], ["patients", "ORGANISM", 216, 224], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 238, 256], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 216, 224], ["COVID-19 treatment", "TREATMENT", 35, 53], ["hydroxychloroquine", "TREATMENT", 90, 108], ["the macrolide antibiotic azithromycin", "TREATMENT", 129, 166], ["hydroxychloroquine", "TREATMENT", 238, 256]]], ["Currently, chloroquine and hydroxychloroquine will be tested (15,16) in patients with pneumonia caused by 2019-nCoV and chloroquine as preventative medicine for COVID-19, as shown in Table 1.RESULTS AND DISCUSSIONImmunoglobulins are useful in several diseases, such as idiopathic thrombocytopenia purpura (ITP), Guillain-Barre Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), Kawasaki disease, and in multiple neurological autoimmune disorders refractory to standard immunosuppressive treatments (17).", [["neurological", "ANATOMY", 435, 447], ["chloroquine", "CHEMICAL", 11, 22], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["pneumonia", "DISEASE", 86, 95], ["2019-nCoV", "CHEMICAL", 106, 115], ["chloroquine", "CHEMICAL", 120, 131], ["idiopathic thrombocytopenia purpura", "DISEASE", 269, 304], ["ITP", "DISEASE", 306, 309], ["Guillain-Barre Syndrome", "DISEASE", 312, 335], ["GBS", "DISEASE", 337, 340], ["chronic inflammatory demyelinating polyneuropathy", "DISEASE", 343, 392], ["CIDP", "DISEASE", 394, 398], ["Kawasaki disease", "DISEASE", 401, 417], ["neurological autoimmune disorders", "DISEASE", 435, 468], ["chloroquine", "CHEMICAL", 11, 22], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["chloroquine", "CHEMICAL", 120, 131], ["chloroquine", "SIMPLE_CHEMICAL", 11, 22], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 27, 45], ["patients", "ORGANISM", 72, 80], ["chloroquine", "SIMPLE_CHEMICAL", 120, 131], ["patients", "SPECIES", 72, 80], ["chloroquine", "TREATMENT", 11, 22], ["hydroxychloroquine", "TREATMENT", 27, 45], ["pneumonia", "PROBLEM", 86, 95], ["chloroquine", "TREATMENT", 120, 131], ["preventative medicine", "TREATMENT", 135, 156], ["COVID", "TREATMENT", 161, 166], ["several diseases", "PROBLEM", 243, 259], ["idiopathic thrombocytopenia purpura", "PROBLEM", 269, 304], ["ITP", "PROBLEM", 306, 309], ["Guillain-Barre Syndrome", "PROBLEM", 312, 335], ["GBS", "PROBLEM", 337, 340], ["chronic inflammatory demyelinating polyneuropathy", "PROBLEM", 343, 392], ["CIDP)", "PROBLEM", 394, 399], ["Kawasaki disease", "PROBLEM", 401, 417], ["multiple neurological autoimmune disorders", "PROBLEM", 426, 468], ["standard immunosuppressive treatments", "TREATMENT", 483, 520], ["pneumonia", "OBSERVATION", 86, 95], ["idiopathic", "OBSERVATION_MODIFIER", 269, 279], ["thrombocytopenia purpura", "OBSERVATION", 280, 304], ["Barre Syndrome", "OBSERVATION", 321, 335], ["chronic", "OBSERVATION_MODIFIER", 343, 350], ["inflammatory", "OBSERVATION_MODIFIER", 351, 363], ["demyelinating polyneuropathy", "OBSERVATION", 364, 392], ["Kawasaki disease", "OBSERVATION", 401, 417], ["multiple", "OBSERVATION_MODIFIER", 426, 434], ["neurological", "OBSERVATION_MODIFIER", 435, 447], ["autoimmune", "OBSERVATION", 448, 458]]], ["Broadly neutralizing antibodies can recognize a wide variety of glycoproteins (GPs) in virus surfaces or the protein shell of a non-enveloped virus.", [["non-enveloped virus", "ORGANISM", 128, 147], ["neutralizing antibodies", "PROTEIN", 8, 31], ["glycoproteins", "PROTEIN", 64, 77], ["GPs", "PROTEIN", 79, 82], ["Broadly neutralizing antibodies", "PROBLEM", 0, 31], ["glycoproteins (GPs) in virus surfaces", "PROBLEM", 64, 101], ["a non-enveloped virus", "PROBLEM", 126, 147], ["neutralizing", "OBSERVATION", 8, 20], ["non-enveloped virus", "OBSERVATION", 128, 147]]], ["However, HIV-1, dengue virus (DENV), influenza viruses, hepatitis C virus (HCV), and Ebola virus (EBOV) can mutate superficial GPs in order to evade the antibody response, an obstacle in the development of new therapies against such infections (18).", [["HIV-1, dengue virus (DENV)", "DISEASE", 9, 35], ["influenza viruses", "DISEASE", 37, 54], ["hepatitis C virus (HCV), and Ebola virus", "DISEASE", 56, 96], ["infections", "DISEASE", 233, 243], ["HIV-1", "ORGANISM", 9, 14], ["dengue virus", "ORGANISM", 16, 28], ["DENV", "ORGANISM", 30, 34], ["influenza viruses", "ORGANISM", 37, 54], ["hepatitis C virus", "ORGANISM", 56, 73], ["HCV", "ORGANISM", 75, 78], ["Ebola virus", "ORGANISM", 85, 96], ["EBOV", "ORGANISM", 98, 102], ["HIV-1", "SPECIES", 9, 14], ["dengue virus", "SPECIES", 16, 28], ["hepatitis C virus", "SPECIES", 56, 73], ["Ebola virus", "SPECIES", 85, 96], ["HIV-1", "SPECIES", 9, 14], ["dengue virus", "SPECIES", 16, 28], ["DENV", "SPECIES", 30, 34], ["hepatitis C virus", "SPECIES", 56, 73], ["HCV", "SPECIES", 75, 78], ["Ebola virus", "SPECIES", 85, 96], ["EBOV", "SPECIES", 98, 102], ["HIV", "TEST", 9, 12], ["dengue virus", "PROBLEM", 16, 28], ["DENV", "PROBLEM", 30, 34], ["influenza viruses", "PROBLEM", 37, 54], ["hepatitis C virus (HCV)", "PROBLEM", 56, 79], ["Ebola virus", "PROBLEM", 85, 96], ["the antibody response", "PROBLEM", 149, 170], ["new therapies", "TREATMENT", 206, 219], ["such infections", "PROBLEM", 228, 243], ["influenza viruses", "OBSERVATION", 37, 54], ["new", "OBSERVATION_MODIFIER", 206, 209]]], ["Trial NCT04261426 (19) is utilizing human immunoglobulin in patients with pneumonia caused by 2019-nCoV (Table 1).RESULTS AND DISCUSSIONTwo clinical studies refer to the use of remdesivir in severe (20) or mild (21) respiratory infections by SARS-CoV-2.", [["respiratory", "ANATOMY", 216, 227], ["pneumonia", "DISEASE", 74, 83], ["remdesivir", "CHEMICAL", 177, 187], ["respiratory infections", "DISEASE", 216, 238], ["SARS", "DISEASE", 242, 246], ["remdesivir", "CHEMICAL", 177, 187], ["human", "ORGANISM", 36, 41], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 42, 56], ["patients", "ORGANISM", 60, 68], ["remdesivir", "SIMPLE_CHEMICAL", 177, 187], ["human immunoglobulin", "PROTEIN", 36, 56], ["human", "SPECIES", 36, 41], ["patients", "SPECIES", 60, 68], ["human", "SPECIES", 36, 41], ["SARS-CoV", "SPECIES", 242, 250], ["human immunoglobulin", "TREATMENT", 36, 56], ["pneumonia", "PROBLEM", 74, 83], ["clinical studies", "TEST", 140, 156], ["remdesivir", "TREATMENT", 177, 187], ["mild (21) respiratory infections", "PROBLEM", 206, 238], ["pneumonia", "OBSERVATION", 74, 83], ["mild", "OBSERVATION_MODIFIER", 206, 210], ["respiratory", "ANATOMY", 216, 227], ["infections", "OBSERVATION", 228, 238]]], ["Remdesivir is a nucleotide analog inhibitor of the EBOV RNA-polymerase RNA-dependent (RdRp).", [["Remdesivir", "CHEMICAL", 0, 10], ["nucleotide", "CHEMICAL", 16, 26], ["Remdesivir", "CHEMICAL", 0, 10], ["nucleotide", "CHEMICAL", 16, 26], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["EBOV", "ORGANISM", 51, 55], ["EBOV RNA-polymerase RNA", "RNA", 51, 74], ["RdRp", "PROTEIN", 86, 90], ["Remdesivir", "TREATMENT", 0, 10], ["a nucleotide analog inhibitor", "TREATMENT", 14, 43], ["the EBOV RNA", "TREATMENT", 47, 59]]], ["Dyer et al. 2019 (22) described preliminary findings of a mortality rate of 33% in 499 patients treated with remdesivir against the EBOV disease in early infection stages.", [["remdesivir", "CHEMICAL", 109, 119], ["EBOV disease", "DISEASE", 132, 144], ["infection", "DISEASE", 154, 163], ["remdesivir", "CHEMICAL", 109, 119], ["patients", "ORGANISM", 87, 95], ["remdesivir", "SIMPLE_CHEMICAL", 109, 119], ["EBOV", "ORGANISM", 132, 136], ["patients", "SPECIES", 87, 95], ["EBOV", "SPECIES", 132, 136], ["a mortality rate", "TEST", 56, 72], ["remdesivir", "TREATMENT", 109, 119], ["the EBOV disease", "PROBLEM", 128, 144], ["early infection stages", "PROBLEM", 148, 170], ["EBOV disease", "OBSERVATION", 132, 144], ["early", "OBSERVATION_MODIFIER", 148, 153], ["infection", "OBSERVATION", 154, 163]]], ["The same authors noted a mortality rate of 75% (almost 1 900 people) of non-treated infected patients during the same epidemic period (22).", [["people", "ORGANISM", 61, 67], ["patients", "ORGANISM", 93, 101], ["people", "SPECIES", 61, 67], ["patients", "SPECIES", 93, 101], ["a mortality rate", "TEST", 23, 39], ["infected", "OBSERVATION", 84, 92]]], ["Wang et al. 2020 (23) presented data showing that remdesivir is effective against the 2019-nCoV in Vero E6 cells (EC90 1.76 \u03bcM).", [["Vero E6 cells", "ANATOMY", 99, 112], ["remdesivir", "CHEMICAL", 50, 60], ["remdesivir", "CHEMICAL", 50, 60], ["remdesivir", "SIMPLE_CHEMICAL", 50, 60], ["Vero E6 cells", "CELL", 99, 112], ["Vero E6 cells", "CELL_LINE", 99, 112], ["Vero E6", "SPECIES", 99, 106], ["Vero E6 cells", "TREATMENT", 99, 112]]], ["The suggested mechanism for remdesivir involves the host cells\u2019 post-entry stage (23).RESULTS AND DISCUSSIONArbidol, also known as umifenovir, is approved in Russia and China for the treatment of influenza virus infections; it does not have significant adverse effects and is patented for SARS treatment (24).", [["cells", "ANATOMY", 57, 62], ["remdesivir", "CHEMICAL", 28, 38], ["umifenovir", "CHEMICAL", 131, 141], ["influenza virus infections", "DISEASE", 196, 222], ["SARS", "DISEASE", 289, 293], ["umifenovir", "CHEMICAL", 131, 141], ["remdesivir", "SIMPLE_CHEMICAL", 28, 38], ["host cells", "CELL", 52, 62], ["umifenovir", "SIMPLE_CHEMICAL", 131, 141], ["influenza virus", "ORGANISM", 196, 211], ["host cells", "CELL_TYPE", 52, 62], ["influenza virus", "SPECIES", 196, 211], ["influenza virus", "SPECIES", 196, 211], ["umifenovir", "TREATMENT", 131, 141], ["influenza virus infections", "PROBLEM", 196, 222], ["SARS treatment", "TREATMENT", 289, 303]]], ["As shown in Table 1, four clinical trials will be conducted for COVID-19 treatment: one with arbidol in comparison with the basic treatment (25), and the other three studies comparing effects with oseltamivir (26,27), lopinavir-ritonavir (27), and carrimycin (28).", [["COVID-19", "CHEMICAL", 64, 72], ["arbidol", "CHEMICAL", 93, 100], ["oseltamivir", "CHEMICAL", 197, 208], ["lopinavir-ritonavir", "CHEMICAL", 218, 237], ["carrimycin", "CHEMICAL", 248, 258], ["COVID-19", "CHEMICAL", 64, 72], ["arbidol", "CHEMICAL", 93, 100], ["oseltamivir", "CHEMICAL", 197, 208], ["lopinavir", "CHEMICAL", 218, 227], ["ritonavir", "CHEMICAL", 228, 237], ["carrimycin", "CHEMICAL", 248, 258], ["arbidol", "SIMPLE_CHEMICAL", 93, 100], ["oseltamivir", "SIMPLE_CHEMICAL", 197, 208], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 218, 237], ["carrimycin", "SIMPLE_CHEMICAL", 248, 258], ["COVID-19 treatment", "TREATMENT", 64, 82], ["arbidol", "TREATMENT", 93, 100], ["the basic treatment", "TREATMENT", 120, 139], ["oseltamivir", "TREATMENT", 197, 208], ["lopinavir", "TREATMENT", 218, 227], ["ritonavir", "TREATMENT", 228, 237], ["carrimycin", "TREATMENT", 248, 258]]], ["The arbidol anti-viral mechanism against influenza A and B involves viral fusion inhibition with the targeted membrane, which blocks virus entry into the cell (24).", [["membrane", "ANATOMY", 110, 118], ["cell", "ANATOMY", 154, 158], ["arbidol", "CHEMICAL", 4, 11], ["arbidol", "CHEMICAL", 4, 11], ["arbidol", "SIMPLE_CHEMICAL", 4, 11], ["influenza A", "ORGANISM", 41, 52], ["B", "GENE_OR_GENE_PRODUCT", 57, 58], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["cell", "CELL", 154, 158], ["The arbidol anti-viral mechanism", "TREATMENT", 0, 32], ["influenza A", "PROBLEM", 41, 52], ["viral fusion inhibition", "TREATMENT", 68, 91], ["the targeted membrane", "TREATMENT", 97, 118], ["viral fusion", "OBSERVATION", 68, 80]]], ["Oseltamivir is another drug approved for influenza A and B treatment; it inhibits the viral neuraminidase and, consequently, blocks the release of viral particles from host cells, reducing the spread in the respiratory tract (29).", [["cells", "ANATOMY", 173, 178], ["respiratory tract", "ANATOMY", 207, 224], ["Oseltamivir", "CHEMICAL", 0, 11], ["influenza A and B", "CHEMICAL", 41, 58], ["Oseltamivir", "CHEMICAL", 0, 11], ["Oseltamivir", "SIMPLE_CHEMICAL", 0, 11], ["B", "CELL", 57, 58], ["host cells", "CELL", 168, 178], ["respiratory tract", "ORGANISM_SUBDIVISION", 207, 224], ["viral neuraminidase", "PROTEIN", 86, 105], ["host cells", "CELL_TYPE", 168, 178], ["Oseltamivir", "TREATMENT", 0, 11], ["another drug", "TREATMENT", 15, 27], ["influenza", "PROBLEM", 41, 50], ["B treatment", "TREATMENT", 57, 68], ["the viral neuraminidase", "PROBLEM", 82, 105], ["viral particles", "PROBLEM", 147, 162], ["host cells", "PROBLEM", 168, 178], ["viral neuraminidase", "OBSERVATION", 86, 105], ["viral particles", "OBSERVATION", 147, 162], ["host cells", "OBSERVATION", 168, 178], ["spread", "OBSERVATION_MODIFIER", 193, 199], ["respiratory tract", "ANATOMY", 207, 224]]], ["Additionally, the use of oseltamivir was already reported during the COVID-19 epidemic in China, either with or without antibiotics and corticosteroids (30).", [["oseltamivir", "CHEMICAL", 25, 36], ["corticosteroids", "CHEMICAL", 136, 151], ["oseltamivir", "CHEMICAL", 25, 36], ["corticosteroids", "CHEMICAL", 136, 151], ["oseltamivir", "SIMPLE_CHEMICAL", 25, 36], ["oseltamivir", "TREATMENT", 25, 36], ["the COVID", "TEST", 65, 74], ["antibiotics", "TREATMENT", 120, 131], ["corticosteroids", "TREATMENT", 136, 151]]], ["Oseltamivir is also used in a clinical trial with multiple combinations with chloroquine and favipiravir (31), a nucleoside analog that is well-known as a broad-spectrum antiviral drug; it has shown (23) an EC50 of 61.88 \u03bcM against SARS-CoV-2 and low toxicity (CC50 >400 \u03bcM).RESULTS AND DISCUSSIONThe lopinavir-ritonavir combination is approved for AIDS treatment in several countries.", [["Oseltamivir", "CHEMICAL", 0, 11], ["chloroquine", "CHEMICAL", 77, 88], ["favipiravir", "CHEMICAL", 93, 104], ["nucleoside", "CHEMICAL", 113, 123], ["toxicity", "DISEASE", 251, 259], ["lopinavir-ritonavir", "CHEMICAL", 301, 320], ["AIDS", "DISEASE", 349, 353], ["Oseltamivir", "CHEMICAL", 0, 11], ["chloroquine", "CHEMICAL", 77, 88], ["favipiravir", "CHEMICAL", 93, 104], ["nucleoside", "CHEMICAL", 113, 123], ["lopinavir", "CHEMICAL", 301, 310], ["ritonavir", "CHEMICAL", 311, 320], ["Oseltamivir", "SIMPLE_CHEMICAL", 0, 11], ["chloroquine", "SIMPLE_CHEMICAL", 77, 88], ["favipiravir", "SIMPLE_CHEMICAL", 93, 104], ["nucleoside", "SIMPLE_CHEMICAL", 113, 123], ["lopinavir", "SIMPLE_CHEMICAL", 301, 310], ["ritonavir", "SIMPLE_CHEMICAL", 311, 320], ["SARS-CoV", "SPECIES", 232, 240], ["Oseltamivir", "TREATMENT", 0, 11], ["chloroquine", "TREATMENT", 77, 88], ["favipiravir", "TREATMENT", 93, 104], ["a nucleoside analog", "TREATMENT", 111, 130], ["a broad-spectrum antiviral drug", "TREATMENT", 153, 184], ["an EC50", "TEST", 204, 211], ["SARS", "TEST", 232, 236], ["CoV", "TEST", 237, 240], ["low toxicity", "PROBLEM", 247, 259], ["The lopinavir", "TREATMENT", 297, 310], ["ritonavir combination", "TREATMENT", 311, 332], ["AIDS treatment", "TREATMENT", 349, 363], ["antiviral drug", "OBSERVATION", 170, 184], ["low toxicity", "OBSERVATION_MODIFIER", 247, 259]]], ["Both drugs are HIV protease inhibitors, but ritonavir is also a cytochrome P450 and GP inhibitor, a fact that endorses the lopinavir pharmacokinetic and pharmacodynamic activities against HIV (32).", [["ritonavir", "CHEMICAL", 44, 53], ["lopinavir", "CHEMICAL", 123, 132], ["ritonavir", "CHEMICAL", 44, 53], ["lopinavir", "CHEMICAL", 123, 132], ["ritonavir", "SIMPLE_CHEMICAL", 44, 53], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 64, 79], ["GP", "GENE_OR_GENE_PRODUCT", 84, 86], ["lopinavir", "SIMPLE_CHEMICAL", 123, 132], ["HIV", "ORGANISM", 188, 191], ["HIV", "SPECIES", 188, 191], ["HIV", "SPECIES", 15, 18], ["HIV", "SPECIES", 188, 191], ["Both drugs", "TREATMENT", 0, 10], ["HIV protease inhibitors", "TREATMENT", 15, 38], ["ritonavir", "TREATMENT", 44, 53], ["a cytochrome P450", "TREATMENT", 62, 79], ["GP inhibitor", "TREATMENT", 84, 96], ["the lopinavir pharmacokinetic", "TREATMENT", 119, 148], ["HIV", "PROBLEM", 188, 191]]], ["Such a combination, plus \u03b2-1b interferon, is in phase 2 for the MERS treatment (33).", [["\u03b2-1b interferon", "CHEMICAL", 25, 40], ["\u03b2-1b interferon", "GENE_OR_GENE_PRODUCT", 25, 40], ["\u03b2", "PROTEIN", 25, 26], ["interferon", "PROTEIN", 30, 40], ["\u03b2-1b interferon", "TREATMENT", 25, 40], ["the MERS treatment", "TREATMENT", 60, 78]]], ["Several trials involve lopinavir-ritonavir treatment in comparison with the use of other drugs for COVID-19: arbidol (26,27), carrimycin (28), TCM (34,35), xiyanping (36,37), danoprevir-ritonavir (38) and interferon inhalation (34,38).", [["lopinavir-ritonavir", "CHEMICAL", 23, 42], ["COVID-19", "CHEMICAL", 99, 107], ["arbidol", "CHEMICAL", 109, 116], ["carrimycin", "CHEMICAL", 126, 136], ["TCM", "CHEMICAL", 143, 146], ["xiyanping", "CHEMICAL", 156, 165], ["danoprevir-ritonavir", "CHEMICAL", 175, 195], ["interferon", "CHEMICAL", 205, 215], ["lopinavir", "CHEMICAL", 23, 32], ["ritonavir", "CHEMICAL", 33, 42], ["COVID-19", "CHEMICAL", 99, 107], ["arbidol", "CHEMICAL", 109, 116], ["carrimycin", "CHEMICAL", 126, 136], ["TCM", "CHEMICAL", 143, 146], ["xiyanping", "CHEMICAL", 156, 165], ["danoprevir", "CHEMICAL", 175, 185], ["ritonavir", "CHEMICAL", 186, 195], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 23, 42], ["COVID-19", "SIMPLE_CHEMICAL", 99, 107], ["arbidol", "SIMPLE_CHEMICAL", 109, 116], ["carrimycin", "SIMPLE_CHEMICAL", 126, 136], ["xiyanping", "SIMPLE_CHEMICAL", 156, 165], ["danoprevir-ritonavir", "SIMPLE_CHEMICAL", 175, 195], ["interferon", "PROTEIN", 205, 215], ["lopinavir", "TREATMENT", 23, 32], ["ritonavir treatment", "TREATMENT", 33, 52], ["other drugs", "TREATMENT", 83, 94], ["COVID", "TEST", 99, 104], ["arbidol", "TREATMENT", 109, 116], ["carrimycin", "TREATMENT", 126, 136], ["danoprevir", "TREATMENT", 175, 185], ["ritonavir", "TREATMENT", 186, 195], ["interferon inhalation", "TREATMENT", 205, 226]]], ["Nevertheless, one previous article argued that in a clinical trial with 199 patients with laboratory-confirmed SARS-CoV-2 infection, the lopinavir-ritonavir combination was not associated with clinical improvement comparing with standard care procedures (39).RESULTS AND DISCUSSIONCarrimycin is a macrolide antibiotic with effects against some gram-positive bacteria and in vitro effects on Mycobacterium tuberculosis (40).RESULTS AND DISCUSSIONDanoprevir is an HCV NS3 protease inhibitor approved in China for the treatment of non-cirrhotic genotype 1b chronic hepatitis C, in combination with ritonavir, peginterferon-a, and ribavirin (41).RESULTS AND DISCUSSIONTraditional Chinese medicine (TCM) uses phytotherapeutic formulations such as teas, pills, powders or tinctures, and cultural components that originated 5000 years ago in Chinese medicine (42).", [["SARS-CoV-2 infection", "DISEASE", 111, 131], ["lopinavir-ritonavir", "CHEMICAL", 137, 156], ["macrolide", "CHEMICAL", 297, 306], ["Mycobacterium tuberculosis", "DISEASE", 391, 417], ["chronic hepatitis C", "DISEASE", 554, 573], ["ritonavir", "CHEMICAL", 595, 604], ["peginterferon-a", "CHEMICAL", 606, 621], ["ribavirin", "CHEMICAL", 627, 636], ["lopinavir", "CHEMICAL", 137, 146], ["ritonavir", "CHEMICAL", 147, 156], ["macrolide", "CHEMICAL", 297, 306], ["ritonavir", "CHEMICAL", 595, 604], ["peginterferon-a", "CHEMICAL", 606, 621], ["ribavirin", "CHEMICAL", 627, 636], ["patients", "ORGANISM", 76, 84], ["SARS-CoV-2", "ORGANISM", 111, 121], ["lopinavir", "SIMPLE_CHEMICAL", 137, 146], ["ritonavir", "SIMPLE_CHEMICAL", 147, 156], ["macrolide", "SIMPLE_CHEMICAL", 297, 306], ["Mycobacterium tuberculosis", "ORGANISM", 391, 417], ["HCV", "ORGANISM", 462, 465], ["ritonavir", "SIMPLE_CHEMICAL", 595, 604], ["peginterferon-a", "SIMPLE_CHEMICAL", 606, 621], ["ribavirin", "SIMPLE_CHEMICAL", 627, 636], ["teas", "ORGANISM_SUBDIVISION", 742, 746], ["pills", "SIMPLE_CHEMICAL", 748, 753], ["patients", "SPECIES", 76, 84], ["Mycobacterium tuberculosis", "SPECIES", 391, 417], ["Mycobacterium tuberculosis", "SPECIES", 391, 417], ["HCV", "SPECIES", 462, 465], ["laboratory", "TEST", 90, 100], ["SARS", "PROBLEM", 111, 115], ["CoV", "PROBLEM", 116, 119], ["2 infection", "PROBLEM", 120, 131], ["the lopinavir", "TREATMENT", 133, 146], ["ritonavir combination", "TREATMENT", 147, 168], ["a macrolide antibiotic", "TREATMENT", 295, 317], ["some gram-positive bacteria", "PROBLEM", 339, 366], ["Mycobacterium tuberculosis", "PROBLEM", 391, 417], ["an HCV NS3 protease inhibitor", "TREATMENT", 459, 488], ["non-cirrhotic genotype 1b chronic hepatitis C", "PROBLEM", 528, 573], ["ritonavir", "TREATMENT", 595, 604], ["peginterferon", "TREATMENT", 606, 619], ["ribavirin", "TREATMENT", 627, 636], ["DISCUSSIONTraditional Chinese medicine", "TREATMENT", 654, 692], ["phytotherapeutic formulations", "TREATMENT", 704, 733], ["teas", "TREATMENT", 742, 746], ["pills", "TREATMENT", 748, 753], ["powders", "TREATMENT", 755, 762], ["tinctures", "TREATMENT", 766, 775], ["cultural components", "TREATMENT", 781, 800], ["infection", "OBSERVATION", 122, 131], ["positive bacteria", "OBSERVATION_MODIFIER", 349, 366], ["Mycobacterium tuberculosis", "OBSERVATION", 391, 417], ["non-cirrhotic", "OBSERVATION", 528, 541], ["chronic", "OBSERVATION_MODIFIER", 554, 561], ["hepatitis", "OBSERVATION", 562, 571]]], ["TCMs were already used for SARS-CoV infection in 2002 as coadjuvant therapy with the enhancement of patients\u2019 symptoms, increased oxyhemoglobin arterial saturation; they proved useful in the early stages of this infection (42).RESULTS AND DISCUSSIONInterferons (IFNs) are proteins that bind to cellular surfaces\u2019 receptors and initiate JAK-STAT signaling cascades, with transcriptional regulation of genes controlled by interferons and effects against some viruses like hepatitis B virus and HCV (43).RESULTS AND DISCUSSIONXiyanping is a TCM preparation with andrographolide as a principal component; it has significant antibacterial and antiviral effects (44).RESULTS AND DISCUSSIONDarunavir, in combination with cobicistat, will be used in trial number NCT04252274 (45) in patients with COVID-19 pneumonia.", [["arterial", "ANATOMY", 144, 152], ["cellular", "ANATOMY", 294, 302], ["SARS-CoV infection", "DISEASE", 27, 45], ["infection", "DISEASE", 212, 221], ["hepatitis B", "DISEASE", 470, 481], ["andrographolide", "CHEMICAL", 559, 574], ["cobicistat", "CHEMICAL", 714, 724], ["pneumonia", "DISEASE", 798, 807], ["oxyhemoglobin", "CHEMICAL", 130, 143], ["andrographolide", "CHEMICAL", 559, 574], ["cobicistat", "CHEMICAL", 714, 724], ["TCMs", "SIMPLE_CHEMICAL", 0, 4], ["CoV", "ORGANISM", 32, 35], ["patients", "ORGANISM", 100, 108], ["oxyhemoglobin", "SIMPLE_CHEMICAL", 130, 143], ["arterial", "MULTI-TISSUE_STRUCTURE", 144, 152], ["DISCUSSIONInterferons", "GENE_OR_GENE_PRODUCT", 239, 260], ["IFNs", "GENE_OR_GENE_PRODUCT", 262, 266], ["cellular", "CELL", 294, 302], ["JAK", "GENE_OR_GENE_PRODUCT", 336, 339], ["STAT", "GENE_OR_GENE_PRODUCT", 340, 344], ["hepatitis B virus", "ORGANISM", 470, 487], ["HCV", "ORGANISM", 492, 495], ["andrographolide", "SIMPLE_CHEMICAL", 559, 574], ["cobicistat", "SIMPLE_CHEMICAL", 714, 724], ["patients", "ORGANISM", 775, 783], ["DISCUSSIONInterferons", "PROTEIN", 239, 260], ["IFNs", "PROTEIN", 262, 266], ["JAK", "PROTEIN", 336, 339], ["STAT", "PROTEIN", 340, 344], ["interferons", "PROTEIN", 420, 431], ["patients", "SPECIES", 100, 108], ["hepatitis B virus", "SPECIES", 470, 487], ["patients", "SPECIES", 775, 783], ["SARS-CoV", "SPECIES", 27, 35], ["hepatitis B virus", "SPECIES", 470, 487], ["HCV", "SPECIES", 492, 495], ["SARS", "PROBLEM", 27, 31], ["CoV infection", "PROBLEM", 32, 45], ["coadjuvant therapy", "TREATMENT", 57, 75], ["patients\u2019 symptoms", "PROBLEM", 100, 118], ["increased oxyhemoglobin arterial saturation", "PROBLEM", 120, 163], ["this infection", "PROBLEM", 207, 221], ["JAK", "TEST", 336, 339], ["STAT signaling cascades", "PROBLEM", 340, 363], ["interferons", "TREATMENT", 420, 431], ["some viruses", "PROBLEM", 452, 464], ["hepatitis B virus", "PROBLEM", 470, 487], ["HCV", "PROBLEM", 492, 495], ["a TCM preparation", "TREATMENT", 536, 553], ["andrographolide", "TREATMENT", 559, 574], ["significant antibacterial and antiviral effects", "PROBLEM", 608, 655], ["COVID", "TEST", 789, 794], ["pneumonia", "PROBLEM", 798, 807], ["infection", "OBSERVATION", 36, 45], ["oxyhemoglobin arterial saturation", "OBSERVATION", 130, 163], ["infection", "OBSERVATION", 212, 221], ["viruses", "OBSERVATION", 457, 464], ["hepatitis", "OBSERVATION", 470, 479], ["significant", "OBSERVATION_MODIFIER", 608, 619], ["antibacterial", "OBSERVATION_MODIFIER", 620, 633], ["antiviral effects", "OBSERVATION", 638, 655], ["pneumonia", "OBSERVATION", 798, 807]]], ["The United States Food and Drug Administration (FDA) currently approves such a combination in AIDS treatment.", [["AIDS", "DISEASE", 94, 98], ["AIDS treatment", "TREATMENT", 94, 108]]], ["Darunavir is another HIV protease inhibitor, and cobicistat, like ritonavir, is a booster for enhancing the pharmacokinetics and pharmacodynamics of darunavir by cytochrome P450 (CYP3A) inhibition (46,47).RESULTS AND DISCUSSIONRecombinant human interferon \u03b12\u03b2 is described to have inhibitory effects on MERS-CoV and SARS-CoV (48), and the purpose of the clinical trials found for this paper is to evaluate the efficacy and safety of recombinant human interferon \u03b12\u03b2 in treating patients with new coronavirus infection (49).RESULTS AND DISCUSSIONThalidomide will be used in two trials against COVID-19 (49, 50).", [["Darunavir", "CHEMICAL", 0, 9], ["cobicistat", "CHEMICAL", 49, 59], ["ritonavir", "CHEMICAL", 66, 75], ["darunavir", "CHEMICAL", 149, 158], ["interferon \u03b12\u03b2", "CHEMICAL", 451, 465], ["coronavirus infection", "DISEASE", 496, 517], ["Darunavir", "CHEMICAL", 0, 9], ["cobicistat", "CHEMICAL", 49, 59], ["ritonavir", "CHEMICAL", 66, 75], ["darunavir", "CHEMICAL", 149, 158], ["Darunavir", "SIMPLE_CHEMICAL", 0, 9], ["cobicistat", "SIMPLE_CHEMICAL", 49, 59], ["ritonavir", "SIMPLE_CHEMICAL", 66, 75], ["darunavir", "SIMPLE_CHEMICAL", 149, 158], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 162, 177], ["CYP3A", "GENE_OR_GENE_PRODUCT", 179, 184], ["human", "ORGANISM", 239, 244], ["interferon \u03b12\u03b2", "GENE_OR_GENE_PRODUCT", 245, 259], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 303, 311], ["SARS-CoV", "ORGANISM", 316, 324], ["human", "ORGANISM", 445, 450], ["interferon \u03b12\u03b2", "GENE_OR_GENE_PRODUCT", 451, 465], ["patients", "ORGANISM", 478, 486], ["coronavirus", "ORGANISM", 496, 507], ["cytochrome P450", "PROTEIN", 162, 177], ["CYP3A", "PROTEIN", 179, 184], ["human interferon \u03b12\u03b2", "PROTEIN", 239, 259], ["recombinant human interferon \u03b12\u03b2", "PROTEIN", 433, 465], ["human", "SPECIES", 239, 244], ["human", "SPECIES", 445, 450], ["patients", "SPECIES", 478, 486], ["HIV", "SPECIES", 21, 24], ["human", "SPECIES", 239, 244], ["MERS-CoV", "SPECIES", 303, 311], ["SARS-CoV", "SPECIES", 316, 324], ["human", "SPECIES", 445, 450], ["Darunavir", "TREATMENT", 0, 9], ["another HIV protease inhibitor", "TREATMENT", 13, 43], ["cobicistat", "TREATMENT", 49, 59], ["ritonavir", "TREATMENT", 66, 75], ["enhancing the pharmacokinetics", "TREATMENT", 94, 124], ["darunavir", "TREATMENT", 149, 158], ["cytochrome P450 (CYP3A) inhibition", "TREATMENT", 162, 196], ["DISCUSSIONRecombinant human interferon \u03b12", "TREATMENT", 217, 258], ["recombinant human interferon \u03b12", "TREATMENT", 433, 464], ["new coronavirus infection", "PROBLEM", 492, 517], ["DISCUSSIONThalidomide", "TREATMENT", 535, 556], ["COVID", "TEST", 592, 597]]], ["Thalidomide has an anti-inflammatory action due to its ability to speed up the degradation of messenger RNA in blood cells and thus reduce tumor necrosis factor-\u03b1 (TNF\u03b1).", [["blood cells", "ANATOMY", 111, 122], ["Thalidomide", "CHEMICAL", 0, 11], ["tumor", "DISEASE", 139, 144], ["necrosis", "DISEASE", 145, 153], ["Thalidomide", "CHEMICAL", 0, 11], ["Thalidomide", "SIMPLE_CHEMICAL", 0, 11], ["blood cells", "CELL", 111, 122], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 139, 162], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 164, 168], ["messenger RNA", "RNA", 94, 107], ["blood cells", "CELL_TYPE", 111, 122], ["tumor necrosis factor-\u03b1", "PROTEIN", 139, 162], ["TNF\u03b1", "PROTEIN", 164, 168], ["Thalidomide", "TREATMENT", 0, 11], ["an anti-inflammatory action", "TREATMENT", 16, 43], ["messenger RNA in blood cells", "PROBLEM", 94, 122], ["tumor necrosis factor", "PROBLEM", 139, 160], ["tumor", "OBSERVATION_MODIFIER", 139, 144], ["necrosis", "OBSERVATION", 145, 153]]], ["Furthermore, thalidomide can increase the secretion of interleukins, such as IL-12, and activate natural killer cells (51).RESULTS AND DISCUSSIONThe corticosteroid methylprednisolone will be tested against COVID-19 (52).", [["natural killer cells", "ANATOMY", 97, 117], ["thalidomide", "CHEMICAL", 13, 24], ["methylprednisolone", "CHEMICAL", 164, 182], ["thalidomide", "CHEMICAL", 13, 24], ["methylprednisolone", "CHEMICAL", 164, 182], ["COVID-19", "CHEMICAL", 206, 214], ["thalidomide", "SIMPLE_CHEMICAL", 13, 24], ["interleukins", "GENE_OR_GENE_PRODUCT", 55, 67], ["IL-12", "GENE_OR_GENE_PRODUCT", 77, 82], ["natural killer cells", "CELL", 97, 117], ["methylprednisolone", "SIMPLE_CHEMICAL", 164, 182], ["interleukins", "PROTEIN", 55, 67], ["IL-12", "PROTEIN", 77, 82], ["natural killer cells", "CELL_TYPE", 97, 117], ["thalidomide", "TREATMENT", 13, 24], ["the secretion of interleukins", "PROBLEM", 38, 67], ["corticosteroid methylprednisolone", "TREATMENT", 149, 182], ["COVID", "TEST", 206, 211], ["killer cells", "OBSERVATION", 105, 117]]], ["Long et al. 2016 (53) reported that corticosteroid therapy (methylprednisolone, dexamethasone, and hydrocortisone) is beneficial in treating SARS-CoV patients; it significantly prolongs the survival time of clinical cases.", [["methylprednisolone", "CHEMICAL", 60, 78], ["dexamethasone", "CHEMICAL", 80, 93], ["hydrocortisone", "CHEMICAL", 99, 113], ["SARS-CoV", "DISEASE", 141, 149], ["methylprednisolone", "CHEMICAL", 60, 78], ["dexamethasone", "CHEMICAL", 80, 93], ["hydrocortisone", "CHEMICAL", 99, 113], ["corticosteroid", "SIMPLE_CHEMICAL", 36, 50], ["methylprednisolone", "SIMPLE_CHEMICAL", 60, 78], ["dexamethasone", "SIMPLE_CHEMICAL", 80, 93], ["hydrocortisone", "SIMPLE_CHEMICAL", 99, 113], ["SARS-CoV", "ORGANISM", 141, 149], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["SARS-CoV", "SPECIES", 141, 149], ["corticosteroid therapy", "TREATMENT", 36, 58], ["methylprednisolone", "TREATMENT", 60, 78], ["dexamethasone", "TREATMENT", 80, 93], ["hydrocortisone", "TREATMENT", 99, 113]]], ["Nevertheless, other authors described the use of corticosteroids in the early stages of SARS infection with increasing values of viral load (54).", [["corticosteroids", "CHEMICAL", 49, 64], ["SARS infection", "DISEASE", 88, 102], ["corticosteroids", "CHEMICAL", 49, 64], ["corticosteroids", "SIMPLE_CHEMICAL", 49, 64], ["corticosteroids", "TREATMENT", 49, 64], ["SARS infection", "PROBLEM", 88, 102], ["increasing values of viral load", "PROBLEM", 108, 139], ["infection", "OBSERVATION", 93, 102]]], ["Furthermore, studies with corticosteroids in the adjuvant therapy of MERS-CoV infection were unable to prove efficacy because all patients died (55).", [["corticosteroids", "CHEMICAL", 26, 41], ["MERS-CoV infection", "DISEASE", 69, 87], ["corticosteroids", "CHEMICAL", 26, 41], ["MERS-CoV", "ORGANISM", 69, 77], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["MERS-CoV", "SPECIES", 69, 77], ["studies", "TEST", 13, 20], ["corticosteroids", "TREATMENT", 26, 41], ["the adjuvant therapy", "TREATMENT", 45, 65], ["MERS", "PROBLEM", 69, 73], ["CoV infection", "PROBLEM", 74, 87]]], ["Methylprednisolone has already been used in COVID-19 patients in combination with antibiotics, oseltamivir, and oxygen therapy (56).RESULTS AND DISCUSSIONFinally, vitamin C (ascorbic acid), pirfenidone, bevacizumab, fingolimod, and bromhexine hydrochloride are going to be tested on COVID-19 (57-61).", [["Methylprednisolone", "CHEMICAL", 0, 18], ["oseltamivir", "CHEMICAL", 95, 106], ["oxygen", "CHEMICAL", 112, 118], ["vitamin C", "CHEMICAL", 163, 172], ["ascorbic acid", "CHEMICAL", 174, 187], ["pirfenidone", "CHEMICAL", 190, 201], ["bevacizumab", "CHEMICAL", 203, 214], ["fingolimod", "CHEMICAL", 216, 226], ["bromhexine hydrochloride", "CHEMICAL", 232, 256], ["Methylprednisolone", "CHEMICAL", 0, 18], ["oseltamivir", "CHEMICAL", 95, 106], ["oxygen", "CHEMICAL", 112, 118], ["vitamin C", "CHEMICAL", 163, 172], ["ascorbic acid", "CHEMICAL", 174, 187], ["pirfenidone", "CHEMICAL", 190, 201], ["bevacizumab", "CHEMICAL", 203, 214], ["fingolimod", "CHEMICAL", 216, 226], ["bromhexine hydrochloride", "CHEMICAL", 232, 256], ["COVID-19", "CHEMICAL", 283, 291], ["Methylprednisolone", "SIMPLE_CHEMICAL", 0, 18], ["patients", "ORGANISM", 53, 61], ["oseltamivir", "SIMPLE_CHEMICAL", 95, 106], ["oxygen", "SIMPLE_CHEMICAL", 112, 118], ["vitamin C", "SIMPLE_CHEMICAL", 163, 172], ["ascorbic acid", "SIMPLE_CHEMICAL", 174, 187], ["pirfenidone", "SIMPLE_CHEMICAL", 190, 201], ["bevacizumab", "SIMPLE_CHEMICAL", 203, 214], ["fingolimod", "SIMPLE_CHEMICAL", 216, 226], ["bromhexine hydrochloride", "SIMPLE_CHEMICAL", 232, 256], ["patients", "SPECIES", 53, 61], ["Methylprednisolone", "TREATMENT", 0, 18], ["antibiotics", "TREATMENT", 82, 93], ["oseltamivir", "TREATMENT", 95, 106], ["oxygen therapy", "TREATMENT", 112, 126], ["vitamin C (ascorbic acid)", "TREATMENT", 163, 188], ["pirfenidone", "TREATMENT", 190, 201], ["bevacizumab", "TREATMENT", 203, 214], ["fingolimod", "TREATMENT", 216, 226], ["bromhexine hydrochloride", "TREATMENT", 232, 256], ["COVID", "TEST", 283, 288]]], ["Vitamin C has antioxidant activity and may reduce oxidative stress and inflammation (57,62), effects that improve vasopressor synthesis, enhance immune cell function, improve endovascular function, and provide epigenetic immunologic modifications.", [["immune cell", "ANATOMY", 145, 156], ["endovascular", "ANATOMY", 175, 187], ["Vitamin C", "CHEMICAL", 0, 9], ["inflammation", "DISEASE", 71, 83], ["Vitamin C", "CHEMICAL", 0, 9], ["Vitamin C", "SIMPLE_CHEMICAL", 0, 9], ["immune cell", "CELL", 145, 156], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 175, 187], ["Vitamin C", "TREATMENT", 0, 9], ["antioxidant activity", "TREATMENT", 14, 34], ["oxidative stress", "PROBLEM", 50, 66], ["inflammation", "PROBLEM", 71, 83], ["vasopressor synthesis", "TREATMENT", 114, 135], ["endovascular function", "TEST", 175, 196], ["epigenetic immunologic modifications", "TREATMENT", 210, 246], ["immune cell", "OBSERVATION", 145, 156]]], ["Clinical trials have demonstrated promising data on mortality improvement in sepsis, but more extensive studies are necessary to validate these conclusions (63).", [["sepsis", "DISEASE", 77, 83], ["Clinical trials", "TEST", 0, 15], ["sepsis", "PROBLEM", 77, 83], ["extensive studies", "TEST", 94, 111], ["sepsis", "OBSERVATION", 77, 83]]], ["Pirfenidone has been used in the treatment of idiopathic pulmonary fibrosis diseases due to anti-inflammatory and anti-oxidant effects, namely by inhibiting IL-1\u03b2 and IL-4 (58).", [["pulmonary", "ANATOMY", 57, 66], ["Pirfenidone", "CHEMICAL", 0, 11], ["idiopathic pulmonary fibrosis diseases", "DISEASE", 46, 84], ["Pirfenidone", "CHEMICAL", 0, 11], ["Pirfenidone", "SIMPLE_CHEMICAL", 0, 11], ["pulmonary", "ORGAN", 57, 66], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 157, 162], ["IL-4", "GENE_OR_GENE_PRODUCT", 167, 171], ["IL-1\u03b2", "PROTEIN", 157, 162], ["Pirfenidone", "TREATMENT", 0, 11], ["idiopathic pulmonary fibrosis diseases", "PROBLEM", 46, 84], ["anti-inflammatory and anti-oxidant effects", "TREATMENT", 92, 134], ["IL", "TEST", 157, 159], ["idiopathic", "OBSERVATION_MODIFIER", 46, 56], ["pulmonary", "ANATOMY", 57, 66], ["fibrosis", "OBSERVATION", 67, 75], ["anti-inflammatory", "OBSERVATION_MODIFIER", 92, 109]]], ["Trial NCT04282902 claimed (58) that anti-inflammatory effects may be helpful in SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 80, 100], ["SARS-CoV-2", "ORGANISM", 80, 90], ["SARS-CoV-2", "SPECIES", 80, 90], ["anti-inflammatory effects", "TREATMENT", 36, 61], ["SARS", "PROBLEM", 80, 84], ["CoV", "PROBLEM", 85, 88], ["2 infection", "PROBLEM", 89, 100], ["infection", "OBSERVATION", 91, 100]]], ["Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) (59,63), and it may reduce the levels of VEGF caused by hypoxia, severe inflammation, and upregulation of the infected respiratory tract epithelium, all of which might suppress the edema in patients with COVID-19 (63).", [["respiratory tract epithelium", "ANATOMY", 221, 249], ["edema", "ANATOMY", 283, 288], ["Bevacizumab", "CHEMICAL", 0, 11], ["hypoxia", "DISEASE", 158, 165], ["inflammation", "DISEASE", 174, 186], ["edema", "DISEASE", 283, 288], ["COVID-19", "CHEMICAL", 306, 314], ["Bevacizumab", "CHEMICAL", 0, 11], ["COVID-19", "CHEMICAL", 306, 314], ["Bevacizumab", "SIMPLE_CHEMICAL", 0, 11], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 60, 94], ["VEGF", "GENE_OR_GENE_PRODUCT", 96, 100], ["VEGF", "GENE_OR_GENE_PRODUCT", 143, 147], ["respiratory tract epithelium", "TISSUE", 221, 249], ["edema", "PATHOLOGICAL_FORMATION", 283, 288], ["patients", "ORGANISM", 292, 300], ["humanized monoclonal antibody", "PROTEIN", 17, 46], ["vascular endothelial growth factor", "PROTEIN", 60, 94], ["VEGF", "PROTEIN", 96, 100], ["VEGF", "PROTEIN", 143, 147], ["patients", "SPECIES", 292, 300], ["Bevacizumab", "TREATMENT", 0, 11], ["a humanized monoclonal antibody", "TREATMENT", 15, 46], ["the levels of VEGF", "PROBLEM", 129, 147], ["hypoxia", "PROBLEM", 158, 165], ["severe inflammation", "PROBLEM", 167, 186], ["the infected respiratory tract epithelium", "PROBLEM", 208, 249], ["the edema", "PROBLEM", 279, 288], ["COVID", "TEST", 306, 311], ["VEGF", "OBSERVATION", 143, 147], ["hypoxia", "OBSERVATION", 158, 165], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["inflammation", "OBSERVATION", 174, 186], ["infected", "OBSERVATION_MODIFIER", 212, 220], ["respiratory tract", "ANATOMY", 221, 238], ["epithelium", "ANATOMY_MODIFIER", 239, 249], ["edema", "OBSERVATION", 283, 288]]], ["Fingolimod is a sphingosine-1-phosphate receptor regulator (FTY720) with an effective immunology modulator that is useful in multiple sclerosis (60).", [["Fingolimod", "CHEMICAL", 0, 10], ["sphingosine-1-phosphate", "CHEMICAL", 16, 39], ["FTY720", "CHEMICAL", 60, 66], ["multiple sclerosis", "DISEASE", 125, 143], ["Fingolimod", "CHEMICAL", 0, 10], ["sphingosine-1-phosphate", "CHEMICAL", 16, 39], ["FTY720", "CHEMICAL", 60, 66], ["Fingolimod", "SIMPLE_CHEMICAL", 0, 10], ["sphingosine-1-phosphate receptor", "GENE_OR_GENE_PRODUCT", 16, 48], ["FTY720", "SIMPLE_CHEMICAL", 60, 66], ["a sphingosine-1-phosphate receptor regulator", "TREATMENT", 14, 58], ["an effective immunology modulator", "TREATMENT", 73, 106], ["multiple sclerosis", "PROBLEM", 125, 143], ["multiple", "OBSERVATION_MODIFIER", 125, 133], ["sclerosis", "OBSERVATION", 134, 143]]], ["According to some pathological findings of pulmonary edema and hyaline membrane formation, the use of immune modulators, together with ventilator support, should be considered for severe patients to prevent the development of acute respiratory distress syndrome (ARDS).", [["pulmonary", "ANATOMY", 43, 52], ["hyaline membrane", "ANATOMY", 63, 79], ["respiratory", "ANATOMY", 232, 243], ["pulmonary edema", "DISEASE", 43, 58], ["acute respiratory distress syndrome", "DISEASE", 226, 261], ["ARDS", "DISEASE", 263, 267], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 43, 58], ["hyaline membrane", "MULTI-TISSUE_STRUCTURE", 63, 79], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["pulmonary edema", "PROBLEM", 43, 58], ["hyaline membrane formation", "PROBLEM", 63, 89], ["immune modulators", "TREATMENT", 102, 119], ["ventilator support", "TREATMENT", 135, 153], ["acute respiratory distress syndrome", "PROBLEM", 226, 261], ["ARDS", "PROBLEM", 263, 267], ["pulmonary", "ANATOMY", 43, 52], ["edema", "OBSERVATION", 53, 58], ["hyaline membrane formation", "OBSERVATION", 63, 89], ["acute", "OBSERVATION_MODIFIER", 226, 231], ["respiratory distress", "OBSERVATION", 232, 252]]], ["Study NCT04280588 aims to determine the efficacy of fingolimod for COVID-19 (60).", [["fingolimod", "CHEMICAL", 52, 62], ["COVID-19", "CHEMICAL", 67, 75], ["fingolimod", "CHEMICAL", 52, 62], ["COVID-19", "CHEMICAL", 67, 75], ["fingolimod", "SIMPLE_CHEMICAL", 52, 62], ["Study", "TEST", 0, 5], ["fingolimod", "TREATMENT", 52, 62], ["COVID", "TEST", 67, 72]]], ["Bromhexine is a transmembrane protease serine inhibitor; such a protease is responsible for the activation of S-glycoprotein of SARS-CoV and MERS-CoV for viral entry through the plasma membrane (61,64).", [["plasma membrane", "ANATOMY", 178, 193], ["Bromhexine", "CHEMICAL", 0, 10], ["SARS", "DISEASE", 128, 132], ["Bromhexine", "CHEMICAL", 0, 10], ["serine", "CHEMICAL", 39, 45], ["Bromhexine", "SIMPLE_CHEMICAL", 0, 10], ["serine", "AMINO_ACID", 39, 45], ["S-glycoprotein", "GENE_OR_GENE_PRODUCT", 110, 124], ["SARS-CoV", "ORGANISM", 128, 136], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 141, 149], ["plasma membrane", "CELLULAR_COMPONENT", 178, 193], ["protease", "PROTEIN", 64, 72], ["S-glycoprotein", "PROTEIN", 110, 124], ["SARS-CoV", "SPECIES", 128, 136], ["MERS-CoV", "SPECIES", 141, 149], ["Bromhexine", "TREATMENT", 0, 10], ["a transmembrane protease serine inhibitor", "TREATMENT", 14, 55], ["a protease", "TREATMENT", 62, 72], ["SARS", "PROBLEM", 128, 132], ["the plasma membrane", "TEST", 174, 193]]], ["One study (60) will evaluate the efficacy of bromhexine combined with standard treatment/standard treatment in patients with COVID-19.RESULTS AND DISCUSSIONIn conclusion, the WHO declared an epidemic of pneumonia caused by the SARS-CoV-2 in 2020.", [["bromhexine", "CHEMICAL", 45, 55], ["pneumonia", "DISEASE", 203, 212], ["SARS", "DISEASE", 227, 231], ["bromhexine", "CHEMICAL", 45, 55], ["bromhexine", "SIMPLE_CHEMICAL", 45, 55], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["SARS-CoV", "SPECIES", 227, 235], ["One study", "TEST", 0, 9], ["bromhexine", "TREATMENT", 45, 55], ["standard treatment", "TREATMENT", 70, 88], ["standard treatment", "TREATMENT", 89, 107], ["COVID", "TEST", 125, 130], ["pneumonia", "PROBLEM", 203, 212], ["pneumonia", "OBSERVATION", 203, 212]]], ["In this review, we found 24 clinical trials that have already started with the repositioning of more than 20 medicines for COVID-19 treatment, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, oseltamivir, thalidomide, methylprednisolone, bevacizumab, and TCM.", [["COVID-19", "CHEMICAL", 123, 131], ["chloroquine", "CHEMICAL", 186, 197], ["hydroxychloroquine", "CHEMICAL", 199, 217], ["arbidol", "CHEMICAL", 219, 226], ["remdesivir", "CHEMICAL", 228, 238], ["favipiravir", "CHEMICAL", 240, 251], ["oseltamivir", "CHEMICAL", 253, 264], ["thalidomide", "CHEMICAL", 266, 277], ["methylprednisolone", "CHEMICAL", 279, 297], ["bevacizumab", "CHEMICAL", 299, 310], ["TCM", "CHEMICAL", 316, 319], ["COVID-19", "CHEMICAL", 123, 131], ["chloroquine", "CHEMICAL", 186, 197], ["hydroxychloroquine", "CHEMICAL", 199, 217], ["arbidol", "CHEMICAL", 219, 226], ["remdesivir", "CHEMICAL", 228, 238], ["favipiravir", "CHEMICAL", 240, 251], ["oseltamivir", "CHEMICAL", 253, 264], ["thalidomide", "CHEMICAL", 266, 277], ["methylprednisolone", "CHEMICAL", 279, 297], ["bevacizumab", "CHEMICAL", 299, 310], ["COVID-19", "SIMPLE_CHEMICAL", 123, 131], ["human", "ORGANISM", 151, 156], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 157, 171], ["interferons", "GENE_OR_GENE_PRODUCT", 173, 184], ["chloroquine", "SIMPLE_CHEMICAL", 186, 197], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 199, 217], ["arbidol", "SIMPLE_CHEMICAL", 219, 226], ["remdesivir", "SIMPLE_CHEMICAL", 228, 238], ["favipiravir", "SIMPLE_CHEMICAL", 240, 251], ["oseltamivir", "SIMPLE_CHEMICAL", 253, 264], ["thalidomide", "SIMPLE_CHEMICAL", 266, 277], ["methylprednisolone", "SIMPLE_CHEMICAL", 279, 297], ["bevacizumab", "SIMPLE_CHEMICAL", 299, 310], ["human immunoglobulin", "PROTEIN", 151, 171], ["interferons", "PROTEIN", 173, 184], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["the repositioning of more than 20 medicines", "TREATMENT", 75, 118], ["COVID-19 treatment", "TREATMENT", 123, 141], ["human immunoglobulin", "TREATMENT", 151, 171], ["interferons", "TREATMENT", 173, 184], ["chloroquine", "TREATMENT", 186, 197], ["hydroxychloroquine", "TREATMENT", 199, 217], ["arbidol", "TREATMENT", 219, 226], ["remdesivir", "TREATMENT", 228, 238], ["favipiravir", "TREATMENT", 240, 251], ["oseltamivir", "TREATMENT", 253, 264], ["thalidomide", "TREATMENT", 266, 277], ["methylprednisolone", "TREATMENT", 279, 297], ["bevacizumab", "TREATMENT", 299, 310], ["TCM", "TREATMENT", 316, 319]]], ["The Hydroxychloroquine-azithromycin combination was the first drug repurposed with excellent results in clinical trials against SARS-CoV-2, but further, more extended studies, with a higher number of patients, are needed to confirm these results.", [["Hydroxychloroquine", "CHEMICAL", 4, 22], ["azithromycin", "CHEMICAL", 23, 35], ["SARS", "DISEASE", 128, 132], ["Hydroxychloroquine", "CHEMICAL", 4, 22], ["azithromycin", "CHEMICAL", 23, 35], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 4, 22], ["azithromycin", "SIMPLE_CHEMICAL", 23, 35], ["SARS-CoV-2", "ORGANISM", 128, 138], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["SARS-CoV", "SPECIES", 128, 136], ["The Hydroxychloroquine", "TREATMENT", 0, 22], ["azithromycin combination", "TREATMENT", 23, 47], ["SARS", "PROBLEM", 128, 132]]], ["Besides its limitations, repositioning clinical trials are still an attractive strategy: they may facilitate the discovery of new classes of medicines; they may reduce the costs and time to reach the market; there is an existing pharmaceutical supply chain for formulation and distribution; and there is the possibility of combinations with other drugs in treatments that are more effective than monotherapy.", [["repositioning clinical trials", "TREATMENT", 25, 54], ["medicines", "TREATMENT", 141, 150], ["other drugs", "TREATMENT", 341, 352], ["treatments", "TREATMENT", 356, 366], ["monotherapy", "TREATMENT", 396, 407]]], ["Most of the studies found in this article are scheduled to end in 2020, and we hope these repositioning trials may help to find solutions for COVID-19 treatment by this year.Disclaimer.Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH and/or PAHO.", [["COVID-19", "CHEMICAL", 142, 150], ["the studies", "TEST", 8, 19], ["these repositioning trials", "TREATMENT", 84, 110], ["COVID-19 treatment", "TREATMENT", 142, 160], ["the views", "TEST", 222, 231], ["the RPSP/PAJPH", "PROBLEM", 320, 334]]]], "PMC7417983": [["HCWs were excluded if they had symptoms of COVID-19 or previously tested positive for SARS-CoV-2.", [["SARS", "DISEASE", 86, 90], ["HCWs", "ORGANISM", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 86, 96], ["SARS-CoV", "SPECIES", 86, 94], ["symptoms", "PROBLEM", 31, 39], ["COVID", "TEST", 43, 48], ["SARS", "PROBLEM", 86, 90], ["CoV", "TEST", 91, 94]]], ["The program was made available to personnel who cared for COVID-19\u2013positive patients in the ED or on the COVID-19 care unit.", [["patients", "ORGANISM", 76, 84], ["COVID-19 care unit", "DNA", 105, 123], ["patients", "SPECIES", 76, 84]]], ["Screening was performed using nasopharyngeal swabs and the Cepheid GeneXpert RT-PCR assay.", [["nasopharyngeal swabs", "ANATOMY", 30, 50], ["Screening", "TEST", 0, 9], ["nasopharyngeal swabs", "TEST", 30, 50], ["the Cepheid GeneXpert", "TEST", 55, 76]]], ["Staff were permitted to return to work while awaiting test results.ResultsIn total, 499 staff members were eligible for screening.", [["screening", "TEST", 120, 129]]], ["Among them, 121 personnel volunteered to undergo testing (24.2% of those eligible).", [["testing", "TEST", 49, 56]]], ["The results of all 121 tests were negative for SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["SARS-CoV", "SPECIES", 47, 55], ["all 121 tests", "TEST", 15, 28], ["SARS", "PROBLEM", 47, 51], ["CoV", "TEST", 52, 55]]], ["Breaking down the uptake in testing by role: 6 of 53 of eligible respiratory therapists (11.3%) were tested, 33 of 92 eligible providers (35.9%) were tested, 71 of 262 eligible registered nurses (27.1%) were tested, and 11 of 82 of the eligible patient care assistants (13.4%) were tested.DiscussionThe voluntary hospital staff testing program described here was implemented as a method of ensuring the safety of our personnel and patients from the established threat of asymptomatic transmission.", [["patient", "ORGANISM", 245, 252], ["patients", "ORGANISM", 431, 439], ["patient", "SPECIES", 245, 252], ["patients", "SPECIES", 431, 439], ["eligible respiratory therapists", "TREATMENT", 56, 87]]], ["Had any staff members received a positive test result, appropriate isolation measures would have been implemented to prevent viral spread, including a 10-day minimum administrative leave.", [["appropriate isolation measures", "TREATMENT", 55, 85], ["viral spread", "PROBLEM", 125, 137]]], ["The negative results of all tested individuals allowed these personnel to return to work in confidence and also informed the hospital\u2019s decision to not continue routine testing of employees.DiscussionThe 0% positive test rate among asymptomatic staff, despite the local community and hospital system experiencing a large burden of COVID-19 cases, is a testament to the ongoing work underway to ensure safety throughout the hospital.", [["COVID", "DISEASE", 331, 336], ["routine testing", "TEST", 161, 176], ["large", "OBSERVATION_MODIFIER", 315, 320]]], ["The following precautionary measures were implemented at our hospital:Universal SARS-CoV-2 testing of all patients admitted to the hospital, regardless of symptomatology or reason for stayTesting of all patients undergoing surgical procedures 24\u201348 hours prior to operationIsolation of all positive patients into designated COVID-19 care unitsNegative pressure ventilation systems for all COVID-19 care floorsPersonal protective equipment requirements including surgical masks and universal precautions on all floors, with the addition of gowns and eye protection on COVID-19 unitsMandatory N95 mask or PAPR/CAPR use for any aerosol-generating procedures in COVID-19 units\u201cNo visitors\u201d policy throughout the hospital, absent exigent circumstances (in accordance with Michigan\u2019s March 14 executive order)Universal symptom screening of all staff arriving to work, excluding workers if they presented with any of the following symptoms: fever, cough, shortness of breath, chills, body aches, loss of taste, or loss of smell.", [["eye", "ANATOMY", 549, 552], ["body", "ANATOMY", 977, 981], ["fever", "DISEASE", 934, 939], ["cough", "DISEASE", 941, 946], ["shortness of breath", "DISEASE", 948, 967], ["chills", "DISEASE", 969, 975], ["body aches", "DISEASE", 977, 987], ["loss of taste", "DISEASE", 989, 1002], ["loss of smell", "DISEASE", 1007, 1020], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 203, 211], ["patients", "ORGANISM", 299, 307], ["eye", "ORGAN", 549, 552], ["body", "ORGANISM_SUBDIVISION", 977, 981], ["aches", "ORGANISM_SUBDIVISION", 982, 987], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 299, 307], ["symptomatology", "PROBLEM", 155, 169], ["surgical procedures", "TREATMENT", 223, 242], ["pressure ventilation systems", "TREATMENT", 352, 380], ["Personal protective equipment requirements", "TREATMENT", 409, 451], ["surgical masks", "TREATMENT", 462, 476], ["universal precautions", "TREATMENT", 481, 502], ["gowns", "TREATMENT", 539, 544], ["eye protection", "TREATMENT", 549, 563], ["COVID", "TREATMENT", 567, 572], ["N95 mask", "TREATMENT", 591, 599], ["PAPR", "TREATMENT", 603, 607], ["CAPR", "TREATMENT", 608, 612], ["any aerosol", "TREATMENT", 621, 632], ["the following symptoms", "PROBLEM", 910, 932], ["fever", "PROBLEM", 934, 939], ["cough", "PROBLEM", 941, 946], ["shortness of breath", "PROBLEM", 948, 967], ["chills", "PROBLEM", 969, 975], ["body aches", "PROBLEM", 977, 987], ["loss of taste", "PROBLEM", 989, 1002], ["loss of smell", "PROBLEM", 1007, 1020], ["eye", "ANATOMY", 549, 552]]]], "01f6065c24a67a6ca254ebac15d86459bb963786": [["INTRODUCTIONProcessing of complex materials in non-ferrous smelting has traditionally been approached as a niche opportunity to capture the economic value contained in the mining resources.", [["complex", "OBSERVATION_MODIFIER", 26, 33], ["materials", "OBSERVATION_MODIFIER", 34, 43], ["non-ferrous smelting", "OBSERVATION", 47, 67]]], ["Depending on the nature and complexity of the resources, miners have sometimes adopted processing options at the mine site, such as ultra-fine grinding, alternative flotation circuits, or hydrometallurgical processes, to reduce the concentration of elements that would reduce the value of their product.", [["ultra-fine grinding", "TREATMENT", 132, 151], ["alternative flotation circuits", "TREATMENT", 153, 183], ["hydrometallurgical processes", "PROBLEM", 188, 216]]], ["Meanwhile, their customers, the smelters, addressed complexity either by developing new processes or by modifying operating conditions to enhance the removal of deleterious elements.", [["the removal of deleterious elements", "TREATMENT", 146, 181], ["new", "OBSERVATION_MODIFIER", 84, 87], ["deleterious elements", "OBSERVATION", 161, 181]]], ["In some cases, synergies and cooperation between base metal processing facilities have improved recovery and waste management.", [["base metal processing facilities", "TREATMENT", 49, 81], ["waste management", "TREATMENT", 109, 125]]], ["However, in most cases, the copper industry has used dilution as the main response, either by blending of complex materials in central facilities or by diluting small quantities in large feed streams to smelters.INTRODUCTIONCopper is recognized a cornerstone element to support the move towards a more sustainable society with eco-efficient living standards, e-mobility, efficient house designs, environmentallyfriendly public spaces, transportation designs, and medical applications to reduce disease transmission.INTRODUCTIONAt the time of writing, the global economy faces an unprecedented shock from the impact of coronavirus which has reduced copper demand and prices.", [["copper", "CHEMICAL", 28, 34], ["shock", "DISEASE", 593, 598], ["coronavirus", "DISEASE", 618, 629], ["copper", "CHEMICAL", 648, 654], ["copper", "CHEMICAL", 28, 34], ["copper", "CHEMICAL", 648, 654], ["copper", "SIMPLE_CHEMICAL", 28, 34], ["coronavirus", "ORGANISM", 618, 629], ["copper", "SIMPLE_CHEMICAL", 648, 654], ["dilution", "TREATMENT", 53, 61], ["medical applications", "TREATMENT", 463, 483], ["disease transmission", "PROBLEM", 494, 514], ["an unprecedented shock", "PROBLEM", 576, 598], ["coronavirus", "PROBLEM", 618, 629], ["small", "OBSERVATION_MODIFIER", 161, 166], ["quantities", "OBSERVATION_MODIFIER", 167, 177], ["large", "OBSERVATION_MODIFIER", 181, 186], ["feed streams", "OBSERVATION", 187, 199], ["unprecedented", "OBSERVATION_MODIFIER", 579, 592], ["shock", "OBSERVATION", 593, 598], ["coronavirus", "OBSERVATION", 618, 629], ["reduced", "OBSERVATION_MODIFIER", 640, 647], ["copper demand", "OBSERVATION", 648, 661]]], ["This will change as global stimulus and infrastructure programs lift the economy, and this will be an opportunity to stress the positive aspects of copper, not only in the traditional applications of infrastructure but also in less widespread applications in hospitals and public spaces to reduce the risk of disease transmission.INTRODUCTIONIt is therefore essential that the copper industry prepares itself by getting a clear understanding of future supply volume and resource quality.", [["copper", "CHEMICAL", 148, 154], ["copper", "CHEMICAL", 377, 383], ["copper", "CHEMICAL", 148, 154], ["copper", "CHEMICAL", 377, 383], ["copper", "SIMPLE_CHEMICAL", 148, 154], ["copper", "SIMPLE_CHEMICAL", 377, 383], ["global stimulus", "TEST", 20, 35], ["disease transmission", "PROBLEM", 309, 329], ["infrastructure", "OBSERVATION", 200, 214], ["less", "OBSERVATION_MODIFIER", 227, 231], ["widespread", "OBSERVATION_MODIFIER", 232, 242], ["disease", "OBSERVATION", 309, 316]]], ["If we face increased copper demand, we need to understand the expected complexity in supply and how this will impact processing facilities in terms of recoveries, product quality, and waste management.", [["copper", "CHEMICAL", 21, 27], ["copper", "CHEMICAL", 21, 27], ["copper", "SIMPLE_CHEMICAL", 21, 27], ["face increased copper demand", "PROBLEM", 6, 34], ["waste management", "TREATMENT", 184, 200]]], ["This analysis should also consider the increasing pressure to process urban mining resources in existing industrial facilities, since these resources will bring additional complexity that will impact business performance.", [["This analysis", "TEST", 0, 13], ["the increasing pressure", "TREATMENT", 35, 58]]], ["Table I shows a list of identified trends in the copper industry in recent years.", [["copper", "CHEMICAL", 49, 55], ["copper", "CHEMICAL", 49, 55], ["copper", "SIMPLE_CHEMICAL", 49, 55]]], ["1 It identifies challenges from:UNDERSTANDING THE SUPPLY Trends Affecting Copper MinesResource complexity and regulatory pressures.", [["Copper", "CHEMICAL", 74, 80], ["Copper", "CHEMICAL", 74, 80], ["regulatory pressures", "TEST", 110, 130], ["pressures", "OBSERVATION_MODIFIER", 121, 130]]], ["Increases in impurity content in concentrates.", [["impurity content", "OBSERVATION", 13, 29], ["concentrates", "OBSERVATION_MODIFIER", 33, 45]]], ["Bottlenecks derived from recycling restrictions.", [["recycling restrictions", "OBSERVATION", 25, 47]]], ["Energy and water access and cost.UNDERSTANDING THE SUPPLY Trends Affecting Copper MinesWhat type of complex materials will copper smelters potentially receive in the coming years?", [["Copper", "CHEMICAL", 75, 81], ["copper", "CHEMICAL", 123, 129], ["Copper", "CHEMICAL", 75, 81], ["copper", "CHEMICAL", 123, 129], ["complex materials", "PROBLEM", 100, 117], ["water access", "OBSERVATION", 11, 23]]], ["What impurities are going to increase in the copper concentrates?", [["copper", "CHEMICAL", 45, 51], ["copper", "CHEMICAL", 45, 51], ["copper", "SIMPLE_CHEMICAL", 45, 51]]], ["How will size distribution for liberation of copper species in the concentrator impact pyrometallurgical processing?", [["copper", "CHEMICAL", 45, 51], ["copper", "CHEMICAL", 45, 51], ["copper species", "SIMPLE_CHEMICAL", 45, 59], ["copper species", "PROBLEM", 45, 59], ["size", "OBSERVATION_MODIFIER", 9, 13], ["copper species", "OBSERVATION", 45, 59]]], ["What synergies between base metals processors will be required to optimize recoveries and minimize environmental impact?", [["base metals processors", "TREATMENT", 23, 45]]], ["Addressing these queries will allow smelters to understand how they should adjust their operations to maximize the recovery of copper and other valuable elements, and the impact on secondary streams such as slag, acid and dust.Copper Content in Ores and ConcentratesA global copper mine-by-mine review undertaken by ICSG found that the global average copper ore grade was as low as 0.45% copper in reported reserves and only 0.65% copper in 2015 copper mine production.", [["copper", "CHEMICAL", 127, 133], ["Copper", "CHEMICAL", 227, 233], ["copper", "CHEMICAL", 275, 281], ["copper", "CHEMICAL", 351, 357], ["copper", "CHEMICAL", 388, 394], ["copper", "CHEMICAL", 431, 437], ["copper", "CHEMICAL", 446, 452], ["copper", "CHEMICAL", 127, 133], ["Copper", "CHEMICAL", 227, 233], ["copper", "CHEMICAL", 275, 281], ["copper", "CHEMICAL", 351, 357], ["copper", "CHEMICAL", 388, 394], ["copper", "CHEMICAL", 431, 437], ["copper", "CHEMICAL", 446, 452], ["copper", "SIMPLE_CHEMICAL", 127, 133], ["acid", "SIMPLE_CHEMICAL", 213, 217], ["Copper", "SIMPLE_CHEMICAL", 227, 233], ["copper", "SIMPLE_CHEMICAL", 351, 357], ["copper", "SIMPLE_CHEMICAL", 388, 394], ["copper", "SIMPLE_CHEMICAL", 431, 437], ["copper mine", "SIMPLE_CHEMICAL", 446, 457], ["their operations", "TREATMENT", 82, 98], ["secondary streams", "PROBLEM", 181, 198]]], ["Global weighted average of copper concentrate output in a large sample of plants was around 25% copper in 2015 data.", [["copper", "CHEMICAL", 27, 33], ["copper", "CHEMICAL", 96, 102], ["copper", "CHEMICAL", 27, 33], ["copper", "CHEMICAL", 96, 102], ["copper", "SIMPLE_CHEMICAL", 27, 33], ["copper", "SIMPLE_CHEMICAL", 96, 102], ["copper concentrate output", "PROBLEM", 27, 52], ["output", "OBSERVATION_MODIFIER", 46, 52], ["large", "OBSERVATION_MODIFIER", 58, 63]]], ["There are significant data published on the falling copper ore grades in recent decades, but a factor of concern is that the ore grades in recently operational mines are not over 0.53%, while copper grades in new projects and in undeveloped mines are not over 0.43% copper on average.", [["copper", "CHEMICAL", 52, 58], ["copper", "CHEMICAL", 192, 198], ["copper", "CHEMICAL", 266, 272], ["copper", "CHEMICAL", 52, 58], ["copper", "CHEMICAL", 192, 198], ["copper", "CHEMICAL", 266, 272], ["copper", "SIMPLE_CHEMICAL", 266, 272], ["significant data", "PROBLEM", 10, 26], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["new", "OBSERVATION_MODIFIER", 209, 212]]], ["2 The results of the copper mine ore grades survey carried out by the ICSG are shown in Fig. 1 .", [["copper", "CHEMICAL", 21, 27], ["copper", "CHEMICAL", 21, 27], ["copper", "SIMPLE_CHEMICAL", 21, 27], ["ICSG", "DNA", 70, 74], ["the copper mine ore grades survey", "TEST", 17, 50]]], ["A review of the copper reserves in million tonnes of copper and the copper ore grades (percentage of copper) using the latest data for the top 56 copper mines of the world, ranked by reserves, produced the following findings: only 9 of the 56 copper mines with the largest reserves of copper presented copper ore grades over 1% copper content; and only 7 of the 56 copper mines with more copper reserves presented reserves over 40 million tonnes each.", [["copper", "CHEMICAL", 16, 22], ["copper", "CHEMICAL", 53, 59], ["copper", "CHEMICAL", 68, 74], ["copper", "CHEMICAL", 101, 107], ["copper", "CHEMICAL", 146, 152], ["copper", "CHEMICAL", 243, 249], ["copper", "CHEMICAL", 285, 291], ["copper", "CHEMICAL", 302, 308], ["copper", "CHEMICAL", 328, 334], ["copper", "CHEMICAL", 365, 371], ["copper", "CHEMICAL", 388, 394], ["copper", "CHEMICAL", 16, 22], ["copper", "CHEMICAL", 53, 59], ["copper", "CHEMICAL", 68, 74], ["copper", "CHEMICAL", 101, 107], ["copper", "CHEMICAL", 146, 152], ["copper", "CHEMICAL", 243, 249], ["copper", "CHEMICAL", 285, 291], ["copper", "CHEMICAL", 302, 308], ["copper", "CHEMICAL", 328, 334], ["copper", "CHEMICAL", 365, 371], ["copper", "CHEMICAL", 388, 394], ["copper", "SIMPLE_CHEMICAL", 16, 22], ["copper", "SIMPLE_CHEMICAL", 53, 59], ["copper", "SIMPLE_CHEMICAL", 68, 74], ["copper", "SIMPLE_CHEMICAL", 101, 107], ["copper", "SIMPLE_CHEMICAL", 285, 291], ["copper", "SIMPLE_CHEMICAL", 302, 308], ["copper", "SIMPLE_CHEMICAL", 328, 334], ["copper", "SIMPLE_CHEMICAL", 388, 394], ["copper ore grades", "PROBLEM", 302, 319]]], ["So, in 40 cases, representing almost 73% of the copper mines with important reported reserves, the copper ore grades are below 1% copper and the reserves are below 40 million tonnes copper content.Copper Content in Ores and ConcentratesIf we consider only the top 20 copper mines with the most important reserves of copper (over 1,000 million tonnes of copper reserves) the average If we look at mines with high reserve volumes and lower copper contents, we can report Butte Group with 0.48%Cu.", [["copper", "CHEMICAL", 48, 54], ["copper", "CHEMICAL", 99, 105], ["copper", "CHEMICAL", 130, 136], ["copper", "CHEMICAL", 182, 188], ["Copper", "CHEMICAL", 197, 203], ["copper", "CHEMICAL", 267, 273], ["copper", "CHEMICAL", 316, 322], ["copper", "CHEMICAL", 353, 359], ["copper", "CHEMICAL", 438, 444], ["Cu.", "CHEMICAL", 491, 494], ["copper", "CHEMICAL", 48, 54], ["copper", "CHEMICAL", 99, 105], ["copper", "CHEMICAL", 130, 136], ["copper", "CHEMICAL", 182, 188], ["Copper", "CHEMICAL", 197, 203], ["copper", "CHEMICAL", 267, 273], ["copper", "CHEMICAL", 316, 322], ["copper", "CHEMICAL", 353, 359], ["copper", "CHEMICAL", 438, 444], ["copper", "SIMPLE_CHEMICAL", 99, 105], ["copper", "SIMPLE_CHEMICAL", 130, 136], ["copper", "SIMPLE_CHEMICAL", 182, 188], ["Copper", "SIMPLE_CHEMICAL", 197, 203], ["Ores", "SIMPLE_CHEMICAL", 215, 219], ["copper", "SIMPLE_CHEMICAL", 316, 322], ["copper", "SIMPLE_CHEMICAL", 353, 359], ["copper", "SIMPLE_CHEMICAL", 438, 444], ["the copper ore grades", "PROBLEM", 95, 116], ["the top 20 copper mines", "TREATMENT", 256, 279], ["high reserve volumes and lower copper contents", "PROBLEM", 407, 453], ["lower copper", "OBSERVATION_MODIFIER", 432, 444]]], ["The reserves in the expansion of Escondida-Pampa Escondida only report 0.45%Cu, meanwhile Chuquicamata report 0.43%Cu, similar to Buenavista del Cobre (Cananea) reporting 0.42%Cu, and Radomiro Tomic also reporting 0.42%Cu.", [["Cu", "CHEMICAL", 76, 78], ["Chuquicamata", "CHEMICAL", 90, 102], ["Cu", "CHEMICAL", 115, 117], ["Cu", "CHEMICAL", 176, 178], ["Cu.", "CHEMICAL", 219, 222], ["Cu", "CHEMICAL", 76, 78], ["Cu", "CHEMICAL", 115, 117], ["Cu", "CHEMICAL", 176, 178], ["reserves", "OBSERVATION_MODIFIER", 4, 12]]], ["Lower grades in large reserves are reported by the Pebble project with only 0.34%Cu and Morenci with 0.25%Cu.Ore Grades and TechnologiesMany copper resources and reserves in mineral deposits report higher copper content than porphyry deposit, however, the most abundant low-grade porphyry deposits were mined first, and this is the reason why global copper ore grades went down on average during 1990-2018.", [["Cu", "CHEMICAL", 81, 83], ["copper", "CHEMICAL", 141, 147], ["copper", "CHEMICAL", 205, 211], ["copper", "CHEMICAL", 350, 356], ["Cu", "CHEMICAL", 81, 83], ["copper", "CHEMICAL", 141, 147], ["copper", "CHEMICAL", 205, 211], ["copper", "CHEMICAL", 350, 356], ["copper", "SIMPLE_CHEMICAL", 205, 211], ["Lower grades in large reserves", "PROBLEM", 0, 30], ["Morenci", "TREATMENT", 88, 95], ["the most abundant low-grade porphyry deposits", "PROBLEM", 252, 297], ["global copper ore grades", "PROBLEM", 343, 367], ["large", "OBSERVATION_MODIFIER", 16, 21], ["reserves", "OBSERVATION", 22, 30], ["higher copper content", "OBSERVATION_MODIFIER", 198, 219], ["abundant", "OBSERVATION_MODIFIER", 261, 269], ["low-grade", "OBSERVATION_MODIFIER", 270, 279], ["porphyry deposits", "OBSERVATION", 280, 297]]], ["Current technology to extract low-grade copper reserves indicates that higher-grade copper deposits are not necessarily mined first.", [["copper", "CHEMICAL", 40, 46], ["copper", "CHEMICAL", 84, 90], ["copper", "CHEMICAL", 40, 46], ["copper", "CHEMICAL", 84, 90], ["copper", "SIMPLE_CHEMICAL", 40, 46], ["copper", "SIMPLE_CHEMICAL", 84, 90], ["low-grade copper reserves", "PROBLEM", 30, 55], ["higher-grade copper deposits", "PROBLEM", 71, 99], ["grade copper", "OBSERVATION_MODIFIER", 78, 90], ["deposits", "OBSERVATION", 91, 99], ["not necessarily", "UNCERTAINTY", 104, 119]]], ["Many low ore grade deposits remain operating as is the case of Morenci, Toquepala, Cerro Verde, Centinela, Quebrada Blanca, Cuajone, Radomiro Tomic, and Los Bronces.", [["Many low ore grade deposits", "PROBLEM", 0, 27], ["Cuajone", "TREATMENT", 124, 131], ["low", "OBSERVATION_MODIFIER", 5, 8], ["ore grade", "OBSERVATION_MODIFIER", 9, 18], ["deposits", "OBSERVATION", 19, 27], ["Los Bronces", "OBSERVATION", 153, 164]]], ["Other relatively low-grades deposit, such as Quellaveco, are advancing in the project pipeline.", [["Other relatively low-grades deposit", "PROBLEM", 0, 35], ["Quellaveco", "TREATMENT", 45, 55], ["relatively", "OBSERVATION_MODIFIER", 6, 16], ["low-grades", "OBSERVATION_MODIFIER", 17, 27], ["deposit", "OBSERVATION", 28, 35]]], ["However other high-grade deposits, such as the Olympic Dam expansions, Pokowice, Oyu Tolgoy, Grasberg Underground, and other higher ore grade projects, are slowly advancing to the production stage.", [["other high-grade deposits", "PROBLEM", 8, 33], ["high-grade", "OBSERVATION_MODIFIER", 14, 24], ["deposits", "OBSERVATION", 25, 33], ["Olympic Dam", "OBSERVATION", 47, 58]]], ["3 Higher throughput rates and more efficient mineral processing has maintained copper output; however, with lower feed copper content and increasing energy and water use per unit of output, extraction costs have been increasing in important copper mines.", [["copper", "CHEMICAL", 79, 85], ["copper", "CHEMICAL", 119, 125], ["copper", "CHEMICAL", 241, 247], ["copper", "CHEMICAL", 79, 85], ["copper", "CHEMICAL", 119, 125], ["copper", "CHEMICAL", 241, 247], ["copper", "SIMPLE_CHEMICAL", 79, 85], ["copper", "SIMPLE_CHEMICAL", 119, 125], ["copper mines", "SIMPLE_CHEMICAL", 241, 253], ["lower feed copper content", "PROBLEM", 108, 133], ["extraction", "TREATMENT", 190, 200], ["copper output", "OBSERVATION_MODIFIER", 79, 92], ["increasing", "OBSERVATION_MODIFIER", 217, 227]]], ["Using the Chilean copper mining industry as an example, the use of fossil fuels increased over 33% in 2010-2018, while the use of electricity increased by around 38% in this same period.", [["copper", "CHEMICAL", 18, 24], ["copper", "CHEMICAL", 18, 24], ["fossil fuels", "TEST", 67, 79]]], ["4 From the mine processing point of view, the reduction in ore grades and mineralogy changes suggest the need to adapt current mining and mineral processing techniques to maintain production targets of metal units and quality.", [["the reduction in ore grades", "PROBLEM", 42, 69], ["mineralogy changes", "PROBLEM", 74, 92], ["mineral processing techniques", "TREATMENT", 138, 167], ["metal units", "TREATMENT", 202, 213], ["reduction", "OBSERVATION_MODIFIER", 46, 55], ["ore grades", "OBSERVATION", 59, 69], ["mineralogy", "OBSERVATION", 74, 84]]], ["For example, some Chinese operations have processed low-grade copper concentrates.", [["copper", "CHEMICAL", 62, 68], ["copper", "CHEMICAL", 62, 68], ["copper", "SIMPLE_CHEMICAL", 62, 68], ["some Chinese operations", "TREATMENT", 13, 36], ["low-grade copper concentrates", "PROBLEM", 52, 81], ["low-grade copper", "OBSERVATION_MODIFIER", 52, 68], ["concentrates", "OBSERVATION_MODIFIER", 69, 81]]], ["5 These trends suggest a dynamic balance between copper mines and processers in terms of defining where to invest and where is the best place to remove each impurity.", [["copper", "CHEMICAL", 49, 55], ["copper", "CHEMICAL", 49, 55], ["copper", "SIMPLE_CHEMICAL", 49, 55]]], ["This requires a balance between metal recovery, processing cost, acid production, and slag generation.", [["acid", "SIMPLE_CHEMICAL", 65, 69], ["a balance between metal recovery", "TREATMENT", 14, 46], ["acid production", "TREATMENT", 65, 80], ["slag generation", "OBSERVATION", 86, 101]]], ["Figure 2 shows data on the composition of 32 major traded concentrates, with the mineral composition calculated from publicly available assay data (which should therefore be considered to be approximate).", [["the mineral composition", "TEST", 77, 100], ["assay data", "TEST", 136, 146]]], ["6 Expanding the data to 180 traded concentrates shows an average grade of 27% Cu, even though concentrates average only around 55-60% copper sulfides.", [["Cu", "CHEMICAL", 78, 80], ["copper sulfides", "CHEMICAL", 134, 149], ["Cu", "CHEMICAL", 78, 80], ["copper sulfides", "CHEMICAL", 134, 149], ["Cu", "SIMPLE_CHEMICAL", 78, 80], ["copper sulfides", "SIMPLE_CHEMICAL", 134, 149], ["Expanding the data", "TEST", 2, 20], ["27% Cu", "OBSERVATION_MODIFIER", 74, 80]]], ["This is due to the presence of the minerals chalcocite (79.9%Cu) and covellite (66.4%Cu), which are much higher grade than chalcopyrite (34.6%Cu).Concentrate QualityHowever, chalcocite and covellite are secondary copper sulfides that occur in higher proportions in the close-to-surface ore zones.", [["chalcocite", "CHEMICAL", 44, 54], ["Cu", "CHEMICAL", 61, 63], ["covellite", "CHEMICAL", 69, 78], ["Cu", "CHEMICAL", 85, 87], ["chalcopyrite", "CHEMICAL", 123, 135], ["Cu", "CHEMICAL", 142, 144], ["chalcocite", "CHEMICAL", 174, 184], ["copper", "CHEMICAL", 213, 219], ["chalcocite", "CHEMICAL", 44, 54], ["Cu", "CHEMICAL", 61, 63], ["covellite", "CHEMICAL", 69, 78], ["Cu", "CHEMICAL", 85, 87], ["chalcopyrite", "CHEMICAL", 123, 135], ["Cu", "CHEMICAL", 142, 144], ["chalcocite", "CHEMICAL", 174, 184], ["copper sulfides", "CHEMICAL", 213, 228], ["chalcocite", "SIMPLE_CHEMICAL", 44, 54], ["covellite", "SIMPLE_CHEMICAL", 69, 78], ["chalcopyrite", "SIMPLE_CHEMICAL", 123, 135], ["chalcocite", "SIMPLE_CHEMICAL", 174, 184], ["copper sulfides", "SIMPLE_CHEMICAL", 213, 228], ["the minerals chalcocite", "TEST", 31, 54], ["covellite", "TEST", 69, 78], ["chalcopyrite", "TEST", 123, 135], ["chalcocite and covellite", "PROBLEM", 174, 198], ["copper sulfides", "PROBLEM", 213, 228], ["copper sulfides", "OBSERVATION", 213, 228], ["higher", "OBSERVATION_MODIFIER", 243, 249], ["proportions", "OBSERVATION_MODIFIER", 250, 261], ["surface", "ANATOMY_MODIFIER", 278, 285], ["zones", "ANATOMY_MODIFIER", 290, 295]]], ["As the shallower zones are depleted, more mines are moving into deeper areas with increased primary mineralization, that is, a higher proportion of copper is contained in chalcopyrite (New African deposits are the exception to the industry trend towards higher chalcopyrite, but concentrates from African mines are rarely traded internationally.)", [["copper", "CHEMICAL", 148, 154], ["chalcopyrite", "CHEMICAL", 171, 183], ["chalcopyrite", "CHEMICAL", 261, 273], ["copper", "CHEMICAL", 148, 154], ["chalcopyrite", "CHEMICAL", 171, 183], ["chalcopyrite", "CHEMICAL", 261, 273], ["copper", "SIMPLE_CHEMICAL", 148, 154], ["chalcopyrite", "SIMPLE_CHEMICAL", 171, 183], ["chalcopyrite", "SIMPLE_CHEMICAL", 261, 273], ["increased primary mineralization", "PROBLEM", 82, 114], ["New African deposits", "PROBLEM", 185, 205], ["higher chalcopyrite", "TREATMENT", 254, 273], ["shallower", "OBSERVATION_MODIFIER", 7, 16], ["zones", "OBSERVATION_MODIFIER", 17, 22], ["depleted", "OBSERVATION", 27, 35], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["primary", "OBSERVATION_MODIFIER", 92, 99], ["mineralization", "OBSERVATION", 100, 114]]], ["This will cause a gradual decrease in the copper concentrate grade of traded concentrates, unless efforts are made to make concentrates mineralogically cleaner; that is, the proportion of copper sulfides would have to increase above the current level of 55-60% by removing more iron sulfides and non-sulfide gangue minerals.", [["copper", "CHEMICAL", 42, 48], ["copper sulfides", "CHEMICAL", 188, 203], ["iron sulfides", "CHEMICAL", 278, 291], ["copper", "CHEMICAL", 42, 48], ["copper sulfides", "CHEMICAL", 188, 203], ["iron sulfides", "CHEMICAL", 278, 291], ["non-sulfide", "CHEMICAL", 296, 307], ["copper", "SIMPLE_CHEMICAL", 42, 48], ["copper sulfides", "SIMPLE_CHEMICAL", 188, 203], ["iron sulfides", "SIMPLE_CHEMICAL", 278, 291], ["non-sulfide gangue minerals", "SIMPLE_CHEMICAL", 296, 323], ["a gradual decrease", "PROBLEM", 16, 34], ["copper sulfides", "TREATMENT", 188, 203], ["more iron sulfides", "TREATMENT", 273, 291], ["non-sulfide gangue minerals", "TREATMENT", 296, 323], ["gradual", "OBSERVATION_MODIFIER", 18, 25], ["decrease", "OBSERVATION_MODIFIER", 26, 34]]], ["To achieve this, concentrators would need to increase the mineral processing ''power'', including finer regrinding and more intense flotation cleaning of the concentrates.", [["the mineral processing ''power''", "TREATMENT", 54, 86]]], ["These modifications to grinding and flotation require more capital investment and increase operating costs at the mine site, so many operators will choose to pass the lower-grade concentrates to smelters instead, so long as their concentrate is marketable and the penalties are less than the required capital and operating costs.", [["flotation", "TREATMENT", 36, 45], ["more capital investment", "TREATMENT", 54, 77], ["increase operating costs", "TREATMENT", 82, 106], ["marketable", "OBSERVATION", 245, 255], ["less", "OBSERVATION_MODIFIER", 278, 282]]], ["This is reflected in the increase in the use of blending facilities as the primary tool to reduce the impact of complexity in smelters.", [["blending facilities", "TREATMENT", 48, 67], ["increase", "OBSERVATION_MODIFIER", 25, 33]]], ["Figure 3 shows the blending facilities strategically located around the globe.", [["globe", "ANATOMY", 72, 77]]], ["Table II summarizes the effects on copper smelting of this trend to the increasing proportion of copper from chalcopyrite from deeper copper mines.COMPLEXITY IN COPPER CONCENTRATES AND POTENTIAL COUNTER MEASURE IN COPPER SMELTINGIncreases in gangue and sulfur content directly impact the production of slag and sulfuric acid, both considered secondary products in copper production.", [["copper", "CHEMICAL", 35, 41], ["copper", "CHEMICAL", 97, 103], ["chalcopyrite", "CHEMICAL", 109, 121], ["copper", "CHEMICAL", 134, 140], ["gangue", "CHEMICAL", 242, 248], ["sulfur", "CHEMICAL", 253, 259], ["sulfuric acid", "CHEMICAL", 311, 324], ["copper", "CHEMICAL", 364, 370], ["copper", "CHEMICAL", 35, 41], ["copper", "CHEMICAL", 97, 103], ["chalcopyrite", "CHEMICAL", 109, 121], ["copper", "CHEMICAL", 134, 140], ["sulfur", "CHEMICAL", 253, 259], ["sulfuric acid", "CHEMICAL", 311, 324], ["copper", "CHEMICAL", 364, 370], ["copper", "SIMPLE_CHEMICAL", 35, 41], ["copper", "SIMPLE_CHEMICAL", 97, 103], ["chalcopyrite", "SIMPLE_CHEMICAL", 109, 121], ["copper mines", "SIMPLE_CHEMICAL", 134, 146], ["sulfur", "SIMPLE_CHEMICAL", 253, 259], ["slag", "SIMPLE_CHEMICAL", 302, 306], ["sulfuric acid", "SIMPLE_CHEMICAL", 311, 324], ["copper", "SIMPLE_CHEMICAL", 364, 370], ["COPPER SMELTINGIncreases in gangue", "PROBLEM", 214, 248], ["the production of slag", "TREATMENT", 284, 306], ["sulfuric acid", "TREATMENT", 311, 324], ["COPPER CONCENTRATES", "OBSERVATION_MODIFIER", 161, 180], ["POTENTIAL COUNTER", "OBSERVATION_MODIFIER", 185, 202]]], ["Minor element concentration will not only affect the secondary products but also the main output of the smelter, copper anodes.", [["copper", "CHEMICAL", 113, 119], ["copper", "CHEMICAL", 113, 119], ["copper", "SIMPLE_CHEMICAL", 113, 119], ["Minor element concentration", "PROBLEM", 0, 27], ["element concentration", "OBSERVATION", 6, 27], ["secondary products", "OBSERVATION", 53, 71], ["main", "OBSERVATION_MODIFIER", 85, 89], ["output", "OBSERVATION_MODIFIER", 90, 96], ["smelter", "OBSERVATION_MODIFIER", 104, 111], ["copper anodes", "OBSERVATION", 113, 126]]], ["Figure 4 shows a comparison for copper anode impurities between 2007 and 2019: 8 arsenic, tellurium, bismuth, selenium, nickel, and antimony concentrations in copper anodes have all increased.", [["copper", "CHEMICAL", 32, 38], ["arsenic", "CHEMICAL", 81, 88], ["tellurium", "CHEMICAL", 90, 99], ["bismuth", "CHEMICAL", 101, 108], ["selenium", "CHEMICAL", 110, 118], ["nickel", "CHEMICAL", 120, 126], ["antimony", "CHEMICAL", 132, 140], ["copper", "CHEMICAL", 159, 165], ["copper", "CHEMICAL", 32, 38], ["arsenic", "CHEMICAL", 81, 88], ["tellurium", "CHEMICAL", 90, 99], ["bismuth", "CHEMICAL", 101, 108], ["selenium", "CHEMICAL", 110, 118], ["nickel", "CHEMICAL", 120, 126], ["antimony", "CHEMICAL", 132, 140], ["copper", "CHEMICAL", 159, 165], ["copper anode impurities", "SIMPLE_CHEMICAL", 32, 55], ["arsenic", "SIMPLE_CHEMICAL", 81, 88], ["tellurium", "SIMPLE_CHEMICAL", 90, 99], ["bismuth", "SIMPLE_CHEMICAL", 101, 108], ["selenium", "SIMPLE_CHEMICAL", 110, 118], ["nickel", "SIMPLE_CHEMICAL", 120, 126], ["antimony", "SIMPLE_CHEMICAL", 132, 140], ["copper anodes", "SIMPLE_CHEMICAL", 159, 172], ["copper anode impurities", "PROBLEM", 32, 55], ["selenium, nickel", "TREATMENT", 110, 126], ["antimony concentrations in copper anodes", "TREATMENT", 132, 172], ["increased", "OBSERVATION_MODIFIER", 182, 191]]], ["Potential impact on furnace heat balance due to increase sulfur content potentially balanced by gangue content in the concentrate Increased slag generation Increased copper losses as slag amounts increase Increased acid production (higher sulfur content) Increase in gangue concentration (specific)COMPLEXITY IN COPPER CONCENTRATES AND POTENTIAL COUNTER MEASURE IN COPPER SMELTINGAlumina: An increment in alumina content in the feed will increase slag viscosity.", [["sulfur", "CHEMICAL", 57, 63], ["gangue", "CHEMICAL", 96, 102], ["copper", "CHEMICAL", 166, 172], ["sulfur", "CHEMICAL", 239, 245], ["alumina", "CHEMICAL", 405, 412], ["sulfur", "CHEMICAL", 57, 63], ["copper", "CHEMICAL", 166, 172], ["sulfur", "CHEMICAL", 239, 245], ["alumina", "CHEMICAL", 405, 412], ["sulfur", "SIMPLE_CHEMICAL", 57, 63], ["gangue", "SIMPLE_CHEMICAL", 96, 102], ["copper", "SIMPLE_CHEMICAL", 166, 172], ["sulfur", "SIMPLE_CHEMICAL", 239, 245], ["gangue", "SIMPLE_CHEMICAL", 267, 273], ["alumina", "SIMPLE_CHEMICAL", 405, 412], ["furnace heat balance", "TREATMENT", 20, 40], ["increase sulfur content", "PROBLEM", 48, 71], ["the concentrate Increased slag generation", "TREATMENT", 114, 155], ["Increased copper losses", "PROBLEM", 156, 179], ["slag amounts", "PROBLEM", 183, 195], ["Increased acid production", "PROBLEM", 205, 230], ["Increase in gangue concentration", "TREATMENT", 255, 287], ["An increment in alumina content in the feed", "TREATMENT", 389, 432], ["slag generation", "OBSERVATION", 140, 155], ["Increased", "OBSERVATION_MODIFIER", 205, 214], ["acid production", "OBSERVATION", 215, 230], ["gangue concentration", "OBSERVATION", 267, 287], ["alumina content", "OBSERVATION", 405, 420], ["slag viscosity", "OBSERVATION", 447, 461]]], ["Copper losses potentially impacted due to increased matte entrained (i.e., increase in Al 2 O 3 content in slag over 4% could drastically increases slag viscosity) Magnesia: Impact on slag liquidus temperature required to increase operating temperature to keep slag with required fluidity, depending on smelting technology Iron oxide: Will require addition fluxing agent (silica) to keep Fe/SiO 2 target Increase in pyrite Increase in slag generation Direct impact on heat balance of the furnace might result in reducing copper matte grade or additional cooling agents (reverts) to balance heat, replacing new feed, and reducing produced copper units Increase inCOMPLEXITY IN COPPER CONCENTRATES AND POTENTIAL COUNTER MEASURE IN COPPER SMELTINGPb and Zn Zinc Increase in zinc content in slag (bath smelting) and dust (flash furnace) might allow options to recover via dust leaching Lead Increase in dust concentration during converting process might also option for recovery via dust leaching in an integrated Cu-As-Pb-Zn recovery circuit Potential requirement for a lead removal stage at the end of copper blowing by adding silicacontaining fluxes.", [["Copper", "CHEMICAL", 0, 6], ["Al 2 O", "CHEMICAL", 87, 93], ["Magnesia", "DISEASE", 164, 172], ["Iron oxide", "CHEMICAL", 323, 333], ["silica", "CHEMICAL", 372, 378], ["Fe", "CHEMICAL", 388, 390], ["pyrite", "CHEMICAL", 416, 422], ["copper", "CHEMICAL", 521, 527], ["copper", "CHEMICAL", 638, 644], ["Zn", "CHEMICAL", 751, 753], ["zinc", "CHEMICAL", 771, 775], ["Cu", "CHEMICAL", 1010, 1012], ["Pb", "CHEMICAL", 1016, 1018], ["Zn", "CHEMICAL", 1019, 1021], ["copper", "CHEMICAL", 1100, 1106], ["Copper", "CHEMICAL", 0, 6], ["Al 2 O 3", "CHEMICAL", 87, 95], ["Iron oxide", "CHEMICAL", 323, 333], ["silica", "CHEMICAL", 372, 378], ["Fe", "CHEMICAL", 388, 390], ["SiO 2", "CHEMICAL", 391, 396], ["pyrite", "CHEMICAL", 416, 422], ["copper", "CHEMICAL", 521, 527], ["copper", "CHEMICAL", 638, 644], ["Zn", "CHEMICAL", 751, 753], ["Zinc", "CHEMICAL", 754, 758], ["zinc", "CHEMICAL", 771, 775], ["Cu", "CHEMICAL", 1010, 1012], ["As", "CHEMICAL", 1013, 1015], ["Pb", "CHEMICAL", 1016, 1018], ["Zn", "CHEMICAL", 1019, 1021], ["copper", "CHEMICAL", 1100, 1106], ["Copper", "SIMPLE_CHEMICAL", 0, 6], ["Iron oxide", "SIMPLE_CHEMICAL", 323, 333], ["silica", "SIMPLE_CHEMICAL", 372, 378], ["Fe", "SIMPLE_CHEMICAL", 388, 390], ["SiO 2", "SIMPLE_CHEMICAL", 391, 396], ["pyrite", "SIMPLE_CHEMICAL", 416, 422], ["copper", "SIMPLE_CHEMICAL", 521, 527], ["copper", "SIMPLE_CHEMICAL", 638, 644], ["Zn Zinc", "SIMPLE_CHEMICAL", 751, 758], ["zinc", "SIMPLE_CHEMICAL", 771, 775], ["Lead", "SIMPLE_CHEMICAL", 882, 886], ["Pb-Zn", "SIMPLE_CHEMICAL", 1016, 1021], ["copper", "SIMPLE_CHEMICAL", 1100, 1106], ["silicacontaining", "SIMPLE_CHEMICAL", 1125, 1141], ["Copper losses", "PROBLEM", 0, 13], ["increased matte entrained", "PROBLEM", 42, 67], ["drastically increases slag viscosity", "PROBLEM", 126, 162], ["Magnesia", "TREATMENT", 164, 172], ["slag liquidus temperature", "TREATMENT", 184, 209], ["smelting technology Iron oxide", "TREATMENT", 303, 333], ["addition fluxing agent (silica)", "TREATMENT", 348, 379], ["Fe/SiO", "TREATMENT", 388, 394], ["slag generation", "TREATMENT", 435, 450], ["heat balance of the furnace", "TREATMENT", 468, 495], ["reducing copper matte grade", "PROBLEM", 512, 539], ["additional cooling agents", "TREATMENT", 543, 568], ["new feed", "TREATMENT", 606, 614], ["reducing produced copper units", "TREATMENT", 620, 650], ["COPPER SMELTINGPb", "TREATMENT", 729, 746], ["Zn Zinc Increase in zinc content in slag (bath smelting", "TREATMENT", 751, 806], ["dust (flash furnace", "TREATMENT", 812, 831], ["dust leaching Lead Increase in dust concentration", "TREATMENT", 868, 917], ["dust leaching", "TREATMENT", 979, 992], ["Zn recovery circuit", "TREATMENT", 1019, 1038], ["a lead removal stage", "TREATMENT", 1065, 1085], ["silicacontaining fluxes", "PROBLEM", 1125, 1148], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["matte", "OBSERVATION", 52, 57], ["slag viscosity", "OBSERVATION", 148, 162], ["Increase", "OBSERVATION_MODIFIER", 759, 767], ["silicacontaining fluxes", "OBSERVATION", 1125, 1148]]], ["Slag will need to be recycled to smelting unit Increase in the concentration of deleterious elementsCOMPLEXITY IN COPPER CONCENTRATES AND POTENTIAL COUNTER MEASURE IN COPPER SMELTINGArsenic: Increase in arsenic concentration in streams from primary smelting reactor: Requirements for additional operating costs in gas cleaning Increase in arsenic concentration in slag could jeopardize slag disposal or use in secondary applications Increase in arsenic in anode could require use of fluxing to meet anode standards Halogens: Increase in mercury, fluorine, and chlorines in concentrate: Additional gas cleaning required Precious metal losses to gas might increase due to volatilization as chlorides Corrosion of gas-cleaning equipment This increase in impurities in the copper anodes has not only affected the electrorefining process but also intermediate streams, sub-product quality, and the options for dust and residue recycling to the smelting furnace.", [["arsenic", "CHEMICAL", 203, 210], ["arsenic", "CHEMICAL", 339, 346], ["arsenic", "CHEMICAL", 445, 452], ["Halogens", "CHEMICAL", 515, 523], ["mercury", "CHEMICAL", 537, 544], ["fluorine", "CHEMICAL", 546, 554], ["chlorines", "CHEMICAL", 560, 569], ["copper", "CHEMICAL", 769, 775], ["arsenic", "CHEMICAL", 203, 210], ["arsenic", "CHEMICAL", 339, 346], ["arsenic", "CHEMICAL", 445, 452], ["mercury", "CHEMICAL", 537, 544], ["fluorine", "CHEMICAL", 546, 554], ["chlorines", "CHEMICAL", 560, 569], ["chlorides", "CHEMICAL", 688, 697], ["copper", "CHEMICAL", 769, 775], ["arsenic", "SIMPLE_CHEMICAL", 203, 210], ["arsenic", "SIMPLE_CHEMICAL", 339, 346], ["arsenic", "SIMPLE_CHEMICAL", 445, 452], ["Halogens", "SIMPLE_CHEMICAL", 515, 523], ["mercury", "SIMPLE_CHEMICAL", 537, 544], ["fluorine", "SIMPLE_CHEMICAL", 546, 554], ["chlorines", "SIMPLE_CHEMICAL", 560, 569], ["copper", "SIMPLE_CHEMICAL", 769, 775], ["deleterious elements", "PROBLEM", 80, 100], ["arsenic concentration", "PROBLEM", 203, 224], ["additional operating costs", "TREATMENT", 284, 310], ["gas cleaning", "TREATMENT", 314, 326], ["arsenic concentration in slag", "TREATMENT", 339, 368], ["slag disposal", "TREATMENT", 386, 399], ["Increase in arsenic in anode", "PROBLEM", 433, 461], ["fluxing", "TREATMENT", 483, 490], ["anode standards Halogens", "TREATMENT", 499, 523], ["fluorine", "TREATMENT", 546, 554], ["chlorines", "TREATMENT", 560, 569], ["Additional gas cleaning", "TREATMENT", 586, 609], ["Precious metal losses to gas", "TREATMENT", 619, 647], ["gas", "TEST", 711, 714], ["cleaning equipment", "TREATMENT", 715, 733], ["This increase in impurities in the copper anodes", "PROBLEM", 734, 782], ["dust and residue recycling", "TREATMENT", 905, 931], ["the smelting furnace", "PROBLEM", 935, 955], ["deleterious elements", "OBSERVATION", 80, 100], ["COPPER CONCENTRATES", "OBSERVATION_MODIFIER", 114, 133], ["POTENTIAL COUNTER", "OBSERVATION_MODIFIER", 138, 155], ["Increase", "OBSERVATION_MODIFIER", 191, 199], ["arsenic concentration", "OBSERVATION_MODIFIER", 203, 224], ["smelting reactor", "OBSERVATION", 249, 265], ["arsenic", "OBSERVATION_MODIFIER", 445, 452], ["increase", "OBSERVATION_MODIFIER", 739, 747], ["impurities", "OBSERVATION_MODIFIER", 751, 761], ["intermediate", "OBSERVATION_MODIFIER", 842, 854], ["streams", "OBSERVATION_MODIFIER", 855, 862], ["smelting furnace", "OBSERVATION", 939, 955]]], ["This has increased the need to incorporate bleeding options or synergies with other base metal operations to achieve more sustainable metal recovery, waste stabilization, and overall sustainable processing.PROCESSING OF COPPER COMPLEX MATERIALS IN THE COPPER INDUSTRYPyrometallurgical processing of complex copper concentrates has been traditionally associated with the smelting of specific materials containing substantial concentrations of deleterious elements, such as arsenic and/or smelted polymetallic base metal concentrates containing relevant quantities of copper, lead, and zinc as carrier metals, associated with precious metals and other elements.", [["bleeding", "DISEASE", 43, 51], ["copper", "CHEMICAL", 307, 313], ["arsenic", "CHEMICAL", 472, 479], ["copper", "CHEMICAL", 566, 572], ["zinc", "CHEMICAL", 584, 588], ["copper", "CHEMICAL", 307, 313], ["arsenic", "CHEMICAL", 472, 479], ["copper", "CHEMICAL", 566, 572], ["zinc", "CHEMICAL", 584, 588], ["copper", "SIMPLE_CHEMICAL", 307, 313], ["arsenic", "SIMPLE_CHEMICAL", 472, 479], ["copper", "SIMPLE_CHEMICAL", 566, 572], ["lead", "SIMPLE_CHEMICAL", 574, 578], ["zinc", "SIMPLE_CHEMICAL", 584, 588], ["bleeding options", "TREATMENT", 43, 59], ["synergies", "TREATMENT", 63, 72], ["other base metal operations", "TREATMENT", 78, 105], ["waste stabilization", "TREATMENT", 150, 169], ["complex copper concentrates", "PROBLEM", 299, 326], ["deleterious elements", "PROBLEM", 442, 462], ["smelted polymetallic base metal concentrates", "TREATMENT", 487, 531], ["copper, lead, and zinc as carrier metals", "PROBLEM", 566, 606], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["waste stabilization", "OBSERVATION", 150, 169], ["COPPER", "OBSERVATION_MODIFIER", 220, 226], ["COMPLEX", "OBSERVATION_MODIFIER", 227, 234], ["MATERIALS", "OBSERVATION", 235, 244], ["complex", "OBSERVATION_MODIFIER", 299, 306], ["copper concentrates", "OBSERVATION", 307, 326], ["substantial", "OBSERVATION_MODIFIER", 412, 423], ["concentrations", "OBSERVATION_MODIFIER", 424, 438], ["deleterious elements", "OBSERVATION", 442, 462], ["metal concentrates", "OBSERVATION", 513, 531]]], ["In most cases, such materials have been processed in facilities integrated with or close to the mine site.", [["mine site", "DNA", 96, 105]]], ["Examples include the processing of Cu-As concentrates in Kosaka in Japan, the roasting of Cu-As concentrates at El Indio in Chile, and the processing of Cu-As concentrates from the Consolidated Mine in The Philippines at the Lepanto Roaster.", [["Cu", "CHEMICAL", 35, 37], ["Cu", "CHEMICAL", 90, 92], ["Cu", "CHEMICAL", 153, 155], ["Cu", "CHEMICAL", 35, 37], ["As", "CHEMICAL", 38, 40], ["Cu", "CHEMICAL", 90, 92], ["As", "CHEMICAL", 93, 95], ["Cu", "CHEMICAL", 153, 155], ["As", "CHEMICAL", 156, 158], ["Cu-As", "SIMPLE_CHEMICAL", 35, 40]]], ["However, with the commissioning of the Ministro Hales roaster in Chile, a renewed interest in roasting has emerged as a niche solution for processing high-arsenic concentrates.", [["arsenic", "CHEMICAL", 155, 162], ["arsenic", "CHEMICAL", 155, 162], ["a niche solution", "TREATMENT", 118, 134], ["processing high-arsenic concentrates", "TREATMENT", 139, 175], ["arsenic concentrates", "OBSERVATION", 155, 175]]], ["This could potentially allow simpler and more cost-effective integrated metallurgical plants using one-step pyrometallurgical processing, i.e., direct-to-blister processing of roaster calcine.", [["blister", "ANATOMY", 154, 161], ["roaster calcine", "CHEMICAL", 176, 191], ["calcine", "CHEMICAL", 184, 191], ["roaster calcine", "SIMPLE_CHEMICAL", 176, 191], ["one-step pyrometallurgical processing", "TREATMENT", 99, 136], ["blister", "ANATOMY", 154, 161], ["roaster calcine", "OBSERVATION", 176, 191]]], ["In principle, the overall capital cost of such a facility should be competitive considering the reduction in equipment and material handling.PROCESSING OF COPPER COMPLEX MATERIALS IN THE COPPER INDUSTRYIn the case of polymetallic concentrates, a more robust approach to increase metal recovery and multi-metal production has been to develop multimetal recovery facilities.", [["multi-metal", "SIMPLE_CHEMICAL", 298, 309], ["the reduction in equipment", "TREATMENT", 92, 118], ["polymetallic concentrates", "PROBLEM", 217, 242], ["COPPER COMPLEX", "OBSERVATION_MODIFIER", 155, 169], ["polymetallic concentrates", "OBSERVATION", 217, 242], ["increase", "OBSERVATION_MODIFIER", 270, 278], ["metal recovery", "OBSERVATION", 279, 293]]], ["The main goals of these facilities are to achieve maximum metal recoveries and optimum waste and effluent management by the exchange of metal flows between the different metallurgical circuits.", [["maximum metal recoveries", "TREATMENT", 50, 74], ["optimum waste", "TREATMENT", 79, 92], ["effluent management", "TREATMENT", 97, 116], ["the exchange of metal flows", "TREATMENT", 120, 147], ["the different metallurgical circuits", "TREATMENT", 156, 192], ["main", "OBSERVATION_MODIFIER", 4, 8], ["metal flows", "OBSERVATION", 136, 147], ["metallurgical circuits", "OBSERVATION", 170, 192]]], ["This principle, shown in Fig. 5 , is applied in metallurgical integrated plants, such as the Kazzinc Ust-Kamenogorsk Metallurgical Complex in Kazakhstan, 10 the Boliden R\u00f6nnsk\u00e4 r Smelter, 11 or in multi-integrated sites in Japan, 12 Germany 13 and Korea, 14 among others.PROCESSING OF COPPER COMPLEX MATERIALS IN THE COPPER INDUSTRYHowever, even in these integrated facilities, it still not yet feasible to recover elements such as W, Mo, V, Mn, Cr, Nb, Ta, Li, and the rare earths.", [["W", "CHEMICAL", 432, 433], ["Mo", "CHEMICAL", 435, 437], ["V", "CHEMICAL", 439, 440], ["Mn", "CHEMICAL", 442, 444], ["Cr", "CHEMICAL", 446, 448], ["Nb", "CHEMICAL", 450, 452], ["Ta", "CHEMICAL", 454, 456], ["Li", "CHEMICAL", 458, 460], ["Mn", "SIMPLE_CHEMICAL", 442, 444], ["Cr", "SIMPLE_CHEMICAL", 446, 448], ["Mn", "TEST", 442, 444], ["Cr", "TEST", 446, 448], ["COPPER COMPLEX", "OBSERVATION_MODIFIER", 285, 299]]], ["Considering the future challenges that will arise from processing increasing quantities of batteries, additional efforts will be required to adapt metallurgical circuits to recover new elements.PROCESSING OF COPPER COMPLEX MATERIALS IN THE COPPER INDUSTRYAdditional efforts have been made in countries like Japan and Germany to develop technologies to recover rare metals from waste from small electronic and electric appliances, prioritizing pre-processing of these materials before being fed into copper smelting circuits.", [["copper", "CHEMICAL", 499, 505], ["copper", "CHEMICAL", 499, 505], ["copper", "SIMPLE_CHEMICAL", 499, 505], ["metallurgical circuits", "TREATMENT", 147, 169], ["rare metals", "PROBLEM", 360, 371], ["small electronic and electric appliances", "TREATMENT", 388, 428], ["these materials", "TREATMENT", 461, 476], ["COPPER COMPLEX", "OBSERVATION_MODIFIER", 208, 222], ["small", "OBSERVATION_MODIFIER", 388, 393]]], ["Table III shows a compilation of metallurgical complex processing plants that were or are currently operating in the western world, aiming to use base metal carrier properties to optimize and maximize precious metal recovery.", [["metallurgical complex processing plants", "TREATMENT", 33, 72], ["base metal carrier properties", "TREATMENT", 146, 175]]], ["In most of these plants, base metal volume production is not as relevant as the concentration of valuable precious metals.", [["base metal volume production", "TEST", 25, 53], ["plants", "OBSERVATION", 17, 23], ["base", "OBSERVATION_MODIFIER", 25, 29], ["metal", "OBSERVATION_MODIFIER", 30, 35], ["volume production", "OBSERVATION", 36, 53]]], ["These plants can potentially process industrial wastes, city incinerator metallic sub-products, recycling oils, and others.", [["industrial wastes", "TREATMENT", 37, 54]]], ["Metallurgical plants in Japan are using a similar approach by integrating primary and secondary complex processing sites and maximizing synergies between them to increase metal recovery.", [["a similar approach", "TREATMENT", 40, 58], ["secondary complex processing sites", "PROBLEM", 86, 120], ["increase", "OBSERVATION_MODIFIER", 162, 170], ["metal recovery", "OBSERVATION", 171, 185]]], ["In the case of Japan, special emphasis has been made to process complex secondary raw materials and industrial waste using the ability of existing smelting facilities to recover valuable metals.", [["existing smelting facilities", "TREATMENT", 138, 166]]], ["Figure 6 shows the concept applied by JX Nippon Mining to combine primary resources with secondary and industrial waste resources.Example 2: Aurubis Primary and SecondaryMaterials Processing Systems Figure 7 shows the process flowsheet of the lead secondary copper smelter.", [["copper", "CHEMICAL", 258, 264], ["copper", "CHEMICAL", 258, 264], ["copper", "SIMPLE_CHEMICAL", 258, 264], ["secondary and industrial waste resources", "TREATMENT", 89, 129], ["Secondary", "OBSERVATION", 161, 170], ["copper smelter", "OBSERVATION", 258, 272]]], ["20 The flowsheet allows the integration and transfer of materials with the primary copper smelter.", [["copper", "CHEMICAL", 83, 89], ["copper", "CHEMICAL", 83, 89], ["copper", "SIMPLE_CHEMICAL", 83, 89]]], ["The lead smelter and refinery involve:Example 2: Aurubis Primary and SecondarySmelting of complex copper lead concentrates in an electric furnace.", [["copper", "CHEMICAL", 98, 104], ["copper", "CHEMICAL", 98, 104], ["copper", "SIMPLE_CHEMICAL", 98, 104], ["complex copper lead concentrates", "PROBLEM", 90, 122], ["an electric furnace", "TREATMENT", 126, 145], ["complex", "OBSERVATION_MODIFIER", 90, 97], ["copper lead concentrates", "OBSERVATION", 98, 122], ["electric furnace", "OBSERVATION", 129, 145]]], ["Converting of copper lead matte in a Peirce-Smith converter.", [["copper", "CHEMICAL", 14, 20], ["copper", "CHEMICAL", 14, 20], ["copper", "SIMPLE_CHEMICAL", 14, 20]]], ["Refining of lead bullion.", [["lead bullion", "PROBLEM", 12, 24], ["lead bullion", "OBSERVATION", 12, 24]]], ["Integration with anode slime plant.", [["anode slime plant", "TREATMENT", 17, 34], ["anode", "OBSERVATION", 17, 22], ["slime plant", "OBSERVATION", 23, 34]]], ["Integration with precious metal refinery.Example 2: Aurubis Primary and SecondaryOn the secondary copper side, one of the most successful expressions of an integrated recycling system has been the implementation of the Kayser Recycling System (KRS + ).", [["copper", "CHEMICAL", 98, 104], ["copper", "CHEMICAL", 98, 104], ["precious metal refinery", "TREATMENT", 17, 40]]], ["This flowsheet, which was developed to recover copper, lead, tin, and precious metals, has been in operation since 2002 in L\u00fc nen, Germany.", [["copper", "CHEMICAL", 47, 53], ["tin", "CHEMICAL", 61, 64], ["copper", "CHEMICAL", 47, 53], ["tin", "CHEMICAL", 61, 64], ["copper", "SIMPLE_CHEMICAL", 47, 53], ["This flowsheet", "TEST", 0, 14]]], ["23 The flowsheet encompasses the following unit operations:Example 2: Aurubis Primary and SecondaryISAMELT TM furnace for smelting reduction.", [["SecondaryISAMELT TM furnace", "TREATMENT", 90, 117], ["smelting reduction", "TREATMENT", 122, 140], ["smelting reduction", "OBSERVATION", 122, 140]]], ["Settling furnace for copper recovery.", [["copper", "CHEMICAL", 21, 27], ["copper", "CHEMICAL", 21, 27], ["copper", "SIMPLE_CHEMICAL", 21, 27]]], ["Pb-Sn furnace for Pb-Sn alloy production.", [["Pb-Sn", "CHEMICAL", 0, 5], ["Pb", "CHEMICAL", 18, 20], ["Pb", "CHEMICAL", 0, 2], ["Sn", "CHEMICAL", 3, 5], ["Pb", "CHEMICAL", 18, 20], ["Sn", "CHEMICAL", 21, 23], ["Pb-Sn", "SIMPLE_CHEMICAL", 0, 5], ["Pb-Sn alloy", "SIMPLE_CHEMICAL", 18, 29], ["Sn alloy production", "TREATMENT", 21, 40], ["Sn furnace", "OBSERVATION", 3, 13], ["alloy production", "OBSERVATION", 24, 40]]], ["TBRC for copper conversion.", [["TBRC", "CHEMICAL", 0, 4], ["copper", "CHEMICAL", 9, 15], ["copper", "CHEMICAL", 9, 15], ["TBRC", "SIMPLE_CHEMICAL", 0, 4], ["copper", "SIMPLE_CHEMICAL", 9, 15], ["TBRC", "TREATMENT", 0, 4], ["copper conversion", "PROBLEM", 9, 26], ["copper conversion", "OBSERVATION", 9, 26]]], ["Anode furnace.", [["Anode furnace", "TREATMENT", 0, 13], ["furnace", "OBSERVATION", 6, 13]]], ["The Ust-Kamenogorsk Metallurgical Complex is a multi-metal recovery plant combining lead, copper and zinc base metal metallurgy.", [["copper", "CHEMICAL", 90, 96], ["zinc", "CHEMICAL", 101, 105], ["copper", "CHEMICAL", 90, 96], ["zinc", "CHEMICAL", 101, 105], ["copper", "SIMPLE_CHEMICAL", 90, 96], ["zinc", "SIMPLE_CHEMICAL", 101, 105], ["copper and zinc base metal metallurgy", "TREATMENT", 90, 127], ["Metallurgical Complex", "OBSERVATION", 20, 41], ["base", "OBSERVATION_MODIFIER", 106, 110], ["metal metallurgy", "OBSERVATION", 111, 127]]], ["The plant consists of:Example 2: Aurubis Primary and SecondaryZinc refinery with a capacity of 190,000 tpa.", [["190,000 tpa", "TREATMENT", 95, 106]]], ["Lead smelter and refinery with a lead bullion production capacity of 144,000 tpa.", [["Lead", "CHEMICAL", 0, 4], ["Lead smelter", "PROBLEM", 0, 12], ["a lead bullion production capacity", "TREATMENT", 31, 65], ["smelter", "OBSERVATION", 5, 12]]], ["Copper smelter and refinery with a copper cathode production capacity of 70,000 tpa.Example 2: Aurubis Primary and SecondaryA precious metal plant is also integrated into the base metal operation to produce gold and silver.", [["Copper", "CHEMICAL", 0, 6], ["copper", "CHEMICAL", 35, 41], ["gold and silver", "CHEMICAL", 207, 222], ["Copper", "CHEMICAL", 0, 6], ["copper", "CHEMICAL", 35, 41], ["silver", "CHEMICAL", 216, 222], ["Copper", "SIMPLE_CHEMICAL", 0, 6], ["copper", "SIMPLE_CHEMICAL", 35, 41], ["gold", "SIMPLE_CHEMICAL", 207, 211], ["silver", "SIMPLE_CHEMICAL", 216, 222], ["a copper cathode production capacity", "TREATMENT", 33, 69], ["A precious metal plant", "TREATMENT", 124, 146], ["the base metal operation", "TREATMENT", 171, 195], ["gold and silver", "TREATMENT", 207, 222], ["base", "ANATOMY_MODIFIER", 175, 179], ["metal operation", "OBSERVATION", 180, 195], ["gold", "OBSERVATION_MODIFIER", 207, 211], ["silver", "OBSERVATION_MODIFIER", 216, 222]]], ["The Ust-Kamenogorsk metallurgical complex is able to process highly complex materials with high recoveries given by the integrated nature of the plant.", [["Ust-Kamenogorsk metallurgical complex", "PROTEIN", 4, 41]]], ["Figure 9 shows a simplified process flowsheet.THE ARSENIC CHALLENGEArsenic has been a recurrent challenge in the management of deleterious elements in the processing of copper concentrates.", [["CHALLENGEArsenic", "CHEMICAL", 58, 74], ["copper", "CHEMICAL", 169, 175], ["copper", "CHEMICAL", 169, 175], ["copper", "SIMPLE_CHEMICAL", 169, 175], ["a recurrent challenge", "TREATMENT", 84, 105], ["deleterious elements", "PROBLEM", 127, 147], ["ARSENIC CHALLENGEArsenic", "OBSERVATION", 50, 74], ["recurrent", "OBSERVATION_MODIFIER", 86, 95], ["deleterious elements", "OBSERVATION", 127, 147]]], ["Arsenic content has gradually increased in copper concentrates to levels that are almost above the standard arsenic blending concentrations that most western smelters in Europe, Asia (excluding China), and North America can operate.", [["Arsenic", "CHEMICAL", 0, 7], ["copper", "CHEMICAL", 43, 49], ["arsenic", "CHEMICAL", 108, 115], ["Arsenic", "CHEMICAL", 0, 7], ["copper", "CHEMICAL", 43, 49], ["arsenic", "CHEMICAL", 108, 115], ["Arsenic", "SIMPLE_CHEMICAL", 0, 7], ["copper", "SIMPLE_CHEMICAL", 43, 49], ["arsenic", "SIMPLE_CHEMICAL", 108, 115], ["Arsenic content", "PROBLEM", 0, 15], ["content", "OBSERVATION", 8, 15], ["gradually", "OBSERVATION_MODIFIER", 20, 29], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["copper concentrates", "OBSERVATION_MODIFIER", 43, 62]]], ["A clear example of the gradual increase of arsenic in copper concentrates can be demonstrated by the behavior in the blends processed in Japan.", [["arsenic", "CHEMICAL", 43, 50], ["copper", "CHEMICAL", 54, 60], ["arsenic", "CHEMICAL", 43, 50], ["copper", "CHEMICAL", 54, 60], ["arsenic", "SIMPLE_CHEMICAL", 43, 50], ["copper", "SIMPLE_CHEMICAL", 54, 60], ["arsenic in copper concentrates", "PROBLEM", 43, 73], ["clear", "OBSERVATION", 2, 7], ["gradual", "OBSERVATION_MODIFIER", 23, 30], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["arsenic", "OBSERVATION_MODIFIER", 43, 50]]], ["According to the Metals Economics Institute of Japan, arsenic content in copper concentrates processed in Japanese smelters has gradually increased since 1991 from 400 ppm to over 1,000 ppm in 2016, while the copper content in the concentrates decreased from near 33% to 27%Cu.", [["arsenic", "CHEMICAL", 54, 61], ["copper", "CHEMICAL", 73, 79], ["copper", "CHEMICAL", 209, 215], ["Cu", "CHEMICAL", 274, 276], ["arsenic", "CHEMICAL", 54, 61], ["copper", "CHEMICAL", 73, 79], ["copper", "CHEMICAL", 209, 215], ["Cu", "CHEMICAL", 274, 276], ["arsenic", "SIMPLE_CHEMICAL", 54, 61], ["copper", "SIMPLE_CHEMICAL", 73, 79], ["copper", "SIMPLE_CHEMICAL", 209, 215], ["gradually", "OBSERVATION_MODIFIER", 128, 137], ["increased", "OBSERVATION_MODIFIER", 138, 147]]], ["26 This represents a 3 times increase in the units of As per unit of Cu in the feed.", [["Cu", "CHEMICAL", 69, 71], ["As", "CHEMICAL", 54, 56], ["Cu", "CHEMICAL", 69, 71], ["Cu", "SIMPLE_CHEMICAL", 69, 71], ["As per unit of Cu in the feed", "TREATMENT", 54, 83], ["3 times", "OBSERVATION_MODIFIER", 21, 28], ["increase", "OBSERVATION_MODIFIER", 29, 37]]], ["The same report estimates that standard copper concentrate blends could increase to 3,000 ppm if new high As-containing deposits are brought into operation.", [["copper", "CHEMICAL", 40, 46], ["copper", "CHEMICAL", 40, 46], ["As", "CHEMICAL", 106, 108], ["copper", "SIMPLE_CHEMICAL", 40, 46], ["standard copper concentrate blends", "TREATMENT", 31, 65], ["new high As-containing deposits", "PROBLEM", 97, 128]]], ["Introducing such complex high-arsenic copper concentrates would require large amounts of clean concentrates to dilute the arsenic contents to levels acceptable from the technical and economic points of view by copper smelter.", [["copper", "CHEMICAL", 38, 44], ["arsenic", "CHEMICAL", 122, 129], ["copper", "CHEMICAL", 210, 216], ["arsenic", "CHEMICAL", 30, 37], ["copper", "CHEMICAL", 38, 44], ["arsenic", "CHEMICAL", 122, 129], ["copper", "CHEMICAL", 210, 216], ["copper", "SIMPLE_CHEMICAL", 38, 44], ["arsenic", "SIMPLE_CHEMICAL", 122, 129], ["copper", "SIMPLE_CHEMICAL", 210, 216], ["such complex high-arsenic copper concentrates", "TREATMENT", 12, 57], ["large amounts of clean concentrates", "TREATMENT", 72, 107], ["complex", "OBSERVATION_MODIFIER", 17, 24], ["high", "OBSERVATION_MODIFIER", 25, 29], ["arsenic copper", "OBSERVATION_MODIFIER", 30, 44], ["large", "OBSERVATION_MODIFIER", 72, 77], ["amounts", "OBSERVATION_MODIFIER", 78, 85], ["clean concentrates", "OBSERVATION_MODIFIER", 89, 107], ["arsenic contents", "OBSERVATION", 122, 138]]], ["27 The impact of a small increase in the tonnes of high-arsenic concentrates is illustrated in Fig. 10 .", [["arsenic", "CHEMICAL", 56, 63], ["arsenic", "CHEMICAL", 56, 63], ["a small increase", "PROBLEM", 17, 33], ["high-arsenic concentrates", "TREATMENT", 51, 76], ["small", "OBSERVATION_MODIFIER", 19, 24], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["high", "OBSERVATION_MODIFIER", 51, 55], ["arsenic concentrates", "OBSERVATION_MODIFIER", 56, 76]]], ["28 Because of the more than tenfold higher arsenic units per unit of concentrate, what appears to be a small increase in the amount of high-arsenic concentrates forecast in Mayhew et al. 28 almost doubles the arsenic units at smelting.", [["arsenic", "CHEMICAL", 43, 50], ["arsenic", "CHEMICAL", 140, 147], ["arsenic", "CHEMICAL", 209, 216], ["arsenic", "CHEMICAL", 43, 50], ["arsenic", "CHEMICAL", 140, 147], ["arsenic", "CHEMICAL", 209, 216], ["arsenic", "SIMPLE_CHEMICAL", 209, 216], ["a small increase", "PROBLEM", 101, 117], ["appears to be", "UNCERTAINTY", 87, 100], ["small", "OBSERVATION_MODIFIER", 103, 108], ["increase", "OBSERVATION_MODIFIER", 109, 117], ["amount", "OBSERVATION_MODIFIER", 125, 131], ["high", "OBSERVATION_MODIFIER", 135, 139], ["arsenic concentrates", "OBSERVATION", 140, 160], ["arsenic units", "OBSERVATION_MODIFIER", 209, 222]]], ["Even if there were sufficient low-arsenic concentrates to dilute the average arsenic to acceptable limits, the smelting industry would still face a significant increase in the units (tonnes) of arsenic to be processed and disposed.", [["arsenic", "CHEMICAL", 34, 41], ["arsenic", "CHEMICAL", 77, 84], ["arsenic", "CHEMICAL", 194, 201], ["arsenic", "CHEMICAL", 34, 41], ["arsenic", "CHEMICAL", 77, 84], ["arsenic", "CHEMICAL", 194, 201], ["arsenic", "SIMPLE_CHEMICAL", 77, 84], ["arsenic", "SIMPLE_CHEMICAL", 194, 201], ["sufficient low-arsenic concentrates", "PROBLEM", 19, 54], ["significant", "OBSERVATION_MODIFIER", 148, 159], ["increase", "OBSERVATION_MODIFIER", 160, 168]]], ["This would appear to be an unsustainable position for the predominantly urban-located smelting industry.", [["appear to be", "UNCERTAINTY", 11, 23], ["unsustainable", "OBSERVATION_MODIFIER", 27, 40], ["position", "OBSERVATION_MODIFIER", 41, 49], ["predominantly", "OBSERVATION_MODIFIER", 58, 71], ["smelting industry", "OBSERVATION", 86, 103]]], ["It indicates that technologies need to be adopted to reduce the arsenic content of copper concentrates at mine sites.Strategies to Process Complex Arsenic Containing MaterialsA large amount of fundamental work has been conducted to understand the behavior of arsenic in copper smelting.", [["arsenic", "CHEMICAL", 64, 71], ["copper", "CHEMICAL", 83, 89], ["Arsenic", "CHEMICAL", 147, 154], ["arsenic", "CHEMICAL", 259, 266], ["copper", "CHEMICAL", 270, 276], ["arsenic", "CHEMICAL", 64, 71], ["copper", "CHEMICAL", 83, 89], ["Arsenic", "CHEMICAL", 147, 154], ["arsenic", "CHEMICAL", 259, 266], ["copper", "CHEMICAL", 270, 276], ["arsenic", "SIMPLE_CHEMICAL", 64, 71], ["copper", "SIMPLE_CHEMICAL", 83, 89], ["mine sites", "MULTI-TISSUE_STRUCTURE", 106, 116], ["arsenic", "SIMPLE_CHEMICAL", 259, 266], ["copper", "SIMPLE_CHEMICAL", 270, 276], ["the arsenic content", "PROBLEM", 60, 79], ["Complex Arsenic Containing Materials", "PROBLEM", 139, 175], ["large", "OBSERVATION_MODIFIER", 177, 182], ["amount", "OBSERVATION_MODIFIER", 183, 189]]], ["Thermodynamic and kinetic aspects as well as strategies to optimize capture and stabilization were summarised by Piret et al., who conducted an extensive review on the state of the art in 1989.", [["kinetic", "OBSERVATION_MODIFIER", 18, 25]]], ["29 The main conclusions of the Piret review are:Strategies to Process Complex Arsenic Containing MaterialsMetallurgical slags offer a limited capacity to capture arsenic, mainly due to the reducing conditions in which they are treated.", [["Arsenic", "CHEMICAL", 78, 85], ["arsenic", "CHEMICAL", 162, 169], ["Arsenic", "CHEMICAL", 78, 85], ["arsenic", "CHEMICAL", 162, 169], ["arsenic", "SIMPLE_CHEMICAL", 162, 169], ["Complex Arsenic Containing Materials", "TREATMENT", 70, 106], ["a limited capacity", "PROBLEM", 132, 150], ["the reducing conditions", "PROBLEM", 185, 208], ["main", "OBSERVATION_MODIFIER", 7, 11]]], ["Gas phase elimination and subsequent processing of condensed dust are more suitable for arsenic capture.", [["arsenic", "CHEMICAL", 88, 95], ["arsenic", "CHEMICAL", 88, 95], ["dust", "ORGANISM_SUBSTANCE", 61, 65], ["arsenic", "SIMPLE_CHEMICAL", 88, 95], ["Gas phase elimination", "TEST", 0, 21], ["condensed dust", "PROBLEM", 51, 65], ["condensed dust", "OBSERVATION", 51, 65]]], ["Arsenic capture as speiss form is advantageous.", [["Arsenic", "CHEMICAL", 0, 7], ["Arsenic", "CHEMICAL", 0, 7], ["Arsenic", "SIMPLE_CHEMICAL", 0, 7], ["Arsenic capture", "PROBLEM", 0, 15]]], ["Recycling of intermediate products should be directed to processes in which arsenic can be effectively separated from the metal phase.", [["arsenic", "CHEMICAL", 76, 83], ["arsenic", "CHEMICAL", 76, 83], ["arsenic", "SIMPLE_CHEMICAL", 76, 83], ["intermediate products", "TREATMENT", 13, 34], ["intermediate products", "OBSERVATION", 13, 34]]], ["Hydrometallurgical processing is the most suitable process route for separate processing of intermediate arsenic-containing materials.", [["arsenic", "CHEMICAL", 105, 112], ["arsenic", "CHEMICAL", 105, 112], ["arsenic", "SIMPLE_CHEMICAL", 105, 112], ["Hydrometallurgical processing", "PROBLEM", 0, 29], ["most suitable", "OBSERVATION_MODIFIER", 37, 50], ["intermediate arsenic", "OBSERVATION", 92, 112]]], ["Effluent processing techniques allow the separation and recovery of arsenic in intermediate product.", [["arsenic", "CHEMICAL", 68, 75], ["arsenic", "CHEMICAL", 68, 75], ["arsenic", "SIMPLE_CHEMICAL", 68, 75], ["Effluent processing techniques", "TREATMENT", 0, 30], ["the separation", "TREATMENT", 37, 51], ["arsenic", "OBSERVATION", 68, 75], ["intermediate product", "OBSERVATION", 79, 99]]], ["However, safe disposal of these arsenic intermediate streams will require developing environmentally stable compounds.", [["arsenic", "CHEMICAL", 32, 39], ["arsenic", "CHEMICAL", 32, 39], ["arsenic", "SIMPLE_CHEMICAL", 32, 39]]], ["Wet gas cleaning is an unavoidable step if lower gas emission standards are applied.Strategies to Process Complex Arsenic Containing MaterialsMost of the above criteria have been gradually applied to modern smelting operations, with new technologies being used for arsenic recovery, and safe disposal from copper smelting dust, refinery effluents, gas cleaning, and wastewater processing being gradually achieved.", [["Arsenic", "CHEMICAL", 114, 121], ["arsenic", "CHEMICAL", 265, 272], ["copper", "CHEMICAL", 306, 312], ["Arsenic", "CHEMICAL", 114, 121], ["arsenic", "CHEMICAL", 265, 272], ["copper", "CHEMICAL", 306, 312], ["arsenic", "SIMPLE_CHEMICAL", 265, 272], ["copper", "SIMPLE_CHEMICAL", 306, 312], ["Wet gas cleaning", "TREATMENT", 0, 16], ["lower gas emission standards", "TREATMENT", 43, 71], ["Complex Arsenic Containing Materials", "PROBLEM", 106, 142], ["modern smelting operations", "TREATMENT", 200, 226], ["new technologies", "TREATMENT", 233, 249], ["refinery effluents", "TREATMENT", 328, 346], ["gas cleaning", "TREATMENT", 348, 360], ["wastewater processing", "TREATMENT", 366, 387], ["gas cleaning", "OBSERVATION", 4, 16], ["effluents", "OBSERVATION_MODIFIER", 337, 346], ["gas cleaning", "OBSERVATION", 348, 360]]], ["In the last 30 years, a great deal of effort has also been made to develop alternative technologies to process high-arsenic-containing materials.", [["arsenic", "CHEMICAL", 116, 123], ["arsenic", "CHEMICAL", 116, 123], ["high-arsenic-containing materials", "PROBLEM", 111, 144]]], ["Focus has been on:Strategies to Process Complex Arsenic Containing MaterialsDeveloping niche technologies for processing specific ore bodies from mine to cathode using a combination of hydrometallurgical techniques and solvent extraction and electrowinning.", [["Arsenic", "CHEMICAL", 48, 55], ["Arsenic", "CHEMICAL", 48, 55], ["Complex Arsenic Containing Materials", "TREATMENT", 40, 76], ["niche technologies", "TREATMENT", 87, 105], ["processing specific ore bodies", "PROBLEM", 110, 140], ["cathode", "TREATMENT", 154, 161], ["hydrometallurgical techniques", "TREATMENT", 185, 214], ["solvent extraction", "TREATMENT", 219, 237], ["electrowinning", "TREATMENT", 242, 256]]], ["Selective flotation to depress and concentrate high-arsenic streams.", [["arsenic", "CHEMICAL", 52, 59], ["arsenic", "CHEMICAL", 52, 59], ["Selective flotation", "TREATMENT", 0, 19], ["arsenic streams", "OBSERVATION", 52, 67]]], ["Renewed interest in roasting of high-arseniccontaining materials.", [["high-arseniccontaining materials", "TREATMENT", 32, 64], ["roasting", "OBSERVATION_MODIFIER", 20, 28], ["high-arseniccontaining materials", "OBSERVATION_MODIFIER", 32, 64]]], ["Leaching of high-arsenic copper concentrates (alkaline and acid environments).", [["copper", "CHEMICAL", 25, 31], ["arsenic copper", "CHEMICAL", 17, 31], ["copper", "SIMPLE_CHEMICAL", 25, 31], ["alkaline", "SIMPLE_CHEMICAL", 46, 54], ["high-arsenic copper concentrates", "TREATMENT", 12, 44], ["alkaline and acid environments", "TREATMENT", 46, 76], ["high-arsenic copper concentrates", "OBSERVATION_MODIFIER", 12, 44]]], ["Stabilization of arsenic residues in crystalline stable structures such as scorodite.", [["arsenic", "CHEMICAL", 17, 24], ["scorodite", "CHEMICAL", 75, 84], ["arsenic", "CHEMICAL", 17, 24], ["scorodite", "CHEMICAL", 75, 84], ["arsenic", "SIMPLE_CHEMICAL", 17, 24], ["scorodite", "SIMPLE_CHEMICAL", 75, 84], ["arsenic residues in crystalline stable structures", "PROBLEM", 17, 66], ["arsenic residues", "OBSERVATION", 17, 33], ["crystalline", "OBSERVATION_MODIFIER", 37, 48], ["stable", "OBSERVATION_MODIFIER", 49, 55]]], ["Vitrification of high-arsenic-containing materials in smelting slags.", [["arsenic", "CHEMICAL", 22, 29], ["arsenic", "CHEMICAL", 22, 29], ["Vitrification", "TREATMENT", 0, 13], ["high-arsenic-containing materials in smelting slags", "PROBLEM", 17, 68], ["high", "OBSERVATION_MODIFIER", 17, 21], ["-arsenic", "OBSERVATION_MODIFIER", 21, 29], ["smelting slags", "OBSERVATION", 54, 68]]], ["Table IV shows the level of development of some technology responses for processing complex arsenic-containing materials.", [["arsenic", "CHEMICAL", 92, 99], ["arsenic", "CHEMICAL", 92, 99], ["arsenic", "SIMPLE_CHEMICAL", 92, 99], ["Table IV", "TREATMENT", 0, 8]]], ["30 , 31 Most of these technologies have been developed to process high-arsenic-containing streams.", [["arsenic", "CHEMICAL", 71, 78], ["arsenic", "CHEMICAL", 71, 78], ["arsenic", "SIMPLE_CHEMICAL", 71, 78]]], ["However, with blending continuing to be the most popular approach, a gradual increase in arsenic content in copper concentrates-and a faster increase in the tonnes of arsenic processed-should be expected.", [["arsenic", "CHEMICAL", 89, 96], ["copper", "CHEMICAL", 108, 114], ["arsenic", "CHEMICAL", 167, 174], ["arsenic", "CHEMICAL", 89, 96], ["copper", "CHEMICAL", 108, 114], ["arsenic", "CHEMICAL", 167, 174], ["arsenic", "SIMPLE_CHEMICAL", 89, 96], ["copper", "SIMPLE_CHEMICAL", 108, 114], ["arsenic", "SIMPLE_CHEMICAL", 167, 174], ["a gradual increase in arsenic content", "PROBLEM", 67, 104], ["a faster increase", "PROBLEM", 132, 149], ["gradual", "OBSERVATION_MODIFIER", 69, 76], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["arsenic content", "OBSERVATION", 89, 104], ["copper concentrates", "OBSERVATION_MODIFIER", 108, 127], ["faster", "OBSERVATION_MODIFIER", 134, 140], ["increase", "OBSERVATION_MODIFIER", 141, 149]]], ["This will exert more pressure on smelters, increasing their operating costs, jeopardizing their competitiveness, and increasing environmental compliance requirements.Strategies to Process Complex Arsenic Containing MaterialsComplexity, therefore, can be understood not only in terms of supply but also in terms of the effect on the business need to invest in peripherical equipment to increase capture, reduce emissions, and stabilize residues according to local regulations.Strategies to Process Complex Arsenic Containing MaterialsThis gradual increase associated with operational procedures aimed to minimize waste outlets has gradually increased arsenic concentration in slags and, subsequently, reduced market opportunities for sub-products.", [["Arsenic", "CHEMICAL", 196, 203], ["Arsenic", "CHEMICAL", 505, 512], ["arsenic", "CHEMICAL", 650, 657], ["Arsenic", "CHEMICAL", 196, 203], ["Arsenic", "CHEMICAL", 505, 512], ["arsenic", "CHEMICAL", 650, 657], ["arsenic", "SIMPLE_CHEMICAL", 650, 657], ["increasing environmental compliance requirements", "PROBLEM", 117, 165], ["Complex Arsenic Containing MaterialsComplexity", "PROBLEM", 188, 234], ["peripherical equipment", "TREATMENT", 359, 381], ["Complex Arsenic Containing Materials", "PROBLEM", 497, 533], ["operational procedures", "TREATMENT", 571, 593], ["gradually increased arsenic concentration in slags", "PROBLEM", 630, 680], ["pressure", "OBSERVATION_MODIFIER", 21, 29], ["increasing", "OBSERVATION_MODIFIER", 117, 127], ["environmental compliance", "OBSERVATION", 128, 152], ["Complex", "OBSERVATION_MODIFIER", 188, 195], ["Arsenic", "OBSERVATION", 196, 203], ["gradual", "OBSERVATION_MODIFIER", 538, 545], ["increase", "OBSERVATION_MODIFIER", 546, 554], ["gradually", "OBSERVATION_MODIFIER", 630, 639], ["increased", "OBSERVATION_MODIFIER", 640, 649], ["arsenic", "OBSERVATION_MODIFIER", 650, 657], ["concentration", "OBSERVATION_MODIFIER", 658, 671]]], ["Several efforts are currently undergoing in Chile, Germany, Australia, Japan, and Canada, among others, to develop pre-processing alternatives for safe arsenic removal prior to smelting or processing of secondary streams generated in the copper smelting processes.Strategies to Process Complex Arsenic Containing MaterialsThe last two items in Table IV should be the first investigated in any integrated industry response.", [["arsenic", "CHEMICAL", 152, 159], ["copper", "CHEMICAL", 238, 244], ["Arsenic", "CHEMICAL", 294, 301], ["arsenic", "CHEMICAL", 152, 159], ["copper", "CHEMICAL", 238, 244], ["Arsenic", "CHEMICAL", 294, 301], ["arsenic", "SIMPLE_CHEMICAL", 152, 159], ["copper", "SIMPLE_CHEMICAL", 238, 244], ["pre-processing alternatives", "TREATMENT", 115, 142], ["safe arsenic removal", "TREATMENT", 147, 167], ["smelting", "TREATMENT", 177, 185], ["secondary streams", "PROBLEM", 203, 220], ["Complex Arsenic Containing Materials", "PROBLEM", 286, 322], ["Table IV", "TREATMENT", 344, 352], ["secondary streams", "OBSERVATION", 203, 220]]], ["It is almost always more efficient to remove an impurity at ambient temperature and pressure in mineral processing rather than in smelting-so long as that impurity is in a discrete identifiable mineral.", [["an impurity at ambient temperature", "PROBLEM", 45, 79], ["pressure in mineral processing", "TREATMENT", 84, 114], ["pressure", "OBSERVATION_MODIFIER", 84, 92]]], ["When arsenic in the current ''baseload'' of traded concentrates occurs in the form of arsenopyrite (FeAsS), or is apparently dissolved in iron sulfides, then it can be reduced by mineral separation applying modern fine regrinding and washed-froth cleaning.", [["arsenic", "CHEMICAL", 5, 12], ["arsenopyrite", "CHEMICAL", 86, 98], ["FeAsS", "CHEMICAL", 100, 105], ["iron sulfides", "CHEMICAL", 138, 151], ["arsenic", "CHEMICAL", 5, 12], ["arsenopyrite", "CHEMICAL", 86, 98], ["FeAsS", "CHEMICAL", 100, 105], ["iron sulfides", "CHEMICAL", 138, 151], ["arsenic", "SIMPLE_CHEMICAL", 5, 12], ["arsenopyrite", "SIMPLE_CHEMICAL", 86, 98], ["FeAsS", "SIMPLE_CHEMICAL", 100, 105], ["iron sulfides", "SIMPLE_CHEMICAL", 138, 151], ["iron sulfides", "TREATMENT", 138, 151], ["mineral separation", "TREATMENT", 179, 197]]], ["This is more technically efficient than removing the arsenic in smelting, but it is not always more economic for the miner.", [["arsenic", "CHEMICAL", 53, 60], ["arsenic", "CHEMICAL", 53, 60], ["arsenic", "SIMPLE_CHEMICAL", 53, 60], ["more", "OBSERVATION_MODIFIER", 8, 12], ["technically", "OBSERVATION_MODIFIER", 13, 24], ["efficient", "OBSERVATION", 25, 34], ["arsenic", "OBSERVATION_MODIFIER", 53, 60], ["smelting", "OBSERVATION", 64, 72]]], ["Though the technology is well proven, it requires capital investment and increases mine-site operating costs.", [["capital investment", "TREATMENT", 50, 68]]], ["Usually mine sites only adopt these technologies if they are essential to market their concentrate-for example, some of the sites that produce the highest quality concentrates in Fig. 2 do so in order to achieve limits on impurities such as U or F. The mineral processing steps to reduce the impurities to acceptable levels for marketing coincidentally reduce other mineral contamination, resulting in a significantly higher concentrate grade in high copper recovery (though in a finer-grained concentrate).", [["U", "CHEMICAL", 241, 242], ["copper", "CHEMICAL", 451, 457], ["copper", "CHEMICAL", 451, 457], ["copper", "SIMPLE_CHEMICAL", 451, 457], ["The mineral processing steps", "TREATMENT", 249, 277], ["other mineral contamination", "PROBLEM", 360, 387], ["high copper recovery", "PROBLEM", 446, 466], ["high copper recovery", "OBSERVATION_MODIFIER", 446, 466]]], ["If more accurate economic signals were sent through concentrate contracts, or if the copper industry agreed to an ''arsenic code'', then the average arsenic level of currently traded concentrates could also be reduced.Strategies to Process Complex Arsenic Containing MaterialsA much more difficult mineral processing challenge is the selective flotation of arsenic-bearing copper minerals (e.g., enargite, Cu 3 AsS 4 , and tennantite, (Cu, Fe) 12 As 4 S 13 ).", [["copper", "CHEMICAL", 85, 91], ["arsenic", "CHEMICAL", 116, 123], ["arsenic", "CHEMICAL", 149, 156], ["Arsenic", "CHEMICAL", 248, 255], ["arsenic", "CHEMICAL", 357, 364], ["copper", "CHEMICAL", 373, 379], ["Cu 3 AsS 4 , and tennantite", "CHEMICAL", 406, 433], ["Cu", "CHEMICAL", 436, 438], ["Fe", "CHEMICAL", 440, 442], ["copper", "CHEMICAL", 85, 91], ["arsenic", "CHEMICAL", 116, 123], ["arsenic", "CHEMICAL", 149, 156], ["Arsenic", "CHEMICAL", 248, 255], ["arsenic", "CHEMICAL", 357, 364], ["copper", "CHEMICAL", 373, 379], ["enargite", "CHEMICAL", 396, 404], ["Cu 3 AsS 4", "CHEMICAL", 406, 416], ["tennantite", "CHEMICAL", 423, 433], ["(Cu, Fe)", "CHEMICAL", 435, 443], ["As 4 S 13", "CHEMICAL", 447, 456], ["copper", "SIMPLE_CHEMICAL", 85, 91], ["arsenic", "SIMPLE_CHEMICAL", 149, 156], ["arsenic", "SIMPLE_CHEMICAL", 357, 364], ["copper minerals", "SIMPLE_CHEMICAL", 373, 388], ["enargite", "SIMPLE_CHEMICAL", 396, 404], ["Cu 3 AsS 4", "SIMPLE_CHEMICAL", 406, 416], ["tennantite", "SIMPLE_CHEMICAL", 423, 433], ["Complex Arsenic Containing MaterialsA", "PROBLEM", 240, 277], ["arsenic-bearing copper minerals", "TREATMENT", 357, 388], ["enargite", "TEST", 396, 404], ["reduced", "OBSERVATION_MODIFIER", 210, 217]]], ["These minerals have flotation characteristics very similar to nonarsenic-bearing copper minerals (chalcopyrite, chalcocite and bornite).", [["nonarsenic", "CHEMICAL", 62, 72], ["copper", "CHEMICAL", 81, 87], ["chalcopyrite, chalcocite and bornite", "CHEMICAL", 98, 134], ["nonarsenic", "CHEMICAL", 62, 72], ["copper", "CHEMICAL", 81, 87], ["chalcopyrite", "CHEMICAL", 98, 110], ["chalcocite", "CHEMICAL", 112, 122], ["bornite", "CHEMICAL", 127, 134], ["nonarsenic", "SIMPLE_CHEMICAL", 62, 72], ["copper minerals", "SIMPLE_CHEMICAL", 81, 96], ["chalcopyrite", "SIMPLE_CHEMICAL", 98, 110], ["chalcocite", "SIMPLE_CHEMICAL", 112, 122], ["bornite", "SIMPLE_CHEMICAL", 127, 134], ["nonarsenic-bearing copper minerals", "TREATMENT", 62, 96], ["chalcopyrite", "TREATMENT", 98, 110], ["chalcocite", "TREATMENT", 112, 122]]], ["Very small chemical ''windows'' for partial separation have been demonstrated in laboratory work, but these do not appear robust enough for practical application.", [["Very small chemical ''windows''", "PROBLEM", 0, 31], ["partial separation", "PROBLEM", 36, 54], ["practical application", "TREATMENT", 140, 161], ["small", "OBSERVATION_MODIFIER", 5, 10]]], ["Even if they were, they would still only split the same amount of arsenic between a low-arsenic copper concentrate and a high-arsenic copper concentrate.", [["arsenic", "CHEMICAL", 66, 73], ["copper", "CHEMICAL", 96, 102], ["copper", "CHEMICAL", 134, 140], ["arsenic", "CHEMICAL", 66, 73], ["arsenic", "CHEMICAL", 88, 95], ["copper", "CHEMICAL", 96, 102], ["arsenic", "CHEMICAL", 126, 133], ["copper", "CHEMICAL", 134, 140], ["arsenic", "SIMPLE_CHEMICAL", 66, 73], ["copper", "SIMPLE_CHEMICAL", 96, 102], ["copper", "SIMPLE_CHEMICAL", 134, 140], ["a low-arsenic copper concentrate", "TREATMENT", 82, 114], ["a high-arsenic copper concentrate", "TREATMENT", 119, 152]]], ["Either way, a new processing technology needs to be adopted if the copper industry is to avoid the transport and smelting of increased units of arsenic from these deposits.", [["copper", "CHEMICAL", 67, 73], ["arsenic", "CHEMICAL", 144, 151], ["copper", "CHEMICAL", 67, 73], ["arsenic", "CHEMICAL", 144, 151], ["copper", "SIMPLE_CHEMICAL", 67, 73], ["arsenic", "SIMPLE_CHEMICAL", 144, 151], ["these deposits", "PROBLEM", 157, 171], ["deposits", "OBSERVATION", 163, 171]]], ["The atmospheric leaching processes in Table IV appear the most likely candidates, and they could be applied on-site or at a central facility to reduce arsenic content and dispose it locally and safely before transport to smelters.RECOGNIZING COMPLEXITY AS A DRIVER FOR THE FUTUREPrimary and secondary sources of base metals are gradually increasing in complexity.", [["arsenic", "CHEMICAL", 151, 158], ["arsenic", "CHEMICAL", 151, 158], ["arsenic", "SIMPLE_CHEMICAL", 151, 158], ["The atmospheric leaching processes", "TREATMENT", 0, 34], ["Table IV", "TREATMENT", 38, 46], ["arsenic content", "PROBLEM", 151, 166], ["base metals", "PROBLEM", 312, 323], ["atmospheric", "OBSERVATION_MODIFIER", 4, 15], ["leaching processes", "OBSERVATION", 16, 34], ["most likely", "UNCERTAINTY", 58, 69], ["arsenic content", "OBSERVATION", 151, 166], ["base metals", "OBSERVATION", 312, 323], ["gradually", "OBSERVATION_MODIFIER", 328, 337], ["increasing", "OBSERVATION_MODIFIER", 338, 348]]], ["This complexity includes lower grade ore, lower grade concentrates, and increases in the concentration of minor metals and slagging elements.", [["lower grade ore", "PROBLEM", 25, 40], ["lower grade concentrates", "PROBLEM", 42, 66], ["minor metals and slagging elements", "PROBLEM", 106, 140], ["lower grade", "OBSERVATION_MODIFIER", 25, 36], ["ore", "OBSERVATION_MODIFIER", 37, 40], ["lower grade", "OBSERVATION_MODIFIER", 42, 53], ["concentrates", "OBSERVATION", 54, 66], ["increases", "OBSERVATION_MODIFIER", 72, 81], ["concentration", "OBSERVATION_MODIFIER", 89, 102], ["minor", "OBSERVATION_MODIFIER", 106, 111], ["metals", "OBSERVATION", 112, 118], ["slagging elements", "OBSERVATION", 123, 140]]], ["This pattern has clearly affected non-ferrous metal production, increasing operating costs, environmental compliance pressures, and the investment required to ensure a sustainable production of metals.RECOGNIZING COMPLEXITY AS A DRIVER FOR THE FUTUREAlvear et al. 32 discussed some key elements associated with the increasing complexity for primary copper production.", [["copper", "CHEMICAL", 349, 355], ["primary copper", "CHEMICAL", 341, 355], ["copper", "SIMPLE_CHEMICAL", 349, 355], ["affected non-ferrous metal production", "PROBLEM", 25, 62], ["environmental compliance pressures", "TEST", 92, 126], ["primary copper production", "PROBLEM", 341, 366], ["affected", "OBSERVATION_MODIFIER", 25, 33], ["non-ferrous", "OBSERVATION_MODIFIER", 34, 45], ["metal production", "OBSERVATION", 46, 62], ["increasing", "OBSERVATION_MODIFIER", 64, 74], ["pressures", "OBSERVATION_MODIFIER", 117, 126]]], ["This has been observed in the operation of secondary materials, such as the Kayser Recycling System, with increasing complexity and reduction in the concentration of base and precious metals in the sourced raw materials.RECOGNIZING COMPLEXITY AS A DRIVER FOR THE FUTUREThis pattern constantly challenges the competitiveness of smelters, who need regular evaluation of cost-effective measures to remain competitive.", [["secondary materials", "PROBLEM", 43, 62], ["increasing complexity", "PROBLEM", 106, 127], ["the concentration of base", "PROBLEM", 145, 170], ["regular evaluation", "TEST", 346, 364], ["cost-effective measures", "TREATMENT", 368, 391], ["secondary materials", "OBSERVATION", 43, 62], ["increasing", "OBSERVATION_MODIFIER", 106, 116], ["complexity", "OBSERVATION_MODIFIER", 117, 127], ["reduction", "OBSERVATION_MODIFIER", 132, 141], ["concentration", "OBSERVATION_MODIFIER", 149, 162], ["base", "OBSERVATION_MODIFIER", 166, 170]]], ["Clearly, adequate technology transformation, selection and performance will play a crucial role in this race to enhance (1) superior metallurgical performance, (2) a sustainable and environmentally friendly operation, (3) adequate impurity management, and (4) proper product quality.RECOGNIZING COMPLEXITY AS A DRIVER FOR THE FUTUREAsset optimization is key.", [["a sustainable and environmentally friendly operation", "TREATMENT", 164, 216], ["adequate impurity management", "TREATMENT", 222, 250], ["THE FUTUREAsset optimization", "TREATMENT", 322, 350]]], ["In a previous publication, we recognized the following elements as essential aspects to adjust metallurgical operations to the change in supply:RECOGNIZING COMPLEXITY AS A DRIVER FOR THE FUTUREFlexibility of the process configuration to adapt to new grades: find new operating conditions and adjust production to this reality.", [["metallurgical operations", "TREATMENT", 95, 119], ["new operating conditions", "PROBLEM", 263, 287]]], ["Energy utilization: how to adjust operating conditions for a given feed to optimize energy efficiency and utilization.", [["operating conditions", "TREATMENT", 34, 54], ["a given feed", "TREATMENT", 59, 71]]], ["Ultimately, considerations for new/improved technologies to meet the challenge of resource efficiency.RECOGNIZING COMPLEXITY AS A DRIVER FOR THE FUTURETo this list, we add the need for better integration of mine-site technologies with smelting, to find the most efficient place for the industry to remove impurities.", [["mine-site technologies", "TREATMENT", 207, 229]]], ["When the most efficient technical option is identified, then either concentrate contracts should send the right market signals, or the industry may need to agree to a code of practice to achieve the most sustainable outcome.KNOWLEDGE INTEGRATION: FROM FUNDAMENTAL KNOWLEDGE TO TECHNOLOGY IMPLEMENTATIONKnowledge integration plays a key role in the conceptualization and development of metallurgical processes.", [["metallurgical processes", "PROBLEM", 385, 408], ["right", "ANATOMY_MODIFIER", 106, 111], ["metallurgical processes", "OBSERVATION", 385, 408]]], ["As complexity is expected to rise, modifications of existing metallurgical processes and/or developments of new ones will be required.", [["existing metallurgical processes", "PROBLEM", 52, 84], ["metallurgical processes", "OBSERVATION", 61, 84]]], ["Increased amounts of minor elements from copper complex concentrates as well as complex e-wastes and industrial residues will require sustainable processing.KNOWLEDGE INTEGRATION: FROM FUNDAMENTAL KNOWLEDGE TO TECHNOLOGY IMPLEMENTATIONIn addition, with e-mobility as a target for the future, new processes able to recycle and recover battery elements will be required.", [["copper", "CHEMICAL", 41, 47], ["copper", "CHEMICAL", 41, 47], ["copper", "SIMPLE_CHEMICAL", 41, 47], ["battery elements", "DNA", 334, 350], ["copper complex concentrates", "PROBLEM", 41, 68], ["complex e-wastes", "PROBLEM", 80, 96], ["industrial residues", "PROBLEM", 101, 120], ["sustainable processing", "TREATMENT", 134, 156], ["amounts", "OBSERVATION_MODIFIER", 10, 17], ["minor elements", "OBSERVATION", 21, 35], ["copper complex", "OBSERVATION_MODIFIER", 41, 55], ["concentrates", "OBSERVATION_MODIFIER", 56, 68], ["industrial residues", "OBSERVATION", 101, 120]]], ["These potential new processes will benefit from synergies from existing metallurgical plants; however, careful evaluation of the impact on existing streams will be required.", [["existing metallurgical plants", "TREATMENT", 63, 92], ["careful evaluation", "TEST", 103, 121], ["existing streams", "TREATMENT", 139, 155], ["new", "OBSERVATION_MODIFIER", 16, 19], ["metallurgical plants", "OBSERVATION", 72, 92]]], ["New smelters will need to move from a standard processing that is becoming more competitive and less profitable to explore processing of complex urban wastes, metallurgical residues, and complex materials to secure profitable business.", [["New smelters", "PROBLEM", 0, 12], ["a standard processing", "TREATMENT", 36, 57], ["complex urban wastes", "PROBLEM", 137, 157], ["metallurgical residues", "PROBLEM", 159, 181], ["smelters", "OBSERVATION", 4, 12], ["metallurgical residues", "OBSERVATION", 159, 181]]], ["Competition with low-cost smelters, mostly located in China, will become more difficult.KNOWLEDGE INTEGRATION: FROM FUNDAMENTAL KNOWLEDGE TO TECHNOLOGY IMPLEMENTATIONAs these operations move to consider new business opportunities, integrated approaches to develop technologies will be required.", [["low-cost smelters", "PROBLEM", 17, 34], ["these operations", "TREATMENT", 169, 185], ["technologies", "TREATMENT", 264, 276]]], ["Integration will mean not only technical knowledge but also business expertise in non-traditional materials and full understanding of supply chains.KNOWLEDGE INTEGRATION: FROM FUNDAMENTAL KNOWLEDGE TO TECHNOLOGY IMPLEMENTATIONKey aspects to consider when analysing the need for further development of existing assets and/or new technology to meet the needs from the market are shown in Table V .CONCLUDING REMARKSSustainable production of metals is of paramount importance to meet community demand along with a sustainable future of our planet.", [["metals", "CHEMICAL", 439, 445]]], ["As demand for copper and contained valuable metals increases and the grade of available ores decreases, processing of more complex materials will be necessary.CONCLUDING REMARKSThe most efficient technical solutions will involve a combination of mineral processing and hydrometallurgical and pyrometallurgical processing techniques, and will include processing complex materials from both primary and secondary sources at both mine sites and smelters.CONCLUDING REMARKSIn this framework, a resource-to-cathode vision that incorporates synergies between mines, concentrators, smelters, and refineries will be required.", [["copper", "CHEMICAL", 14, 20], ["copper", "CHEMICAL", 14, 20], ["copper", "SIMPLE_CHEMICAL", 14, 20], ["valuable metals", "PROBLEM", 35, 50], ["available ores", "PROBLEM", 78, 92], ["more complex materials", "PROBLEM", 118, 140], ["mineral processing", "TREATMENT", 246, 264], ["hydrometallurgical and pyrometallurgical processing techniques", "TREATMENT", 269, 331], ["processing complex materials", "PROBLEM", 350, 378], ["smelters", "OBSERVATION", 442, 450]]], ["This needs to start with open technical dialogue, followed by commercial understanding of the most efficient ways to remove impurities, and then be supported by the right market signals to achieve the more efficient outcomes.", [["right", "ANATOMY_MODIFIER", 165, 170]]]], "1a80dc1262cab763224f77237dc3d94fa741dd64": [], "7f3bb4c0c70a92dced371117d63c8692fc8d404e": [["Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, familyCoronaviridae) is the causative agent of the current coronavirus disease pandemic.", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["coronavirus disease", "DISEASE", 120, 139], ["Severe acute respiratory syndrome coronavirus-2", "ORGANISM", 0, 47], ["SARS-CoV-2", "ORGANISM", 49, 59], ["coronavirus", "ORGANISM", 120, 131], ["coronavirus-2", "SPECIES", 34, 47], ["SARS-CoV", "SPECIES", 49, 57], ["Severe acute respiratory syndrome coronavirus-2", "SPECIES", 0, 47], ["SARS-CoV-2", "SPECIES", 49, 59], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["the current coronavirus disease pandemic", "PROBLEM", 108, 148], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome coronavirus", "OBSERVATION", 13, 45], ["coronavirus disease", "OBSERVATION", 120, 139]]], ["Since emerging in Wuhan, Hubei province, China in December 2019 [1] , SARS-CoV-2 has spread across the globe, causing an estimated (as of 3 August 2020) 17.7 million infections and over 680,000 deaths [2] .", [["infections", "DISEASE", 166, 176], ["deaths", "DISEASE", 194, 200], ["SARS-CoV-2", "ORGANISM", 70, 80], ["SARS-CoV", "SPECIES", 70, 78], ["SARS-CoV", "TEST", 70, 78], ["globe", "ANATOMY", 103, 108]]], ["There are currently no FDA-approved medicines or therapies available to treat COVID-19, with most mitigation strategies focused on physical distancing and other public health measures [3] .", [["COVID", "DISEASE", 78, 83], ["medicines", "TREATMENT", 36, 45], ["therapies", "TREATMENT", 49, 58], ["COVID", "TEST", 78, 83], ["no", "UNCERTAINTY", 20, 22]]], ["According to the World Health Organisation there are over 120 vaccine candidates currently in various stages of development [4] .Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, familyThe development of several countermeasures against COVID-19, including antiviral compound screening, vaccine virus production and host-virus interactive studies, are reliant on robust viral assays that can be rapidly implemented in diverse laboratory settings.", [["acute respiratory syndrome coronavirus", "DISEASE", 136, 174], ["COVID-19", "CHEMICAL", 247, 255], ["SARS-CoV-2", "ORGANISM", 178, 188], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 129, 174], ["SARS-CoV", "SPECIES", 178, 186], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 129, 174], ["COVID", "TEST", 247, 252], ["antiviral compound screening", "TREATMENT", 267, 295], ["vaccine virus production", "TREATMENT", 297, 321], ["host-virus interactive studies", "TEST", 326, 356], ["robust viral assays", "TEST", 373, 392], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["respiratory syndrome", "OBSERVATION", 142, 162]]], ["SARS-CoV-2 is often propagated in African green monkey kidney epithelial (VeroE6) cells for several reasons, including visible cytopathic effect and the VeroE6 deficiency in type I interferon secretion [5] , which allows the virus to grow to higher titres.", [["kidney epithelial (VeroE6) cells", "ANATOMY", 55, 87], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["monkey", "ORGANISM", 48, 54], ["kidney epithelial (VeroE6) cells", "CELL", 55, 87], ["VeroE6", "SIMPLE_CHEMICAL", 153, 159], ["type I interferon", "GENE_OR_GENE_PRODUCT", 174, 191], ["African green monkey kidney epithelial (VeroE6) cells", "CELL_LINE", 34, 87], ["green monkey", "SPECIES", 42, 54], ["African green monkey", "SPECIES", 34, 54], ["epithelial (VeroE6) cells", "TREATMENT", 62, 87], ["visible cytopathic effect", "PROBLEM", 119, 144], ["the VeroE6 deficiency", "PROBLEM", 149, 170], ["type I interferon secretion", "PROBLEM", 174, 201], ["the virus", "PROBLEM", 221, 230], ["kidney", "ANATOMY", 55, 61], ["epithelial", "ANATOMY_MODIFIER", 62, 72], ["cytopathic", "OBSERVATION_MODIFIER", 127, 137]]], ["The tropism and replication kinetics of SARS-CoV-2 has been investigated in a range of primary and immortalized cell lines (both animal and human) [6] , and while SARS-CoV-2 replication is observed in several immortalized human cell lines High molecular weight polyethylene glycol-6000 (PEG) has been used for the concentrating of virus samples for decades.", [["cell lines", "ANATOMY", 112, 122], ["cell lines", "ANATOMY", 228, 238], ["samples", "ANATOMY", 337, 344], ["SARS", "DISEASE", 40, 44], ["polyethylene glycol-6000", "CHEMICAL", 261, 285], ["PEG", "CHEMICAL", 287, 290], ["polyethylene glycol-6000", "CHEMICAL", 261, 285], ["PEG", "CHEMICAL", 287, 290], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["cell lines", "CELL", 112, 122], ["human", "ORGANISM", 140, 145], ["SARS-CoV-2", "ORGANISM", 163, 173], ["human", "ORGANISM", 222, 227], ["cell lines", "CELL", 228, 238], ["polyethylene glycol-6000", "SIMPLE_CHEMICAL", 261, 285], ["PEG", "SIMPLE_CHEMICAL", 287, 290], ["primary and immortalized cell lines", "CELL_LINE", 87, 122], ["immortalized human cell lines", "CELL_LINE", 209, 238], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 222, 227], ["SARS-CoV", "SPECIES", 40, 48], ["human", "SPECIES", 140, 145], ["SARS-CoV", "SPECIES", 163, 171], ["human", "SPECIES", 222, 227], ["The tropism", "PROBLEM", 0, 11], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["primary and immortalized cell lines", "TREATMENT", 87, 122], ["SARS", "TEST", 163, 167], ["CoV", "TEST", 168, 171], ["several immortalized human cell lines", "TREATMENT", 201, 238], ["High molecular weight polyethylene glycol", "TREATMENT", 239, 280], ["PEG", "TREATMENT", 287, 290], ["tropism", "OBSERVATION_MODIFIER", 4, 11], ["replication", "OBSERVATION_MODIFIER", 16, 27], ["kinetics", "OBSERVATION_MODIFIER", 28, 36], ["immortalized cell lines", "OBSERVATION", 99, 122], ["cell lines", "OBSERVATION", 228, 238]]], ["Initially developed for arbovirus [7] and bacteriophage purification [8] , PEG precipitation has subsequently been adapted to many RNA viruses including influenza virus (Orthomyxoviridae) [9] , respiratory syncytial virus (Paramyxoviridae) [10] and HCoV-229E coronavirus (Coronaviridae) [11] .", [["PEG", "CHEMICAL", 75, 78], ["influenza virus", "DISEASE", 153, 168], ["respiratory syncytial virus", "DISEASE", 194, 221], ["PEG", "CHEMICAL", 75, 78], ["PEG", "SIMPLE_CHEMICAL", 75, 78], ["influenza virus", "ORGANISM", 153, 168], ["Orthomyxoviridae) [9]", "ORGANISM", 170, 191], ["respiratory syncytial virus", "ORGANISM", 194, 221], ["HCoV-229E coronavirus", "ORGANISM", 249, 270], ["influenza virus", "SPECIES", 153, 168], ["respiratory syncytial virus", "SPECIES", 194, 221], ["HCoV-229E coronavirus", "SPECIES", 249, 270], ["respiratory syncytial virus", "SPECIES", 194, 221], ["HCoV-229E coronavirus", "SPECIES", 249, 270], ["arbovirus", "PROBLEM", 24, 33], ["bacteriophage purification", "TREATMENT", 42, 68], ["PEG precipitation", "TREATMENT", 75, 92], ["many RNA viruses", "PROBLEM", 126, 142], ["influenza virus (Orthomyxoviridae)", "TREATMENT", 153, 187], ["respiratory syncytial virus (Paramyxoviridae)", "TREATMENT", 194, 239], ["HCoV", "TEST", 249, 253], ["coronavirus (Coronaviridae)", "TREATMENT", 259, 286]]], ["While there are several alternative approaches for virus concentration, including ultracentrifugation, PEG precipitation is appealing due to its simplicity and the precipitation of virus in low-temperature, high-salt environment that stabilizes viral particles and produces a carrier medium that is isotonic to cells.", [["cells", "ANATOMY", 311, 316], ["PEG", "CHEMICAL", 103, 106], ["PEG", "CHEMICAL", 103, 106], ["PEG", "SIMPLE_CHEMICAL", 103, 106], ["cells", "CELL", 311, 316], ["virus concentration", "TREATMENT", 51, 70], ["ultracentrifugation", "TREATMENT", 82, 101], ["PEG precipitation", "TREATMENT", 103, 120], ["its simplicity", "PROBLEM", 141, 155], ["virus", "PROBLEM", 181, 186], ["high-salt environment", "TREATMENT", 207, 228], ["viral particles", "PROBLEM", 245, 260], ["a carrier medium", "PROBLEM", 274, 290], ["isotonic to cells", "PROBLEM", 299, 316], ["virus", "OBSERVATION", 181, 186], ["viral particles", "OBSERVATION", 245, 260]]], ["Given that infectious SARS-CoV-2 is handled at high containment, it is important that research protocols are compatible with constraints of working in a physical containment (PC)-3 or PC-4 laboratory.Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, familyThis method describes SARS-CoV-2 propagated in VeroE6 cells (ATCC CRL-1586) that were maintained as described previously [12] .", [["VeroE6 cells", "ANATOMY", 314, 326], ["ATCC CRL-1586", "ANATOMY", 328, 341], ["SARS", "DISEASE", 22, 26], ["acute respiratory syndrome coronavirus", "DISEASE", 207, 245], ["CRL-1586", "CHEMICAL", 333, 341], ["SARS-CoV-2", "ORGANISM", 22, 32], ["SARS-CoV-2", "ORGANISM", 249, 259], ["SARS-CoV-2", "ORGANISM", 289, 299], ["VeroE6 cells", "CELL", 314, 326], ["ATCC CRL-1586", "CELL", 328, 341], ["VeroE6 cells", "CELL_LINE", 314, 326], ["SARS-CoV", "SPECIES", 22, 30], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 200, 245], ["ATCC CRL-1586)", "SPECIES", 328, 342], ["infectious SARS", "PROBLEM", 11, 26], ["research protocols", "TREATMENT", 86, 104], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 200, 245], ["CoV", "TEST", 254, 257], ["SARS", "TEST", 289, 293], ["CoV", "TEST", 294, 297], ["ATCC CRL", "TEST", 328, 336], ["infectious", "OBSERVATION_MODIFIER", 11, 21], ["high containment", "OBSERVATION_MODIFIER", 47, 63], ["acute", "OBSERVATION_MODIFIER", 207, 212], ["respiratory syndrome", "OBSERVATION", 213, 233]]], ["All virology work was conducted The infectious titres of SARS-CoV-2 stocks, both before and after PEG-precipitation, was determined by TCID50 assays performed as described previously [13] .", [["SARS", "DISEASE", 57, 61], ["PEG", "CHEMICAL", 98, 101], ["PEG", "CHEMICAL", 98, 101], ["SARS-CoV-2", "ORGANISM", 57, 67], ["PEG", "SIMPLE_CHEMICAL", 98, 101], ["CoV-2", "SPECIES", 62, 67], ["SARS-CoV", "SPECIES", 57, 65], ["The infectious titres", "TEST", 32, 53], ["SARS", "TEST", 57, 61], ["CoV-2 stocks", "TREATMENT", 62, 74], ["PEG", "TREATMENT", 98, 101]]], ["Samples were titrated in quadruplicate in 96-well plates, co-cultured with VeroE6, Caco-2 or Calu-3 cells for four days.", [["Samples", "ANATOMY", 0, 7], ["VeroE6", "ANATOMY", 75, 81], ["Caco-2", "ANATOMY", 83, 89], ["Calu-3 cells", "ANATOMY", 93, 105], ["VeroE6", "CELL", 75, 81], ["Caco-2", "CELL", 83, 89], ["Calu-3 cells", "CELL", 93, 105], ["VeroE6, Caco-2", "CELL_LINE", 75, 89], ["Calu-3 cells", "CELL_LINE", 93, 105], ["Samples", "TEST", 0, 7], ["VeroE6", "TREATMENT", 75, 81], ["Caco", "TREATMENT", 83, 87]]], ["VeroE6 cells and Calu-3 cells displayed cytopathic effect, consistent with previous findings (Figure 1 ).", [["VeroE6 cells", "ANATOMY", 0, 12], ["Calu-3 cells", "ANATOMY", 17, 29], ["VeroE6 cells", "CELL", 0, 12], ["Calu-3 cells", "CELL", 17, 29], ["VeroE6 cells", "CELL_LINE", 0, 12], ["Calu-3 cells", "CELL_LINE", 17, 29], ["VeroE6 cells", "TEST", 0, 12], ["Calu", "TEST", 17, 21], ["cytopathic effect", "PROBLEM", 40, 57], ["cytopathic effect", "OBSERVATION", 40, 57], ["consistent with", "UNCERTAINTY", 59, 74]]], ["As cytopathic effect was not observed in Caco-2 cells, virus titres were measured by immunofluorescence (Figure 2 ).", [["Caco-2 cells", "ANATOMY", 41, 53], ["Caco-2 cells", "CELL", 41, 53], ["Caco-2 cells", "CELL_LINE", 41, 53], ["cytopathic effect", "PROBLEM", 3, 20], ["virus titres", "TEST", 55, 67]]], ["For this, cells were fixed for 30 minutes in 4 % paraformaldehyde (PFA) and stained with a polyclonal antibody targeting the SARS-CoV-2 Nucleocapsid (N) protein (Jomar J o u r n a l P r e -p r o o f Sciences, catalog number: 40588-T62, used at 1/2,000) for 1 hour.", [["cells", "ANATOMY", 10, 15], ["paraformaldehyde", "CHEMICAL", 49, 65], ["PFA", "CHEMICAL", 67, 70], ["cells", "CELL", 10, 15], ["paraformaldehyde", "SIMPLE_CHEMICAL", 49, 65], ["PFA", "SIMPLE_CHEMICAL", 67, 70], ["polyclonal antibody", "PROTEIN", 91, 110], ["SARS-CoV-2 Nucleocapsid (N) protein", "PROTEIN", 125, 160], ["PFA", "TEST", 67, 70], ["a polyclonal antibody", "TEST", 89, 110], ["the SARS", "TEST", 121, 129], ["CoV", "TEST", 130, 133], ["Nucleocapsid", "TEST", 136, 148], ["protein", "TEST", 153, 160], ["Jomar", "TEST", 162, 167]]], ["Cells were subsequently stained with 1/1,000 dilution of an anti-rabbit AF488 antibody (Invitrogen catalog number A110008).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["anti-rabbit AF488 antibody", "PROTEIN", 60, 86], ["Invitrogen catalog number A110008", "PROTEIN", 88, 121], ["anti-rabbit", "SPECIES", 60, 71], ["anti-rabbit", "SPECIES", 60, 71], ["an anti-rabbit", "TEST", 57, 71]]], ["Nuclei were counter-stained with DAPI.", [["Nuclei", "ANATOMY", 0, 6], ["DAPI", "CHEMICAL", 33, 37], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["DAPI", "SIMPLE_CHEMICAL", 33, 37], ["DAPI", "TEST", 33, 37]]], ["Cells were imaged using the CellInsight quantitative fluorescence microscope (Thermo Fisher Scientific) at a magnification of 10 x, 49 fields/well, capturing the entire well.Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, familyThe infectious titre for all three cell types was calculated by the method of Reed and Muench [14] .", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 276, 280], ["acute respiratory syndrome coronavirus", "DISEASE", 181, 219], ["Cells", "CELL", 0, 5], ["SARS-CoV-2", "ORGANISM", 223, 233], ["cell", "CELL", 276, 280], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 174, 219], ["SARS-CoV", "SPECIES", 223, 231], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 174, 219], ["The infectious titre", "PROBLEM", 241, 261], ["acute", "OBSERVATION_MODIFIER", 181, 186], ["respiratory syndrome", "OBSERVATION", 187, 207], ["infectious", "OBSERVATION", 245, 255]]], ["Unconcentrated virus titres were highest in VeroE6 cells, followed by", [["VeroE6 cells", "ANATOMY", 44, 56], ["VeroE6 cells", "CELL", 44, 56], ["VeroE6 cells", "CELL_LINE", 44, 56], ["Unconcentrated virus titres", "PROBLEM", 0, 27], ["virus titres", "OBSERVATION", 15, 27], ["VeroE6 cells", "OBSERVATION", 44, 56]]]], "1a1e8d72785bbd53a2ccec172d72cf8c29031509": [["Humankind is currently confronting a new type of coronavirus, and it may take considerable time before the human population and the virus arrive at a mutual equilibrium.", [["coronavirus", "DISEASE", 49, 60], ["coronavirus", "ORGANISM", 49, 60], ["human", "ORGANISM", 107, 112], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["coronavirus", "PROBLEM", 49, 60], ["the human population", "PROBLEM", 103, 123], ["the virus", "PROBLEM", 128, 137], ["coronavirus", "OBSERVATION", 49, 60]]], ["The first patients with coronavirus disease 2019 were recorded in December 2019 in China , and since then the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally.", [["coronavirus disease", "DISEASE", 24, 43], ["acute respiratory syndrome coronavirus", "DISEASE", 117, 155], ["patients", "ORGANISM", 10, 18], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 110, 157], ["SARS-CoV-2", "ORGANISM", 159, 169], ["patients", "SPECIES", 10, 18], ["coronavirus", "SPECIES", 24, 35], ["severe acute respiratory syndrome coronavirus", "SPECIES", 110, 155], ["SARS-CoV-2", "SPECIES", 159, 169], ["coronavirus disease", "PROBLEM", 24, 43], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 106, 155], ["SARS", "TEST", 159, 163], ["CoV", "TEST", 164, 167], ["coronavirus disease", "OBSERVATION", 24, 43], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["respiratory syndrome", "OBSERVATION", 123, 143], ["spread", "OBSERVATION_MODIFIER", 175, 181], ["globally", "OBSERVATION_MODIFIER", 182, 190]]], ["Other reputed members of the coronavirus family are SARS-CoV-1 and MERS-CoV, which caused zoonotic events that resulted in epidemics in 2002 and 2012, respectively (Peiris et al. 2003; Zaki et al. 2012) .", [["coronavirus", "ORGANISM", 29, 40], ["SARS-CoV-1", "ORGANISM", 52, 62], ["MERS-CoV", "ORGANISM", 67, 75], ["coronavirus", "SPECIES", 29, 40], ["CoV-1", "SPECIES", 57, 62], ["SARS-CoV-1", "SPECIES", 52, 62], ["MERS-CoV", "SPECIES", 67, 75], ["CoV", "TEST", 57, 60], ["zoonotic events", "PROBLEM", 90, 105], ["epidemics", "PROBLEM", 123, 132]]], ["According to the WHO (22/4/2020), more than 2,400,000 individuals have been infected by SARS-CoV-2, and at least 165,000 have succumbed to the disease (https:// covid19.who.int).", [["SARS", "DISEASE", 88, 92], ["individuals", "ORGANISM", 54, 65], ["SARS-CoV-2", "ORGANISM", 88, 98], ["SARS-CoV", "SPECIES", 88, 96], ["CoV", "TEST", 93, 96], ["infected", "OBSERVATION", 76, 84]]], ["Most patients with COVID-19 suffer from severe respiratory problems, and elderly people in particular or persons with comorbidities seem to be at greatest risk (Wang et al. 2020 ).", [["respiratory", "ANATOMY", 47, 58], ["respiratory problems", "DISEASE", 47, 67], ["patients", "ORGANISM", 5, 13], ["people", "ORGANISM", 81, 87], ["persons", "ORGANISM", 105, 112], ["patients", "SPECIES", 5, 13], ["people", "SPECIES", 81, 87], ["persons", "SPECIES", 105, 112], ["COVID", "TEST", 19, 24], ["severe respiratory problems", "PROBLEM", 40, 67], ["comorbidities", "PROBLEM", 118, 131], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["respiratory", "ANATOMY", 47, 58], ["problems", "OBSERVATION", 59, 67]]], ["Gender-related social factors, immunological differences, hormonal disparaties, and lifestyle habits such as smoking and alcohol consumption are considered to play a role (Wenham et al. 2020) .", [["smoking", "CHEMICAL", 109, 116], ["alcohol", "CHEMICAL", 121, 128], ["alcohol", "CHEMICAL", 121, 128], ["alcohol", "SIMPLE_CHEMICAL", 121, 128], ["immunological differences", "PROBLEM", 31, 56], ["hormonal disparaties", "PROBLEM", 58, 78]]], ["The vulnerability of the male population with regard to the COVID-19 pandemic may to some extent be a result of gender-defined genetic polymorphisms.", [["the COVID", "TEST", 56, 65], ["gender-defined genetic polymorphisms", "PROBLEM", 112, 148], ["vulnerability", "OBSERVATION_MODIFIER", 4, 17], ["genetic polymorphisms", "OBSERVATION", 127, 148]]]], "04fb1656b773a1db9bc2b340aa503fe12132c670": [["substrate scanning form complex in the entire asymmetric unit of the crystal.", [["substrate scanning form complex", "PROTEIN", 0, 31], ["substrate scanning", "TEST", 0, 18], ["complex", "OBSERVATION_MODIFIER", 24, 31], ["asymmetric", "OBSERVATION_MODIFIER", 46, 56], ["crystal", "OBSERVATION_MODIFIER", 69, 76]]], ["Table 1 , 2) were resolved in a 18% polyacrylamide denaturing gel 36 running for 3 hours. (c) 0.5, 2, 5 nM of FAN1 373-1017 wild type or 5 nM of D960A mutant 37 was incubated with 5' 32 P-radiolabeled 5' flap (10-1-10) substrate (5 nM) at 37 \u00b0C for 5 38 minutes, and the reaction mixtures were resolved in a 18% polyacrylamide denaturing 39 gel. dT 5 and dT 10 were loaded as size markers.", [["FAN1 373-1017", "CHEMICAL", 110, 123], ["10-1-10)", "CHEMICAL", 210, 218], ["polyacrylamide", "CHEMICAL", 36, 50], ["polyacrylamide", "CHEMICAL", 312, 326], ["10-1-10) substrate", "SIMPLE_CHEMICAL", 210, 228], ["dT 5", "ORGANISM", 346, 350], ["dT 5 and dT 10", "DNA", 346, 360], ["a 18% polyacrylamide denaturing gel", "TREATMENT", 30, 65], ["FAN1", "TEST", 110, 114], ["D960A mutant", "TEST", 145, 157], ["flap", "TEST", 204, 208], ["the reaction mixtures", "PROBLEM", 267, 288], ["a 18% polyacrylamide denaturing", "TREATMENT", 306, 337], ["dT", "TEST", 346, 348], ["dT", "TEST", 355, 357], ["size", "OBSERVATION_MODIFIER", 376, 380]]], ["TTGATAAGAGGTCATTTGAATTCATGGCTTAGAG M36 TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCT M38 TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTA M40 TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTAAT M42 TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTAATTG M44 TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTAATTGCT M46 TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTAATTGCTGA X0F TTGATCAGAG GTCATTTGAA TTCATGGCTT CGAGCTTCAT GTAGAGTCGAC GGTGCTGGGA TCCAACATGT TTTCAATCTG X0R CAGATTGAAA ACATGTTGGA TCCCAGCACC GTCGACTCTAC TCCGTTTCCG ATCGTCCGTT CGATGCTGGC TCCTGCTTGC X2F TTGATCAGAG GTCATTTGAA TTCATGGCTT CGAGCTTCAT GGATAGTCGAC GGTGCTGGGA TCCAACATGT TTTCAATCTG X2R CAGATTGAAA ACATGTTGGA TCCCAGCACC GTCGACTATCC TCCGTTTCCG ATCGTCCGTT CGATGCTGGC TCCTGCTTGC X6F TTGATCAGAG GTCATTTGAA TTCATGGCTT CGAGCTTCAT GGAGTCGTAAC GGTGCTGGGA TCCAACATGT TTTCAATCTG X6R CAGATTGAAA ACATGTTGGA TCCCAGCACC GTTACGACTCC TCCGTTTCCG ATCGTCCGTT CGATGCTGGC TCCTGCTTGC X12F TTGATCAGAG GTCATTTGAA TTCATGGCTT CGAGCTTCAT GGAGTCGACGG TGTACTGGGA TCCAACATGT TTTCAATCTG X12R CAGATTGAAA ACATGTTGGA TCCCAGTACACC GTCGACTCC TCCGTTTCCG ATCGTCCGTT CGATGCTGGC TCCTGCTTGC X16F TTGATCAGAG GTCATTTGAA TTCATGGCTT CGAGCTTCAT GGAGTCGACGG TGCTGGTAGA TCCAACATGT TTTCAATCTG X16R CAGATTGAAA H3, H4 5'-flap (10-1-10) a3-10-1, c10, b22 5'-flap (AT)(10-1-10) a3-10-1, c10, b22(AT) 5'Flap (crosslink at fork, \"0\") X0F, X0R, X40 5'Flap (crosslink at -2 bp from fork, \"-2\") X2F, X2R, X40 5'Flap (crosslink at -6 bp from fork, \"-6\") X6F, X6R, X40 5'Flap (crosslink at -12 bp from fork, \"-12\") X12F, X12R, X40 5'Flap (crosslink at -16 bp from fork, \"-16\") X16F, X16R, X40", [["X16R CAGATTGAAA H3", "GENE_OR_GENE_PRODUCT", 1151, 1169], ["a3-10-1", "GENE_OR_GENE_PRODUCT", 1192, 1199], ["c10", "GENE_OR_GENE_PRODUCT", 1201, 1204], ["H4 5'-flap (10-1-10) a3-10-1, c10, b22 5'-flap (AT)(10-1-10) a3-10-1, c10, b22(AT) 5'Flap", "DNA", 1171, 1260], ["X0F", "DNA", 1286, 1289], ["X0R", "DNA", 1291, 1294], ["X40 5'Flap", "DNA", 1296, 1306], ["X2F", "DNA", 1344, 1347], ["X2R", "DNA", 1349, 1352], ["X40 5'Flap", "DNA", 1354, 1364], ["X6F", "DNA", 1402, 1405], ["X6R", "DNA", 1407, 1410], ["X40 5'Flap", "DNA", 1412, 1422], ["X12F", "DNA", 1462, 1466], ["X12R", "DNA", 1468, 1472], ["X40 5'Flap", "DNA", 1474, 1484], ["X16F", "DNA", 1524, 1528], ["X16R", "DNA", 1530, 1534], ["X40", "DNA", 1536, 1539], ["TTGATAAGAGGTCATTTGAATTCATGGCTTAGAG", "TEST", 0, 34], ["TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCT", "TEST", 39, 75], ["TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTA", "TEST", 80, 118], ["M40", "TEST", 119, 122], ["TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTAAT", "TEST", 123, 163], ["M42", "TEST", 164, 167], ["TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTAATTG", "TEST", 168, 210], ["M44", "TEST", 211, 214], ["TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTAATTGCT", "TEST", 215, 259], ["M46", "TEST", 260, 263], ["TTGATAAGAGGTCATTTGAATTCATGGCTTAGAGCTTAATTGCTGA", "TEST", 264, 310], ["X0F", "TEST", 311, 314], ["TTGATCAGAG", "TEST", 315, 325], ["GTCATTTGAA", "TEST", 326, 336], ["TTCATGGCTT", "TEST", 337, 347], ["CGAGCTTCAT", "TEST", 348, 358], ["GTAGAGTCGAC", "TEST", 359, 370], ["GGTGCTGGGA", "TEST", 371, 381], ["TCCAACATGT", "TEST", 382, 392], ["TTTCAATCTG", "TEST", 393, 403], ["X0R", "TEST", 404, 407], ["CAGATTGAAA", "TEST", 408, 418], ["ACATGTTGGA", "TEST", 419, 429], ["TCCCAGCACC", "TEST", 430, 440], ["GTCGACTCTAC", "TEST", 441, 452], ["TCCGTTTCCG", "TEST", 453, 463], ["ATCGTCCGTT", "TEST", 464, 474], ["CGATGCTGGC", "TEST", 475, 485], ["TCCTGCTTGC", "TEST", 486, 496], ["X2F", "TEST", 497, 500], ["TTGATCAGAG", "TEST", 501, 511], ["GTCATTTGAA", "TEST", 512, 522], ["TTCATGGCTT", "TEST", 523, 533], ["CGAGCTTCAT", "TEST", 534, 544], ["GGATAGTCGAC", "TEST", 545, 556], ["GGTGCTGGGA", "TEST", 557, 567], ["TCCAACATGT", "TEST", 568, 578], ["TTTCAATCTG", "TEST", 579, 589], ["X2R", "TEST", 590, 593], ["CAGATTGAAA", "TEST", 594, 604], ["ACATGTTGGA", "TEST", 605, 615], ["TCCCAGCACC", "TEST", 616, 626], ["GTCGACTATCC", "TEST", 627, 638], ["TCCGTTTCCG", "TEST", 639, 649], ["ATCGTCCGTT", "TEST", 650, 660], ["CGATGCTGGC", "TEST", 661, 671], ["TCCTGCTTGC", "TEST", 672, 682], ["X6F", "TEST", 683, 686], ["TTGATCAGAG", "TEST", 687, 697], ["GTCATTTGAA", "TEST", 698, 708], ["TTCATGGCTT", "TEST", 709, 719], ["CGAGCTTCAT", "TEST", 720, 730], ["GGAGTCGTAAC", "TEST", 731, 742], ["GGTGCTGGGA", "TEST", 743, 753], ["TCCAACATGT", "TEST", 754, 764], ["TTTCAATCTG", "TEST", 765, 775], ["X6R", "TEST", 776, 779], ["CAGATTGAAA", "TEST", 780, 790], ["ACATGTTGGA", "TEST", 791, 801], ["TCCCAGCACC", "TEST", 802, 812], ["GTTACGACTCC", "TEST", 813, 824], ["TCCGTTTCCG", "TEST", 825, 835], ["ATCGTCCGTT", "TEST", 836, 846], ["CGATGCTGGC", "TEST", 847, 857], ["TCCTGCTTGC", "TEST", 858, 868], ["X12F", "TEST", 869, 873], ["TTGATCAGAG", "TEST", 874, 884], ["GTCATTTGAA", "TEST", 885, 895], ["TTCATGGCTT", "TEST", 896, 906], ["CGAGCTTCAT", "TEST", 907, 917], ["GGAGTCGACGG", "TEST", 918, 929], ["TGTACTGGGA", "TEST", 930, 940], ["TCCAACATGT", "TEST", 941, 951], ["TTTCAATCTG", "TEST", 952, 962], ["X12R", "TEST", 963, 967], ["CAGATTGAAA", "TEST", 968, 978], ["ACATGTTGGA", "TEST", 979, 989], ["TCCCAGTACACC", "TEST", 990, 1002], ["GTCGACTCC", "TEST", 1003, 1012], ["TCCGTTTCCG", "TEST", 1013, 1023], ["ATCGTCCGTT", "TEST", 1024, 1034], ["CGATGCTGGC", "TEST", 1035, 1045], ["TCCTGCTTGC", "TEST", 1046, 1056], ["X16F", "TEST", 1057, 1061], ["TTGATCAGAG", "TEST", 1062, 1072], ["GTCATTTGAA", "TEST", 1073, 1083], ["TTCATGGCTT", "TEST", 1084, 1094], ["CGAGCTTCAT", "TEST", 1095, 1105], ["GGAGTCGACGG", "TEST", 1106, 1117], ["TGCTGGTAGA", "TEST", 1118, 1128], ["TCCAACATGT", "TEST", 1129, 1139], ["flap", "TREATMENT", 1177, 1181], ["a3", "TEST", 1232, 1234], ["c10", "TEST", 1241, 1244], ["Flap (crosslink at fork", "TEST", 1256, 1279], ["X0R", "TEST", 1291, 1294], ["Flap", "TEST", 1302, 1306], ["crosslink", "TEST", 1308, 1317], ["bp", "TEST", 1324, 1326], ["fork", "TEST", 1332, 1336], ["\"", "TEST", 1338, 1339], ["X2R", "TEST", 1349, 1352], ["Flap", "TEST", 1360, 1364], ["crosslink", "TEST", 1366, 1375], ["bp", "TEST", 1382, 1384], ["fork", "TEST", 1390, 1394], ["\"", "TEST", 1396, 1397], ["X6F", "TEST", 1402, 1405], ["X6R", "TEST", 1407, 1410], ["Flap", "TEST", 1418, 1422], ["crosslink", "TEST", 1424, 1433], ["bp", "TEST", 1441, 1443], ["fork", "TEST", 1449, 1453], ["\"", "TEST", 1455, 1456], ["X12F", "TEST", 1462, 1466], ["X12R", "TEST", 1468, 1472], ["Flap", "TEST", 1480, 1484], ["crosslink", "TEST", 1486, 1495], ["bp from fork", "TEST", 1503, 1515], ["\"", "TEST", 1517, 1518], ["X16F", "TEST", 1524, 1528], ["flap", "ANATOMY", 1177, 1181], ["c10", "ANATOMY", 1201, 1204], ["flap", "ANATOMY", 1213, 1217], ["c10", "ANATOMY", 1241, 1244], ["Flap", "ANATOMY", 1256, 1260]]]]}